PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33990641-0 2021 trans-Fatty acids promote p53-dependent apoptosis triggered by cisplatin-induced DNA interstrand crosslinks via the Nox-RIP1-ASK1-MAPK pathway. Cisplatin 63-72 tumor protein p53 Homo sapiens 26-29 33990641-5 2021 However, here we found that in the case of CDDP-induced apoptosis, EA-mediated pro-apoptotic action was reversed by knockout of either p53 or ASK1, despite no increase in p53 apoptotic activity. Cisplatin 43-47 tumor protein p53 Homo sapiens 135-138 33990641-7 2021 These results demonstrate that in response to CDDP ICLs, TFAs promote p53-dependent apoptosis through the enhancement of the Nox-RIP1-ASK1-MAPK pathway activation, providing insight into the diverse pathogenetic mechanisms of TFAs according to the types of DNA damage. Cisplatin 46-50 tumor protein p53 Homo sapiens 70-73 33906321-10 2021 EGCG combined with DDP treatment caused cell cycle arrest in G1 phase in BGC-823 cells, increase of apoptosis (21.3%) vs EGCG (7.25%) and DDP (3.86%) single-use group (p <0.01), up-regulated gene and protein expressions of p19Arf, p53, p21Cip1 (p <0.01). Cisplatin 19-22 tumor protein p53 Homo sapiens 231-234 33952795-9 2021 Moreover, co-administration of Cisplatin and APS was more efficacious for the antitumor effect than either agent alone, as evidenced by the significant decrease in MMP-9 level and increase in p53. Cisplatin 31-40 tumor protein p53 Homo sapiens 192-195 33922989-8 2021 Targeting p53-mediated DNA damage signaling provides another therapeutic strategy to circumvent cisplatin resistance. Cisplatin 96-105 tumor protein p53 Homo sapiens 10-13 33907694-5 2021 Knowing that bladder cancer cell lines that lack TP53 are more resistant to cisplatin and because the tumor lacked any other DNA mutation, this patient may have been a candidate for upfront surgery without neoadjuvant chemotherapy. Cisplatin 76-85 tumor protein p53 Homo sapiens 49-53 33868388-0 2021 Interplay Between Thiamine and p53/p21 Axes Affects Antiproliferative Action of Cisplatin in Lung Adenocarcinoma Cells by Changing Metabolism of 2-Oxoglutarate/Glutamate. Cisplatin 80-89 tumor protein p53 Homo sapiens 31-34 33868388-5 2021 Our work focuses on dependence of the action of the DNA damaging anticancer drug cisplatin on metabolic regulation through p53/p21 axes and cellular thiamine status in human lung adenocarcinoma cells A549. Cisplatin 81-90 tumor protein p53 Homo sapiens 123-126 33868388-12 2021 Thus, a p53/p21-dependent change in partitioning of the glutamate conversion to 2-oxoglutarate through GOT2 or GDH, linked to NAD(P)-dependent metabolism of 2-oxoglutarate in affiliated pathways, adapts A549 cells to thiamine deficiency or cisplatin treatment. Cisplatin 240-249 tumor protein p53 Homo sapiens 8-11 33850897-12 2021 Our results finally showed that high-risk cases were associated with cell proliferation and cell cycle related gene sets, high tumor protein P53 (TP53) mutation rate, suppressive immunity and increased sensitivity to cisplatin, gemcitabine and docetaxel. Cisplatin 217-226 tumor protein p53 Homo sapiens 141-144 33868388-13 2021 Cellular thiamine deficiency may interfere with antiproliferative action of cisplatin due to their common modulation of the p53/p21-dependent metabolic switch between the glutamate oxidation and transamination. Cisplatin 76-85 tumor protein p53 Homo sapiens 124-127 33705152-6 2021 The mechanism underling the synergism of JQ1 with CDDP in PGP-CDDP/JQ1 was uncovered to be inhibiting Plk1-mutant Trp53 axis. Cisplatin 50-54 tumor protein p53 Homo sapiens 114-119 33669781-7 2021 In addition, downregulation of p53 and/or cyclin D1 may also impact the responsiveness of HEC-1-A and KLE cells to cisplatin. Cisplatin 115-124 tumor protein p53 Homo sapiens 31-34 33650658-11 2021 These data suggested that the accumulated CRY1 in cisplatin-resistant cells could prevent PTX-induced senescence by promoting p53 degradation. Cisplatin 50-59 tumor protein p53 Homo sapiens 126-129 33627632-8 2021 The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide. Cisplatin 126-135 tumor protein p53 Homo sapiens 89-92 33456714-0 2021 Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Cisplatin 124-133 tumor protein p53 Homo sapiens 161-164 33530952-9 2021 INI-43 pre-treatment resulted in moderately stabilized p53 and induced p53 reporter activity, which translated to increased p21 and decreased Mcl-1 upon cisplatin combination treatment. Cisplatin 153-162 tumor protein p53 Homo sapiens 71-74 33183422-12 2021 The p53-related signaling pathway may participate in the process of apoptosis and reverse the process of cisplatin resistance, but the specific mechanism and whether there are other signaling pathways involved Further research is needed. Cisplatin 105-114 tumor protein p53 Homo sapiens 4-7 33473103-9 2021 This was most evident when the p53-deficient neurons were globally exposed to cisplatin. Cisplatin 78-87 tumor protein p53 Homo sapiens 31-34 33520705-0 2020 TIPE1 Promotes Cervical Cancer Cell Chemoresistance to Cisplatin in a Wild-Type p53-Dependent Manner. Cisplatin 55-64 tumor protein p53 Homo sapiens 80-83 31897925-10 2020 Neoadjuvant chemotherapy with cisplatin, 5-fluorouracil and leucovorin may offer high response rates and long-term control in a subgroup of patients affected by intestinal-type adenocarcinoma, and in particular in those whose tumors harbor a functional p53 protein. Cisplatin 30-39 tumor protein p53 Homo sapiens 253-256 33390811-16 2021 Conclusions: LncRNA XIST competitively bound to miRNA 520 in the regulation of cisplatin resistance by BAX, participating apoptosis in the p53 signaling pathway. Cisplatin 79-88 tumor protein p53 Homo sapiens 139-142 33302475-4 2020 We found that phenanthriplatin may regulate the genes GPRC5a, TFF1, and TNFRSF10D, which act through p53 to control apoptosis, differently or to a greater extent than cisplatin, and that it, unlike cisplatin, could upregulate ATP5MD, a gene which signals through the Wnt/beta catenin pathway. Cisplatin 198-207 tumor protein p53 Homo sapiens 101-104 33240412-0 2021 Blockade of TRIM59 enhances esophageal cancer cell chemosensitivity to cisplatin by upregulating p53. Cisplatin 71-80 tumor protein p53 Homo sapiens 97-100 33240412-5 2021 At the molecular level, TRIM59 was indicated to be an E3 putative ubiquitin ligase that targeted the p53 protein, leading to increased degradation of p53, which resulted in decreased chemosensitivity to cisplatin. Cisplatin 203-212 tumor protein p53 Homo sapiens 101-104 33240412-5 2021 At the molecular level, TRIM59 was indicated to be an E3 putative ubiquitin ligase that targeted the p53 protein, leading to increased degradation of p53, which resulted in decreased chemosensitivity to cisplatin. Cisplatin 203-212 tumor protein p53 Homo sapiens 150-153 33240412-8 2021 The results indicated a relationship between TRIM59, p53 and the chemosensitivity of cisplatin. Cisplatin 85-94 tumor protein p53 Homo sapiens 53-56 33396303-8 2020 We also found that a fraction of p53 in stress-adapted cells was translocated to the nucleus, and that these cells exhibited a significant decline in the level of cisplatin-DNA damage. Cisplatin 163-172 tumor protein p53 Homo sapiens 33-36 33163850-7 2020 TP53 pathway alterations were identified in nine cisplatin-resistant patients and had the highest degree of concordance in primary and metastatic specimens, consistent with their association with this treatment-resistant phenotype. Cisplatin 49-58 tumor protein p53 Homo sapiens 0-4 32947166-8 2020 Moreover, the acetazolamide/cisplatin combination could decrease the level of PCNA but increase the level of p53; decrease the ratio of Bcl-2/Bax and increase the expression of caspase-3 compared with the single drug treated group. Cisplatin 28-37 tumor protein p53 Homo sapiens 109-112 33174043-9 2020 Cisplatin increased the expression of genes related to the p53 and FoxO pathways, such as Fas, p21/CDKN1A, and Bcl-2 binding component 3, but decreased the expression of insulin-like growth factor 1 (IGF1), as well as genes in the histone (Hist)1 and Hist2 clusters. Cisplatin 0-9 tumor protein p53 Homo sapiens 59-62 32738659-6 2020 The synchronization of enhanced G2/M arrest and ROS-P53 crosstalk devotes to reverse the cisplatin resistance with a high level of resistance reversion index (50.22). Cisplatin 89-98 tumor protein p53 Homo sapiens 52-55 33086658-3 2020 Thus, a better understanding of the molecular changes of epithelial ovarian cancer cells with wild-type p53 in response to treatment with cisplatin could reveal novel mechanisms of chemoresistance. Cisplatin 138-147 tumor protein p53 Homo sapiens 104-107 33086658-4 2020 METHODS: Gene expression profiling was performed on an ovarian cancer cell line A2780 with wild-type p53 treated with cisplatin. Cisplatin 118-127 tumor protein p53 Homo sapiens 101-104 32044796-9 2020 The combination of C61-LNP and CDDP changed in alterations of the cell cycle regulatory proteins p53, p21, p27, cyclin D1 and cyclin E levels. Cisplatin 31-35 tumor protein p53 Homo sapiens 97-100 32818504-0 2020 Aconitase 2 sensitizes MCF-7 cells to cisplatin eliciting p53-mediated apoptosis in a ROS-dependent manner. Cisplatin 38-47 tumor protein p53 Homo sapiens 58-61 32818504-5 2020 This response was driven by the accumulation of reactive oxygen species (ROS) following both ACO2 overexpression and CDDP exposure that permit the stabilization/activation of p53 in nuclear and mitochondrial compartments. Cisplatin 117-121 tumor protein p53 Homo sapiens 175-178 32881246-10 2020 These results implied PIO attenuated cisplatin nephrotoxicity by suppressing mitochondria-mediated apoptosis through regulating SIRT1/p53 signalling. Cisplatin 37-46 tumor protein p53 Homo sapiens 134-137 32974127-0 2020 p53 Affects PGC1alpha Stability Through AKT/GSK-3beta to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer. Cisplatin 65-74 tumor protein p53 Homo sapiens 0-3 32825184-4 2020 As a follow-up study of our previous findings, here we have identified that the pharmacological substances, leptomycin B and doxorubicin, can improve the sensitivity of cervical cancer cells to cisplatin inducing HP1gamma-mediated elevation of p53. Cisplatin 194-203 tumor protein p53 Homo sapiens 244-247 32825184-5 2020 Leptomycin B, which inhibits the nuclear export of HP1gamma, increased cisplatin-dependent apoptosis induction by promoting the activation of p53 signaling. Cisplatin 71-80 tumor protein p53 Homo sapiens 142-145 32825184-8 2020 Doxorubicin sensitized the cisplatin-resistant cervical cancer cells, enhancing their p53 levels and rate of apoptosis when administered together with cisplatin. Cisplatin 27-36 tumor protein p53 Homo sapiens 86-89 32825184-9 2020 Our findings reveal a therapeutic strategy to target a specific molecular pathway that contributes to p53 degradation for the treatment of patients with cervical cancer, particularly with cisplatin resistance. Cisplatin 188-197 tumor protein p53 Homo sapiens 102-105 32757802-7 2021 The synergistic antitumor effect of API and CDDP was blocked by addition of the p53 inhibitor Pifithrin-alpha, and siRNA targeting the p53 gene in A549R cells. Cisplatin 44-48 tumor protein p53 Homo sapiens 80-83 32757802-7 2021 The synergistic antitumor effect of API and CDDP was blocked by addition of the p53 inhibitor Pifithrin-alpha, and siRNA targeting the p53 gene in A549R cells. Cisplatin 44-48 tumor protein p53 Homo sapiens 135-138 32757802-8 2021 Furthermore, API eliminates CDDP-induced CSC via p53, since A549R cells lacking p53 and Pifithrin-alpha addition derepressed the decrease in CD 133 positive cells after API treatment in CDDP-treated A549 and A549R cells. Cisplatin 28-32 tumor protein p53 Homo sapiens 49-52 32757802-8 2021 Furthermore, API eliminates CDDP-induced CSC via p53, since A549R cells lacking p53 and Pifithrin-alpha addition derepressed the decrease in CD 133 positive cells after API treatment in CDDP-treated A549 and A549R cells. Cisplatin 186-190 tumor protein p53 Homo sapiens 49-52 32757802-9 2021 The findings indicate that API might eliminate cancer stem cells and enhance the antitumor effects of CDDP in NSCLC via p53. Cisplatin 102-106 tumor protein p53 Homo sapiens 120-123 32742376-5 2020 In HCT116 cells expressing wild-type (wt) TP53, SIRT inhibitors were found to act antagonistically with multiple chemotherapeutic agents (cisplatin, 5-fluorouracil, oxaliplatin, gefitinib, LY294002 and metformin), and decreased the anti-tumor effects of these agents. Cisplatin 138-147 tumor protein p53 Homo sapiens 42-46 32641008-7 2020 Immunoprecipitation was further employed to reveal the molecular interaction of APE1, p53, and LC3 when A549 cells were exposed to cisplatin. Cisplatin 131-140 tumor protein p53 Homo sapiens 86-89 32641008-11 2020 Immunoprecipitation results revealed the triple complex of APE1-p53-LC3 in response to cisplatin plus CQ in A549 cells. Cisplatin 87-96 tumor protein p53 Homo sapiens 64-67 32641008-13 2020 CONCLUSIONS: Dual inhibition of APE1 and autophagy greatly enhances apoptosis in parental KRASG12S-mutant A549 cells and cisplatin-resistant A549 cells via regulation of APE1-p53-LC3 complex assembly, providing therapeutic vulnerability to overcome cisplatin resistance in the context of KRASG12S-mutant lung cancer. Cisplatin 121-130 tumor protein p53 Homo sapiens 175-178 32641008-13 2020 CONCLUSIONS: Dual inhibition of APE1 and autophagy greatly enhances apoptosis in parental KRASG12S-mutant A549 cells and cisplatin-resistant A549 cells via regulation of APE1-p53-LC3 complex assembly, providing therapeutic vulnerability to overcome cisplatin resistance in the context of KRASG12S-mutant lung cancer. Cisplatin 249-258 tumor protein p53 Homo sapiens 175-178 32695207-10 2020 Conclusion: Ginsenoside Rh1 alleviated HK-2 apoptosis in a cisplatin-induced injury model by inhibiting ROS production and the JNK/p53 pathway. Cisplatin 59-68 tumor protein p53 Homo sapiens 131-134 32630700-0 2020 The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis. Cisplatin 57-66 tumor protein p53 Homo sapiens 130-133 32533982-6 2020 In contrast, deactivating MAPK pathway by ZXF1 silencing enhanced cisplatin-induced cell cycle arrest and apoptosis by activating p53/p21 axis. Cisplatin 66-75 tumor protein p53 Homo sapiens 130-133 32881246-0 2020 Pioglitazone alleviates cisplatin nephrotoxicity by suppressing mitochondria-mediated apoptosis via SIRT1/p53 signalling. Cisplatin 24-33 tumor protein p53 Homo sapiens 106-109 32867831-0 2020 Boswellic acid sensitizes gastric cancer cells to Cisplatin-induced apoptosis via p53-mediated pathway. Cisplatin 50-59 tumor protein p53 Homo sapiens 82-85 32867831-1 2020 BACKGROUND: Cisplatin (CDDP) is an effective anticancer drug for Gastric cancer (GC) that induces apoptosis by altering pro- (p53) and anti-apoptotic (Akt and NFkB) proteins; however, chemoresistance remains a big challenge. Cisplatin 12-21 tumor protein p53 Homo sapiens 126-129 32867831-1 2020 BACKGROUND: Cisplatin (CDDP) is an effective anticancer drug for Gastric cancer (GC) that induces apoptosis by altering pro- (p53) and anti-apoptotic (Akt and NFkB) proteins; however, chemoresistance remains a big challenge. Cisplatin 23-27 tumor protein p53 Homo sapiens 126-129 32867831-4 2020 This study aimed to examine the effectiveness of AKBA on p53-mediated, CDDP-induced apoptosis in GC cells. Cisplatin 71-75 tumor protein p53 Homo sapiens 57-60 32867831-12 2020 CONCLUSIONS: Altogether, our findings suggest that AKBA enhances GC cell sensitivity to CDDP-induced apoptosis via the p53 pathway. Cisplatin 88-92 tumor protein p53 Homo sapiens 119-122 33040724-5 2020 The predictions were validated by studying cell metabolic response to the p53 inducer cisplatin. Cisplatin 86-95 tumor protein p53 Homo sapiens 74-77 33040724-6 2020 Expression of p53 and its known target, p21, has been evaluated in cisplatin-treated and control human lung adenocarcinoma A549 cells that possess functional p53 pathway. Cisplatin 67-76 tumor protein p53 Homo sapiens 14-17 33040724-6 2020 Expression of p53 and its known target, p21, has been evaluated in cisplatin-treated and control human lung adenocarcinoma A549 cells that possess functional p53 pathway. Cisplatin 67-76 tumor protein p53 Homo sapiens 158-161 33040724-8 2020 Along with upregulating the expression of p53 and p21, cisplatin affected the activities of metabolic enzymes, whose genes were predicted as carrying the p53-binding sites. Cisplatin 55-64 tumor protein p53 Homo sapiens 42-45 33040724-8 2020 Along with upregulating the expression of p53 and p21, cisplatin affected the activities of metabolic enzymes, whose genes were predicted as carrying the p53-binding sites. Cisplatin 55-64 tumor protein p53 Homo sapiens 154-157 32489467-9 2020 We observed that cisplatin regulates p53 stability through the depletion of ubiquitination following SIRT1 downregulation. Cisplatin 17-26 tumor protein p53 Homo sapiens 37-40 32512936-0 2020 A Co-Delivery System of Curcumin and p53 for Enhancing the Sensitivity of Drug-Resistant Ovarian Cancer Cells to Cisplatin. Cisplatin 113-122 tumor protein p53 Homo sapiens 37-40 32468080-8 2020 This correlated with differential upregulation of p53/p21 pathway, with S and G2/M arrests by cisplatin and satraplatin in contrast to G1 arrest by oxaliplatin and DAP. Cisplatin 94-103 tumor protein p53 Homo sapiens 50-53 32237195-5 2020 This compound is found to be highly cytotoxic: 5 to 60 times more potent than cisplatin towards ovarian (A2780 and A2780cisR), colon (HCT116 p53+/+ and HCT116 p53-/-), and non-small lung H460 cancer cell lines. Cisplatin 78-87 tumor protein p53 Homo sapiens 141-144 32237195-5 2020 This compound is found to be highly cytotoxic: 5 to 60 times more potent than cisplatin towards ovarian (A2780 and A2780cisR), colon (HCT116 p53+/+ and HCT116 p53-/-), and non-small lung H460 cancer cell lines. Cisplatin 78-87 tumor protein p53 Homo sapiens 159-162 32217375-0 2020 Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance. Cisplatin 109-118 tumor protein p53 Homo sapiens 75-78 32217375-3 2020 Moreover, 1 promoted the expression of p53 gene and protein more effectively than cisplatin, leading to the increased anticancer activity of 1 through p53 pathway. Cisplatin 82-91 tumor protein p53 Homo sapiens 39-42 32217375-3 2020 Moreover, 1 promoted the expression of p53 gene and protein more effectively than cisplatin, leading to the increased anticancer activity of 1 through p53 pathway. Cisplatin 82-91 tumor protein p53 Homo sapiens 151-154 32152233-7 2020 Given the prevalence of mutations in p53 and the PI3K pathways in HNSCC in conjunction with loss of p16 genetically or epigenetically, this universal increased sensitivity to cisplatin and BYL719 combination therapy in cancer cells with PIK3CA mutation represents an opportunity to a subset of HNSCC patients. Cisplatin 175-184 tumor protein p53 Homo sapiens 37-40 32466567-0 2020 Activation of Mitochondrial 2-Oxoglutarate Dehydrogenase by Cocarboxylase in Human Lung Adenocarcinoma Cells A549 Is p53/p21-Dependent and Impairs Cellular Redox State, Mimicking the Cisplatin Action. Cisplatin 183-192 tumor protein p53 Homo sapiens 117-120 32382008-0 2020 The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53. Cisplatin 29-38 tumor protein p53 Homo sapiens 98-101 32382008-6 2020 Furthermore, reintroducing either USP10 or HDAC6 into a USP10-knockdown NSCLC H1299 cell line with null-p53 renders cisplatin resistance. Cisplatin 116-125 tumor protein p53 Homo sapiens 104-107 32135156-2 2020 The current work provides further evidence of an autophagic switch, in this case in response to the antitumor drug, cisplatin, in non-small cell lung cancer cells that are either wild-type (p53wt) or functionally null in p53 (crp53), the latter generated using CRISPR/Cas9 technology. Cisplatin 116-125 tumor protein p53 Homo sapiens 190-193 32088177-5 2020 Mechanistically, BDMC attenuates cisplatin-induced apoptosis of renal tubular epithelial cells by inhibiting cisplatin-induced up-regulation of p53. Cisplatin 33-42 tumor protein p53 Homo sapiens 144-147 32088177-5 2020 Mechanistically, BDMC attenuates cisplatin-induced apoptosis of renal tubular epithelial cells by inhibiting cisplatin-induced up-regulation of p53. Cisplatin 109-118 tumor protein p53 Homo sapiens 144-147 32135156-5 2020 Specifically, autophagy inhibition in the crp53 cells converts the temporal profile for the loss of cell viability in response to cisplatin to essentially parallel that observed in the p53wt cells. Cisplatin 130-139 tumor protein p53 Homo sapiens 44-47 32135156-8 2020 Taken together, our current studies provide evidence that nonprotective autophagy in p53wt non-small cell lung cancer cells can be "switched" to protective autophagy in isogenic crp53 cells, and furthermore that inhibition of cytoprotective autophagy is sufficient to restore cisplatin sensitivity in the crp53 cells, largely through the increased promotion of apoptosis, despite the absence of functional p53. Cisplatin 276-285 tumor protein p53 Homo sapiens 85-88 32368398-0 2020 Cisplatin sensitivity mediated by NKX2-1 in lung adenocarcinoma is dependent on p53 mutational status via modulating TNFSF10 expression. Cisplatin 0-9 tumor protein p53 Homo sapiens 80-83 32211658-2 2020 Consequently, cisplatin inhibits the MDM2-mediated ubiquitination, which is the molecular basis of p53 activation. Cisplatin 14-23 tumor protein p53 Homo sapiens 99-102 32211658-3 2020 This work provides insight into the cisplatin-induced p53-elevation that is involved in cell apoptosis. Cisplatin 36-45 tumor protein p53 Homo sapiens 54-57 32355541-12 2020 Protein levels of the cell cycle regulators and senescence markers p21 and p53 showed opposite expression patterns in cisplatin-resistant compared with cisplatin sensitive cells. Cisplatin 118-127 tumor protein p53 Homo sapiens 75-78 32355541-12 2020 Protein levels of the cell cycle regulators and senescence markers p21 and p53 showed opposite expression patterns in cisplatin-resistant compared with cisplatin sensitive cells. Cisplatin 152-161 tumor protein p53 Homo sapiens 75-78 31935430-8 2020 Moreover, GATA3 acted as a regulator for macrophage polarization and interactions between TAMs and HGSOC to support proliferation, motility, and cisplatin chemoresistance in mutant TP53 HGSOC cell lines. Cisplatin 145-154 tumor protein p53 Homo sapiens 181-185 32368398-3 2020 We hypothesized that NKX2-1 may confer cisplatin resistance in p53-mutated (p53-MT) lung adenocarcinoma cells but may enhance cisplatin sensitivity in wild-type (p53-WT) cells. Cisplatin 39-48 tumor protein p53 Homo sapiens 63-66 32063580-2 2020 Cisplatin-resistant cells, however, can demonstrate increased binding of both MDM2 and MDM4 to p53 but in absence of cellular overexpression. Cisplatin 0-9 tumor protein p53 Homo sapiens 95-98 32052927-0 2020 LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling. Cisplatin 77-86 tumor protein p53 Homo sapiens 111-114 32063580-10 2020 In conclusion, Nutlin-3 fully destabilizes the p53-MDM2-MDM4 complex and synergizes with cisplatin to intensify p53 function, which then downregulates Rad51 through a bimodal mechanism. Cisplatin 89-98 tumor protein p53 Homo sapiens 112-115 32122297-10 2020 Interestingly, changes in the p53 pathway, ECM-receptor interactions, and cytokine-cytokine receptor interactions were induced by cisplatin only in Sirt2-deficient cells. Cisplatin 130-139 tumor protein p53 Homo sapiens 30-33 32731241-5 2020 Intestinal-type adenocarcinoma carrying a functional p53 protein may be treated with preoperative cisplatin, 5-fluorouracil, and leucovorin. Cisplatin 98-107 tumor protein p53 Homo sapiens 53-56 31841768-7 2020 We specifically discuss the roles of p53 in the development of chemoresistance to classical cytotoxic agents including for example cisplatin, doxorubicin, 5-fluorouracil, temozolomide, and paclitaxel. Cisplatin 131-140 tumor protein p53 Homo sapiens 37-40 32010177-8 2019 Suppression of SOCS1-STAT3-Bcl-2 pathway and activation of p53-Pten signaling both contribute to anti-miR-221/222-induced sensitivity to cisplatin in MDA-MB-231 cells. Cisplatin 137-146 tumor protein p53 Homo sapiens 59-62 31898732-10 2020 Conversely, SRPK2 silencing decreased cell migration and invasion and increased chemosensitivity to 5-fluorouracil or cisplatin, yet these effects could be reversed by p53 knockdown under chemical agent treatment. Cisplatin 118-127 tumor protein p53 Homo sapiens 168-171 31866582-0 2019 Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis. Cisplatin 100-109 tumor protein p53 Homo sapiens 142-145 32238696-0 2020 Pro-apoptotic functions of TRAF2 in p53-mediated apoptosis induced by cisplatin. Cisplatin 70-79 tumor protein p53 Homo sapiens 36-39 32238696-4 2020 In this study, we assessed the function of TRAF2 in DDR induced by cisplatin, a representative DNA-damaging agent, and found that TRAF2 exerts pro-apoptotic activity through p53-dependent mechanisms at least in human fibrosarcoma cell line HT1080. Cisplatin 67-76 tumor protein p53 Homo sapiens 174-177 32238696-6 2020 Moreover, cisplatin-induced JNK activation was attenuated in TRAF2-deficient cells, and pharmacological inhibition of JNK signaling suppressed p53 stabilization. Cisplatin 10-19 tumor protein p53 Homo sapiens 143-146 31866582-10 2019 Taken together, overexpression of METTL1 sensitized CR-CC cells to cisplatin by modulating miR-149-3p/S100A4/p53 axis. Cisplatin 67-76 tumor protein p53 Homo sapiens 109-112 31807162-13 2019 The results demonstrated that combined treatment of radiation and cisplatin exhibited superior therapeutic effects on osteosarcoma MG-63 cells compared with radiation or cisplatin treatment alone, which may be mediated by the BRCA1-p53 signaling pathway. Cisplatin 170-179 tumor protein p53 Homo sapiens 232-235 31541355-8 2019 Cisplatin + compound 4 significantly enhanced p53 phosphorylation, induced Bax amount, reduced Bcl2 protein levels, enhanced PARP cleavage and modulated miRNAs expression profile in TNBCs, with a particular overexpression of miR-125a-5p and miR-181a-5p. Cisplatin 0-9 tumor protein p53 Homo sapiens 46-49 31807162-0 2019 The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments. Cisplatin 26-35 tumor protein p53 Homo sapiens 116-119 31891063-5 2019 Chlorido drugs showed similar behavior to cisplatin; they both required p53 to induce apoptosis but only cis-ipa showed DNA damage requirement for apoptosis induction. Cisplatin 42-51 tumor protein p53 Homo sapiens 72-75 31706153-2 2019 It is well established that cisplatin alters the expression of many genes involved in several cellular processes and pathways including transcription, p53 signaling pathway, and apoptosis. Cisplatin 28-37 tumor protein p53 Homo sapiens 151-154 31781681-0 2019 Mutated p53 Promotes the Symmetric Self-Renewal of Cisplatin-Resistant Lung Cancer Stem-Like Cells and Inhibits the Recruitment of Macrophages. Cisplatin 51-60 tumor protein p53 Homo sapiens 8-11 31545555-3 2019 These complexes are 12 to 34x more potent than cisplatin against HCT116 p53+/+ and HCT116 p53-/- cells. Cisplatin 47-56 tumor protein p53 Homo sapiens 72-75 31703394-0 2019 HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cisplatin 40-49 tumor protein p53 Homo sapiens 76-79 31703394-10 2019 This was further confirmed by silencing of HDAC4, which favored cisplatin-induced apoptosis characterized by cleavage of caspase 3 and induction of proapoptotic genes, such as BIK, in part via a p53-dependent mechanism. Cisplatin 64-73 tumor protein p53 Homo sapiens 195-198 31486135-5 2019 We demonstrated that cisplatin (CDDP)-induced p53-mediated HKII downregulation is a determinant of chemosensitivity in OVCA. Cisplatin 21-30 tumor protein p53 Homo sapiens 46-49 31486135-5 2019 We demonstrated that cisplatin (CDDP)-induced p53-mediated HKII downregulation is a determinant of chemosensitivity in OVCA. Cisplatin 32-36 tumor protein p53 Homo sapiens 46-49 31807162-10 2019 Furthermore, combined treatment with radiation and cisplatin decreased the mRNA and protein expression levels of BRCA1 and p53. Cisplatin 51-60 tumor protein p53 Homo sapiens 123-126 31807162-11 2019 Additionally, combined treatment with radiation and cisplatin had a more potent inhibitory effect on p53 expression than on BRCA1 expression. Cisplatin 52-61 tumor protein p53 Homo sapiens 101-104 31807162-13 2019 The results demonstrated that combined treatment of radiation and cisplatin exhibited superior therapeutic effects on osteosarcoma MG-63 cells compared with radiation or cisplatin treatment alone, which may be mediated by the BRCA1-p53 signaling pathway. Cisplatin 66-75 tumor protein p53 Homo sapiens 232-235 31781681-4 2019 Cisplatin-resistant lung cancer cells with different TP53 backgrounds were generated in vitro by exposing A549, H460, and H661 lung cancer cell lines repeatedly to cisplatin. Cisplatin 0-9 tumor protein p53 Homo sapiens 53-57 31703757-0 2019 Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Cisplatin 54-63 tumor protein p53 Homo sapiens 84-87 31597912-0 2019 The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Cisplatin 86-95 tumor protein p53 Homo sapiens 32-35 31597912-7 2019 Thus, our data provide strong evidence that the crosstalk between STAT3 and p53/RAS signaling controls ovarian cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Cisplatin 138-147 tumor protein p53 Homo sapiens 76-79 31308060-10 2019 Combination of COTI-2 with cisplatin or radiation may be highly relevant in treating patients with HNSCC harboring TP53 mutations. Cisplatin 27-36 tumor protein p53 Homo sapiens 115-119 31148231-0 2019 p53 induces miR-199a-3p to suppress mechanistic target of rapamycin activation in cisplatin-induced acute kidney injury. Cisplatin 82-91 tumor protein p53 Homo sapiens 0-3 31148231-2 2019 For this issue, it is important to probe into the role of p53 in cisplatin-induced AKI. Cisplatin 65-74 tumor protein p53 Homo sapiens 58-61 31148231-8 2019 In conclusion, our findings reveal that p53, upregulating the expression of miR-199a-3p affects the progress of cisplatin-induced AKI, which might provide a promising therapeutic target of AKI. Cisplatin 112-121 tumor protein p53 Homo sapiens 40-43 31498788-4 2019 The model"s predictions, that a combination treatment of cisplatin and TRAIL would enhance cancer cell death and exhibit a "two-wave killing" temporal pattern, was validated by measuring the dynamics of p53 accumulation, cell fate, and cell death in single cells. Cisplatin 57-66 tumor protein p53 Homo sapiens 203-206 31538075-7 2019 In the CaSki cells, the p-ERK1/2 level decreased by 37%, the p53 expression level increased by 304%, and the cleaved caspase 3 level increased by 115% in the cisplatin+genistein group compared to that in the cisplatin group. Cisplatin 158-167 tumor protein p53 Homo sapiens 61-64 31088908-0 2019 HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Cisplatin 82-91 tumor protein p53 Homo sapiens 20-23 30918974-3 2019 COL17 was induced upon p53 activation by cisplatin in SAS; however, this effect was more limited in NA and hardly in Ca9-22 and Sa3, with mutated p53. Cisplatin 41-50 tumor protein p53 Homo sapiens 23-26 31336611-10 2019 Activation of DNA damage/repair factors (gammaH2AX, p53, and GADD45) in response to cisplatin was measured. Cisplatin 84-93 tumor protein p53 Homo sapiens 52-55 31323026-0 2019 Simulated microgravity enhances CDDP-induced apoptosis signal via p53-independent mechanisms in cancer cells. Cisplatin 32-36 tumor protein p53 Homo sapiens 66-69 31360122-2 2019 Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. Cisplatin 111-120 tumor protein p53 Homo sapiens 20-24 31360122-2 2019 Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. Cisplatin 122-126 tumor protein p53 Homo sapiens 20-24 31360122-10 2019 Results: We have demonstrated for the first time that activation of p53 sensitizes chemoresistant NSCLC cells to CDDP by down-regulating EGFR signaling pathway and promoting intracellular ROS production. Cisplatin 113-117 tumor protein p53 Homo sapiens 68-71 31360122-12 2019 Our findings suggest that CDDP-induced apoptosis in chemosensitive NSCLC cells involves p53 activation, leading to suppressed EGFR signaling and ROS production. Cisplatin 26-30 tumor protein p53 Homo sapiens 88-91 31360122-14 2019 Conclusion: Collectively, our study reveals that the interaction of the p53 and Akt feedback loops determine the fate of NSCLC cells and their CDDP sensitivity. Cisplatin 143-147 tumor protein p53 Homo sapiens 72-75 31323026-4 2019 Therefore, we aimed to clarify the molecular mechanisms of modified cis-diamminedichloroplatinum (CDDP)-sensitivity under simulated microgravity by focusing on p53-related cell death mechanisms. Cisplatin 68-96 tumor protein p53 Homo sapiens 160-163 31323026-9 2019 The CDDP-induced cleavage of caspase-3 was increased during the early phase in Group MG (+), and cleaved caspase-3 was detected even in Group MG (+) with constitutive expression of a mutant type of p53 (hereafter, "+" indicates CDDP treatment). Cisplatin 228-232 tumor protein p53 Homo sapiens 198-201 31323026-10 2019 These results interestingly indicate that microgravity altered CDDP sensitivity through activation of caspase-3 by p53-independent mechanism. Cisplatin 63-67 tumor protein p53 Homo sapiens 115-118 31323026-4 2019 Therefore, we aimed to clarify the molecular mechanisms of modified cis-diamminedichloroplatinum (CDDP)-sensitivity under simulated microgravity by focusing on p53-related cell death mechanisms. Cisplatin 98-102 tumor protein p53 Homo sapiens 160-163 31323026-5 2019 Immunoblotting analyses indicated that, under microgravity, CDDP-induced ATM/p53 signaling increased and caspase-3 was cleaved earlier. Cisplatin 60-64 tumor protein p53 Homo sapiens 77-80 31323026-9 2019 The CDDP-induced cleavage of caspase-3 was increased during the early phase in Group MG (+), and cleaved caspase-3 was detected even in Group MG (+) with constitutive expression of a mutant type of p53 (hereafter, "+" indicates CDDP treatment). Cisplatin 4-8 tumor protein p53 Homo sapiens 198-201 30770327-2 2019 The Lung Adjuvant Cisplatin Evaluation Biological Program group found adjuvant chemotherapy to be deleterious in patients with coexisting KRAS/TP53 mutations. Cisplatin 18-27 tumor protein p53 Homo sapiens 143-147 31138778-4 2019 Ectopic expression of ZCCHC10 in lung cancer cells harboring wild-type p53 dramatically suppresses cell proliferation, colony formation, migration, invasion and cisplatin resistance in vitro, as well as tumor growth and metastasis in vivo. Cisplatin 161-170 tumor protein p53 Homo sapiens 71-74 30862715-4 2019 We then performed a genome-wide CRISPR/Cas9 knockout screen in the TP53-null hESC in the presence and absence of sublethal concentrations of cisplatin and identified 137 genes whose loss selectively resensitized the p53-null cells to this chemotherapeutic agent. Cisplatin 141-150 tumor protein p53 Homo sapiens 216-219 30862715-6 2019 Moreover, we confirmed that targeting ZNF207/BuGZ sensitizes p53-null hESC to cisplatin. Cisplatin 78-87 tumor protein p53 Homo sapiens 61-64 31045925-5 2019 Sensitivity to cisplatin-based chemotherapy likely relies on intact TP53, reciprocal loss of heterozygosity, and high mitochondrial priming. Cisplatin 15-24 tumor protein p53 Homo sapiens 68-72 30445600-4 2019 In addition, TIPE1 promoted cell proliferation and suppressed cisplatin susceptibility in a p53-dependent manner, indicating that TIPE1 facilitates cervical cancer progression primarily through the p53 pathway. Cisplatin 62-71 tumor protein p53 Homo sapiens 92-95 30771522-5 2019 RESULTS: Inhibition of Chk1 synergized with cisplatin to induce mitotic cell death in the p53-deficeint SCLC cells. Cisplatin 44-53 tumor protein p53 Homo sapiens 90-93 31106145-7 2019 On the contrary, the sensitivity of cells to cisplatin was decreased after knockdown p53 or in p53 deletion NSCLC cells. Cisplatin 45-54 tumor protein p53 Homo sapiens 85-88 30885437-5 2019 Most importantly, in the cisplatin-resistance A549/DDP cells, this kind of agents could enter the nucleus obviously, and emerged a superior inhibitory and apoptotic effects than A549 via activating p53 protein and the related signaling pathways. Cisplatin 25-34 tumor protein p53 Homo sapiens 198-201 31106145-7 2019 On the contrary, the sensitivity of cells to cisplatin was decreased after knockdown p53 or in p53 deletion NSCLC cells. Cisplatin 45-54 tumor protein p53 Homo sapiens 95-98 31106145-9 2019 Taken together, our results demonstrate SMYD2 is involved into cisplatin resistance through regulating p53 pathway, and might become a promising therapeutic target for cisplatin resistance in NSCLC. Cisplatin 63-72 tumor protein p53 Homo sapiens 103-106 30538112-5 2019 RESULTS: We observe that loss of ERCC1 hypersensitizes cells to cisplatin when wild-type (WT) p53 is retained, whereas there is only modest sensitivity in cell lines that are p53mutant/null. Cisplatin 64-73 tumor protein p53 Homo sapiens 94-97 31023317-16 2019 CONCLUSION: Our findings demonstrate for the first time that Fn14 overcomes cisplatin resistance through modulation of the degradation of p53-R248Q and restoration of Fn14 expression might be a novel strategy for the treatment of HGSOC. Cisplatin 76-85 tumor protein p53 Homo sapiens 138-141 30827507-8 2019 Mechanistic analysis corroborated that depression of PACT notably enhanced cisplatin-induced p53 expression, concomitant with the increases in p53-downstream Bax, p21 expression and decrease in Bcl-2 expression. Cisplatin 75-84 tumor protein p53 Homo sapiens 93-96 30827507-9 2019 Intriguingly, blocking the p53 pathway notably reversed PACT inhibition-increased cell sensitivity to cisplatin in A2780 cells by elevating cell viability and depressing cell apoptosis. Cisplatin 102-111 tumor protein p53 Homo sapiens 27-30 30827507-10 2019 Additionally, abrogation of p53 signaling also blunts PACT suppression-overcomed chemotherapy resistance to cisplatin in A2780/CP cells. Cisplatin 108-117 tumor protein p53 Homo sapiens 28-31 30144378-8 2019 Both ADP and cisplatin increased p53 protein, but ADP was also able to enhance p53 messenger RNA. Cisplatin 13-22 tumor protein p53 Homo sapiens 33-36 30728154-2 2019 It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.See related article by Heyza et al., p. 2523. Cisplatin 107-116 tumor protein p53 Homo sapiens 30-33 30144378-8 2019 Both ADP and cisplatin increased p53 protein, but ADP was also able to enhance p53 messenger RNA. Cisplatin 13-22 tumor protein p53 Homo sapiens 79-82 30144378-9 2019 P53 silencing resulted in a very large decrement of cell death induced by ADP or by cisplatin and reverted ADP effects on mTOR/S6K phosphorylation, suggesting that activated p53 may act as a negative regulator of mTOR. Cisplatin 84-93 tumor protein p53 Homo sapiens 0-3 30144378-9 2019 P53 silencing resulted in a very large decrement of cell death induced by ADP or by cisplatin and reverted ADP effects on mTOR/S6K phosphorylation, suggesting that activated p53 may act as a negative regulator of mTOR. Cisplatin 84-93 tumor protein p53 Homo sapiens 174-177 30690027-9 2019 In this study, we observed an enhanced DNA damage and cellular apoptosis via the ATM/CHK2/P53 pathway(s) in HeLa and SiHa cells treated with cisplatin combined with DAPT of Notch1 inhibitor. Cisplatin 141-150 tumor protein p53 Homo sapiens 90-93 30841620-0 2019 Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma. Cisplatin 0-9 tumor protein p53 Homo sapiens 97-100 30841620-8 2019 In conclusion, cisplatin synergistically increased the tumor-killing of CRAd by (1) increasing CRAd transduction via enhanced CAR expression and (2) increasing p53 dependent or independent apoptosis of lung cancer cell lines. Cisplatin 15-24 tumor protein p53 Homo sapiens 160-163 30723502-5 2019 The presence of R273H-P53 conferred the cancer cells with drug resistance not only against the widely used chemotherapeutic agents like cisplatin (CDDP) or 5-flurouracil (5-FU) but also against potent alternative modes of therapy like proteasomal inhibition. Cisplatin 136-145 tumor protein p53 Homo sapiens 22-25 30675226-0 2019 MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53. Cisplatin 60-69 tumor protein p53 Homo sapiens 83-86 30675226-12 2019 These results indicate that miR-504 contributes to cisplatin resistance in MG63 osteosarcoma cells by suppressing p53. Cisplatin 51-60 tumor protein p53 Homo sapiens 114-117 31933859-5 2019 Finally, c-MYC, OCT4 and p53 were determined to contribute to the transcriptional regulation of NEAT1.1 under cisplatin using ChIP assay. Cisplatin 110-119 tumor protein p53 Homo sapiens 25-28 31933864-12 2019 CONCLUSION: Our study clarified that OGF inhibits cell migration and proliferation of HCC in animal experiments and that exogenous OGF enhances the anti-tumor activity of cisplatin on HCC by upregulating p21 and p53. Cisplatin 171-180 tumor protein p53 Homo sapiens 212-215 30478746-1 2019 The purpose of this study was to evaluate the synergistic apoptotic effect of CKD-602 in combination with cisplatin on different p53 statuses of oral squamous cell carcinoma (OSCC) cell lines, YD-8, YD-9, and YD-38. Cisplatin 106-115 tumor protein p53 Homo sapiens 129-132 30867818-0 2019 Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1alpha-mediated regulation of apoptosis and autophagy. Cisplatin 51-60 tumor protein p53 Homo sapiens 20-23 30867818-15 2019 Conclusion: HIF-1alpha and HDAC4 may mediate the interaction between p53 and RAS signaling to actively control ovarian cancer cisplatin resistance through dysregulation of apoptosis and autophagy. Cisplatin 126-135 tumor protein p53 Homo sapiens 69-72 30723502-5 2019 The presence of R273H-P53 conferred the cancer cells with drug resistance not only against the widely used chemotherapeutic agents like cisplatin (CDDP) or 5-flurouracil (5-FU) but also against potent alternative modes of therapy like proteasomal inhibition. Cisplatin 147-151 tumor protein p53 Homo sapiens 22-25 30447351-0 2019 N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation. Cisplatin 29-38 tumor protein p53 Homo sapiens 128-131 30755813-4 2019 Cisplatin, a DNA damaging agent, induced cleavages of PARP and caspase-3 without increase of p53 levels, indicating that the p53 down-stream pathway was disrupted in these cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 125-128 30446605-0 2018 Withdrawal: Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. Cisplatin 82-91 tumor protein p53 Homo sapiens 133-136 31089357-0 2019 Sensitization of Resistance Ovarian Cancer Cells to Cisplatin by Biogenic Synthesized Silver Nanoparticles through p53 Activation. Cisplatin 52-61 tumor protein p53 Homo sapiens 115-118 30480671-5 2018 The complexes that were most active, with sub-micromolar IC50 (72 h) values against HCT116wt cells, that is 8b, 9b, 10a-c, worked by a mode of action that was dependent on the functional p53, yet were still far more active than cisplatin in both of the HCT116wt and HCT116-/- variants. Cisplatin 228-237 tumor protein p53 Homo sapiens 187-190 31089357-12 2019 The combined use of cAgNPs and cisplatin resulted in upregulated expression of p53 gene and downregulated expression of MPP-9 gene. Cisplatin 31-40 tumor protein p53 Homo sapiens 79-82 30375398-0 2018 The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cisplatin 4-13 tumor protein p53 Homo sapiens 113-116 29970902-2 2018 P53-like muscle-invasive bladder cancers are generally resistant to cisplatin-based chemotherapy, but exhibit heterogeneous clinical outcomes with a prognosis intermediate to that of the luminal and basal subtypes. Cisplatin 68-77 tumor protein p53 Homo sapiens 0-3 30375398-7 2018 Further investigation revealed that PANDAR-reduced cisplatin sensitivity was likely or partly due to the PANDAR-binding protein SFRS2 (arginine/serine-rich 2), a splicing factor with the ability to negative regulate p53 and its phosphorylation at Serine 15 (Ser15). Cisplatin 51-60 tumor protein p53 Homo sapiens 216-219 30375398-3 2018 In this study, we report that PANDAR serves as a negative regulator of cisplatin sensitivity in human ovarian cancer via PANDAR-SRFS2-p53 feedback regulation in nuclear. Cisplatin 71-80 tumor protein p53 Homo sapiens 134-137 30197676-2 2018 RBEL1A may block the transcriptional activity of p53, which is important in the induction of cisplatin sensitivity. Cisplatin 93-102 tumor protein p53 Homo sapiens 49-52 30443171-7 2018 In addition, cisplatin significantly upregulated ATF3, phospho-P53(ser46), and cleaved caspase 3 expression in lung cancer cells, but overexpression of NDRG1 in the presence of cisplatin reduced the level of these proteins elevated by cisplatin (P < 0.05). Cisplatin 13-22 tumor protein p53 Homo sapiens 63-66 30410558-4 2018 We found that the combined use of A549/DDP cells with SFI and cisplatin enhanced cell cycle arrested in the G2/M phase, which was accompanied by upregulation of p53 and p21 protein expression and induced mitochondrial apoptosis in conjunction with the upregulation of Bax and the downregulation of Bcl-2 protein expression. Cisplatin 62-71 tumor protein p53 Homo sapiens 161-164 30197676-6 2018 Consistent with previous studies, the present study demonstrated that cisplatin treatment and RBEL1A overexpression blocked the oligomerization of p53 in MCF-7 cells and led to a decrease of the transcriptional activity of p53 and its downstream target gene p21. Cisplatin 70-79 tumor protein p53 Homo sapiens 147-150 30197676-6 2018 Consistent with previous studies, the present study demonstrated that cisplatin treatment and RBEL1A overexpression blocked the oligomerization of p53 in MCF-7 cells and led to a decrease of the transcriptional activity of p53 and its downstream target gene p21. Cisplatin 70-79 tumor protein p53 Homo sapiens 223-226 30197676-11 2018 Taken together, these results suggest that the induction of RBEL1A following cisplatin treatment may partially inhibit chemosensitivity in a p53-dependent manner. Cisplatin 77-86 tumor protein p53 Homo sapiens 141-144 29963152-6 2018 Expression of the apoptosis-related gene TP53 and caspase 3 activation were enhanced in cisplatin-treated U251 cells. Cisplatin 88-97 tumor protein p53 Homo sapiens 41-45 30142917-6 2018 We have shown that Resv induces sensitivity to CDDP in MCF-7 and MCF-7R cells and that the downregulation of p53 protein expression and inhibition of p53 protein activity enhances resistance to CDDP in both cell lines. Cisplatin 194-198 tumor protein p53 Homo sapiens 109-112 30142917-6 2018 We have shown that Resv induces sensitivity to CDDP in MCF-7 and MCF-7R cells and that the downregulation of p53 protein expression and inhibition of p53 protein activity enhances resistance to CDDP in both cell lines. Cisplatin 194-198 tumor protein p53 Homo sapiens 150-153 30142917-9 2018 Interestingly, Resv attenuates CDDP-induced p53 phosphorylation in serine 15 (S15) and serine 46 (S46) probably through dephosphorylation and deactivation of ATM. Cisplatin 31-35 tumor protein p53 Homo sapiens 44-47 30142917-10 2018 It also activates different kinases, such as CK1, CHK2, and AMPK to induce phosphorylation of p53 in S20, suggesting a novel mechanism of p53 activation and chemosensitization to CDDP. Cisplatin 179-183 tumor protein p53 Homo sapiens 94-97 30142917-10 2018 It also activates different kinases, such as CK1, CHK2, and AMPK to induce phosphorylation of p53 in S20, suggesting a novel mechanism of p53 activation and chemosensitization to CDDP. Cisplatin 179-183 tumor protein p53 Homo sapiens 138-141 29980405-5 2018 Upon introduction of the WT-TP53 gene into the MIA-PaCa-2 pancreatic cancer cell line, the sensitivity to drugs used to treat pancreatic cancer cells such as: gemcitabine, fluorouracil (5FU), cisplatin, irinotecan, oxaliplatin, and paclitaxel increased significantly. Cisplatin 192-201 tumor protein p53 Homo sapiens 28-32 30064446-15 2018 shRNA p53 reversed TNFAIP8 shRNA-mediated regulation of cell proliferation, cell cycle, cisplatin sensitivity, and expression levels of RAD51, a DNA repair gene. Cisplatin 88-97 tumor protein p53 Homo sapiens 6-9 30064446-16 2018 CONCLUSION: Our work uncovers a hitherto unappreciated role of TNFAIP8 in NSCLC proliferation and cisplatin chemoresistance that is mediated through the MDM2/p53 pathway. Cisplatin 98-107 tumor protein p53 Homo sapiens 158-161 30142917-0 2018 Induction of p53 Phosphorylation at Serine 20 by Resveratrol Is Required to Activate p53 Target Genes, Restoring Apoptosis in MCF-7 Cells Resistant to Cisplatin. Cisplatin 151-160 tumor protein p53 Homo sapiens 13-16 29971135-0 2018 Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1alpha in non-small cell lung cancer A549 cells. Cisplatin 25-34 tumor protein p53 Homo sapiens 71-74 29971135-4 2018 In the present study, the effects of hypoxia on the response of the NSCLC A549 cell line to the clinically relevant cytotoxic cisplatin were evaluated via regulating hypoxia inducible facor-1alpha (HIF-1alpha) and p53. Cisplatin 126-135 tumor protein p53 Homo sapiens 214-217 29971135-8 2018 As a result, activated p53 desensitized A549 cells to cisplatin potentially through increasing the non-proliferation status of A549 cells and therefore minimizing the influence of cisplatin. Cisplatin 54-63 tumor protein p53 Homo sapiens 23-26 29971135-8 2018 As a result, activated p53 desensitized A549 cells to cisplatin potentially through increasing the non-proliferation status of A549 cells and therefore minimizing the influence of cisplatin. Cisplatin 180-189 tumor protein p53 Homo sapiens 23-26 29971135-9 2018 Taken together, these results identified the exact effects of HIF-1alpha and p53 induced by hypoxia and potentially elucidated their protective effects on A549 cells against cisplatin. Cisplatin 174-183 tumor protein p53 Homo sapiens 77-80 29928326-8 2018 The results of the present study demonstrated that miltirone induces apoptosis in cisplatin-resistant lung cancer cells through ROS-p53, AIF, PARP and MMP2/9 signaling pathways. Cisplatin 82-91 tumor protein p53 Homo sapiens 132-135 29772519-2 2018 The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). Cisplatin 53-62 tumor protein p53 Homo sapiens 91-94 29352505-0 2018 p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells. Cisplatin 34-43 tumor protein p53 Homo sapiens 0-3 29352505-5 2018 Here, we show that the upregulation of Noxa is critical for cisplatin-induced apoptosis in p53-null HNSCC cells. Cisplatin 60-69 tumor protein p53 Homo sapiens 91-94 29352505-11 2018 In conclusion, ATF3 and ATF4 are important regulators that induce Noxa by cisplatin treatment in a p53-independent manner. Cisplatin 74-83 tumor protein p53 Homo sapiens 99-102 29928326-0 2018 Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways. Cisplatin 31-40 tumor protein p53 Homo sapiens 93-96 29697201-0 2018 Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. Cisplatin 19-28 tumor protein p53 Homo sapiens 96-99 29684847-5 2018 RESULTS: Cell lines and tumor cells p53+, p53- revealed a significant decrease in cell survival after camptothecin, paclitaxel, cisplatin treatment, compared to the control group (p < 0.01). Cisplatin 128-137 tumor protein p53 Homo sapiens 36-39 29684847-5 2018 RESULTS: Cell lines and tumor cells p53+, p53- revealed a significant decrease in cell survival after camptothecin, paclitaxel, cisplatin treatment, compared to the control group (p < 0.01). Cisplatin 128-137 tumor protein p53 Homo sapiens 42-45 29542252-7 2018 We subsequently showed that USP4 regulated cisplatin-induced cell apoptosis via p53 signalling. Cisplatin 43-52 tumor protein p53 Homo sapiens 80-83 29899847-5 2018 Furthermore, the inhibitors increased the endogenous p53 levels that were induced by cisplatin. Cisplatin 85-94 tumor protein p53 Homo sapiens 53-56 29690507-0 2018 Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1alpha and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. Cisplatin 16-25 tumor protein p53 Homo sapiens 110-113 29690507-3 2018 This study focusses on the role of hypoxia-inducible factor-1&alpha; (HIF-1&alpha;) and the p53 tumor suppressor protein in hypoxia-induced cisplatin resistance in non-small cell lung cancer (NSCLC) cells and the potential of APR-246 to overcome this resistance. Cisplatin 148-157 tumor protein p53 Homo sapiens 100-103 29690507-4 2018 We observed that hypoxia-induced cisplatin resistance only occurred in the p53 mutant NCI-H2228Q331* cell line, and not in the wild type A549 and mutant NCI-H1975R273H cell lines. Cisplatin 33-42 tumor protein p53 Homo sapiens 75-78 29690507-5 2018 Cisplatin reduced HIF-1&alpha; protein levels in NCI-H2228Q331* cells, leading to a shift in expression from HIF-1&alpha;-dependent to p53-dependent transcription targets under hypoxia. Cisplatin 0-9 tumor protein p53 Homo sapiens 143-146 29690507-8 2018 Our data further support the rationale of combining APR-246 with cisplatin in NSCLC, since their synergistic interaction is retained or enforced under hypoxic conditions in the presence of mutant p53. Cisplatin 65-74 tumor protein p53 Homo sapiens 196-199 29471006-5 2018 Astilbin significantly decreased reactive oxygen species (ROS) accumulation and alleviated ROS-induced activation of p53, MAPKs and AKT signaling cascades, which in turn attenuated cisplatin-induced HEK-293 cell apoptosis. Cisplatin 181-190 tumor protein p53 Homo sapiens 117-120 28577130-0 2018 Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation. Cisplatin 12-21 tumor protein p53 Homo sapiens 162-166 29393335-5 2018 Additionally, the mechanism underlying the cis-DDP-induced apoptosis was indicated to involve the activation of p53, c-Jun-N-terminal kinase (JNK) and p38 signaling. Cisplatin 43-50 tumor protein p53 Homo sapiens 112-115 29196192-7 2018 Moreover, macrovipecetin alone or combined with cisplatin induced the expression of TRADD, p53, Bax, Bim and Bad and down-regulated the Bcl-2 expression and ROS levels in SK-MEL-28 cells. Cisplatin 48-57 tumor protein p53 Homo sapiens 91-94 29471073-4 2018 We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Cisplatin 173-182 tumor protein p53 Homo sapiens 158-161 29345296-10 2018 The decrease in the VEGF-A level following incubation with cisplatin correlated with a higher p53 protein expression, while no such correlation was observed following treatment of the A549 cells with sunitinib. Cisplatin 59-68 tumor protein p53 Homo sapiens 94-97 29487530-0 2018 Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways. Cisplatin 22-31 tumor protein p53 Homo sapiens 135-138 29487530-5 2018 Mechanistic analyses indicated that cisplatin-induced caspase-3-dependent apoptosis was elevated in the presence of scutellarin through activating extracellular signal-regulated kinases (ERK)-mediated p53 pathway. Cisplatin 36-45 tumor protein p53 Homo sapiens 201-204 29397938-4 2018 In human osteosarcoma cell line U2OS cells, DRAK1 was mainly localized in the nucleus and translocated outside the nucleus through Ser395 phosphorylation by protein kinase C. In the nucleus, DRAK1 associated with tumor suppressor p53 and positively regulated p53 transcriptional activity in response to DNA-damaging agent cisplatin. Cisplatin 322-331 tumor protein p53 Homo sapiens 230-233 29348517-4 2018 In this study, we investigated the role of NDRG2 in chemo-sensitivity, focusing on cisplatin in U937 histiocytic lymphoma, which has the loss-of-functional mutation in p53. Cisplatin 83-92 tumor protein p53 Homo sapiens 168-171 29307819-0 2018 Absence of REV3L promotes p53-regulated cancer cell metabolism in cisplatin-treated lung carcinoma cells. Cisplatin 66-75 tumor protein p53 Homo sapiens 26-29 29307819-2 2018 The use of low fidelity DNA polymerases in the translesional synthesis (TLS) DNA damage response pathway that repairs lesions caused by cisplatin also presents a mutational carcinogenic burden on cells that needs to be regulated by the tumor suppressor protein p53. Cisplatin 136-145 tumor protein p53 Homo sapiens 261-264 29307819-4 2018 In this study, the fluorescence lifetime of the metabolic coenzyme NADH reveals that the absence of REV3L can promote the p53-mediated upregulation of oxidative phosphorylation in cisplatin-treated H1299 lung carcinoma cells and increases cancer cell sensitivity to this platinum-based chemotherapy. Cisplatin 180-189 tumor protein p53 Homo sapiens 122-125 29307819-5 2018 These results demonstrate a previously unrecognized relationship between p53 and REV3L in cancer cell metabolism and may lead to improvements in chemotherapy treatment plans that reduce cisplatin resistance in lung cancer. Cisplatin 186-195 tumor protein p53 Homo sapiens 73-76 29493466-8 2018 Drug interactions showed dissimilar results with antagonistic effects with any drug combination in MCF-7 and clear synergic interactions between both PLK1 inhibitors and cisplatin, temozolomide or doxorubicin in Hs578T, which is TP53 mutated. Cisplatin 170-179 tumor protein p53 Homo sapiens 229-233 29039478-6 2017 Cisplatin induced eIF2alpha phosphorylation as well as p53 activation. Cisplatin 0-9 tumor protein p53 Homo sapiens 55-58 28287251-0 2018 Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals. Cisplatin 0-9 tumor protein p53 Homo sapiens 80-83 28287251-7 2018 The results shown that treatment of A2780s cells with CDDP (3 mug/ml) for 6-24h induced apoptosis, resulting in the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and accumulation of p53 and PUMA (p53 upregulated modulator of apoptosis) protein. Cisplatin 54-58 tumor protein p53 Homo sapiens 201-204 28287251-7 2018 The results shown that treatment of A2780s cells with CDDP (3 mug/ml) for 6-24h induced apoptosis, resulting in the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and accumulation of p53 and PUMA (p53 upregulated modulator of apoptosis) protein. Cisplatin 54-58 tumor protein p53 Homo sapiens 215-218 28287251-8 2018 Knockdown of P53 or PUMA by siRNA transfection blocked CDDP-induced apoptosis. Cisplatin 55-59 tumor protein p53 Homo sapiens 13-16 28884479-8 2018 Moreover, the p53-HDAC1-mSin3a repressive complex also involved in the inhibition of Aurora-A gene expression upon cisplatin treatment. Cisplatin 115-124 tumor protein p53 Homo sapiens 14-17 28287251-9 2018 Inhibition of ERK1/2 using PD98059, a selective MEK inhibitor, blocked the apoptotic cell death but prevented CDDP-induced accumulation of p53 and PUMA. Cisplatin 110-114 tumor protein p53 Homo sapiens 139-142 28287251-10 2018 Knockdown of P53 by siRNA transfection also blocked CDDP-induced accumulation of PUMA. Cisplatin 52-56 tumor protein p53 Homo sapiens 13-16 28287251-11 2018 We therefore concluded that CDDP activated ERK1/2 and induced-p53-dependent PUMA upregulation, resulting in triggering apoptosis in A2780s cells. Cisplatin 28-32 tumor protein p53 Homo sapiens 62-65 28287251-12 2018 Our study clearly demonstrates that the ERK1/2/p53/PUMA axis is related to CDDP-induced cell death in A2780s cells. Cisplatin 75-79 tumor protein p53 Homo sapiens 47-50 29039478-0 2017 Phosphorylation of eIF2alpha suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in human renal proximal tubular cells. Cisplatin 40-49 tumor protein p53 Homo sapiens 58-61 29039478-3 2017 It has been suggested that oxidative stress and p53 activation play important roles in cisplatin-induced nephrotoxicity. Cisplatin 87-96 tumor protein p53 Homo sapiens 48-51 29039478-8 2017 Of note, Sal003-mediated upregulation of eIF2alpha phosphorylation suppressed cisplatin-induced p53 activation. Cisplatin 78-87 tumor protein p53 Homo sapiens 96-99 29039478-9 2017 Furthermore, reduction of eIF2alpha phosphorylation by PERK knockdown enhanced cisplatin-induced p53 activation and apoptosis. Cisplatin 79-88 tumor protein p53 Homo sapiens 97-100 29039478-12 2017 Taken together, these results suggest that phosphorylation of eIF2alpha suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in HK-2 cells, as ATF4 expression is usually dependent on the phosphorylation of eIF2alpha and may also transcriptionally induce the expression of HO-1 in response to oxidative stress. Cisplatin 83-92 tumor protein p53 Homo sapiens 101-104 29161238-0 2017 Downregulation of Inhibition of Apoptosis-Stimulating Protein of p53 (iASPP) Suppresses Cisplatin-Resistant Gastric Carcinoma In Vitro. Cisplatin 88-97 tumor protein p53 Homo sapiens 65-68 29039558-0 2017 Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation. Cisplatin 28-37 tumor protein p53 Homo sapiens 88-91 29296177-0 2017 ISG15 silencing increases cisplatin resistance via activating p53-mediated cell DNA repair. Cisplatin 26-35 tumor protein p53 Homo sapiens 62-65 29093644-0 2017 Synergistic anticancer effect of combined crocetin and cisplatin on KYSE-150 cells via p53/p21 pathway. Cisplatin 55-64 tumor protein p53 Homo sapiens 87-90 28867193-7 2017 Our results indicate that TRIM25 is associated with cisplatin resistance and 14-3-3sigma-MDM2-p53 signaling pathway is involved in this process, suggesting targeting TRIM25 may be a potential strategy for the reversal of cisplatin resistance. Cisplatin 221-230 tumor protein p53 Homo sapiens 94-97 29093644-14 2017 The wild-type p53 inhibitor, PFT-alpha suppressed the overexpression of p53/p21 and the synergistic effect induced by the combination of crocetin and cisplatin. Cisplatin 150-159 tumor protein p53 Homo sapiens 72-75 28696156-4 2017 In this study we isolated cisplatin-resistant clones from MHM cells, an MDM2-amplified and p53 wild-type osteosarcoma cell line. Cisplatin 26-35 tumor protein p53 Homo sapiens 91-94 28944886-9 2017 In addition, the results demonstrated that even at the lowest concentrations (5 microM), SFN increased the sensitivity of p53-proficient HCT-116 cells to cisplatin. Cisplatin 154-163 tumor protein p53 Homo sapiens 122-125 29093644-15 2017 Conclusions: We concluded that crocetin combined with cisplatin exerts a synergistic anticancer effect by up-regulating the p53/p21 pathway. Cisplatin 54-63 tumor protein p53 Homo sapiens 124-127 29093644-14 2017 The wild-type p53 inhibitor, PFT-alpha suppressed the overexpression of p53/p21 and the synergistic effect induced by the combination of crocetin and cisplatin. Cisplatin 150-159 tumor protein p53 Homo sapiens 14-17 28756530-0 2017 Intricatinol synergistically enhances the anticancerous activity of cisplatin in human A549 cells via p38 MAPK/p53 signalling. Cisplatin 68-77 tumor protein p53 Homo sapiens 111-114 28767065-4 2017 Herein we report similar observations with cancer cell lines expressing wild-type p53 (A549 lung carcinoma) or mutant p53 (MDA-MB-231 breast carcinoma) after treatment with the chemotherapeutic drug cisplatin. Cisplatin 199-208 tumor protein p53 Homo sapiens 82-85 28291626-7 2017 Mus81 knockdown also induced S phase arrest and elevated apoptosis in CDDP treated HCT116 cells through activating CHK1/CDC25A/CDK2 and CHK1/p53/Bax pathways, while these effects could be counteracted by CHK1 inhibition. Cisplatin 70-74 tumor protein p53 Homo sapiens 141-144 28888100-5 2017 In contrast to their wt counterparts, the p53- or p21-deficient cells treated with SCH900776 and cisplatin or LA-12 enter mitosis and become polyploid, and the senescence phenotype is strongly suppressed. Cisplatin 97-106 tumor protein p53 Homo sapiens 42-45 28878262-0 2017 Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma. Cisplatin 30-39 tumor protein p53 Homo sapiens 69-72 28878262-7 2017 Gene manipulation studies revealed that O-GlcNAcylation of p53/c-Myc is in part a regulator of CDDP-induced apoptosis. Cisplatin 95-99 tumor protein p53 Homo sapiens 59-62 28878262-8 2017 Accordingly, we classified CDDP resistance by hyper-O-GlcNAcylation in lung carcinoma cells as either p53 or c-Myc dependence based on their molecular targets. Cisplatin 27-31 tumor protein p53 Homo sapiens 102-105 28214344-5 2017 Furthermore our results revealed that neferine combined with cisplatin down regulate the expression of Bcl-2 and up regulate the expression of Bax, Bad, Bak, release of cytochrome c, p53 levels, then activated cleavage forms of caspase-9, caspase-3, and PARP. Cisplatin 61-70 tumor protein p53 Homo sapiens 183-186 28796811-4 2017 Nonetheless, early single peak of ROS formation along with lysosomal membrane permeabilization and cathepsin activation regulated cisplatin- and UV-induced necrosis in p53-null HCT-116 cells. Cisplatin 130-139 tumor protein p53 Homo sapiens 168-171 28789701-7 2017 Ad5/F11p-PSCAE-UPII-E1A plus cisplatin could upregulate the proteins expression of p53, Bax, and cleaved caspase-3, and downregulated Bcl-2 protein expression in T24, EJ and 5637 cells. Cisplatin 29-38 tumor protein p53 Homo sapiens 83-86 28843398-5 2017 Compared to the E6/E7 SP alone, E6/E7 SP with cisplatin treatment effectively restored TP53 and RB/E2F signaling and contributes to differences in cell fate, such as apoptosis or cell cycle arrest. Cisplatin 46-55 tumor protein p53 Homo sapiens 87-91 28886730-0 2017 Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. Cisplatin 26-35 tumor protein p53 Homo sapiens 68-71 28886730-11 2017 CONCLUSIONS: These data suggested that Annexin A2 induces cisplatin resistance of NSCLCs via regulation of JNK/c-Jun/p53 signaling, and provided an evidence that blockade of Annexin A2 could serve as a novel therapeutic approach for overcoming drug resistance in NSCLCs. Cisplatin 58-67 tumor protein p53 Homo sapiens 117-120 29084683-8 2017 The treatment of crocin plus cisplatin significantly increased the expression of p53 and Bax (p< 0.05), and significantly decreased the Bcl-2 expression (p<0.05). Cisplatin 29-38 tumor protein p53 Homo sapiens 81-84 28686074-4 2017 Increased levels of phosphorylated ATM (p-ATM) and its downstream molecules, CHK2, p-CHK2, p-53, and p-p53 were also detected in cisplatin-resistant cells, suggesting an activation of ATM signaling in these cells. Cisplatin 129-138 tumor protein p53 Homo sapiens 91-95 28686074-4 2017 Increased levels of phosphorylated ATM (p-ATM) and its downstream molecules, CHK2, p-CHK2, p-53, and p-p53 were also detected in cisplatin-resistant cells, suggesting an activation of ATM signaling in these cells. Cisplatin 129-138 tumor protein p53 Homo sapiens 103-106 28767065-4 2017 Herein we report similar observations with cancer cell lines expressing wild-type p53 (A549 lung carcinoma) or mutant p53 (MDA-MB-231 breast carcinoma) after treatment with the chemotherapeutic drug cisplatin. Cisplatin 199-208 tumor protein p53 Homo sapiens 118-121 29137250-4 2017 This chaperone-mediated mutated p53-TAp73alpha complex induced chemoresistance to DNA damaging reagents, like Cisplatin, Doxorubicin, Etoposide or Camptothecin. Cisplatin 110-119 tumor protein p53 Homo sapiens 32-35 28446729-0 2017 WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas. Cisplatin 18-27 tumor protein p53 Homo sapiens 53-56 28446729-4 2017 After being combined with WP1130, cisplatin sensitivity was significantly increased in A549 and HCC827 cells with decreased p53 expression, inhibiting their proliferation, but not in p53-deficient NCI-H1299 cells. Cisplatin 34-43 tumor protein p53 Homo sapiens 124-127 28446729-5 2017 The synergistic cytotoxicity of the cisplatin and WP1130 co-treatment was abolished in p53-knockdown cells. Cisplatin 36-45 tumor protein p53 Homo sapiens 87-90 28446729-6 2017 Western blotting verified the decreased p53 expression in A549 and HCC827 cells treated with cisplatin and WP1130. Cisplatin 93-102 tumor protein p53 Homo sapiens 40-43 28446729-8 2017 Taken together, our findings confirm that the inclusion of WP1130 is potentially contributes to better therapeutic effects of cisplatin-based chemotherapy of NSCLCs in a manner dependent on the USP9X-p53 ubiquitination-mediated degradation pathway. Cisplatin 126-135 tumor protein p53 Homo sapiens 200-203 28155807-11 2017 In conclusion, cisplatin affects the viability, proliferation, and differentiation of ADSCs both in vitro and in vivo via certain signaling pathways, such as p53 and Fas/FasL. Cisplatin 15-24 tumor protein p53 Homo sapiens 158-161 28535155-7 2017 The continued expression of APOBEC3B in p53-defective cells not only caused a kataegic mutational signature but also caused hypersensitivity to small-molecule DDR inhibitors (ATR, CHEK1, CHEK2, PARP, WEE1 inhibitors) as well as cisplatin/ATR inhibitor and ATR/PARP inhibitor combinations. Cisplatin 228-237 tumor protein p53 Homo sapiens 40-43 28315428-0 2017 p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells. Cisplatin 67-76 tumor protein p53 Homo sapiens 0-3 28427506-6 2017 Response to adjuvant cisplatin-based chemotherapy appears to be related to basal, luminal, and p53-like intrinsic subtypes. Cisplatin 21-30 tumor protein p53 Homo sapiens 95-98 28678322-0 2017 Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Cisplatin 52-61 tumor protein p53 Homo sapiens 127-130 28588727-11 2017 The expression of p53 was increased in the combined PE and CDDP treatment group. Cisplatin 59-63 tumor protein p53 Homo sapiens 18-21 28588727-12 2017 Upregulation of p53-dependent apoptosis-associated proteins, including Bcl-2-associated X protein and cleaved caspases-9 and -3, was observed in the combined PE and CDDP treatment group. Cisplatin 165-169 tumor protein p53 Homo sapiens 16-19 28412363-7 2017 We also observe that WDR5 is required for p53 induction in response to cisplatin treatment. Cisplatin 71-80 tumor protein p53 Homo sapiens 42-45 28315428-4 2017 To our surprise, S6K1 inhibition decreased cisplatin-induced DNA damage and cell death only in p53-/- BC CML cells but not in p53+/+ BC CML cells. Cisplatin 43-52 tumor protein p53 Homo sapiens 95-98 28315428-7 2017 Our results confirmed that S6K1 inhibition reversed cisplatin toxicity is dependent on p53 expression in CML cells. Cisplatin 52-61 tumor protein p53 Homo sapiens 87-90 28315428-10 2017 Taken together, our results suggest that p53/PDK1/S6K1 is a novel pathway regulating cisplatin toxicity in BC CML cells. Cisplatin 85-94 tumor protein p53 Homo sapiens 41-44 28487608-7 2017 With respect to the other p53 isoforms, mRNA level of Delta133p53 was significantly reduced in a dose-dependent manner by treatment with only PDTC or PTDC in combination with cisplatin (P < 0.01), whereas p53beta mRNA expression was not altered by PDTC treatment (P > 0.05). Cisplatin 175-184 tumor protein p53 Homo sapiens 26-29 28513299-0 2017 Anti-tumor effect of cisplatin in human oral squamous cell carcinoma was enhanced by andrographolide via upregulation of phospho-p53 in vitro and in vivo. Cisplatin 21-30 tumor protein p53 Homo sapiens 129-132 28406482-7 2017 Interestingly, cisplatin treatment also contributed to the increasement of HDAC, the interaction of TRIB1 with HDAC, and inactivation of p53. Cisplatin 15-24 tumor protein p53 Homo sapiens 137-140 28458631-0 2017 Inhibition of Mitochondrial p53 Accumulation by PFT-mu Prevents Cisplatin-Induced Peripheral Neuropathy. Cisplatin 64-73 tumor protein p53 Homo sapiens 28-31 28458631-4 2017 We hypothesized that cisplatin acts as a cellular stressor that triggers p53 accumulation at mitochondria, leading to mitochondrial dysfunction and CIPN. Cisplatin 21-30 tumor protein p53 Homo sapiens 73-76 28458631-6 2017 We show here for the first time that in vivo cisplatin rapidly increases mitochondrial accumulation of p53 in dorsal root ganglia (DRG), spinal cord, and peripheral nerve without evidence for apoptosis. Cisplatin 45-54 tumor protein p53 Homo sapiens 103-106 28458631-8 2017 Pre-treatment with PFT-mu prevented the early cisplatin-induced increase in mitochondrial p53 and the reduction in mitochondrial membrane potential. Cisplatin 46-55 tumor protein p53 Homo sapiens 90-93 28458631-9 2017 Inhibition of the early mitochondrial p53 accumulation by PFT-mu also prevented the abnormalities in mitochondrial morphology and mitochondrial bioenergetics (reduced oxygen consumption rate, maximum respiratory capacity, and adenosine triphosphate synthesis) that develop in DRG and peripheral nerve after cisplatin-treatment. Cisplatin 307-316 tumor protein p53 Homo sapiens 38-41 28458631-11 2017 In conclusion, PFT-mu is a potential neuroprotective agent that prevents cisplatin-induced mitochondrial dysfunction in DRG and peripheral nerves thereby protecting against CIPN through blockade of the early cisplatin-induced increase in mitochondrial p53. Cisplatin 208-217 tumor protein p53 Homo sapiens 252-255 28384067-0 2017 miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. Cisplatin 17-26 tumor protein p53 Homo sapiens 139-143 28107698-11 2017 The combination of the IC50 doses of apigenin (15muM) and cisplatin (7.5muM) for 48h significantly enhanced cisplatin"s cytotoxic and apoptotic effects through downregulation of Bcl-2, sharpin and survivin; and upregulation of caspase-8, Apaf-1 and p53 mRNA expression. Cisplatin 58-67 tumor protein p53 Homo sapiens 249-252 28031409-0 2017 Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Cisplatin 61-70 tumor protein p53 Homo sapiens 32-35 28119452-8 2017 Blockade of P53 or NF-kappaB attenuated cisplatin-induced miR-375 expression, supporting a role of P53 and NF-kappaB in miR-375 induction. Cisplatin 40-49 tumor protein p53 Homo sapiens 12-15 28119452-8 2017 Blockade of P53 or NF-kappaB attenuated cisplatin-induced miR-375 expression, supporting a role of P53 and NF-kappaB in miR-375 induction. Cisplatin 40-49 tumor protein p53 Homo sapiens 99-102 28119452-11 2017 Together, these results suggest that upon cisplatin exposure, P53 and NF-kappaB collaboratively induce miR-375 expression, which, in turn, represses HNF-1beta activity, resulting in renal tubular cell apoptosis and nephrotoxicity. Cisplatin 42-51 tumor protein p53 Homo sapiens 62-65 28348485-0 2017 ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA. Cisplatin 42-51 tumor protein p53 Homo sapiens 119-122 28348485-0 2017 ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA. Cisplatin 55-64 tumor protein p53 Homo sapiens 119-122 28095394-7 2017 RESULTS: Selection of HCT116 cells for trabectedin resistance resulted in p53-independent hypersensitivity of the selected subline against cisplatin. Cisplatin 139-148 tumor protein p53 Homo sapiens 74-77 28347251-8 2017 Meanwhile, knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 activated the p53/Bcl-2 pathway in response to cisplatin. Cisplatin 135-144 tumor protein p53 Homo sapiens 102-105 28231799-5 2017 METHODS: We aimed to compare the cytotoxic effects of cisplatin and a trans-sulfonamide-platinum-complex (TSPC), in two human melanoma cell lines that differ in their TP53 status: SK-MEL-5, TP53 wild type, and SK-MEL-28, TP53 mutated. Cisplatin 54-63 tumor protein p53 Homo sapiens 167-171 28272690-0 2017 Licorice and its active compound glycyrrhizic acid ameliorates cisplatin-induced nephrotoxicity through inactivation of p53 by scavenging ROS and overexpression of p21 in human renal proximal tubular epithelial cells. Cisplatin 63-72 tumor protein p53 Homo sapiens 120-123 28038466-0 2017 Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Cisplatin 64-73 tumor protein p53 Homo sapiens 57-60 28038466-1 2017 Cisplatin (cis-Pt) resistance in tumor cells from p53 dysfunction is a significant clinical problem. Cisplatin 0-9 tumor protein p53 Homo sapiens 50-53 28038466-1 2017 Cisplatin (cis-Pt) resistance in tumor cells from p53 dysfunction is a significant clinical problem. Cisplatin 11-17 tumor protein p53 Homo sapiens 50-53 28038466-3 2017 Therefore, we examined the status of p53 in cisplatin-resistant ovarian tumor models and its functional response to cis-Pt and the mechanistically-distinct non-cross-resistant oxaliplatin (oxali-Pt). Cisplatin 44-53 tumor protein p53 Homo sapiens 37-40 28038466-3 2017 Therefore, we examined the status of p53 in cisplatin-resistant ovarian tumor models and its functional response to cis-Pt and the mechanistically-distinct non-cross-resistant oxaliplatin (oxali-Pt). Cisplatin 116-122 tumor protein p53 Homo sapiens 37-40 28038466-5 2017 Mutant p53 in 2780CP/Cl-16 (p53V172F) and OVCAR-10 (p53V172F and p53G266R) cells, predicted as non-functional in p53 database, displayed attenuated response to cis-Pt, as did the polymorphic p53P72R (functionally equivalent to wild-type p53) in HEY and OVCA-433 cell lines. Cisplatin 160-166 tumor protein p53 Homo sapiens 7-10 28272690-2 2017 Cisplatin-induced apoptosis in renal cells is associated with reactive oxygen species (ROS)-mediated p53 activation. Cisplatin 0-9 tumor protein p53 Homo sapiens 101-104 28272690-15 2017 CONCLUSIONS: These results suggest that LE and GA ameliorate cisplatin-induced apoptosis through reduction of ROS-mediating p53 activation and promotion of p21 expression in HK-2 cells. Cisplatin 61-70 tumor protein p53 Homo sapiens 124-127 28143445-11 2017 RESULTS: The combination of AUY922 with cisplatin, radiation and CCRT was found to be synergistic in p53 mutant HNSCC. Cisplatin 40-49 tumor protein p53 Homo sapiens 101-104 28356995-0 2017 Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. Cisplatin 22-31 tumor protein p53 Homo sapiens 57-60 28356995-6 2017 Treatment with apigenin increased cisplatin-induced DNA damage and the apoptosis of tumor cells in a p53-dependent manner. Cisplatin 34-43 tumor protein p53 Homo sapiens 101-104 27637603-0 2017 The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. Cisplatin 120-129 tumor protein p53 Homo sapiens 22-25 28081228-9 2017 However, upon hypoxia the cisplatin-induced cell cycle arrest and expression of p53 and p21 were abrogated. Cisplatin 26-35 tumor protein p53 Homo sapiens 80-83 27888811-3 2017 Overexpression of mutated p53 with reduced or abolished function is often connected to resistance to standard medications, including cisplatin, alkylating agents (temozolomide), anthracyclines, (doxorubicin), antimetabolites (gemcitabine), antiestrogenes (tamoxifen) and EGFR-inhibitors (cetuximab). Cisplatin 133-142 tumor protein p53 Homo sapiens 26-29 27591972-5 2016 The p53(del) cells was more sensitive to cisplatin (PDD) and 5-fluorouracil (5FU) than p53(wt) cells but there was not significant difference. Cisplatin 41-50 tumor protein p53 Homo sapiens 4-7 27935863-9 2017 For instance, cisplatin triggered preferentially p53 and folate biosynthesis while the ruthenium complex induced endoplasmic reticulum stress and trans-sulfuration pathways. Cisplatin 14-23 tumor protein p53 Homo sapiens 49-52 27836543-0 2017 miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. Cisplatin 40-49 tumor protein p53 Homo sapiens 54-57 27836543-6 2017 In addition, p53 was found to monitor the expression of miR-34a in NSCLC cells after cisplatin treatment. Cisplatin 85-94 tumor protein p53 Homo sapiens 13-16 27836543-7 2017 Therefore, the sensitivity of cisplatin in NSCLC cells was modulated via p53/miR-34a/MYCN axis. Cisplatin 30-39 tumor protein p53 Homo sapiens 73-76 27584029-8 2017 Analysis of cisplatin-resistant cases has identified high rates of alterations within the TP53-MDM2 axis and a high proportion of patients with potentially actionable targets, including TP53-MDM2, PI3 kinase, and MAPK signaling pathway alterations. Cisplatin 12-21 tumor protein p53 Homo sapiens 90-94 27584029-8 2017 Analysis of cisplatin-resistant cases has identified high rates of alterations within the TP53-MDM2 axis and a high proportion of patients with potentially actionable targets, including TP53-MDM2, PI3 kinase, and MAPK signaling pathway alterations. Cisplatin 12-21 tumor protein p53 Homo sapiens 186-190 27794029-0 2017 Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy. Cisplatin 35-44 tumor protein p53 Homo sapiens 11-14 27794029-3 2017 We found activation of the ATM-Chk2-p53 pathway to be a major determinant of cisplatin ototoxicity. Cisplatin 77-86 tumor protein p53 Homo sapiens 36-39 27646943-7 2016 Results TP53 alterations were present exclusively in cisplatin-resistant tumors and were particularly prevalent among primary mediastinal nonseminomas (72%). Cisplatin 53-62 tumor protein p53 Homo sapiens 8-12 28105167-0 2016 Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Cisplatin 0-9 tumor protein p53 Homo sapiens 97-100 28105167-14 2016 The results suggested that the lncRNAs RP11-134G8.8, RP11-363E7.4 and RP1-193H18.2, and their co-expression genes, which annotated into the p53 signaling pathway, could be potential targets for cisplatin treatment. Cisplatin 194-203 tumor protein p53 Homo sapiens 140-143 27984128-3 2016 In cisplatin-induced AKI or nephrotoxicity, the DDR pathway of ATR/Chk2/p53 is activated and contributes to renal tubular cell apoptosis. Cisplatin 3-12 tumor protein p53 Homo sapiens 72-75 27613187-0 2016 Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. Cisplatin 28-37 tumor protein p53 Homo sapiens 116-119 27613187-8 2016 RESULTS: Our results clearly demonstrated that CDDP and VC treatment exhibited ameliorative effect on induction of cell death by p53 overexpression and generation of hydrogen peroxide in SiHa cells, thereby reducing the dosage of CDDP required to induce cell death in cancer cells. Cisplatin 47-51 tumor protein p53 Homo sapiens 129-132 27613187-8 2016 RESULTS: Our results clearly demonstrated that CDDP and VC treatment exhibited ameliorative effect on induction of cell death by p53 overexpression and generation of hydrogen peroxide in SiHa cells, thereby reducing the dosage of CDDP required to induce cell death in cancer cells. Cisplatin 230-234 tumor protein p53 Homo sapiens 129-132 28053903-0 2016 The influence of p53 mutation status on the anti-cancer effect of cisplatin in oral squamous cell carcinoma cell lines. Cisplatin 66-75 tumor protein p53 Homo sapiens 17-20 28053903-1 2016 OBJECTIVES: The purpose of this study was to evaluate the anti-cancer activity of cisplatin by studying its effects on cell viability and identifying the mechanisms underlying the induction of cell cycle arrest and apoptosis on oral squamous cell carcinoma (OSCC) cell lines with varying p53 mutation status. Cisplatin 82-91 tumor protein p53 Homo sapiens 288-291 28053903-10 2016 Also, immunoblotting analysis indicated that p53 and p21 were detected only in YD-8 and YD-9 cell lines after cisplatin treatment. Cisplatin 110-119 tumor protein p53 Homo sapiens 45-48 27646943-11 2016 Conclusion In GCT, TP53 and MDM2 alterations were associated with cisplatin resistance and inferior outcomes, independent of the IGCCCG model. Cisplatin 66-75 tumor protein p53 Homo sapiens 19-23 27514406-0 2016 Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner. Cisplatin 54-63 tumor protein p53 Homo sapiens 81-85 27514406-8 2016 IMPLICATIONS: This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy. Cisplatin 246-255 tumor protein p53 Homo sapiens 157-161 27708247-0 2016 Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells. Cisplatin 36-45 tumor protein p53 Homo sapiens 86-89 27895723-0 2016 Cisplatin-induced regulation of signal transduction pathways and transcription factors in p53-mutated subclone variants of hepatoma cells: Potential application for therapeutic targeting. Cisplatin 0-9 tumor protein p53 Homo sapiens 90-93 27708247-6 2016 Addition of scriptaid also overcomes the cisplatin resistance exhibited in lung cancer cells with stabilized hypoxia inducible factor 1 (HIF1)-alpha (mutant) and mutant p53. Cisplatin 41-50 tumor protein p53 Homo sapiens 169-172 27708247-8 2016 Together, our results suggest that the combination of low dose cisplatin and scriptaid is cytotoxic to NSCLC lines, can overcome hypoxia induced resistance and mutant p53- induced instability often associated with this cancer, and has the potential to be an effective therapeutic modality. Cisplatin 63-72 tumor protein p53 Homo sapiens 167-170 27401370-10 2016 Non-invasive real time imaging using two different luciferase reporters showed that cisplatin could simultaneously induce PIK3CA attenuation and p53 activation with growth regression in sensitive tumours but not in the resistant tumours where only low level of p53 activation and sustained growth was observed. Cisplatin 84-93 tumor protein p53 Homo sapiens 261-264 27401370-3 2016 Cisplatin, a widely used cytotoxic drug represses PIK3CA promoter activity and attenuates PI3K/AKT cell survival pathway through p53 activation in sensitive cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 129-132 27564099-9 2016 Moreover, pretreatment with U0126 suppressed curcumin and cisplatin-induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells. Cisplatin 58-67 tumor protein p53 Homo sapiens 92-95 27401370-4 2016 However, very little is understood about the overall mechanism of p53-PIK3CA interaction and influence of p53 on the transcriptional status of PIK3CA during cisplatin resistance. Cisplatin 157-166 tumor protein p53 Homo sapiens 106-109 27401370-5 2016 Here we showed that cisplatin could dynamically alter p53 occupancy between the p53 binding sequences present in PIK3CA promoter in ovarian and breast cancer cells. Cisplatin 20-29 tumor protein p53 Homo sapiens 54-57 27401370-5 2016 Here we showed that cisplatin could dynamically alter p53 occupancy between the p53 binding sequences present in PIK3CA promoter in ovarian and breast cancer cells. Cisplatin 20-29 tumor protein p53 Homo sapiens 80-83 27401370-7 2016 Interestingly, cisplatin resistant cells when challenged with cisplatin demonstrated abolished PIK3CA promoter attenuation, low level of p53 binding, and loss of p53 serine 46 phosphorylation. Cisplatin 15-24 tumor protein p53 Homo sapiens 137-140 27401370-7 2016 Interestingly, cisplatin resistant cells when challenged with cisplatin demonstrated abolished PIK3CA promoter attenuation, low level of p53 binding, and loss of p53 serine 46 phosphorylation. Cisplatin 15-24 tumor protein p53 Homo sapiens 162-165 27401370-7 2016 Interestingly, cisplatin resistant cells when challenged with cisplatin demonstrated abolished PIK3CA promoter attenuation, low level of p53 binding, and loss of p53 serine 46 phosphorylation. Cisplatin 62-71 tumor protein p53 Homo sapiens 137-140 27401370-7 2016 Interestingly, cisplatin resistant cells when challenged with cisplatin demonstrated abolished PIK3CA promoter attenuation, low level of p53 binding, and loss of p53 serine 46 phosphorylation. Cisplatin 62-71 tumor protein p53 Homo sapiens 162-165 27401370-10 2016 Non-invasive real time imaging using two different luciferase reporters showed that cisplatin could simultaneously induce PIK3CA attenuation and p53 activation with growth regression in sensitive tumours but not in the resistant tumours where only low level of p53 activation and sustained growth was observed. Cisplatin 84-93 tumor protein p53 Homo sapiens 145-148 27564099-7 2016 In addition, when 253J-Bv cells were co-treated with curcumin and cisplatin, p53 and p21 expression levels were markedly increased when compared to controls. Cisplatin 66-75 tumor protein p53 Homo sapiens 77-80 26876197-5 2016 The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53(V172F) mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. Cisplatin 14-23 tumor protein p53 Homo sapiens 109-112 27673332-12 2016 CDDP increased the expression of p53 and p21 indicating cell cycle arrest. Cisplatin 0-4 tumor protein p53 Homo sapiens 33-36 26876197-5 2016 The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53(V172F) mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. Cisplatin 14-23 tumor protein p53 Homo sapiens 109-112 26876197-0 2016 Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Cisplatin 36-45 tumor protein p53 Homo sapiens 13-18 26876197-0 2016 Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Cisplatin 36-45 tumor protein p53 Homo sapiens 13-16 26876197-5 2016 The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53(V172F) mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. Cisplatin 14-23 tumor protein p53 Homo sapiens 109-112 26876197-3 2016 In the present study, cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53(V172F) mutation, which reduced p53 half-life by two- to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. Cisplatin 22-31 tumor protein p53 Homo sapiens 123-128 26876197-7 2016 However, downregulation of MDM2 or MDM4 by small interfering RNA in either resistant cell line induced p53 and restored p21 transactivation at 37 C, as did cisplatin-induced DNA damage at 32.5 C that coincided with reduced p53-MDM4 binding and cisplatin resistance. Cisplatin 157-166 tumor protein p53 Homo sapiens 225-228 26876197-3 2016 In the present study, cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53(V172F) mutation, which reduced p53 half-life by two- to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. Cisplatin 22-31 tumor protein p53 Homo sapiens 123-126 26876197-8 2016 These results demonstrate that cisplatin-mediated p53(V172F) mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53(V172F) complex that inhibits p53-dependent transactivation. Cisplatin 31-40 tumor protein p53 Homo sapiens 50-55 26876197-3 2016 In the present study, cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53(V172F) mutation, which reduced p53 half-life by two- to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. Cisplatin 22-31 tumor protein p53 Homo sapiens 158-161 26876197-5 2016 The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53(V172F) mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. Cisplatin 14-23 tumor protein p53 Homo sapiens 76-79 26876197-5 2016 The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53(V172F) mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. Cisplatin 14-23 tumor protein p53 Homo sapiens 109-114 26876197-8 2016 These results demonstrate that cisplatin-mediated p53(V172F) mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53(V172F) complex that inhibits p53-dependent transactivation. Cisplatin 31-40 tumor protein p53 Homo sapiens 50-53 26876197-5 2016 The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53(V172F) mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. Cisplatin 14-23 tumor protein p53 Homo sapiens 109-112 26876197-8 2016 These results demonstrate that cisplatin-mediated p53(V172F) mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53(V172F) complex that inhibits p53-dependent transactivation. Cisplatin 31-40 tumor protein p53 Homo sapiens 80-83 26876197-8 2016 These results demonstrate that cisplatin-mediated p53(V172F) mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53(V172F) complex that inhibits p53-dependent transactivation. Cisplatin 31-40 tumor protein p53 Homo sapiens 80-83 26876197-9 2016 This represents a novel cellular mechanism of p53 inhibition, and, thereby, induction of cisplatin resistance. Cisplatin 89-98 tumor protein p53 Homo sapiens 46-49 27484725-11 2016 This suggested that the enhanced cisplatin chemosensitivity with Ad-ING4-P53 gene therapy in hypopharyngeal cancer xenografts may be associated with apoptosis induction through upregulation of Bax expression and downregulation of Bcl-2. Cisplatin 33-42 tumor protein p53 Homo sapiens 73-76 26896489-9 2016 In A549 cells with functional p53, the repair of cisplatin/DNA adducts is determined by a complex action of HMGB1 and p53 as an increase of DNA repair capacity was registered only after silencing of both proteins. Cisplatin 49-58 tumor protein p53 Homo sapiens 30-33 27484725-0 2016 Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo. Cisplatin 81-90 tumor protein p53 Homo sapiens 26-29 27484725-3 2016 The current study investigated the effects of co-expression of inhibitor of growth protein 4 (ING4) and P53, a tumor suppressor gene, on chemosensitivity to cisplatin in human hypopharyngeal cancer xenografts in vivo, and the potential molecular mechanisms involved. Cisplatin 157-166 tumor protein p53 Homo sapiens 104-107 27484725-10 2016 The results of immunohistochemistry analysis demonstrated that Bax expression was increased and Bcl-2 was decreased in the Ad-ING4-P53 + cisplatin group. Cisplatin 137-146 tumor protein p53 Homo sapiens 131-134 27494891-6 2016 Mechanistic studies suggested that treatment of cells with PHPO or with PHPO + cisplatin differentially inhibited the PI3K/Akt, MAPK and ATM/Chk2 pathways, which consequently suppressed the anti-apoptotic factors Bcl-xL, Bcl-2 and XIAP, but activated the pro-apoptotic factors Bad, Bax, p53, caspase 9, caspase 8, caspase 7 and PARP. Cisplatin 79-88 tumor protein p53 Homo sapiens 287-290 27486986-6 2016 Here, we demonstrate for the first time that TAp73beta, a p53-family protein, is implicated in Cisplatin-induced apoptosis of Bone Sarcomas". Cisplatin 95-104 tumor protein p53 Homo sapiens 58-61 26370097-0 2016 Extremely low frequency electromagnetic field sensitizes cisplatin-resistant human ovarian adenocarcinoma cells via P53 activation. Cisplatin 57-66 tumor protein p53 Homo sapiens 116-119 26370097-12 2016 Semi-quantitative RT-PCR showed that in synergistic groups of cisplatin and EL-EMF, expression of P53 was increased but the expression level of MPP-2 gene decreased. Cisplatin 62-71 tumor protein p53 Homo sapiens 98-101 26896489-9 2016 In A549 cells with functional p53, the repair of cisplatin/DNA adducts is determined by a complex action of HMGB1 and p53 as an increase of DNA repair capacity was registered only after silencing of both proteins. Cisplatin 49-58 tumor protein p53 Homo sapiens 118-121 26984736-3 2016 In contrast, Cisplatin-resistant cells do not enter apoptosis, i.e., their p53 and downstream signaling are reduced and caspase activity unaltered following Cisplatin exposure. Cisplatin 13-22 tumor protein p53 Homo sapiens 75-78 27223080-7 2016 Median-drug-effect analysis showed Nutlin-3 or RG7388 combination with cisplatin was additive to, or synergistic in a p53-dependent manner, resulting in increased p53 activation, cell cycle arrest and apoptosis, associated with increased p21WAF1 protein and/or caspase-3/7 activity compared to cisplatin alone. Cisplatin 71-80 tumor protein p53 Homo sapiens 118-121 27223080-7 2016 Median-drug-effect analysis showed Nutlin-3 or RG7388 combination with cisplatin was additive to, or synergistic in a p53-dependent manner, resulting in increased p53 activation, cell cycle arrest and apoptosis, associated with increased p21WAF1 protein and/or caspase-3/7 activity compared to cisplatin alone. Cisplatin 71-80 tumor protein p53 Homo sapiens 163-166 27223080-7 2016 Median-drug-effect analysis showed Nutlin-3 or RG7388 combination with cisplatin was additive to, or synergistic in a p53-dependent manner, resulting in increased p53 activation, cell cycle arrest and apoptosis, associated with increased p21WAF1 protein and/or caspase-3/7 activity compared to cisplatin alone. Cisplatin 294-303 tumor protein p53 Homo sapiens 118-121 26984736-0 2016 Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Cisplatin 85-94 tumor protein p53 Homo sapiens 117-120 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 3-12 tumor protein p53 Homo sapiens 59-62 26984736-3 2016 In contrast, Cisplatin-resistant cells do not enter apoptosis, i.e., their p53 and downstream signaling are reduced and caspase activity unaltered following Cisplatin exposure. Cisplatin 157-166 tumor protein p53 Homo sapiens 75-78 26984736-2 2016 In Cisplatin-sensitive cells Cisplatin treatment increases p53-protein level as well as downstream signaling, e.g., expression of p21(Waf1/Cip1), Bax, Noxa, MDM2, and activation of Caspase-9/-3. Cisplatin 29-38 tumor protein p53 Homo sapiens 59-62 26984736-4 2016 Reduced LRRC8A expression and VSOAC activity are previously shown to correlate with Cisplatin resistance, and here we demonstrate that pharmacological inhibition and transient knockdown of LRRC8A reduce the protein level of p53, MDM2, and p21(Waf1/Cip1) as well as Caspase-9/-3 activation in Cisplatin-sensitive cells. Cisplatin 84-93 tumor protein p53 Homo sapiens 224-227 26984736-4 2016 Reduced LRRC8A expression and VSOAC activity are previously shown to correlate with Cisplatin resistance, and here we demonstrate that pharmacological inhibition and transient knockdown of LRRC8A reduce the protein level of p53, MDM2, and p21(Waf1/Cip1) as well as Caspase-9/-3 activation in Cisplatin-sensitive cells. Cisplatin 292-301 tumor protein p53 Homo sapiens 224-227 26984736-7 2016 Our data indicate 1) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its downstream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2; and 2) that downregulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Cisplatin 73-82 tumor protein p53 Homo sapiens 103-106 26984736-7 2016 Our data indicate 1) that expression/activity of LRRC8A is essential for Cisplatin-induced increase in p53 protein level and its downstream signaling, i.e., Caspase-9/-3 activation, expression of p21(Waf1/Cip1) and MDM2; and 2) that downregulation of LRRC8A-dependent osmolyte transporters contributes to acquirement of Cisplatin resistance in ovarian and lung carcinoma cells. Cisplatin 320-329 tumor protein p53 Homo sapiens 103-106 27082635-0 2016 Theaflavin-3, 3"-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells. Cisplatin 106-115 tumor protein p53 Homo sapiens 91-94 27163202-6 2016 However, it inhibited Chk1 activation and G2/M arrest with combination of cisplatin treatment, resulting in p53-independent apoptosis. Cisplatin 74-83 tumor protein p53 Homo sapiens 108-111 26899019-0 2016 Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. Cisplatin 109-118 tumor protein p53 Homo sapiens 36-40 27179933-7 2016 RESULTS: We observed strong synergy with APR-246 and cisplatin in all tumor samples carrying a TP53 missense mutation, while synergistic or additive effects were found in cells with wild type or TP53 nonsense mutations. Cisplatin 53-62 tumor protein p53 Homo sapiens 95-99 27179933-9 2016 Moreover, APR-246 sensitized TP53 mutant primary ovarian cancer cells, isolated from a clinically platinum-resistant patient, to cisplatin; the IC50 value of cisplatin decreased 3.6 fold from 6.5 to 1.8 muM in the presence of clinically relevant concentration of APR-246. Cisplatin 129-138 tumor protein p53 Homo sapiens 29-33 27050276-0 2016 Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Cisplatin 97-106 tumor protein p53 Homo sapiens 74-77 27168162-11 2016 The cisplatin-induced expression of pAkt was not affected by LCN2; however, the expression of p53 and p21 was increased by LCN2-silencing. Cisplatin 4-13 tumor protein p53 Homo sapiens 94-97 27050276-5 2016 Cisplatin (CP) activated the IGF-1R/AKT/mTORC1 pathway and stabilized p53 in osteosarcoma (OS) cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 70-73 27313779-6 2016 There was no detectable difference in basal p53 levels between 3D cultures and 2D cultures but cisplatin induced less p53 in both HCT116 3D cultures and LoVo 3D cultures. Cisplatin 95-104 tumor protein p53 Homo sapiens 118-121 26728272-0 2016 Neuropeptide Y protects kidney against cisplatin-induced nephrotoxicity by regulating p53-dependent apoptosis pathway. Cisplatin 39-48 tumor protein p53 Homo sapiens 86-89 26996126-0 2016 Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 167-170 26996126-2 2016 Accumulating evidence has shown that cisplatin activates the p53-dependent apoptotic pathway, but it also induces apoptosis in p53-mutated cancer cells. Cisplatin 37-46 tumor protein p53 Homo sapiens 61-64 26996126-2 2016 Accumulating evidence has shown that cisplatin activates the p53-dependent apoptotic pathway, but it also induces apoptosis in p53-mutated cancer cells. Cisplatin 37-46 tumor protein p53 Homo sapiens 127-130 26996126-4 2016 In contrast, the expression of proapoptotic multidomain Bcl-2-family members, Bak and Bax, was induced by cisplatin in p53-dependent and -independent manners, respectively. Cisplatin 106-115 tumor protein p53 Homo sapiens 119-122 26996126-5 2016 Moreover, in wild-type p53-expressing cells, cisplatin mainly used the Bak-dependent apoptotic pathway, but this apoptotic pathway shifted to the Bax-dependent pathway by loss-of-function of p53. Cisplatin 45-54 tumor protein p53 Homo sapiens 23-26 26987028-10 2016 The results showed that both GA and cisplatin changed the morphology, inhibited the growth and induced apoptosis in the H446 cells by inducing generation of ROS, disruption of MMP, downregulation of XIAP expression, and upregulation of Bax, Apaf-1, DIABLO and p53 expression. Cisplatin 36-45 tumor protein p53 Homo sapiens 260-263 27313779-9 2016 Knockdown of p53 decreased cleaved caspase 3 and apoptosis induced by cisplatin. Cisplatin 70-79 tumor protein p53 Homo sapiens 13-16 27313779-11 2016 Knockdown of p53 decreased cisplatin"s induction of c-Jun N-terminal kinase 1/2 (JNK1/2) activation, whereas inhibition of JNK1/2 activation increased chemosensitivity. Cisplatin 27-36 tumor protein p53 Homo sapiens 13-16 27313779-12 2016 Inhibition of p38 activation decreased cisplatin"s induction of p53, but no difference in p38 activation by cisplatin was observed between 2D cultures and 3D cultures. Cisplatin 39-48 tumor protein p53 Homo sapiens 64-67 27077811-5 2016 Another criterion of the screen was increased sensitivity of p53-negative tumor cells to cisplatin (CDDP) in a Wip1-dependent manner. Cisplatin 89-98 tumor protein p53 Homo sapiens 61-64 27012201-7 2016 Notably, chemotherapeutic reagent cisplatin induction of p53 is markedly attenuated in response to ectopic expression of TRIM65. Cisplatin 34-43 tumor protein p53 Homo sapiens 57-60 27077811-5 2016 Another criterion of the screen was increased sensitivity of p53-negative tumor cells to cisplatin (CDDP) in a Wip1-dependent manner. Cisplatin 100-104 tumor protein p53 Homo sapiens 61-64 27077811-6 2016 We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors. Cisplatin 135-139 tumor protein p53 Homo sapiens 172-175 27077811-6 2016 We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors. Cisplatin 135-139 tumor protein p53 Homo sapiens 230-233 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Cisplatin 116-125 tumor protein p53 Homo sapiens 26-29 26148235-3 2016 Interestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner. Cisplatin 125-134 tumor protein p53 Homo sapiens 158-161 27044825-14 2016 sCD40L in combination with cisplatin decreased the expression levels of GST-pi, LRP, Survivin, p53 and Bcl-2 in both epithelial ovarian cancer cell lines. Cisplatin 27-36 tumor protein p53 Homo sapiens 95-98 27044825-15 2016 The protein expression level of GST-pi, LRP and P53 protein was also decreased upon sCD40L in combination with cisplatin although the expression level of Bcl-2 and survivin protein had no significant difference. Cisplatin 111-120 tumor protein p53 Homo sapiens 48-51 26341473-6 2016 We provide evidence that the decreases in SIRT1 activity and expression facilitated by increasing poly(ADP-ribose) polymerase-1 (PARP-1) activation and microRNA-34a levels through cisplatin-mediated p53 activation aggravate the associated ototoxicity. Cisplatin 180-189 tumor protein p53 Homo sapiens 199-202 26865836-11 2015 ICC analysis for bcl2 and p53 also confirmed our results; in treated samples for the dose of LD50 in 24 and 48 h of cisplatin and hypercin, more cells expressed p53 (guardian of cells in front of tumor formation/progression) and less expressed bcl2 (which has anti apoptotic activity) compared to untreated samples. Cisplatin 116-125 tumor protein p53 Homo sapiens 161-164 26768586-0 2016 miR214-regulated p53-NOX4/p66shc pathway plays a crucial role in the protective effect of Ginkgolide B against cisplatin-induced cytotoxicity in HEI-OC1 cells. Cisplatin 111-120 tumor protein p53 Homo sapiens 17-20 26768586-8 2016 Moreover, p53 expression was increased by cisplatin. Cisplatin 42-51 tumor protein p53 Homo sapiens 10-13 26540344-0 2015 Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells. Cisplatin 30-34 tumor protein p53 Homo sapiens 16-19 26768586-10 2016 Over-expression of p53 suppressed the inhibitory effects of GB on NOX4 and p66(shc) expression and superoxide generation and the protective effects of GB on loss of cell viability and apoptosis associated with cisplatin. Cisplatin 210-219 tumor protein p53 Homo sapiens 19-22 26768586-13 2016 We demonstrate that GB decreases superoxide generation and the subsequent apoptosis through reduction of p53-mediated NOX4/p66(shc) pathway via up-regulation of miR214, resulting in attenuation of cisplatin-induced cytotoxicity. Cisplatin 197-206 tumor protein p53 Homo sapiens 105-108 26796280-2 2016 Cisplatin may initiate p73-dependent apoptosis in p53 mutant cell lines through Fas trimerization and Caspase-8 activation and Bax up regulation and subsequent Caspase-9 activation. Cisplatin 0-9 tumor protein p53 Homo sapiens 50-53 26540344-3 2015 Here, we report that the transcription elongation factor Ell3 sensitizes luminal type-cancer cell line, MCF7, which have wild-type p53, to the chemotherapeutic agent cis-diamminedichloroplatinum(II) (CDDP) by stabilizing p53. Cisplatin 166-198 tumor protein p53 Homo sapiens 221-224 26497680-5 2015 The MTT assay indicated that an increase in Nrf2 expression by mutant p53 is responsible for cisplatin resistance. Cisplatin 93-102 tumor protein p53 Homo sapiens 70-73 25450742-7 2015 Cisplatin affected several pathways including, p53 signalling, Nrf2 mediated oxidative stress response, mitochondrial processes, mTOR and AMPK signalling. Cisplatin 0-9 tumor protein p53 Homo sapiens 47-50 26384430-0 2015 CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene. Cisplatin 44-53 tumor protein p53 Homo sapiens 68-71 26384430-7 2015 These results demonstrate that CITED2/p300 can be recruited by p53 at the promoter of the repair gene ERCC1 in response to cisplatin-induced DNA damage. Cisplatin 123-132 tumor protein p53 Homo sapiens 63-66 26384430-8 2015 The CITED2/p300/p53/ERCC1 pathway is thus involved in the cell response to cisplatin and represents a potential target for cancer therapy. Cisplatin 75-84 tumor protein p53 Homo sapiens 16-19 26497680-2 2015 Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Cisplatin 120-129 tumor protein p53 Homo sapiens 34-37 26497680-8 2015 The prognostic significance of Nrf2 mRNA levels on OS and RFS was also observed in patients who have received cisplatin-based chemotherapy, particularly in p53-mutant patients. Cisplatin 110-119 tumor protein p53 Homo sapiens 156-159 26497680-9 2015 Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC. Cisplatin 36-45 tumor protein p53 Homo sapiens 21-24 26486083-4 2015 We hypothesized that cisplatin induces cytotoxicity through DNA adduct formation, oxidative stress, transcriptional factors (p53 and AP-1), cell cycle regulation, stress signaling and apoptosis in APL cells. Cisplatin 21-30 tumor protein p53 Homo sapiens 125-128 26486083-7 2015 Cisplatin also activated p53 and phosphorylated activator protein (AP-1) component, c-Jun at serine (63, 73) residue simultaneously leading to cell cycle arrest through stimulation of p21 and down regulation of cyclins and cyclin dependent kinases in APL cell lines. Cisplatin 0-9 tumor protein p53 Homo sapiens 25-28 26505347-10 2015 Given the fact that p53 can regulate autophagy by inactivating mTOR via AMPK, our results suggest that the p53 pathway may also play a critical role in the pathogenesis of cisplatin-induced renal damage. Cisplatin 172-181 tumor protein p53 Homo sapiens 20-23 26586936-9 2015 As4S4 and cisplatin synergistically stimulated p53, phosphor-p38 (p-p38), and increased cleaved caspase 3 (c-caspase 3). Cisplatin 10-19 tumor protein p53 Homo sapiens 47-50 26193055-8 2015 Furthermore, the increase in expression of phosphorylated p53 induced by cisplatin is markedly attenuated by pretreatment with erdosteine in the mitochondrial fraction. Cisplatin 73-82 tumor protein p53 Homo sapiens 58-61 26505347-7 2015 Interestingly, in the kidney, cisplatin treatment can activate AMP-activated protein kinase (AMPK), a signaling molecule that is also critical for p53-mediated inactivation of mammalian target of rapamycin (mTOR) pathways. Cisplatin 30-39 tumor protein p53 Homo sapiens 147-150 26505347-10 2015 Given the fact that p53 can regulate autophagy by inactivating mTOR via AMPK, our results suggest that the p53 pathway may also play a critical role in the pathogenesis of cisplatin-induced renal damage. Cisplatin 172-181 tumor protein p53 Homo sapiens 107-110 26313152-8 2015 Expression of anti-apoptotic proteins Bcl-2 and Mcl-1 and DNA repair associated molecules ATM, CHK1, TP73, p53, and ERCC1 were significantly up regulated in cisplatin-treated A549sc and H157sc cells, but no increase was detected in A549IL-6si and H157IL-6si cells. Cisplatin 157-166 tumor protein p53 Homo sapiens 107-110 26315556-0 2015 Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. Cisplatin 36-45 tumor protein p53 Homo sapiens 79-82 26187504-11 2015 Importantly, APR-246 synergistically enhanced the inhibitory effects of cisplatin and 5-fluorouracil through p53 accumulation. Cisplatin 72-81 tumor protein p53 Homo sapiens 109-112 26205069-5 2015 The typical mechanism of cisplatin action involves DNA damage, activation of p53 protein and induction of cell death, as previously described for titanium ions. Cisplatin 25-34 tumor protein p53 Homo sapiens 77-80 25959925-4 2015 Cisplatin-resistant A549R cells treated with Ru@L-SeNPs-siRNA demonstrated significant downregulation of P-glycoprotein (P-gp) expression, resulting in unprecedented enhanced cytotoxicity through the induction of apoptosis with the involvement of phosphorylation of p53, MAPK and PI3K/Akt signaling pathways. Cisplatin 0-9 tumor protein p53 Homo sapiens 266-269 26317157-0 2015 Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells. Cisplatin 17-26 tumor protein p53 Homo sapiens 76-79 26815194-0 2015 [p14ARF enhances cisplatin-induced apoptosis in human osteosarcoma cells in p53-independent pathway]. Cisplatin 17-26 tumor protein p53 Homo sapiens 76-79 26815194-16 2015 CONCLUSION: p14ARF enhances cisplatin-induced apoptosis in human osteosarcoma MG63 cells in p53-independent caspase-9-dependent pathway, in which the intrinsic mitochondrial apoptotic pathway is involved. Cisplatin 28-37 tumor protein p53 Homo sapiens 92-95 25944617-0 2015 The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Cisplatin 73-82 tumor protein p53 Homo sapiens 34-37 26375862-3 2015 In gynecologic cancers, p53 is a pivotal determinant of cisplatin sensitivity, while BCL-2 family members are associated with taxane sensitivity. Cisplatin 56-65 tumor protein p53 Homo sapiens 24-27 25944617-7 2015 In addition, in low ERCC1 expression NSCLC cell lines, knockdown of GOF mutant p53 enhanced cisplatin sensitivity. Cisplatin 92-101 tumor protein p53 Homo sapiens 79-82 26035065-10 2015 In summary, the results of our present study demonstrate that HSCs protect HepG2 cells against cisplatin-induced apoptosis and its protective effects occur via inhibiting the activation of p53, which is of critical importance for enhanced understanding of fundamental cancer biology. Cisplatin 95-104 tumor protein p53 Homo sapiens 189-192 25944617-8 2015 Further double knockdown of ERCC1 and GOF mutant p53 but not ERCC1 knockdown alone increased the cisplatin sensitivity of cells with both high ERCC1 expression and GOF p53 mutations. Cisplatin 97-106 tumor protein p53 Homo sapiens 49-52 25944617-8 2015 Further double knockdown of ERCC1 and GOF mutant p53 but not ERCC1 knockdown alone increased the cisplatin sensitivity of cells with both high ERCC1 expression and GOF p53 mutations. Cisplatin 97-106 tumor protein p53 Homo sapiens 168-171 25944617-9 2015 Therefore, this study demonstrated that ERCC1 expression combined with p53 mutation status may determine the efficacy of cisplatin and HDACi combined therapy and guide the development of future NSCLC therapies. Cisplatin 121-130 tumor protein p53 Homo sapiens 71-74 25695150-5 2015 The mRNA expression levels of p53, p53beta and B-cell lymphoma 2-associated X protein (Bax) were detected in the MKN45 and SGC-7901 cells following treatment with cisplatin by reverse transcription-PCR. Cisplatin 163-172 tumor protein p53 Homo sapiens 30-33 26209226-12 2015 Also, loss of GTSE1 expression caused a significant increase in P53 mediated apoptosis in cisplatin treated cells. Cisplatin 90-99 tumor protein p53 Homo sapiens 64-67 25982682-2 2015 Rare p53 mutations may be associated with cisplatin resistance. Cisplatin 42-51 tumor protein p53 Homo sapiens 5-8 25912556-1 2015 This letter illustrates the significant chemosensitizing effects of chrysin to resistance cancer cells and refers to the article on "Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53" by Li et al., published in your journal recently. Cisplatin 160-169 tumor protein p53 Homo sapiens 226-229 25695150-10 2015 In the MKN45 cells, p53beta, p53 and Bax mRNA expression levels gradually increased with the dose of cisplatin, and the expression of p53beta was positively correlated with the expression of p53 (tr=6.358, P<0.05) and Bax (tr=8.023, P<0.05). Cisplatin 101-110 tumor protein p53 Homo sapiens 20-23 25695150-10 2015 In the MKN45 cells, p53beta, p53 and Bax mRNA expression levels gradually increased with the dose of cisplatin, and the expression of p53beta was positively correlated with the expression of p53 (tr=6.358, P<0.05) and Bax (tr=8.023, P<0.05). Cisplatin 101-110 tumor protein p53 Homo sapiens 29-32 25992654-10 2015 These findings demonstrate that MEG3 is significantly downregulated in LAD and partially regulates the cisplatin resistance of LAD cells through the control of p53 and Bcl-xl expression. Cisplatin 103-112 tumor protein p53 Homo sapiens 160-163 26086967-6 2015 We also show that treatment with APR-246 completely restores the cisplatin and doxorubicin sensitivity to p53-mutant drug-resistant ovarian cancer cells. Cisplatin 65-74 tumor protein p53 Homo sapiens 106-109 25770930-0 2015 Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53. Cisplatin 27-36 tumor protein p53 Homo sapiens 93-96 25854514-0 2015 Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin. Cisplatin 100-109 tumor protein p53 Homo sapiens 48-51 25854514-3 2015 Once inside cells, cisplatin is released to attack genomic DNA and kill cancer cells; simultaneously, the p53 activator results in active p53, a key protein involved in the apoptotic pathways initiated by platinum drugs. Cisplatin 19-28 tumor protein p53 Homo sapiens 106-109 25854514-3 2015 Once inside cells, cisplatin is released to attack genomic DNA and kill cancer cells; simultaneously, the p53 activator results in active p53, a key protein involved in the apoptotic pathways initiated by platinum drugs. Cisplatin 19-28 tumor protein p53 Homo sapiens 138-141 25770930-4 2015 Combination of chrysin and cisplatin increased the phosphorylation and accumulation of p53 through activating ERK1/2 in Hep G2 cells, which led to the overexpression of the pro-apoptotic proteins Bax and DR5 and the inhibition of the anti-apoptotic protein Bcl-2. Cisplatin 27-36 tumor protein p53 Homo sapiens 87-90 25922718-5 2015 RESULTS: We found that CK could significantly enhance cisplatin-induced p53 expression and activity in two lung cancer cell lines, H460 and A549. Cisplatin 54-63 tumor protein p53 Homo sapiens 72-75 25644651-1 2015 Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells. Cisplatin 16-25 tumor protein p53 Homo sapiens 33-36 25644651-1 2015 Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells. Cisplatin 16-25 tumor protein p53 Homo sapiens 129-132 25644651-1 2015 Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells. Cisplatin 16-25 tumor protein p53 Homo sapiens 129-132 25691460-1 2015 TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. Cisplatin 200-209 tumor protein p53 Homo sapiens 0-4 25691460-3 2015 The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Cisplatin 116-125 tumor protein p53 Homo sapiens 60-64 25499080-3 2015 Silencing of p53 or KRAS in A549 or H358 cells either enhanced or attenuated the resistance of cells to cisplatin and taxol through promotion or suppression of the NF-kappaB p65 nuclear translocation. Cisplatin 104-113 tumor protein p53 Homo sapiens 13-16 25504633-0 2015 Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Cisplatin 34-43 tumor protein p53 Homo sapiens 81-85 25504633-2 2015 We found that cisplatin treatment of HNSCC cells with mutant TP53 leads to arrest of cells in the G2 phase of the cell cycle, leading us to hypothesize that the wee-1 kinase inhibitor MK-1775 would abrogate the cisplatin-induced G2 block and thereby sensitize isogenic HNSCC cells with mutant TP53 or lacking p53 expression to cisplatin. Cisplatin 14-23 tumor protein p53 Homo sapiens 61-65 25504633-2 2015 We found that cisplatin treatment of HNSCC cells with mutant TP53 leads to arrest of cells in the G2 phase of the cell cycle, leading us to hypothesize that the wee-1 kinase inhibitor MK-1775 would abrogate the cisplatin-induced G2 block and thereby sensitize isogenic HNSCC cells with mutant TP53 or lacking p53 expression to cisplatin. Cisplatin 14-23 tumor protein p53 Homo sapiens 293-297 25092068-8 2015 Delivered cisplatin cooperated with piroxicam in modulating cell cycle regulators as caspase-3, p53 and p21. Cisplatin 10-19 tumor protein p53 Homo sapiens 96-99 25504633-2 2015 We found that cisplatin treatment of HNSCC cells with mutant TP53 leads to arrest of cells in the G2 phase of the cell cycle, leading us to hypothesize that the wee-1 kinase inhibitor MK-1775 would abrogate the cisplatin-induced G2 block and thereby sensitize isogenic HNSCC cells with mutant TP53 or lacking p53 expression to cisplatin. Cisplatin 14-23 tumor protein p53 Homo sapiens 309-312 25504633-2 2015 We found that cisplatin treatment of HNSCC cells with mutant TP53 leads to arrest of cells in the G2 phase of the cell cycle, leading us to hypothesize that the wee-1 kinase inhibitor MK-1775 would abrogate the cisplatin-induced G2 block and thereby sensitize isogenic HNSCC cells with mutant TP53 or lacking p53 expression to cisplatin. Cisplatin 211-220 tumor protein p53 Homo sapiens 61-65 25504633-2 2015 We found that cisplatin treatment of HNSCC cells with mutant TP53 leads to arrest of cells in the G2 phase of the cell cycle, leading us to hypothesize that the wee-1 kinase inhibitor MK-1775 would abrogate the cisplatin-induced G2 block and thereby sensitize isogenic HNSCC cells with mutant TP53 or lacking p53 expression to cisplatin. Cisplatin 211-220 tumor protein p53 Homo sapiens 61-65 25504633-4 2015 We also used a novel TP53 mutation classification scheme to identify which TP53 mutations are associated with limited tumor responses to cisplatin treatment. Cisplatin 137-146 tumor protein p53 Homo sapiens 21-25 25504633-4 2015 We also used a novel TP53 mutation classification scheme to identify which TP53 mutations are associated with limited tumor responses to cisplatin treatment. Cisplatin 137-146 tumor protein p53 Homo sapiens 75-79 25504633-6 2015 Consistent with its ability to chemosensitize, MK-1775 abrogated the cisplatin-induced G2 block in p53-defective cells leading to mitotic arrest associated with a senescence-like phenotype. Cisplatin 69-78 tumor protein p53 Homo sapiens 99-102 25504633-7 2015 Furthermore, MK-1775 enhanced the efficacy of cisplatin in vivo in tumors harboring TP53 mutations. Cisplatin 46-55 tumor protein p53 Homo sapiens 84-88 25504633-8 2015 These results indicate that HNSCC cells expressing high-risk p53 mutations are significantly sensitized to cisplatin therapy by the selective wee-1 kinase inhibitor, supporting the clinical evaluation of MK-1775 in combination with cisplatin for the treatment of patients with TP53 mutant HNSCC. Cisplatin 107-116 tumor protein p53 Homo sapiens 61-64 25304379-0 2015 Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells. Cisplatin 93-102 tumor protein p53 Homo sapiens 68-71 25444910-6 2015 By contrast, arsenic trioxide, which by inhibiting wild-type p53-induced phosphatase-1 that serves responses downstream of p53, and by depolymerizing tubulin, synergistically enhanced cisplatin cytotoxicity including loss of SP cells. Cisplatin 184-193 tumor protein p53 Homo sapiens 61-64 26089934-3 2015 Cisplatin was known to exhibit cytotoxic effect to renal cells by inducing apoptosis through activation of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 107-110 26089934-9 2015 Apigenin reduced cisplatin-induced phosphorylation and expression of p53, with no significant influence on production of ROS that is known to induce p53 activation. Cisplatin 17-26 tumor protein p53 Homo sapiens 69-72 26089934-11 2015 Taken together, these results suggest that apigenin ameliorates cisplatin-induced apoptosis through reduction of p53 activation and promotion of PI3K/Akt pathway in HK-2 cells. Cisplatin 64-73 tumor protein p53 Homo sapiens 113-116 25143433-4 2015 Cisplatin treatment elicited apoptosis, ATM phosphorylation, upregulation of p53, Noxa (PMAIP1), and PUMA (BBC3), and cleavage of caspase-9, -7, fodrin, and PARP-1 in MCF-7 cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 77-80 25553088-0 2015 Upregulation of Acetylcholinesterase Mediated by p53 Contributes to Cisplatin-Induced Apoptosis in Human Breast Cancer Cell. Cisplatin 68-77 tumor protein p53 Homo sapiens 49-52 25553088-9 2015 CONCLUSION: Taken together, these results suggested that AChE expression could be upregulated by the activation of p53 during apoptosis induced by cisplatin in MCF-7 cells. Cisplatin 147-156 tumor protein p53 Homo sapiens 115-118 25143433-5 2015 Inducible DeltaNErbB2 expression strongly reduced cisplatin-induced ATM- and p53-phosphorylation, augmented Noxa upregulation and caspase-9 and -7 cleavage, doubled p21(WAF1/Cip1) (CDKN1A) expression, and nearly abolished Bcl-2 expression. Cisplatin 50-59 tumor protein p53 Homo sapiens 77-80 25436001-10 2015 The PDCD5 transfected cells showed higher sensitivity to cisplatin treatment than the HepG2-Neo cells, with a higher p53 protein expression level. Cisplatin 57-66 tumor protein p53 Homo sapiens 117-120 25348361-9 2015 In conclusion, DNA-PKcs suppression had complementary effects in combination with CDDP and 5-Fu treatment in HepG2 cells, which was associated with suppression of NF-kappaB signaling pathway cascade, activation of caspase-3 and p53, as well as down-regulation of Bcl-2 and GSH. Cisplatin 82-86 tumor protein p53 Homo sapiens 228-231 25164962-4 2015 Sequential treatment of Taxol or cisplatin, followed by MK-2206, induced a synergistic inhibition of cell proliferation and effectively promoted cell death, either by inhibiting the phosphorylation of Akt and its downstream effectors 4E-BP1 and p70S6K in SKOV3 cells or by restoring p53 levels, which were downregulated after Taxol or cisplatin treatment, in ES2 cells. Cisplatin 33-42 tumor protein p53 Homo sapiens 283-286 25220870-0 2014 Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells. Cisplatin 102-111 tumor protein p53 Homo sapiens 13-16 25220870-13 2014 Combinational treatment with zerumbone and cisplatin significantly accelerated apoptosis and promoted p53 expression and ROS production in NSCLC cells, compared with each alone. Cisplatin 43-52 tumor protein p53 Homo sapiens 102-105 25135238-13 2014 CONCLUSIONS: The biomarker TP53 divides esophageal cancer patients into 2 categories with markedly different outcomes: patients with a normal TP53 marker status may experience notable benefits from neoadjuvant chemotherapy with cisplatin/fluorouracil, whereas those with a mutant TP53 marker status appear to be at risk for lack of response. Cisplatin 228-237 tumor protein p53 Homo sapiens 27-31 25622680-12 2014 Cisplatin up-regulated p53, Mdm2 and p21 in both cell lines. Cisplatin 0-9 tumor protein p53 Homo sapiens 23-26 25622680-17 2014 CONCLUSION: p14ARF enhances the chemosensitivity to cisplatin in human osteosarcoma U2OS cells through p53 apoptotic pathway. Cisplatin 52-61 tumor protein p53 Homo sapiens 103-106 25356874-5 2014 In that sense, enhanced DNA repair, high glutathione levels and functional p53 have a critical role on cisplatin resistance. Cisplatin 103-112 tumor protein p53 Homo sapiens 75-78 25112877-0 2014 p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers. Cisplatin 20-29 tumor protein p53 Homo sapiens 0-3 24913304-0 2014 A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. Cisplatin 2-11 tumor protein p53 Homo sapiens 70-73 24913304-1 2014 PURPOSE: Head and neck squamous cell carcinoma (HNSCC) cell lines with cytoplasmically sequestered mutant p53 (p53(mut_c)) are frequently more resistant to cisplatin (CDDP) than cells with mutant but nuclear p53 (p53(mut_n)). Cisplatin 156-165 tumor protein p53 Homo sapiens 106-109 24913304-1 2014 PURPOSE: Head and neck squamous cell carcinoma (HNSCC) cell lines with cytoplasmically sequestered mutant p53 (p53(mut_c)) are frequently more resistant to cisplatin (CDDP) than cells with mutant but nuclear p53 (p53(mut_n)). Cisplatin 156-165 tumor protein p53 Homo sapiens 111-114 24913304-1 2014 PURPOSE: Head and neck squamous cell carcinoma (HNSCC) cell lines with cytoplasmically sequestered mutant p53 (p53(mut_c)) are frequently more resistant to cisplatin (CDDP) than cells with mutant but nuclear p53 (p53(mut_n)). Cisplatin 156-165 tumor protein p53 Homo sapiens 111-114 24913304-1 2014 PURPOSE: Head and neck squamous cell carcinoma (HNSCC) cell lines with cytoplasmically sequestered mutant p53 (p53(mut_c)) are frequently more resistant to cisplatin (CDDP) than cells with mutant but nuclear p53 (p53(mut_n)). Cisplatin 156-165 tumor protein p53 Homo sapiens 111-114 24913304-1 2014 PURPOSE: Head and neck squamous cell carcinoma (HNSCC) cell lines with cytoplasmically sequestered mutant p53 (p53(mut_c)) are frequently more resistant to cisplatin (CDDP) than cells with mutant but nuclear p53 (p53(mut_n)). Cisplatin 167-171 tumor protein p53 Homo sapiens 106-109 24913304-2 2014 The aim of the study was to identify underlying mechanisms implicated in CDDP resistance of HNSCC cells carrying cytoplasmic p53(mut). Cisplatin 73-77 tumor protein p53 Homo sapiens 125-128 24913304-3 2014 METHODS: Microarray analysis, quantitative reverse transcription polymerase chain reaction, Western blot analysis and immunocytochemistry were used to identify and evaluate candidate genes involved in CDDP resistance of p53(mut_c) cells. Cisplatin 201-205 tumor protein p53 Homo sapiens 220-223 24913304-10 2014 CONCLUSIONS: The observations in this study point to a major role of p53(mut_c) in conferring a stem cell like phenotype to HNSCC cells that is associated with ABCC2/G2 overexpression, high GSH and metabolic activity levels as well as CDDP resistance. Cisplatin 235-239 tumor protein p53 Homo sapiens 69-72 25208472-9 2014 The Beclin-1-p53 interaction was also disrupted by exposure to cisplatin-induced stress resulting in higher level of Beclin-1 because of lesser ubiquitination. Cisplatin 63-72 tumor protein p53 Homo sapiens 13-16 25149542-8 2014 Finally, we showed that Cisplatin could restrain the invasion of ESCC cells by inducing the expression of ATF3 via P53 signaling. Cisplatin 24-33 tumor protein p53 Homo sapiens 115-118 25112877-5 2014 The requirements of Oma1 and p53 for CDDP-induced L-Opa1 processing, mitochondrial fragmentation, and apoptosis were examined by siRNA or cDNA. Cisplatin 37-41 tumor protein p53 Homo sapiens 29-32 25112877-9 2014 Silencing p53 expression attenuated the effects of CDDP in Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis in chemosensitive OVCA cells, whereas reconstitution of p53 in p53 mutant or null chemoresistant OVCA cells induced Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis irrespective of the presence of CDDP. Cisplatin 51-55 tumor protein p53 Homo sapiens 10-13 25112877-9 2014 Silencing p53 expression attenuated the effects of CDDP in Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis in chemosensitive OVCA cells, whereas reconstitution of p53 in p53 mutant or null chemoresistant OVCA cells induced Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis irrespective of the presence of CDDP. Cisplatin 51-55 tumor protein p53 Homo sapiens 201-204 25112877-9 2014 Silencing p53 expression attenuated the effects of CDDP in Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis in chemosensitive OVCA cells, whereas reconstitution of p53 in p53 mutant or null chemoresistant OVCA cells induced Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis irrespective of the presence of CDDP. Cisplatin 51-55 tumor protein p53 Homo sapiens 201-204 25112877-9 2014 Silencing p53 expression attenuated the effects of CDDP in Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis in chemosensitive OVCA cells, whereas reconstitution of p53 in p53 mutant or null chemoresistant OVCA cells induced Oma1 (40 kDa) increase, L-Opa1 processing, mitochondrial fragmentation, and apoptosis irrespective of the presence of CDDP. Cisplatin 379-383 tumor protein p53 Homo sapiens 10-13 25112877-10 2014 Prohibitin 1 (Phb1) dissociates from Opa1-Phb1 complex and binds phosphorylated p53 (serine 15) in response to CDDP in chemosensitive but not chemoresistant CECA cells. Cisplatin 111-115 tumor protein p53 Homo sapiens 80-83 25112877-11 2014 These findings demonstrate that (a) p53 and Oma1 mediate L-Opa1 processing, (b) mitochondrial fragmentation is involved in CDDP-induced apoptosis in OVCA and CECA cells, and (c) dysregulated mitochondrial dynamics may in part be involved in the pathophysiology of CDDP resistance. Cisplatin 264-268 tumor protein p53 Homo sapiens 36-39 24960055-9 2014 Taken together, HBCD and PCBs at low concentrations could increase the resistance of HCC cells to cisplatin through modulation on NF-kappaB pathway activation and p53 function, which is associated with the activity of PI3K/Akt pathway. Cisplatin 98-107 tumor protein p53 Homo sapiens 163-166 24814195-8 2014 Furthermore, activation of FOXO3a induced cell apoptosis irrespective of p53 status, whereas p53 may act as FOXO3a downstream molecules involved in cisplatin-induced cell apoptosis. Cisplatin 148-157 tumor protein p53 Homo sapiens 93-96 24944268-3 2014 Magnesium deficiency significantly increased cisplatin-associated weight loss and markers of renal damage (plasma blood urea nitrogen and creatinine), histological changes, inflammation, and renal cell apoptosis and modulated signaling pathways (e.g., ERK1/2, p53, and STAT3). Cisplatin 45-54 tumor protein p53 Homo sapiens 260-263 24830845-6 2014 Six dual-point mutants were found to have moderate or high activities with their IC50 values ranging from 16.3 to 137.0 muM, which are better than that of wild-type p53 peptide (IC50 = 182.6 muM) and close to that of classical anticancer agent cis-platin (IC50 = 4.3 muM). Cisplatin 244-254 tumor protein p53 Homo sapiens 165-168 24981574-0 2014 Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Cisplatin 0-9 tumor protein p53 Homo sapiens 116-119 24981574-0 2014 Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Cisplatin 0-9 tumor protein p53 Homo sapiens 134-137 24981574-5 2014 Cisplatin treatments enhanced p53 and BTG2 expression, repressed AR and PSA expression, and blocked the activation of androgen on the PSA secretion in LNCaP cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 30-33 24981574-9 2014 Our results indicated that cisplatin attenuates prostate cancer cell proliferation partly mediated by upregulation of BTG2 through the p53-dependent pathway or p53-independent NFkappaB pathway. Cisplatin 27-36 tumor protein p53 Homo sapiens 135-138 24981574-9 2014 Our results indicated that cisplatin attenuates prostate cancer cell proliferation partly mediated by upregulation of BTG2 through the p53-dependent pathway or p53-independent NFkappaB pathway. Cisplatin 27-36 tumor protein p53 Homo sapiens 160-163 24922076-6 2014 We provide evidence that the decrease in SIRT1 activity and expression facilitated by increasing poly(ADP-ribose) transferase (PARP)-1 activation and microRNA-34a through p53 activation aggravates cisplatin-mediated ototoxicity. Cisplatin 197-206 tumor protein p53 Homo sapiens 171-174 24737586-3 2014 In this current study, we found low expression of UNC5A in bladder cancer, an effective induction of UNC5A by cisplatin in bladder cancer cell lines with wt p53, and a significant reduction of cisplatin-mediated cell death following silencing the endogenous UNC5A. Cisplatin 110-119 tumor protein p53 Homo sapiens 157-160 24710632-8 2014 DNA damage induced p53 stabilization and p21 induction by cisplatin treatment confirmed that wt-AGR2 expression suppressed the p53 pathway. Cisplatin 58-67 tumor protein p53 Homo sapiens 127-130 24480460-5 2014 Treatment of cells overexpressing Aurora-A and ATM/Chk2 with the ATM specific inhibitor KU-55933 increased the cell sensitivity to cisplatin and irradiation through increasing the phosphorylation of p53 at Ser15 and inhibiting the expression of Chk2, gammaH2AX (Ser319), and RAD51. Cisplatin 131-140 tumor protein p53 Homo sapiens 199-202 24756776-5 2014 Forced overexpression of GRP78 protected the cisplatin-sensitive A2780 cells from cisplatin-induced senescence through P53 and CDC2. Cisplatin 45-54 tumor protein p53 Homo sapiens 119-122 24756776-5 2014 Forced overexpression of GRP78 protected the cisplatin-sensitive A2780 cells from cisplatin-induced senescence through P53 and CDC2. Cisplatin 82-91 tumor protein p53 Homo sapiens 119-122 24823795-5 2014 We demonstrate that cisplatin and adriamycin elicit distinct effects on TP53 and TP63 binding events, through which TP53 can induce or repress transcription of an extensive network of genes by direct binding and/or modulation of TP63 activity. Cisplatin 20-29 tumor protein p53 Homo sapiens 72-76 24823795-5 2014 We demonstrate that cisplatin and adriamycin elicit distinct effects on TP53 and TP63 binding events, through which TP53 can induce or repress transcription of an extensive network of genes by direct binding and/or modulation of TP63 activity. Cisplatin 20-29 tumor protein p53 Homo sapiens 116-120 24829158-4 2014 CDDP induced apoptosis within cells through the generation of reactive oxygen species (ROS), regulated the ROS-mediated expression of Bax, Bcl-2, and p53, and induced the degradation of the poly (ADP-ribosyl) polymerase (PARP). Cisplatin 0-4 tumor protein p53 Homo sapiens 150-153 24504010-7 2014 Genes with expression changed by drugs were related to GO term "extracellular region" and "p53 signaling pathway" in both 5-FU- and CDDP-treated cells. Cisplatin 132-136 tumor protein p53 Homo sapiens 91-94 24495481-0 2014 Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Cisplatin 65-74 tumor protein p53 Homo sapiens 16-20 24519527-3 2014 We recently demonstrated that a combination of sodium arsenite (NaAsO2) and hyperthermia sensitizes p53-expressing ovarian cancer cells to cisplatin by modulating DNA repair pathway and enhancing platinum accumulation. Cisplatin 139-148 tumor protein p53 Homo sapiens 100-103 24445997-10 2014 Atox1 expression increased in HCT 116 p53(+/+) and p53(-/-) cells treated with cisplatin; however, Atox1 localized to the nuclei of p53(+/+) cells more than in the p53(-/-) cells. Cisplatin 79-88 tumor protein p53 Homo sapiens 38-41 24366574-8 2014 These findings, together with significantly elevated MT, decreased p53 and Bax indicate PC-3 to be cisplatin-resistant. Cisplatin 99-108 tumor protein p53 Homo sapiens 67-70 24463159-1 2014 OBJECTIVE: TP53 K351N mutation is associated with acquired cisplatin resistance in ovarian cancer cells following exposure to cisplatin. Cisplatin 59-68 tumor protein p53 Homo sapiens 11-15 24463159-1 2014 OBJECTIVE: TP53 K351N mutation is associated with acquired cisplatin resistance in ovarian cancer cells following exposure to cisplatin. Cisplatin 126-135 tumor protein p53 Homo sapiens 11-15 24445997-9 2014 In cells treated with cisplatin, the uptake of (64)Cu in the nucleus of HCT 116 p53(+/+) cells was greater than that in HCT 116 p53(-/-) cells. Cisplatin 22-31 tumor protein p53 Homo sapiens 80-83 24445997-9 2014 In cells treated with cisplatin, the uptake of (64)Cu in the nucleus of HCT 116 p53(+/+) cells was greater than that in HCT 116 p53(-/-) cells. Cisplatin 22-31 tumor protein p53 Homo sapiens 128-131 24445997-10 2014 Atox1 expression increased in HCT 116 p53(+/+) and p53(-/-) cells treated with cisplatin; however, Atox1 localized to the nuclei of p53(+/+) cells more than in the p53(-/-) cells. Cisplatin 79-88 tumor protein p53 Homo sapiens 51-54 24445997-10 2014 Atox1 expression increased in HCT 116 p53(+/+) and p53(-/-) cells treated with cisplatin; however, Atox1 localized to the nuclei of p53(+/+) cells more than in the p53(-/-) cells. Cisplatin 79-88 tumor protein p53 Homo sapiens 51-54 24445997-10 2014 Atox1 expression increased in HCT 116 p53(+/+) and p53(-/-) cells treated with cisplatin; however, Atox1 localized to the nuclei of p53(+/+) cells more than in the p53(-/-) cells. Cisplatin 79-88 tumor protein p53 Homo sapiens 51-54 24712372-6 2014 Meanwhile, as a critical regulator in the cisplatin-induced apoptosis, p53 was elevated by silencing of hsa-miR-98-5p. Cisplatin 42-51 tumor protein p53 Homo sapiens 71-74 24606472-0 2014 Expression of bcl-2 and p53 in induction of esophageal cancer cell apoptosis by ECRG2 in combination with cisplatin. Cisplatin 106-115 tumor protein p53 Homo sapiens 24-27 24161623-0 2014 Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. Cisplatin 126-135 tumor protein p53 Homo sapiens 43-46 24161623-2 2014 Here we show a critical role for cisplatin combined with gene therapy, using transfection of a p53 gene/MDM2-siRNA plasmid, in improving cisplatin sensitivity of SKOV3/DDP cells with a strong inhibition of tumor cell growth in vitro and in vivo. Cisplatin 33-42 tumor protein p53 Homo sapiens 95-98 24161623-2 2014 Here we show a critical role for cisplatin combined with gene therapy, using transfection of a p53 gene/MDM2-siRNA plasmid, in improving cisplatin sensitivity of SKOV3/DDP cells with a strong inhibition of tumor cell growth in vitro and in vivo. Cisplatin 137-146 tumor protein p53 Homo sapiens 95-98 24161623-5 2014 These results indicate that cisplatin chemotherapy combined with targeting the MDM2/p53 axis is an attractive strategy to treat SKOV3/DDP cancer. Cisplatin 28-37 tumor protein p53 Homo sapiens 84-87 24525232-5 2014 p53-like MIBCs were consistently resistant to neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after therapy. Cisplatin 101-110 tumor protein p53 Homo sapiens 0-3 24317338-9 2014 These results suggest that ABCA1, ABCA3, ABCA7 and ABCB10 are candidate genes for the cisplatin efflux transporter that is involved in the cisplatin resistance of KCP-4 cells, and that the mutation at codon 72 of p53 may contribute to the development of cisplatin resistance. Cisplatin 86-95 tumor protein p53 Homo sapiens 213-216 24317338-9 2014 These results suggest that ABCA1, ABCA3, ABCA7 and ABCB10 are candidate genes for the cisplatin efflux transporter that is involved in the cisplatin resistance of KCP-4 cells, and that the mutation at codon 72 of p53 may contribute to the development of cisplatin resistance. Cisplatin 139-148 tumor protein p53 Homo sapiens 213-216 24317338-9 2014 These results suggest that ABCA1, ABCA3, ABCA7 and ABCB10 are candidate genes for the cisplatin efflux transporter that is involved in the cisplatin resistance of KCP-4 cells, and that the mutation at codon 72 of p53 may contribute to the development of cisplatin resistance. Cisplatin 139-148 tumor protein p53 Homo sapiens 213-216 24403501-10 2014 Cisplatin produced a similar profile, with increased p53 protein. Cisplatin 0-9 tumor protein p53 Homo sapiens 53-56 24240108-9 2014 The activation of HDM2 by AURKA led to induction of P53 ubiquitination and attenuation of cisplatin-induced activation of P53 in gastric cancer cells. Cisplatin 90-99 tumor protein p53 Homo sapiens 122-125 24218165-7 2014 The presence of gammaH2AX foci and phosphorylation of TP53(ser15) and CHK1(ser317) were shown in U343 cells, compatible with cisplatin-induced DNA damage. Cisplatin 125-134 tumor protein p53 Homo sapiens 54-58 24173208-0 2014 Autophagy induction by low-dose cisplatin: the role of p53 in autophagy. Cisplatin 32-41 tumor protein p53 Homo sapiens 55-58 24712372-7 2014 These results suggested that EGCG inhibited the expression of hsa-miR-98-5p, followed by an increase of p53, thus the efficacy of cisplatin was enhanced. Cisplatin 130-139 tumor protein p53 Homo sapiens 104-107 24173208-13 2014 Following 3-MA pretreatment, cisplatin-induced autophagy was found to be markedly reduced (a 3-fold reduction) in wild-type p53 compared to null-type p53 cells. Cisplatin 29-38 tumor protein p53 Homo sapiens 124-127 24173208-13 2014 Following 3-MA pretreatment, cisplatin-induced autophagy was found to be markedly reduced (a 3-fold reduction) in wild-type p53 compared to null-type p53 cells. Cisplatin 29-38 tumor protein p53 Homo sapiens 150-153 24173208-14 2014 However, cisplatin-induced apoptosis increased in wild-type p53 compared to null-type p53 cells. Cisplatin 9-18 tumor protein p53 Homo sapiens 60-63 24173208-14 2014 However, cisplatin-induced apoptosis increased in wild-type p53 compared to null-type p53 cells. Cisplatin 9-18 tumor protein p53 Homo sapiens 86-89 24173208-15 2014 Autophagy induction and apoptotic shift after autophagy inhibition may be mediated by p53 activation in lung cancer cells treated with low-dose cisplatin. Cisplatin 144-153 tumor protein p53 Homo sapiens 86-89 24348832-11 2014 In addition, VX680 and cisplatin increased the expression of the p53 protein. Cisplatin 23-32 tumor protein p53 Homo sapiens 65-68 32261335-7 2013 Furthermore, Se@Trolox effectively blocked the cisplatin-induced reactive oxygen species (ROS) accumulation, activation of AKT and MAPK signaling and DNA damage-mediated p53 phosphorylation in HK-2 cells. Cisplatin 47-56 tumor protein p53 Homo sapiens 170-173 24732641-0 2014 MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients. Cisplatin 79-88 tumor protein p53 Homo sapiens 19-23 24076372-5 2013 PLK1 was downregulated in cisplatin exposed HCT116p53(+/+) but not HCT116p53(-/-) cells, indicating p53-suppressed PLK1 upon DNA damage. Cisplatin 26-35 tumor protein p53 Homo sapiens 50-53 23625774-11 2013 p53 levels were inversely associated with the expression of Oct4, Sox2, and Nanog in response to cisplatin. Cisplatin 97-106 tumor protein p53 Homo sapiens 0-3 24136147-9 2013 Addition of the chemotherapeutic drug cisplatin to the combination further increased p53 and DR5 levels and rhTRAIL- and D269H/E195R-induced apoptosis. Cisplatin 38-47 tumor protein p53 Homo sapiens 85-88 24074238-5 2013 The frequent presence of wild-type TP53 and the low levels of p53 in complex with the p53 negative feed-back regulator MDM2 contribute to cisplatin sensitivity. Cisplatin 138-147 tumor protein p53 Homo sapiens 35-39 23929259-7 2013 Cisplatin-induced nephropathy is also mediated through the p53 and protein kinase-Cdelta (PKCdelta) signalling pathways. Cisplatin 0-9 tumor protein p53 Homo sapiens 59-62 24191930-3 2013 The NAPA (protein) Napsin A was described to promote resistance to cisplatin by degradation of the tumor suppressor p53. Cisplatin 67-76 tumor protein p53 Homo sapiens 116-119 23970333-0 2013 p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Cisplatin 29-38 tumor protein p53 Homo sapiens 0-3 23970333-12 2013 The induction of wild-type p53 can enhance CDDP-induced apoptosis not only by inducing Bax protein but also by suppressing anti-apoptotic proteins through inhibition of Akt. Cisplatin 43-47 tumor protein p53 Homo sapiens 27-30 23970333-13 2013 In conclusion, this study suggests that the primary contributor to resistance to CDDP in SNU-16 cells may well be a failure of induction of apoptosis due to a lack of induction of pro-apoptotic proteins rather than suppression of anti-apoptotic proteins, and that restoration of p53 function can overcome the resistance to CDDP not only by augmenting the pro-apoptotic drive through p53-mediated transcriptional activation but also by inhibiting the anti-apoptotic drive through inhibition of Akt activity. Cisplatin 81-85 tumor protein p53 Homo sapiens 279-282 23970333-13 2013 In conclusion, this study suggests that the primary contributor to resistance to CDDP in SNU-16 cells may well be a failure of induction of apoptosis due to a lack of induction of pro-apoptotic proteins rather than suppression of anti-apoptotic proteins, and that restoration of p53 function can overcome the resistance to CDDP not only by augmenting the pro-apoptotic drive through p53-mediated transcriptional activation but also by inhibiting the anti-apoptotic drive through inhibition of Akt activity. Cisplatin 81-85 tumor protein p53 Homo sapiens 383-386 24074238-5 2013 The frequent presence of wild-type TP53 and the low levels of p53 in complex with the p53 negative feed-back regulator MDM2 contribute to cisplatin sensitivity. Cisplatin 138-147 tumor protein p53 Homo sapiens 62-65 24074238-5 2013 The frequent presence of wild-type TP53 and the low levels of p53 in complex with the p53 negative feed-back regulator MDM2 contribute to cisplatin sensitivity. Cisplatin 138-147 tumor protein p53 Homo sapiens 86-89 23839309-0 2013 Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Cisplatin 32-41 tumor protein p53 Homo sapiens 119-122 24086535-3 2013 Akt and p53 are determinants of cisplatin sensitivity. Cisplatin 32-41 tumor protein p53 Homo sapiens 8-11 24086535-5 2013 However, the precise role of rictor and the relationship between rictor and p53 in cisplatin resistance remains poorly understood. Cisplatin 83-92 tumor protein p53 Homo sapiens 76-79 23873478-7 2013 RESULTS: Experiments with HCT116 cells that are p53 +/+ (p53 wild-type) and -/- (p53 null) grown in cell culture demonstrated that preincubation with cisplatin increased expression of p53 and subsequently enhanced localization of (64)Cu from (64)Cu-acetate and (64)Cu-DOTA-cetuximab to the tumor cell nuclei. Cisplatin 150-159 tumor protein p53 Homo sapiens 48-51 23873478-7 2013 RESULTS: Experiments with HCT116 cells that are p53 +/+ (p53 wild-type) and -/- (p53 null) grown in cell culture demonstrated that preincubation with cisplatin increased expression of p53 and subsequently enhanced localization of (64)Cu from (64)Cu-acetate and (64)Cu-DOTA-cetuximab to the tumor cell nuclei. Cisplatin 150-159 tumor protein p53 Homo sapiens 57-60 23873478-7 2013 RESULTS: Experiments with HCT116 cells that are p53 +/+ (p53 wild-type) and -/- (p53 null) grown in cell culture demonstrated that preincubation with cisplatin increased expression of p53 and subsequently enhanced localization of (64)Cu from (64)Cu-acetate and (64)Cu-DOTA-cetuximab to the tumor cell nuclei. Cisplatin 150-159 tumor protein p53 Homo sapiens 57-60 23873478-7 2013 RESULTS: Experiments with HCT116 cells that are p53 +/+ (p53 wild-type) and -/- (p53 null) grown in cell culture demonstrated that preincubation with cisplatin increased expression of p53 and subsequently enhanced localization of (64)Cu from (64)Cu-acetate and (64)Cu-DOTA-cetuximab to the tumor cell nuclei. Cisplatin 150-159 tumor protein p53 Homo sapiens 57-60 23839309-2 2013 TP53 is the most commonly mutated gene in HNSCC, and the impact of p53 mutation on response to cisplatin treatment is poorly understood. Cisplatin 95-104 tumor protein p53 Homo sapiens 67-70 23839309-3 2013 Here, we show unambiguously that wild-type TP53 (wtp53) is associated with sensitivity of HNSCC cells to cisplatin treatment, whereas mutation or loss of TP53 is associated with cisplatin resistance. Cisplatin 105-114 tumor protein p53 Homo sapiens 43-47 23839309-3 2013 Here, we show unambiguously that wild-type TP53 (wtp53) is associated with sensitivity of HNSCC cells to cisplatin treatment, whereas mutation or loss of TP53 is associated with cisplatin resistance. Cisplatin 178-187 tumor protein p53 Homo sapiens 154-158 23839309-4 2013 We also show that senescence is the major cellular response to cisplatin in wtp53 HNSCC cells and that cisplatin resistance in p53-null or -mutant TP53 cells is due to their lack of senescence. Cisplatin 63-72 tumor protein p53 Homo sapiens 78-81 23839309-4 2013 We also show that senescence is the major cellular response to cisplatin in wtp53 HNSCC cells and that cisplatin resistance in p53-null or -mutant TP53 cells is due to their lack of senescence. Cisplatin 103-112 tumor protein p53 Homo sapiens 147-151 23839309-6 2013 Treatment of p53-deficient HNSCC cells with the Chk inhibitor AZD7762 sensitizes them to cisplatin through induction of mitotic cell death. Cisplatin 89-98 tumor protein p53 Homo sapiens 13-16 24067199-0 2013 Cisplatin induces cell cycle arrest and senescence via upregulating P53 and P21 expression in HepG2 cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 68-71 23839309-7 2013 This is the first report showing the ability of a Chk kinase inhibitor to sensitize TP53-deficient HNSCC to cisplatin in a synthetic lethal manner, which has significance given the frequency of TP53 mutations in this disease and because cisplatin has become part of standard therapy for aggressive HNSCC tumors. Cisplatin 108-117 tumor protein p53 Homo sapiens 84-88 24067199-9 2013 Western blotting confirmed P53 and P21 expression changes similar to their mRNA expressions during cisplatin-induced cellular senescence in HepG2 cells. Cisplatin 99-108 tumor protein p53 Homo sapiens 27-30 23839309-7 2013 This is the first report showing the ability of a Chk kinase inhibitor to sensitize TP53-deficient HNSCC to cisplatin in a synthetic lethal manner, which has significance given the frequency of TP53 mutations in this disease and because cisplatin has become part of standard therapy for aggressive HNSCC tumors. Cisplatin 108-117 tumor protein p53 Homo sapiens 194-198 23839309-7 2013 This is the first report showing the ability of a Chk kinase inhibitor to sensitize TP53-deficient HNSCC to cisplatin in a synthetic lethal manner, which has significance given the frequency of TP53 mutations in this disease and because cisplatin has become part of standard therapy for aggressive HNSCC tumors. Cisplatin 237-246 tumor protein p53 Homo sapiens 84-88 23188704-5 2013 From among a panel of apoptosis-related factors (p53, Bcl-2, Bcl-XL, BAX, and survivin), the expression of Livin was upregulated after cisplatin treatment in a dose-dependent manner. Cisplatin 135-144 tumor protein p53 Homo sapiens 49-52 23977343-8 2013 These data demonstrated firstly to our knowledge that IFN-beta produced synergistic anti-tumor effects with cisplatin or pemetrexed on mesothelioma through up-regulated p53 expression. Cisplatin 108-117 tumor protein p53 Homo sapiens 169-172 23934659-0 2013 Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry. Cisplatin 0-9 tumor protein p53 Homo sapiens 51-54 23845906-11 2013 Together, these data suggested that cisplatin-induced non-apoptotic death requires mitochondria Cyp-D-p53 signaling in pancreatic cancer cells. Cisplatin 36-45 tumor protein p53 Homo sapiens 102-105 23399702-6 2013 The p53 band in Figure 3C is very similar to the Caspase 9 blot in Figure 4B and is cropped and duplicated in Figure 6A as p-NFKB by cisplatin in SiHa cells. Cisplatin 133-142 tumor protein p53 Homo sapiens 4-7 23098692-5 2013 1,25(OH)2D3 augmented the effect of cisplatin in an embryonal carcinoma-derived cell line (NTera2), possibly through downregulation of pluripotency genes and simultaneous upregulation of the cell cycle regulators p21, p27, p53, p73 and FOXO1, while no significant effects were found in TCam-2 and 2102Ep cell lines (derived from seminoma and embryonal carcinoma, respectively). Cisplatin 36-45 tumor protein p53 Homo sapiens 223-226 23360684-4 2013 The cleavage of caspases and PARP, activation of p53 and mitochondrial-mediated apoptosis pathways induced by cisplatin were effectively blocked by cyanidin. Cisplatin 110-119 tumor protein p53 Homo sapiens 49-52 23545901-8 2013 Taken together, our results indicate that GABARBP can regulate the pro-apoptotic activity of cisplatin via the upregulation of p53 expression. Cisplatin 93-102 tumor protein p53 Homo sapiens 127-130 23462712-8 2013 Similarly to cisplatin this compound interacts with nuclear DNA and induces both p53 and p21(waf), and thus it represents an interesting starting point for future optimisation of new Pt(II) complexes forming DNA adducts. Cisplatin 13-22 tumor protein p53 Homo sapiens 81-84 22961628-0 2013 Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Cisplatin 53-62 tumor protein p53 Homo sapiens 93-97 22961628-4 2013 Cisplatin is a genotoxic drug that leads cells to apoptosis through the activation of the p53 pathway. Cisplatin 0-9 tumor protein p53 Homo sapiens 90-93 22961628-7 2013 The wild-type p53 cisplatin-resistant ovarian cancer cell-line A2780cis was used to test the effect of Nutlin-3a (Nut3a) on apoptosis response. Cisplatin 18-27 tumor protein p53 Homo sapiens 14-17 22961628-9 2013 Increased apoptosis was also induced in wild-type TP53 primary OVCa cultures by double cisplatin-Nut3a treatment. Cisplatin 87-96 tumor protein p53 Homo sapiens 50-54 22961628-11 2013 As increased response was generalized in primary tumors, this cisplatin-Nut3a combination could be useful for the treatment of patients harboring wild-type TP53 who do not respond to standard chemotherapy. Cisplatin 62-71 tumor protein p53 Homo sapiens 156-160 23845906-0 2013 Cisplatin-induced non-apoptotic death of pancreatic cancer cells requires mitochondrial cyclophilin-D-p53 signaling. Cisplatin 0-9 tumor protein p53 Homo sapiens 102-105 23845906-3 2013 Here, we found that cisplatin mainly induced non-apoptotic death of the pancreatic cancer cells (AsPC-1 and Capan-2), which was associated with a significant p53 activation (phosphorylation and accumulation). Cisplatin 20-29 tumor protein p53 Homo sapiens 158-161 23845906-5 2013 We provided evidences to support that mitochondrial Cyp-D/p53 complexation might be critical for cisplatin-induced non-apoptotic death of pancreatic cancer cells. Cisplatin 97-106 tumor protein p53 Homo sapiens 58-61 23845906-8 2013 Meanwhile, the pancreatic cancer cells with p53 knockdown were resistant to cisplatin. Cisplatin 76-85 tumor protein p53 Homo sapiens 44-47 23356234-6 2013 We also used the MTT assay and flow cytometry to investigate if silencing of mutant p53 by knockdown with small interfering (si)RNA would change the sensitivity to cisplatin treatment. Cisplatin 164-173 tumor protein p53 Homo sapiens 84-87 23302226-4 2013 We previously showed that p53 is a major player in cisplatin hypersensitivity and therefore investigated whether Oct-4 may directly affect p53 activity. Cisplatin 51-60 tumor protein p53 Homo sapiens 26-29 23149124-5 2013 Stable silencing of STAT3 expression sensitized A549 cells to DNA damaging chemotherapeutics doxorubicin and cisplatin in a p53-independent manner. Cisplatin 109-118 tumor protein p53 Homo sapiens 124-127 23076534-6 2013 Periostin-overexpressing cells treated with cisplatin or 5-FU showed significantly (p < 0.05) decreased expression of Bax and p53 proteins and increased expression of Bcl-2 protein, when compared to drug-treated mock counterparts. Cisplatin 44-53 tumor protein p53 Homo sapiens 129-132 23351152-0 2013 PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. Cisplatin 18-27 tumor protein p53 Homo sapiens 84-87 23351152-5 2013 Apoptosis in cells treated with PRIMA-1 (0.156 muM) and CDDP treatment (10 muM) was significantly suppressed by p53-siRNA. Cisplatin 56-60 tumor protein p53 Homo sapiens 112-115 23351152-6 2013 PRIMA-1 increased phospho-p53 (Ser15) content in Akt down-regulated cells treated with CDDP. Cisplatin 87-91 tumor protein p53 Homo sapiens 26-29 23351152-8 2013 Our findings raise the possibility that PRIMA-1 may be useful candidate for adjuvant therapy with CDDP in chemoresistant ovarian cancer with p53 mutation when Akt is down-regulated. Cisplatin 98-102 tumor protein p53 Homo sapiens 141-144 23356234-8 2013 Moreover, our study also showed that the p53-targeting siRNA cooperated with cisplatin in the inhibition of bladder cancer cells. Cisplatin 77-86 tumor protein p53 Homo sapiens 41-44 23054612-6 2013 Importantly, when p53 was activated following the administration of either of three different anticancer chemotherapeutic agents (cisplatin, etoposide or doxorubicin), it was able to induce CYP3A genes, which are the main factors in systemic clearance of these agents. Cisplatin 130-139 tumor protein p53 Homo sapiens 18-21 24289605-7 2013 First, we evaluated whether the genotoxic potential of cisplatin/gemcitabine was dependent on TP53 status. Cisplatin 55-64 tumor protein p53 Homo sapiens 94-98 24289605-13 2013 However, cisplatin was the most effective, causing the highest level of DNA damage in both wild-type and mutated TP53 cells. Cisplatin 9-18 tumor protein p53 Homo sapiens 113-117 23255126-0 2013 Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cisplatin 33-42 tumor protein p53 Homo sapiens 21-24 23255126-9 2013 In a p53-null background, the high-level expression of both exogenous WT and mutant p53 increased the resistance of these cells to cisplatin, and the data showed a correlation between high p53 expression and caspase-9 inhibition. Cisplatin 131-140 tumor protein p53 Homo sapiens 84-87 23255126-9 2013 In a p53-null background, the high-level expression of both exogenous WT and mutant p53 increased the resistance of these cells to cisplatin, and the data showed a correlation between high p53 expression and caspase-9 inhibition. Cisplatin 131-140 tumor protein p53 Homo sapiens 84-87 24335178-14 2013 CONCLUSION: These findings not only indicate NAC as a rational approach for better treatment of cervical cancer with improved therapeutic outcomes, due partly to the ability of cisplatin to promote the p53:miR-34a:E2F1 positive feed-forward loop and the p53:miR-605:Mdm2 positive feedback loop. Cisplatin 177-186 tumor protein p53 Homo sapiens 202-205 24335178-12 2013 Among the three anti-cancer drugs included in NAC, cisplatin was found to be the main component that caused increases in p53 protein levels, miR-34a and miR-605 miRNA levels, and decreases in Mdm2 and E2F1 protein levels. Cisplatin 51-60 tumor protein p53 Homo sapiens 121-124 24335178-14 2013 CONCLUSION: These findings not only indicate NAC as a rational approach for better treatment of cervical cancer with improved therapeutic outcomes, due partly to the ability of cisplatin to promote the p53:miR-34a:E2F1 positive feed-forward loop and the p53:miR-605:Mdm2 positive feedback loop. Cisplatin 177-186 tumor protein p53 Homo sapiens 254-257 23128378-9 2013 Furthermore, iNOS gene-mediated enhancement of cisplatin-mediated antitumor effects in lung cancer may be related to the attenuation of p-mTOR, MMP2 and the activation of p-p53. Cisplatin 59-68 tumor protein p53 Homo sapiens 209-212 23781585-8 2013 Western blotting demonstrated that the expression of P53 protein increased and the expression of HPV E6 survivin protein decreased in HeLa cells treated with MIF at low concentrations (< or = 10 micromol/l) combined with cisplatin. Cisplatin 224-233 tumor protein p53 Homo sapiens 53-56 23781585-10 2013 The strengthening effect of growth inhibition and chemosensitivity to cisplatin of mifepristone are associated with down-regulating HPV E6 survivin protein and upregulating p53 protein. Cisplatin 70-79 tumor protein p53 Homo sapiens 173-176 23784838-6 2013 In this review, building on recent findings of p53-induced apoptosis and DNA-repair mechanisms in TGCTs, we will discuss the molecular bases that drive tumor sensitivity to cisplatin, emphasizing the new therapeutic approaches proposed to eventually constrain tumor recurrence, and target TGCTs which are unresponsive to standard therapies. Cisplatin 173-182 tumor protein p53 Homo sapiens 47-50 22634494-0 2012 The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cisplatin 50-59 tumor protein p53 Homo sapiens 4-7 23064281-7 2013 In addition, sequential or concomitant treatment of bortezomib and cisplatin stimulated the expression of p53, hScrib and p21 and the stimulation was markedly influenced by the order of drugs in HeLa cells. Cisplatin 67-76 tumor protein p53 Homo sapiens 118-121 23165211-0 2012 Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. Cisplatin 42-51 tumor protein p53 Homo sapiens 35-38 23165211-3 2012 We analyzed functionality of wild-type p53 in cisplatin sensitivity in the human TC setting using a p53 short interfering (si)RNA approach. Cisplatin 46-55 tumor protein p53 Homo sapiens 39-42 23165211-6 2012 Following cisplatin exposure, expression levels of p53 increased, with a subsequent increase in MDM2 and p21 mRNA and protein levels and Fas cell membrane levels. Cisplatin 10-19 tumor protein p53 Homo sapiens 51-54 23555949-0 2013 Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels. Cisplatin 61-70 tumor protein p53 Homo sapiens 101-104 23555949-5 2013 ZOL-treated cells as well as CDDP-treated cells induced p53 phosphorylation at Ser 15, a marker of p53 activation, and up-regulated p53 protein expression levels. Cisplatin 29-33 tumor protein p53 Homo sapiens 56-59 23555949-5 2013 ZOL-treated cells as well as CDDP-treated cells induced p53 phosphorylation at Ser 15, a marker of p53 activation, and up-regulated p53 protein expression levels. Cisplatin 29-33 tumor protein p53 Homo sapiens 99-102 23555949-5 2013 ZOL-treated cells as well as CDDP-treated cells induced p53 phosphorylation at Ser 15, a marker of p53 activation, and up-regulated p53 protein expression levels. Cisplatin 29-33 tumor protein p53 Homo sapiens 99-102 23555949-6 2013 Down-regulation of p53 levels with siRNA however did not influence the ZOL-mediated cytotoxicity but negated the combinatory effects by ZOL and CDDP. Cisplatin 144-148 tumor protein p53 Homo sapiens 19-22 23165211-7 2012 Downregulation of p53 with siRNA lowered cisplatin-induced apoptosis in Tera and Tera-CP, which was associated with a diminished Fas membrane expression. Cisplatin 41-50 tumor protein p53 Homo sapiens 18-21 23165211-8 2012 In contrast, p53 suppression augmented cisplatin-induced apoptosis in Scha and 2102EP and concomitantly strongly suppressed MDM2 and p21 mRNA and protein expression. Cisplatin 39-48 tumor protein p53 Homo sapiens 13-16 23165211-9 2012 Our results indicate that p53 is involved in transactivation of pro- and anti-apoptotic genes in untreated and cisplatin-treated TC cells, but subtle differences are present between TC cell lines. Cisplatin 111-120 tumor protein p53 Homo sapiens 26-29 23165211-10 2012 The opposite role of p53 in cisplatin-induced apoptosis among TC cell lines demonstrates the importance of the cellular context for the p53 transactivation phenotype in TC cells. Cisplatin 28-37 tumor protein p53 Homo sapiens 21-24 23165211-10 2012 The opposite role of p53 in cisplatin-induced apoptosis among TC cell lines demonstrates the importance of the cellular context for the p53 transactivation phenotype in TC cells. Cisplatin 28-37 tumor protein p53 Homo sapiens 136-139 22634494-1 2012 We evaluated whether the restoration of p53 function by the p53-reactivating small molecule RITA (reactivation of p53 and induction of tumor cell apoptosis enhances cisplatin-induced cytotoxicity and apoptosis in head-and-neck cancer (HNC). Cisplatin 165-174 tumor protein p53 Homo sapiens 40-43 22634494-1 2012 We evaluated whether the restoration of p53 function by the p53-reactivating small molecule RITA (reactivation of p53 and induction of tumor cell apoptosis enhances cisplatin-induced cytotoxicity and apoptosis in head-and-neck cancer (HNC). Cisplatin 165-174 tumor protein p53 Homo sapiens 60-63 22634494-1 2012 We evaluated whether the restoration of p53 function by the p53-reactivating small molecule RITA (reactivation of p53 and induction of tumor cell apoptosis enhances cisplatin-induced cytotoxicity and apoptosis in head-and-neck cancer (HNC). Cisplatin 165-174 tumor protein p53 Homo sapiens 60-63 22634494-7 2012 Our data suggest that the restoration of p53 tumor-suppressive function by RITA enhances the cytotoxicity and apoptosis of cisplatin, an action that may offer an attractive strategy for treating HNC. Cisplatin 123-132 tumor protein p53 Homo sapiens 41-44 22962266-0 2012 Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin. Cisplatin 70-79 tumor protein p53 Homo sapiens 21-24 22962266-5 2012 Unexpectedly, when CAFs were analyzed, p53 accumulation and induction of p21 was observed only in tumors with constitutively low p53 protein and accumulation upon cisplatin treatment. Cisplatin 163-172 tumor protein p53 Homo sapiens 39-42 22576699-7 2012 Further studies indicated that LKB1-enhancing cisplatin-mediated antitumor effects might be associated with the upregulation of p-p53 and p-JNK, and downregulation of p-mammalian target of rapamycin, matrix metalloproteinase (MMP)-2 and MMP-9. Cisplatin 46-55 tumor protein p53 Homo sapiens 130-133 22951905-1 2012 Tumor protein (TP)-p53 family members (TP63, TP63 and TP73) are guardians of the genome and key players in orchestrating the cellular response to cisplatin treatment. Cisplatin 146-155 tumor protein p53 Homo sapiens 19-22 22888789-0 2012 Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells. Cisplatin 89-98 tumor protein p53 Homo sapiens 58-61 22888789-4 2012 IBP expression was negatively regulated by wild-type p53 and was p53 dependently suppressed by DNA damage agent cisplatin. Cisplatin 112-121 tumor protein p53 Homo sapiens 65-68 22888789-5 2012 Furthermore, high levels of IBP were found to decrease cisplatin-induced growth suppression and apoptotic cell death, which was associated with decreased p53 activity and imbalanced Bcl-2 family member expression. Cisplatin 55-64 tumor protein p53 Homo sapiens 154-157 22531959-3 2012 Compared with the p53 wildtype U2OS cells, miR-34a expression was much lower in p53 deficient Saos2 cells upon cisplatin treatment. Cisplatin 111-120 tumor protein p53 Homo sapiens 80-83 23077460-11 2012 The p53 and ER/PR status may predict tumour response on rHuEpo and cDDP treatment. Cisplatin 67-71 tumor protein p53 Homo sapiens 4-7 22773829-4 2012 Specifically, GR agonists hydrocortisone or dexamethasone inhibited p53-dependent apoptosis induced by cisplatin, ionizing radiation, or the MDM2 antagonist Nutlin-3. Cisplatin 103-112 tumor protein p53 Homo sapiens 68-71 22888789-6 2012 CONCLUSIONS: IBP is a novel p53 target gene which suppresses cisplatin-mediated apoptosis of breast cancer cells via negative feedback regulation of the p53 signalling pathway, suggesting IBP may serve as a target for pharmacologic intervention of breast cancer resistant to cisplatin therapy. Cisplatin 61-70 tumor protein p53 Homo sapiens 28-31 22888789-6 2012 CONCLUSIONS: IBP is a novel p53 target gene which suppresses cisplatin-mediated apoptosis of breast cancer cells via negative feedback regulation of the p53 signalling pathway, suggesting IBP may serve as a target for pharmacologic intervention of breast cancer resistant to cisplatin therapy. Cisplatin 61-70 tumor protein p53 Homo sapiens 153-156 22888789-6 2012 CONCLUSIONS: IBP is a novel p53 target gene which suppresses cisplatin-mediated apoptosis of breast cancer cells via negative feedback regulation of the p53 signalling pathway, suggesting IBP may serve as a target for pharmacologic intervention of breast cancer resistant to cisplatin therapy. Cisplatin 275-284 tumor protein p53 Homo sapiens 28-31 22888789-6 2012 CONCLUSIONS: IBP is a novel p53 target gene which suppresses cisplatin-mediated apoptosis of breast cancer cells via negative feedback regulation of the p53 signalling pathway, suggesting IBP may serve as a target for pharmacologic intervention of breast cancer resistant to cisplatin therapy. Cisplatin 275-284 tumor protein p53 Homo sapiens 153-156 21837762-5 2012 The results showed that cisplatin decreased the protein expression levels of DeltaNp73beta in a dose-dependent manner, and both TAp73 and p53 were upregulated after cisplatin treatment. Cisplatin 24-33 tumor protein p53 Homo sapiens 138-141 21837762-5 2012 The results showed that cisplatin decreased the protein expression levels of DeltaNp73beta in a dose-dependent manner, and both TAp73 and p53 were upregulated after cisplatin treatment. Cisplatin 165-174 tumor protein p53 Homo sapiens 138-141 22356895-2 2012 To seek predictive biomarkers, we analysed single nucleotide polymorphisms (SNPs) in the p53 and MDM2 genes in LAHNSCC patients treated with cisplatin-based CRT. Cisplatin 141-150 tumor protein p53 Homo sapiens 89-92 22359193-9 2012 The stable transfection of PDCD5 demonstrated G2/M cell cycle arrest, increased apoptosis and nuclear translocation of PDCD5 and p53 after cisplatin treatment. Cisplatin 139-148 tumor protein p53 Homo sapiens 129-132 22397410-0 2012 Golgi-SNARE GS28 potentiates cisplatin-induced apoptosis by forming GS28-MDM2-p53 complexes and by preventing the ubiquitination and degradation of p53. Cisplatin 29-38 tumor protein p53 Homo sapiens 78-81 22672905-0 2012 Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance. Cisplatin 60-69 tumor protein p53 Homo sapiens 21-24 22672905-6 2012 Using quantitative mass-spectrometry of protein complexes labeled with isobaric tags, we showed that TP53 and DeltaNp63alpha are involved in numerous protein-protein interactions, which are likely to be implicated in the response of tumor cells to cisplatin exposure. Cisplatin 248-257 tumor protein p53 Homo sapiens 101-105 22672905-9 2012 Overall, our studies provide an integrated proteomic platform in making a case for the role of the p53/p63 interactome in cisplatin chemoresistance. Cisplatin 122-131 tumor protein p53 Homo sapiens 99-102 22397410-0 2012 Golgi-SNARE GS28 potentiates cisplatin-induced apoptosis by forming GS28-MDM2-p53 complexes and by preventing the ubiquitination and degradation of p53. Cisplatin 29-38 tumor protein p53 Homo sapiens 148-151 22397410-9 2012 As expected, ectopic expression of p53 in H1299 cells restored the modulatory effects of GS28 on sensitivity to cisplatin. Cisplatin 112-121 tumor protein p53 Homo sapiens 35-38 22142405-11 2012 The exposure of DPSCs and HDFs to cisplatin provoked an increase in p53 and p21 expression and p53 phosphorylation of serine 15. Cisplatin 34-43 tumor protein p53 Homo sapiens 68-71 22634534-4 2012 The objective of the present study was to clarify the role of the expression status of proteins involved in the Rb and p53 tumour suppressor pathways in sensitivity and resistance of GCTs to cisplatin-based chemotherapy. Cisplatin 191-200 tumor protein p53 Homo sapiens 119-122 22142405-11 2012 The exposure of DPSCs and HDFs to cisplatin provoked an increase in p53 and p21 expression and p53 phosphorylation of serine 15. Cisplatin 34-43 tumor protein p53 Homo sapiens 95-98 22331493-0 2012 Sodium arsenite +- hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Cisplatin 88-97 tumor protein p53 Homo sapiens 43-46 22328720-7 2012 At the molecular level, cisplatin treatment resulted in elevated p53 levels, enhanced caspase-3 activation, and reduced p21 levels in E6-suppressed cells. Cisplatin 24-33 tumor protein p53 Homo sapiens 65-68 21684138-5 2012 Cisplatin triggered marked activation of stress signaling pathways [p53, Jun N-terminal kinase (JNK), and p38-alpha mitogen-activated protein kinase (MAPK)] and promoted cell death in the kidneys (increased DNA fragmentation, caspases-3/7 activity, terminal deoxynucleotidyl transferase-mediated uridine triphosphate nick-end labeling), associated with attenuation of various prosurvival signaling pathways [e.g., extracellular signal-regulated kinase (ERK) and p38-beta MAPK]. Cisplatin 0-9 tumor protein p53 Homo sapiens 68-71 21684138-8 2012 Thus, the cisplatin-induced nephropathy is associated with activation of various cell death and proinflammatory pathways (p53, JNK, p38-alpha, TNF-alpha and NF-kappaB) and impairments of key prosurvival signaling mechanisms (ERK and p38-beta). Cisplatin 10-19 tumor protein p53 Homo sapiens 122-125 22331493-4 2012 In this study, we examined the role of p53 status in EOC response to a novel combination of cisplatin, sodium arsenite, and hyperthermia. Cisplatin 92-101 tumor protein p53 Homo sapiens 39-42 22331493-13 2012 In conclusion, sodium arsenite +- hyperthermia sensitizes wild-type p53-expressing EOC cells to cisplatin by suppressing DNA repair protein XPC and increasing cellular and DNA platinum accumulation. Cisplatin 96-105 tumor protein p53 Homo sapiens 68-71 22331493-5 2012 Human EOC cells were treated with cisplatin +- 20muM sodium arsenite at 37 C or 39 C for 1 h. Sodium arsenite +- hyperthermia sensitized wild-type p53-expressing (A2780, A2780/CP70, OVCA 420, OVCA 429, and OVCA 433) EOC cells to cisplatin. Cisplatin 34-43 tumor protein p53 Homo sapiens 147-150 22331493-6 2012 Hyperthermia sensitized p53-null SKOV-3 and p53-mutant (OVCA 432 and OVCAR-3) cells to cisplatin. Cisplatin 87-96 tumor protein p53 Homo sapiens 24-27 22331493-6 2012 Hyperthermia sensitized p53-null SKOV-3 and p53-mutant (OVCA 432 and OVCAR-3) cells to cisplatin. Cisplatin 87-96 tumor protein p53 Homo sapiens 44-47 22331493-8 2012 XPC, a critical DNA damage recognition protein in global genome repair pathway, was induced by cisplatin only in wild-type p53-expressing cells. Cisplatin 95-104 tumor protein p53 Homo sapiens 123-126 22331493-9 2012 Cotreatment with sodium arsenite +- hyperthermia attenuated cisplatin-induced XPC in wild-type p53-expressing cells. Cisplatin 60-69 tumor protein p53 Homo sapiens 95-98 22331493-10 2012 XPC siRNA transfection sensitized wild-type p53-expressing cells to cisplatin, suggesting that sodium arsenite +- hyperthermia attenuation of XPC is a mechanism by which wild-type p53-expressing cells are sensitized to cisplatin. Cisplatin 68-77 tumor protein p53 Homo sapiens 44-47 21927021-0 2012 The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Cisplatin 40-49 tumor protein p53 Homo sapiens 127-130 21927021-3 2012 A determinant of CDDP sensitivity in OVCA, p53, is activated by checkpoint kinase 1 (Chk1) in response to DNA damage. Cisplatin 17-21 tumor protein p53 Homo sapiens 43-46 21927021-6 2012 Our findings establish for the first time that PPM1D confers CDDP resistance in OVCA cells through attenuating CDDP-induced, Chk1-mediated, p53-dependent apoptosis. Cisplatin 111-115 tumor protein p53 Homo sapiens 140-143 21927021-6 2012 Our findings establish for the first time that PPM1D confers CDDP resistance in OVCA cells through attenuating CDDP-induced, Chk1-mediated, p53-dependent apoptosis. Cisplatin 61-65 tumor protein p53 Homo sapiens 140-143 22223137-0 2012 Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cisplatin 123-132 tumor protein p53 Homo sapiens 12-15 22230478-7 2012 On the other hand, the expression of exogenous p53 in H1299 and Hep3B cells was decreased following overexpression of HURP, and these cells showed decreased sensitivity to cisplatin-induced apoptosis. Cisplatin 172-181 tumor protein p53 Homo sapiens 47-50 22410253-6 2012 Cisplatin induced apoptosis of TYST cells through the activation of p53 expression and down-regulation of Bcl- expression. Cisplatin 0-9 tumor protein p53 Homo sapiens 68-71 22223137-2 2012 We examined whether forced expression of p53 inhibited growth of mesothelioma cells and produced anti-tumor effects by a combination of cisplatin (CDDP) or pemetrexed (PEM), the first-line drugs for mesothelioma treatments. Cisplatin 136-145 tumor protein p53 Homo sapiens 41-44 22223137-6 2012 Transduction with Ad-p53 suppressed viability of mesothelioma cells and augmented the growth inhibition by CDDP or PEM mostly in a synergistic manner. Cisplatin 107-111 tumor protein p53 Homo sapiens 21-24 22223137-2 2012 We examined whether forced expression of p53 inhibited growth of mesothelioma cells and produced anti-tumor effects by a combination of cisplatin (CDDP) or pemetrexed (PEM), the first-line drugs for mesothelioma treatments. Cisplatin 147-151 tumor protein p53 Homo sapiens 41-44 22250642-6 2012 Further studies performed in the cells with wt p53 status show differences between cisplatin and C1 at the level of cell cycle regulation. Cisplatin 83-92 tumor protein p53 Homo sapiens 47-50 22421763-11 2012 The inhibition rate of CDDP was 50+-12% for p53- overexpressed patients, and 50+-12% for patients not overexpressed. Cisplatin 23-27 tumor protein p53 Homo sapiens 44-47 22421763-13 2012 As for 8 adenocarcinoma patients, the inhibition rate of CDDP of p53-overexpressed patients(59+-8%)was significantly(p=0. Cisplatin 57-61 tumor protein p53 Homo sapiens 65-68 22421763-15 2012 p53 overexpression may be a predictive marker for chemotherapy using CDDP in lung adenocarcinoma. Cisplatin 69-73 tumor protein p53 Homo sapiens 0-3 22421763-16 2012 CONCLUSION: p53 overexpression may be a possible predictive marker for adjuvant chemotherapy using CDDP in NSCLC. Cisplatin 99-103 tumor protein p53 Homo sapiens 12-15 22172427-5 2012 Furthermore, PGG suppressed PARP cleavage and caspase-3 activation, cytochrome c release, up-regulation of bax and p53 in cisplatin-treated HRCs. Cisplatin 122-131 tumor protein p53 Homo sapiens 115-118 22117079-1 2012 Resistance to cisplatin (CDDP)-based therapy is a major hurdle to the successful treatment of human ovarian cancer (OVCA), and the chemoresistant phenotype in OVCA cells is associated with Akt-attenuated p53-mediated apoptosis. Cisplatin 14-23 tumor protein p53 Homo sapiens 204-207 22117079-11 2012 The data presented here implicate the regulation of p53 subcellular localization and apoptosis by PARC as a contributing factor in CDDP resistance in OVCA cells and Ca(2+)/calpain in PARC post-translational processing and chemosensitivity. Cisplatin 131-135 tumor protein p53 Homo sapiens 52-55 22117079-1 2012 Resistance to cisplatin (CDDP)-based therapy is a major hurdle to the successful treatment of human ovarian cancer (OVCA), and the chemoresistant phenotype in OVCA cells is associated with Akt-attenuated p53-mediated apoptosis. Cisplatin 25-29 tumor protein p53 Homo sapiens 204-207 22117079-6 2012 Here, we present evidence that CDDP promotes calpain-mediated PARC down-regulation, mitochondrial and nuclear p53 accumulation, and apoptosis in chemosensitive but not resistant OVCA cells. Cisplatin 31-35 tumor protein p53 Homo sapiens 110-113 22117079-7 2012 Inhibition of Akt is required to sensitize chemoresistant cells to CDDP in a p53-dependent manner, an effect enhanced by PARC down-regulation. Cisplatin 67-71 tumor protein p53 Homo sapiens 77-80 22515118-0 2012 Geranylgeranylacetone attenuates cisplatin-induced reductions in cell viability by suppressing the elevation of intracellular p53 content without heat shock protein induction. Cisplatin 33-42 tumor protein p53 Homo sapiens 126-129 22515118-7 2012 We found that GGA suppressed the CDDP-induced elevation of intracellular p53 content. Cisplatin 33-37 tumor protein p53 Homo sapiens 73-76 22515118-8 2012 In conclusion, GGA attenuates viability reductions and caspase-3 activation in CDDP-treated cells by suppressing the elevation of intracellular p53 content without HSP induction. Cisplatin 79-83 tumor protein p53 Homo sapiens 144-147 23272171-0 2012 Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer. Cisplatin 37-46 tumor protein p53 Homo sapiens 59-62 22065775-6 2012 The overexpression of Wip1 in normal tissues provided protection from cisplatin-induced apoptosis through decreased strength of upstream signaling to p53. Cisplatin 70-79 tumor protein p53 Homo sapiens 150-153 21895873-0 2012 Retracted: Modulation of p53 /Akt / phosphatase and tensin homolog expression by esculetin potentiates the anticancer activity of cisplatin and prevents its nephrotoxicity. Cisplatin 130-139 tumor protein p53 Homo sapiens 25-28 22679561-8 2012 In addition, single cisplatin treatment was combined with the silencing of E6AP or p53. Cisplatin 20-29 tumor protein p53 Homo sapiens 83-86 22679561-9 2012 The comparison to HeLa and SiHa cells revealed a higher sensitivity of the novel cell lines to cisplatin treatment, which caused p53 accumulation and transcriptional induction of p21. Cisplatin 95-104 tumor protein p53 Homo sapiens 129-132 22778941-2 2012 Cisplatin forms inter- and intrastrand crosslinked DNA adducts and its cytotoxicity is mediated by propagation of DNA damage recognition signals to downstream pathways involving ATR, p53, p73, and mitogen-activated protein kinases, ultimately resulting in apoptosis. Cisplatin 0-9 tumor protein p53 Homo sapiens 183-186 21918844-6 2012 The desipramine/cisplatin combination resulted in increased levels of p53 as well as mitochondrial damage, caspase activation, and poly(ADP ribose) polymerase cleavage, suggesting that desipramine may synergize with cisplatin more than with other platinum chemotherapeutics partly by activating distinct apoptotic pathways. Cisplatin 16-25 tumor protein p53 Homo sapiens 70-73 21875941-3 2011 We have shown previously that the presence of excess R2 subunits protects p53-deficient human colon cancer cells from cisplatin-induced DNA damage and replication stress. Cisplatin 118-127 tumor protein p53 Homo sapiens 74-77 22590594-4 2012 In this study, we found that genetic variants of Bcl-2 proteins exist among cisplatin-sensitive and -resistant ovarian cancer cells, and the responses of NOXA and Bax to cisplatin are regulated mainly by p53. Cisplatin 170-179 tumor protein p53 Homo sapiens 204-207 21903092-5 2011 Expression of exogenous p53 in H1299 cells was increased following knockdown of NAPA and these cells showed increased sensitivity to cisplatin-induced apoptosis. Cisplatin 133-142 tumor protein p53 Homo sapiens 24-27 21903092-10 2011 These results indicate that NAPA promotes resistance to cisplatin through synoviolin and the ERAD complex which together induce the degradation of p53 and thus prevent apoptosis. Cisplatin 56-65 tumor protein p53 Homo sapiens 147-150 21903092-11 2011 Based on these findings, we propose that the combination of cisplatin and knockdown of NAPA represents a novel and attractive strategy to eradicate p53-sensitive cancer cells. Cisplatin 60-69 tumor protein p53 Homo sapiens 148-151 21602882-2 2011 Phosphorylation of p53 at S46, an apoptosis-specific p53 posttranslational modification, is the most characterized HIPK2 function in response to lethal doses of ultraviolet (UV), ionizing radiation or different anticancer drugs, such as cisplatin, roscovitine and doxorubicin (DOX). Cisplatin 237-246 tumor protein p53 Homo sapiens 19-22 21602882-2 2011 Phosphorylation of p53 at S46, an apoptosis-specific p53 posttranslational modification, is the most characterized HIPK2 function in response to lethal doses of ultraviolet (UV), ionizing radiation or different anticancer drugs, such as cisplatin, roscovitine and doxorubicin (DOX). Cisplatin 237-246 tumor protein p53 Homo sapiens 53-56 21953469-3 2011 Here we characterize the mechanisms accounting for the nuclear accumulation of a new point mutation (Lys-351 to Asn) in the nuclear export sequence of p53 identified in a cisplatin-resistant ovarian carcinoma cell line (A2780 CIS). Cisplatin 171-180 tumor protein p53 Homo sapiens 151-154 21953469-5 2011 As a consequence, cells expressing p53 K351N mutant showed defects in cisplatin-induced translocation of p53 to mitochondria, Bax oligomerization, and mitochondrial membrane depolarization. Cisplatin 70-79 tumor protein p53 Homo sapiens 35-38 21953469-5 2011 As a consequence, cells expressing p53 K351N mutant showed defects in cisplatin-induced translocation of p53 to mitochondria, Bax oligomerization, and mitochondrial membrane depolarization. Cisplatin 70-79 tumor protein p53 Homo sapiens 105-108 21953469-6 2011 These data identify K351N as a critical mutation of p53 that contributes to the development and maintenance of resistance to cisplatin. Cisplatin 125-134 tumor protein p53 Homo sapiens 52-55 22037398-4 2011 Cisplatin and gamma-irradiation activated the DNA damage response in hMSCs, including induction of p53 and p21, and activation of PI3 kinase-related protein kinase (PIKK)-dependent phosphorylation of histone H2AX on serine 139, and replication protein A2 on serine4/serine8. Cisplatin 0-9 tumor protein p53 Homo sapiens 99-102 22071691-4 2011 Finally, miR-885-3p modulated the cisplatin-induced TP53-dependent mitochondrial apoptosis by up regulation of MDM4 levels and down regulation of BCL2 levels in mitochondria. Cisplatin 34-43 tumor protein p53 Homo sapiens 52-56 21552291-7 2011 By contrast, p53(-/-) cells are expectedly resistant to cell death upon exposure to DNA-damaging agents such as cisplatin (CDDP) and etoposide. Cisplatin 112-121 tumor protein p53 Homo sapiens 13-16 21552291-7 2011 By contrast, p53(-/-) cells are expectedly resistant to cell death upon exposure to DNA-damaging agents such as cisplatin (CDDP) and etoposide. Cisplatin 123-127 tumor protein p53 Homo sapiens 13-16 21552291-8 2011 Although p53 and its classical targets such as p21 and Mdm2 are activated by both H(2)O(2) and CDDP, we found that the expression of haeme-oxygenase-1 (HO-1)-an antioxidant and antiapoptotic protein-was directly induced only upon H(2)O(2) treatment in a p53-dependent manner. Cisplatin 95-99 tumor protein p53 Homo sapiens 9-12 22037398-8 2011 In hMSCs isolated from a chronic lymphocytic leukemia (CLL) patient, p53 and p21 were induced by cisplatin and gamma-irradiation, while RPA2 was phosphorylated on serine4/8 in particular following cisplatin. Cisplatin 197-206 tumor protein p53 Homo sapiens 69-72 22037398-8 2011 In hMSCs isolated from a chronic lymphocytic leukemia (CLL) patient, p53 and p21 were induced by cisplatin and gamma-irradiation, while RPA2 was phosphorylated on serine4/8 in particular following cisplatin. Cisplatin 97-106 tumor protein p53 Homo sapiens 69-72 21880462-0 2011 miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Cisplatin 17-26 tumor protein p53 Homo sapiens 65-69 21516123-1 2011 Mammalian Ste20-like kinase-1 (MST1) kinase mediates H2O2-induced cell death by anticancer drugs such as cisplatin in a p53-dependent manner. Cisplatin 105-114 tumor protein p53 Homo sapiens 120-123 21516123-3 2011 Here we show that peroxiredoxin-I (PRX-I) is an essential intermediate in H2O2-induced MST1 activation and cisplatin-induced cell death through p53. Cisplatin 107-116 tumor protein p53 Homo sapiens 144-147 21742020-5 2011 Upregulation of hHR23 expression by low-dose cisplatin was accompanied by an increase in p53, p21, and XPC protein levels. Cisplatin 45-54 tumor protein p53 Homo sapiens 89-92 21880462-8 2011 Moreover, the expression of miR-98 and Bcl-2 was decreased, while miR-34a-c and TP53 was increased after A549 treated with cisplatin. Cisplatin 123-132 tumor protein p53 Homo sapiens 80-84 21660965-7 2011 Overexpression of CITED2 also decreased sensitivity to cisplatin in p53-defective H1299 cells when exogenous p53 expression was re-introduced. Cisplatin 55-64 tumor protein p53 Homo sapiens 68-71 21660965-7 2011 Overexpression of CITED2 also decreased sensitivity to cisplatin in p53-defective H1299 cells when exogenous p53 expression was re-introduced. Cisplatin 55-64 tumor protein p53 Homo sapiens 109-112 21660965-9 2011 Notably, the effects of CITED2 knockdown on p53 accumulation and the increase of p53"s target Bax were more pronounced after treatment with cisplatin. Cisplatin 140-149 tumor protein p53 Homo sapiens 44-47 21660965-9 2011 Notably, the effects of CITED2 knockdown on p53 accumulation and the increase of p53"s target Bax were more pronounced after treatment with cisplatin. Cisplatin 140-149 tumor protein p53 Homo sapiens 81-84 21660965-10 2011 Based on these results, we propose that a combination of cisplatin and CITED2 shRNA may represent an effective treatment against p53-sensitive cancer cells. Cisplatin 57-66 tumor protein p53 Homo sapiens 129-132 21480648-8 2011 In addition, the distinct p53 activation profile of 1 compared with cisplatin provides an explanation for the activity of this ruthenium drug against cisplatin-resistant cells. Cisplatin 150-159 tumor protein p53 Homo sapiens 26-29 21810677-1 2011 INTRODUCTION: Retrospective studies suggest that p53 alteration is prognostic for recurrence in patients with urothelial bladder cancer and predictive for benefit from combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) adjuvant chemotherapy. Cisplatin 224-233 tumor protein p53 Homo sapiens 49-52 21730979-8 2011 In A2780 cells sensitisation to cisplatin was greatest in cells with functional p53 and mismatch repair (MMR) and sensitisation to temozolomide was greatest in p53 mutant cells with functional MMR. Cisplatin 32-41 tumor protein p53 Homo sapiens 80-83 22207897-5 2011 Knockdown of miR-203 following cisplatin treatment enhances p53, p21, and Bax protein expression. Cisplatin 31-40 tumor protein p53 Homo sapiens 60-63 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 0-9 tumor protein p53 Homo sapiens 156-159 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 0-9 tumor protein p53 Homo sapiens 259-262 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 123-132 tumor protein p53 Homo sapiens 156-159 21592546-6 2011 Cisplatin also potently inhibited G1-phase Cdk4/cyclin D1 and Cdk2/cyclin E activities at ~18 h. In agreement, exposure of cisplatin-treated A2780, HCT-116(p53-/-) and HCT-116(p21-/-) tumor cells to nocodazole revealed limited G1-arrest that was dependent on p53 and p21. Cisplatin 123-132 tumor protein p53 Homo sapiens 259-262 21624110-7 2011 Interestingly, Nutlin-3a seemed to potentiate the effect of classical drugs as Doxorubicin and Cisplatin in cell lines with mutated TP53, but inhibited the effect of Methotrexate. Cisplatin 95-104 tumor protein p53 Homo sapiens 132-136 21258400-0 2011 ATR mediates cisplatin resistance in a p53 genotype-specific manner. Cisplatin 13-22 tumor protein p53 Homo sapiens 39-42 21258400-4 2011 Here, we demonstrate that genetic inhibition of ATR expression selectively enhanced cisplatin sensitivity in human colorectal cancer cells with inactivated p53. Cisplatin 84-93 tumor protein p53 Homo sapiens 156-159 21258400-6 2011 Knock-in of functional p53 in ATR-deficient cells restored checkpoint function, suppressed apoptotic pathways and markedly increased clonogenic survival after cisplatin treatment. Cisplatin 159-168 tumor protein p53 Homo sapiens 23-26 21416250-7 2011 CDDP marginally induced acetylated p53 within 24 h after administration. Cisplatin 0-4 tumor protein p53 Homo sapiens 35-38 21489989-1 2011 Testicular cancer is highly curable with cisplatin-based therapy, and testicular cancer-derived human embryonal carcinoma (EC) cells undergo a p53-dominant transcriptional response to cisplatin. Cisplatin 184-193 tumor protein p53 Homo sapiens 143-146 21489989-3 2011 Cisplatin-mediated induction of STK17A in the EC cell line NT2/D1 was prevented with p53 siRNA. Cisplatin 0-9 tumor protein p53 Homo sapiens 85-88 21489989-5 2011 A functional p53 response element that binds endogenous p53 in a cisplatin-dependent manner was identified 5 kb upstream of the first coding exon of STK17A. Cisplatin 65-74 tumor protein p53 Homo sapiens 13-16 21489989-5 2011 A functional p53 response element that binds endogenous p53 in a cisplatin-dependent manner was identified 5 kb upstream of the first coding exon of STK17A. Cisplatin 65-74 tumor protein p53 Homo sapiens 56-59 20623183-4 2011 We report that induction of ERbeta expression causes abrogation of the S-phase, and the Chk1/Cdc25C-mediated G2/M checkpoints after cisplatin and doxorubicin exposure in p53-defective breast cancer cells but not in p53 wild-type mammary cells. Cisplatin 132-141 tumor protein p53 Homo sapiens 170-173 21532991-0 2011 p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. Cisplatin 125-134 tumor protein p53 Homo sapiens 0-3 21575166-11 2011 CONCLUSION: Examining almost all known human micro-RNA species confirmed the miR-371-373 cluster as a promising target for explaining cisplatin resistance, potentially by counteracting wild-type P53 induced senescence or linking it with the potency to differentiate. Cisplatin 134-143 tumor protein p53 Homo sapiens 195-198 21509038-0 2011 Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cisplatin 87-96 tumor protein p53 Homo sapiens 23-26 21509038-0 2011 Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cisplatin 87-96 tumor protein p53 Homo sapiens 60-63 21509038-3 2011 In the present study, we demonstrate that p53 resides in a complex with MDM2 at higher cisplatin concentrations in cisplatin-resistant human TC cells compared with cisplatin-sensitive TC cells. Cisplatin 87-96 tumor protein p53 Homo sapiens 42-45 21509038-3 2011 In the present study, we demonstrate that p53 resides in a complex with MDM2 at higher cisplatin concentrations in cisplatin-resistant human TC cells compared with cisplatin-sensitive TC cells. Cisplatin 115-124 tumor protein p53 Homo sapiens 42-45 21509038-3 2011 In the present study, we demonstrate that p53 resides in a complex with MDM2 at higher cisplatin concentrations in cisplatin-resistant human TC cells compared with cisplatin-sensitive TC cells. Cisplatin 115-124 tumor protein p53 Homo sapiens 42-45 21509038-4 2011 Inhibition of the MDM2-p53 interaction using either Nutlin-3 or MDM2 RNA interference resulted in hyperactivation of the p53 pathway and a strong induction of apoptosis in cisplatin-sensitive and -resistant TC cells. Cisplatin 172-181 tumor protein p53 Homo sapiens 23-26 22087162-8 2011 P53 was expressed by more cells in the Des and cisplatin groups than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and cisplatin groups (p > 0.05). Cisplatin 47-56 tumor protein p53 Homo sapiens 0-3 22087162-8 2011 P53 was expressed by more cells in the Des and cisplatin groups than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and cisplatin groups (p > 0.05). Cisplatin 164-173 tumor protein p53 Homo sapiens 0-3 22087162-8 2011 P53 was expressed by more cells in the Des and cisplatin groups than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and cisplatin groups (p > 0.05). Cisplatin 164-173 tumor protein p53 Homo sapiens 0-3 21532991-4 2011 Here we show that siRNA-mediated silencing of p53 is sufficient to completely abrogate hypersensitivity not only to Cisplatin but also to non-genotoxic inducers of p53 such as the Mdm2 antagonist Nutlin-3 and the proteasome inhibitor Bortezomib. Cisplatin 116-125 tumor protein p53 Homo sapiens 46-49 21366897-5 2011 RESULTS: We found that sensitivity to cisplatin correlates significantly with levels of EGR-1 expression in tumors with wild-type p53/INK4a/p16 status. Cisplatin 38-47 tumor protein p53 Homo sapiens 130-133 21643554-0 2011 Differential DNA damage responses in p53 proficient and deficient cells: cisplatin-induced nuclear import of XPA is independent of ATR checkpoint in p53-deficient lung cancer cells. Cisplatin 73-82 tumor protein p53 Homo sapiens 37-40 21489314-16 2011 The inverse effect was observed in the TP53 mutated T24 cell line where TFAP2alpha silencing augmented cisplatin and gemcitabine sensitivity and did not stimulate proliferation. Cisplatin 103-112 tumor protein p53 Homo sapiens 39-43 21496427-9 2011 CONCLUSIONS: Cisplatin resistance of lung cancer cells is associated with overexpression of GRP75 gene, which could regulate the expressions of p53 and bcl-2. Cisplatin 13-22 tumor protein p53 Homo sapiens 144-147 21429301-0 2011 Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells. Cisplatin 63-72 tumor protein p53 Homo sapiens 52-55 21429301-4 2011 Cisplatin (CDDP) is a DNA damaging agent and is widely used for treating cancer, while the role of p53 in CDDP-induced cell death has been stressed. Cisplatin 106-110 tumor protein p53 Homo sapiens 99-102 21429301-5 2011 Using cell growth assays, morphological methods, Western blotting, flow cytometry, and DNA fragmentation analysis, we measured the expression of p53 level involved in the effect of VC on CDDP-induced apoptosis of HCT116, a human colon cancer cell line. Cisplatin 187-191 tumor protein p53 Homo sapiens 145-148 21429301-6 2011 CDDP plus VC treatment resulted in significantly increased apoptosis along with upregulation of p53 compared to untreated cells and/or CDDP-treated cells. Cisplatin 0-4 tumor protein p53 Homo sapiens 96-99 21429301-7 2011 These results suggest that VC enhanced CDDP sensitivity and apoptosis via upregulation of p53. Cisplatin 39-43 tumor protein p53 Homo sapiens 90-93 21205083-1 2011 We previously reported that mitochondrial transcription factor A (mtTFA) preferentially recognizes cisplatin-damaged DNA via physical interaction with p53 and is upregulated by treatment with cisplatin and fluorouracil (5-FU). Cisplatin 99-108 tumor protein p53 Homo sapiens 151-154 21216935-9 2011 Bid truncation and mitochondrial translocation of Bid and p53 was induced by fisetin in the presence or absence of cisplatin. Cisplatin 115-124 tumor protein p53 Homo sapiens 58-61 21205083-1 2011 We previously reported that mitochondrial transcription factor A (mtTFA) preferentially recognizes cisplatin-damaged DNA via physical interaction with p53 and is upregulated by treatment with cisplatin and fluorouracil (5-FU). Cisplatin 192-201 tumor protein p53 Homo sapiens 151-154 21145397-3 2011 We have previously shown that cisplatin induces apoptosis in dorsal root ganglion (DRG) sensory neurons by covalently binding to nuclear DNA (nDNA), resulting in DNA damage, subsequent p53 activation and Bax-mediated apoptosis via the mitochondria. Cisplatin 30-39 tumor protein p53 Homo sapiens 185-188 21575475-0 2011 [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells]. Cisplatin 101-110 tumor protein p53 Homo sapiens 47-50 21575475-1 2011 OBJECTIVE: To explore Akt-regulated direct p53 mitochondrial translocation in cisplatin-induced apoptosis in ovarian cancer cells and the relationship between this and chemoresistance in ovarian cancer. Cisplatin 78-87 tumor protein p53 Homo sapiens 43-46 21575475-3 2011 The p53 accumulation in mitochondria was determined in purified mitochondrial fractions in cisplatin-sensitive and -resistant ovarian cancer cells. Cisplatin 91-100 tumor protein p53 Homo sapiens 4-7 21575475-6 2011 RESULTS: Cisplatin induced mitochondrial p53 accumulation and apoptosis in chemosensitive cells (P < 0.05), but not in resistant cells (P > 0.05). Cisplatin 9-18 tumor protein p53 Homo sapiens 41-44 21575475-8 2011 CONCLUSIONS: Cisplatin induces direct p53 mitochondrial accumulation in chemosensitive cells, and Akt confers resistance in ovarian cancer cells, in part, by regulating the direct action of p53 in mitochondrial death pathway. Cisplatin 13-22 tumor protein p53 Homo sapiens 38-41 21575475-8 2011 CONCLUSIONS: Cisplatin induces direct p53 mitochondrial accumulation in chemosensitive cells, and Akt confers resistance in ovarian cancer cells, in part, by regulating the direct action of p53 in mitochondrial death pathway. Cisplatin 13-22 tumor protein p53 Homo sapiens 190-193 21214929-10 2011 CONCLUSIONS: Data show that alpha-TEA in combination with DOXO or CDDP synergistically enhances apoptosis in TNBC via targeting p53-mediated genes in a p73-dependent manner, and that p73 responses are downstream of c-Abl, JNK and Yap. Cisplatin 66-70 tumor protein p53 Homo sapiens 128-131 20802529-4 2010 Cisplatin-induced Noxa expression was ERK dependent, but p53 independent, and inhibition of ERK activation markedly attenuated cisplatin-induced cell death, as well as Noxa expression. Cisplatin 0-9 tumor protein p53 Homo sapiens 57-60 21214929-6 2011 Here we report on the reconstitution of the p53 tumor suppressor pathway in a p53-independent manner via p73 with combination treatments of alpha-TEA, a small bioactive lipid, plus DOXO or CDDP. Cisplatin 189-193 tumor protein p53 Homo sapiens 44-47 21214929-8 2011 RESULTS: Combination treatments of alpha-TEA plus DOXO or CDDP act cooperatively to induce apoptosis, caspase-8 and caspase-9 cleavage, p73, phospho-c-Ab1 and phospho-JNK protein expression, and increase expression of p53 downstream mediators; namely, death receptor-5, CD95/APO-1 (Fas), Bax and Noxa, as well as Yap nuclear translocation - plus reduce expression of Bcl-2. Cisplatin 58-62 tumor protein p53 Homo sapiens 218-221 22471498-5 2011 Furthermore, transient knockdown of Wrap53 by siRNAs in U-2OS cells treated with 10 muM cisplatin reduced p53 mRNA transcript levels by up to 50% of those of controls. Cisplatin 88-97 tumor protein p53 Homo sapiens 39-42 22471498-7 2011 Our findings suggest that cisplatin upregulates the expression of p53 in osteosarcoma cells by upregulating the transcript levels of Wrap53. Cisplatin 26-35 tumor protein p53 Homo sapiens 66-69 22312557-0 2011 The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor. Cisplatin 29-38 tumor protein p53 Homo sapiens 22-25 22312557-6 2011 Overexpression of p53 by cDNA transfection in wt-p53 (but not p53 deficient) cells doubled the amount of Chk2 phosphorylation 48 hours after cisplatin treatment. Cisplatin 141-150 tumor protein p53 Homo sapiens 18-21 22312557-8 2011 We conclude that wild-type p53, in response to cisplatin stimulation, plays a role in the upstream regulation of Chk2 phosphorylation at Thr-68. Cisplatin 47-56 tumor protein p53 Homo sapiens 27-30 22312557-9 2011 Cells without normal p53 function survive via an alternative pathway in response to the exogenous influence of cisplatin. Cisplatin 111-120 tumor protein p53 Homo sapiens 21-24 21109480-8 2011 In combination therapy, p53RA small molecules enhanced the anti-tumor activity of cisplatin, 5-fluorouracil, paclitaxel, and erlotinib against HNSCC cells. Cisplatin 82-91 tumor protein p53 Homo sapiens 24-27 21863213-0 2011 The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Cisplatin 114-123 tumor protein p53 Homo sapiens 4-7 21863213-5 2011 In this study, we showed that the induction of PUMA by cisplatin was abolished in p53-deficient SKOV3 cells. Cisplatin 55-64 tumor protein p53 Homo sapiens 82-85 21603599-7 2011 Our online cell biosensor measurements reveal for the first time the time scale of metabolic response until onset of cell death under cisplatin treatment, which is in good agreement with models of p53-mediated cell fate decision. Cisplatin 134-143 tumor protein p53 Homo sapiens 197-200 20807809-3 2010 The aim of this study was to examine the expression of NER gene transcripts, p53, and p21 in melanoma cell lines treated with cisplatin compared with melanocytes. Cisplatin 126-135 tumor protein p53 Homo sapiens 77-80 20655883-3 2010 Here, we showed the effects of knocking down plk1 gene through small interference RNA (siRNA) on cell cycle progression, proliferation and chemosensitivity of p53 mutant A431 cells to cisplatin (CDDP). Cisplatin 184-193 tumor protein p53 Homo sapiens 159-162 20655883-3 2010 Here, we showed the effects of knocking down plk1 gene through small interference RNA (siRNA) on cell cycle progression, proliferation and chemosensitivity of p53 mutant A431 cells to cisplatin (CDDP). Cisplatin 195-199 tumor protein p53 Homo sapiens 159-162 20807809-7 2010 However, induction of p53 was only significant in the melanocytes at 6 and 24 hours after cisplatin treatment. Cisplatin 90-99 tumor protein p53 Homo sapiens 22-25 20807809-8 2010 Inhibition of p53 expression significantly decreased the expression of all the GGR transcripts in melanocytes at 6 and 24 hours after cisplatin treatment. Cisplatin 134-143 tumor protein p53 Homo sapiens 14-17 20944137-0 2010 Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Cisplatin 79-88 tumor protein p53 Homo sapiens 11-14 20935493-5 2010 We have found that some genotoxic insults, namely, UV light and cisplatin, lead to proteasomal degradation of L37 in the nucleoplasm and to the ensuing L11-dependent stabilization of p53. Cisplatin 64-73 tumor protein p53 Homo sapiens 183-186 20944137-7 2010 A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R(2) for CDDP=0.823; R(2) for PAX=0.909; p<0.001). Cisplatin 119-123 tumor protein p53 Homo sapiens 43-46 20944137-8 2010 CONCLUSION: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression. Cisplatin 90-94 tumor protein p53 Homo sapiens 37-40 20945139-8 2010 Importantly, the synergistic effect of CsA or SFA with cisplatin was shown even in p53 defective Hep3B cells. Cisplatin 55-64 tumor protein p53 Homo sapiens 83-86 20945139-10 2010 In conclusion, CsA or SFA synergistically enhances cisplatin-induced apoptosis in HCC cells including the p53-defective Hep3B. Cisplatin 51-60 tumor protein p53 Homo sapiens 106-109 20526748-1 2010 Cisplatin and doxorubicin are widely used anticancer drugs that cause DNA damage, which activates the ATM-Chk2-p53 pathway in cancer cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 111-114 20630997-9 2010 P53 KDs with lower nontreated BARs were less sensitive to TRAIL and cisplatinum than wild-type. Cisplatin 68-79 tumor protein p53 Homo sapiens 0-3 20562210-5 2010 RESULTS: ALC enhanced the sensitivity to cisplatin of tumor cells with functional p53. Cisplatin 41-50 tumor protein p53 Homo sapiens 82-85 20600834-5 2010 Untreated HCT116 cells showed low levels of glut-p53, which increased markedly after H(2)O(2), diamide, cisplatin, and doxorubicin treatments. Cisplatin 104-113 tumor protein p53 Homo sapiens 49-52 20562210-9 2010 The in vivo ALC/cisplatin combination caused the activation of p53, associated with protein acetylation and induction of target genes. Cisplatin 16-25 tumor protein p53 Homo sapiens 63-66 20661724-5 2010 The cisplatin treatment significantly down-regulated the p53 and p21 expression level, while up-regulated the p27 expression in the YCC-3/R cells compared to the parental cells. Cisplatin 4-13 tumor protein p53 Homo sapiens 57-60 20868594-5 2010 CONCLUSION: Following introduction of rAd-p53, many genes regulating cell cycle, proliferation and apoptosis expresses up or down which significantly enhance chemosensitivity and killing efficiency of cisplatin on human lung adenocarcinoma A549 cells. Cisplatin 201-210 tumor protein p53 Homo sapiens 42-45 20428827-3 2010 We also showed that miR-106 and miR-150 were down-regulated while their target genes (RB1 and P53, respectively) were up-regulated after cisplatin treatment. Cisplatin 137-146 tumor protein p53 Homo sapiens 94-97 20558835-0 2010 Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Cisplatin 94-103 tumor protein p53 Homo sapiens 35-39 20558835-8 2010 TP53-wild type cells (RT4) were more sensitive to apoptosis than were mutated TP53 cells when treated with cisplatin or gemcitabine. Cisplatin 107-116 tumor protein p53 Homo sapiens 0-4 20558835-8 2010 TP53-wild type cells (RT4) were more sensitive to apoptosis than were mutated TP53 cells when treated with cisplatin or gemcitabine. Cisplatin 107-116 tumor protein p53 Homo sapiens 78-82 20546244-0 2010 Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy. Cisplatin 99-108 tumor protein p53 Homo sapiens 61-64 20546244-5 2010 MATERIALS AND METHODS: p53-mutated KYSE-510 cells were treated with CDDP alone or in combination with PDT. Cisplatin 68-72 tumor protein p53 Homo sapiens 23-26 20428827-7 2010 The study demonstrated that cisplatin induces K562 cells to apoptosis by reducing miR-106 which up-regulates RB1 or by inhibiting miR-150 which increases P53 expression. Cisplatin 28-37 tumor protein p53 Homo sapiens 154-157 20372863-7 2010 Cisplatin treatment induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK expression, and suppressed Bcl-2 and Bcl-xl expression, whereas cells transfected with pcDNA3.1-ARL6IP1 showed lower levels of cisplatin-induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK up-regulation and higher levels of cisplatin-suppressed Bcl-2 and Bcl-xl down-regulation. Cisplatin 0-9 tumor protein p53 Homo sapiens 43-46 20470425-0 2010 Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin. Cisplatin 148-157 tumor protein p53 Homo sapiens 97-100 20470425-3 2010 Cisplatin resistance is multi-factorial but can be associated with increased DNA repair capacity, mutations in p53 or loss of DNA mismatch repair capacity. Cisplatin 0-9 tumor protein p53 Homo sapiens 111-114 20470425-7 2010 Decreased TC-NER capacity was associated with an increase in the sensitivity of tumour cells to cisplatin-induced apoptosis, even in p53 null and DNA mismatch repair-deficient cell lines. Cisplatin 96-105 tumor protein p53 Homo sapiens 133-136 20459745-0 2010 NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner. Cisplatin 22-31 tumor protein p53 Homo sapiens 56-59 20459745-7 2010 The objective of the present study is to determine if p53 is responsible for cisplatin sensitization by NSC109268. Cisplatin 77-86 tumor protein p53 Homo sapiens 54-57 20459745-10 2010 Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. Cisplatin 0-9 tumor protein p53 Homo sapiens 55-58 20459745-10 2010 Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. Cisplatin 0-9 tumor protein p53 Homo sapiens 109-112 20459745-10 2010 Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. Cisplatin 129-138 tumor protein p53 Homo sapiens 109-112 20459745-11 2010 NSC109268 alone had no effect on p53 but it enhanced p53 level in response to cisplatin. Cisplatin 78-87 tumor protein p53 Homo sapiens 53-56 20372863-7 2010 Cisplatin treatment induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK expression, and suppressed Bcl-2 and Bcl-xl expression, whereas cells transfected with pcDNA3.1-ARL6IP1 showed lower levels of cisplatin-induced caspase-3, -9, p53, Bax, NF-kappaB and MAPK up-regulation and higher levels of cisplatin-suppressed Bcl-2 and Bcl-xl down-regulation. Cisplatin 0-9 tumor protein p53 Homo sapiens 232-235 20372863-8 2010 These novel findings collectively suggest that ARL6IP1 may play a key role in cisplatin-induced apoptosis in CaSki cervical cancer cells by regulating the expression of apoptosis-associated proteins such as caspase-3, -9, p53, NF-kappaB, MAPK, Bcl-2, Bcl-xl, and Bax. Cisplatin 78-87 tumor protein p53 Homo sapiens 222-225 20034524-5 2010 The damage to HK-2 cells caused by cisplatin involved the activation of p53, caspase-7, and poly (ADP-ribose) polymerase-1 (PARP-1). Cisplatin 35-44 tumor protein p53 Homo sapiens 72-75 20103635-7 2010 The lower cisplatin concentration was also accompanied by reduced induction of p53, which could be restored by downregulation of annexin A3. Cisplatin 10-19 tumor protein p53 Homo sapiens 79-82 20034524-11 2010 These results suggest that p53 plays a pivotal role in decreased integrin-mediated extracellular matrix component expression in cisplatin-induced tubule cell apoptosis, and reveal a novel aspect of PACAP-mediated renoprotection. Cisplatin 128-137 tumor protein p53 Homo sapiens 27-30 20100965-10 2010 Factors associated with good cisplatin response include young age (P = .001), low BRCA1 mRNA expression (P = .03), BRCA1 promoter methylation (P = .04), p53 nonsense or frameshift mutations (P = .01), and a gene expression signature of E2F3 activation (P = .03). Cisplatin 29-38 tumor protein p53 Homo sapiens 153-156 19802016-0 2010 Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Cisplatin 73-82 tumor protein p53 Homo sapiens 92-95 20048189-0 2010 TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. Cisplatin 63-72 tumor protein p53 Homo sapiens 0-4 20048189-9 2010 CONCLUSION The results indicate that the loss of function (transactivation activities) of p53 mutant proteins may predict a significant low pCR rate and suboptimal response to cisplatin-based neoadjuvant chemotherapy in patients with oral cavity SCC. Cisplatin 176-185 tumor protein p53 Homo sapiens 90-93 19889954-0 2010 Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Cisplatin 44-53 tumor protein p53 Homo sapiens 62-65 19889954-8 2010 Mechanistically, SAHA inhibited and TSA delayed p53 phosphorylation, acetylation, and activation during cisplatin incubation. Cisplatin 104-113 tumor protein p53 Homo sapiens 48-51 19889954-10 2010 Interestingly, in HCT116 colon cancer cells, SAHA suppressed cisplatin-induced p53 activation, but enhanced apoptosis. Cisplatin 61-70 tumor protein p53 Homo sapiens 79-82 19889954-11 2010 The results suggest that inhibitors of histone deacetylases can protect against cisplatin nephrotoxicity by attenuating DNA damage response and associated p53 activation. Cisplatin 80-89 tumor protein p53 Homo sapiens 155-158 19941080-3 2010 METHODS: Genomic mutation and protein expression of p53 were investigated retrospectively by polymerase chain reaction (PCR) single-strand conformation polymorphism (SSCP) and immunohistochemistry (IHC) using biopsy specimens from 77 ESCC patients before chemotherapy with 5-fluorouracil, adriamycin, and cisplatin. Cisplatin 305-314 tumor protein p53 Homo sapiens 52-55 19802016-1 2010 Although Akt is a determinant of cisplatin (cis-diaminedichloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. Cisplatin 33-42 tumor protein p53 Homo sapiens 169-172 19802016-1 2010 Although Akt is a determinant of cisplatin (cis-diaminedichloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. Cisplatin 44-71 tumor protein p53 Homo sapiens 169-172 19802016-1 2010 Although Akt is a determinant of cisplatin (cis-diaminedichloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. Cisplatin 73-77 tumor protein p53 Homo sapiens 169-172 19802016-2 2010 In this study, we show that CDDP induced p53-dependent Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein (FLIP) degradation in chemosensitive ovarian cancer cells but not their resistant counterparts. Cisplatin 28-32 tumor protein p53 Homo sapiens 41-44 19802016-3 2010 CDDP induced FLIP-p53-Itch interaction, colocalization and FLIP ubiquitination in chemosensitive but not chemoresistant ovarian cancer cells. Cisplatin 0-4 tumor protein p53 Homo sapiens 18-21 19802016-6 2010 These results suggest that Akt confers resistance, in part, by modulating CDDP-induced, p53-dependent FLIP ubiquitination. Cisplatin 74-78 tumor protein p53 Homo sapiens 88-91 19952113-5 2009 However, the anticancer drug cisplatin, known to stabilize and activate p53 and p73, downregulated PDGFRB expression not only in SH-SY5Y but also in IMR-32. Cisplatin 29-38 tumor protein p53 Homo sapiens 72-75 20681406-3 2010 Deficient tumor suppressor functions, such as TP53 mutations and p14(ARF)/p16(INK4a) deletions, are characteristic for GBM and can cause resistance to DNA damaging agents such as cisplatin and to HDACi like TSA. Cisplatin 179-188 tumor protein p53 Homo sapiens 46-50 19934315-0 2009 Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cisplatin 26-35 tumor protein p53 Homo sapiens 101-104 19934315-9 2009 Furthermore, p53 accumulated predominantly in the cytoplasm in Bcr-Abl(+) cells treated with imatinib and cisplatin. Cisplatin 106-115 tumor protein p53 Homo sapiens 13-16 19934315-10 2009 Silencing of p53 significantly reduced sensitivity to cisplatin in imatinib-treated Bcr-Abl(+) cells, indicating that p53 retains its proapoptotic activity. Cisplatin 54-63 tumor protein p53 Homo sapiens 13-16 19934315-10 2009 Silencing of p53 significantly reduced sensitivity to cisplatin in imatinib-treated Bcr-Abl(+) cells, indicating that p53 retains its proapoptotic activity. Cisplatin 54-63 tumor protein p53 Homo sapiens 118-121 19934315-11 2009 Simultaneous downregulation of Bcl-x(L) was an additional requirement for cisplatin hypersensitivity, as p53-dependent cell death could be antagonized by exogenous Bcl-x(L). Cisplatin 74-83 tumor protein p53 Homo sapiens 105-108 19548002-0 2009 Adenovirally mediated p53 overexpression diversely influence the cell cycle of HEp-2 and CAL 27 cell lines upon cisplatin and methotrexate treatment. Cisplatin 112-121 tumor protein p53 Homo sapiens 22-25 19548002-7 2009 RESULTS: In CAL 27 cells overexpression of p53 completely abrogated high S phase content observed in methotrexate-treated cells into a G1 and slight G2 arrest, while it sustained G2 arrest of the cells treated with cisplatin, along with the reduction of DNA synthesis and cyclin B1 expression. Cisplatin 215-224 tumor protein p53 Homo sapiens 43-46 19548002-8 2009 On the other hand, in HEp-2 cell line p53 overexpression slightly slowed down the progression through S phase in cells treated with methotrexate, decreased the cyclin B1 expression only after 24 h, and failed to sustain the G2 arrest after treatment with cisplatin alone. Cisplatin 255-264 tumor protein p53 Homo sapiens 38-41 19548002-10 2009 CONCLUSIONS: This study demonstrates that adenovirally mediated p53 overexpression at sub-cytotoxic levels enhanced the activity of low doses of cisplatin and methotrexate in HEp-2 and CAL 27 cells through changes in the cell cycle. Cisplatin 145-154 tumor protein p53 Homo sapiens 64-67 19629643-5 2010 Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity. Cisplatin 128-137 tumor protein p53 Homo sapiens 224-227 19629643-5 2010 Here, we show that four of seven types of DNA damage signals we examined (induction by etoposide, doxorubicin, camptothecin and cisplatin treatment) resulted in significant Apak phosphorylation and dissociation of Apak from p53, releasing the inhibition of p53 transcriptional activity. Cisplatin 128-137 tumor protein p53 Homo sapiens 257-260 19952113-6 2009 Chromatin immunoprecipitation showed that cisplatin removed DeltaNp73 from the PDGFRB promoter and recruited p53 and p73, leading to binding of histone deacetylase 4. Cisplatin 42-51 tumor protein p53 Homo sapiens 109-112 19806023-4 2009 Here we investigated the properties of a new p53 mutant (Lys 351 to Asn) in the TD identified in a cisplatin-resistant ovarian carcinoma cell line (A2780 CIS). Cisplatin 99-108 tumor protein p53 Homo sapiens 45-48 19670329-6 2009 The p53 response to cisplatin was also largely confined to peripheral cell layers. Cisplatin 20-29 tumor protein p53 Homo sapiens 4-7 19887545-6 2009 MK-1775 abrogates G(2) DNA damage checkpoint, leading to apoptosis in combination with DNA-damaging chemotherapeutic agents such as gemcitabine, carboplatin, and cisplatin selectively in p53-deficient cells. Cisplatin 162-171 tumor protein p53 Homo sapiens 187-190 19770592-4 2009 The present study demonstrates that cisplatin induces the PIDD (p53 induced protein with a death domain) dependent activation of caspase-2. Cisplatin 36-45 tumor protein p53 Homo sapiens 64-67 19806023-7 2009 Data obtained from the analysis of p53 subcellular localization revealed that K351N mutation inhibits the nuclear export of p53 and accumulation in the cytoplasm induced by cisplatin treatment. Cisplatin 173-182 tumor protein p53 Homo sapiens 35-38 19806023-7 2009 Data obtained from the analysis of p53 subcellular localization revealed that K351N mutation inhibits the nuclear export of p53 and accumulation in the cytoplasm induced by cisplatin treatment. Cisplatin 173-182 tumor protein p53 Homo sapiens 124-127 19444912-9 2009 These findings represent a novel strategy that could be exploited to overcome cisplatin resistance in patients regardless of p53 status or ability to perform MMR. Cisplatin 78-87 tumor protein p53 Homo sapiens 125-128 19561079-4 2009 Gene expression profiling of the human fibrosarcoma HT1080 cells showed that, while cisplatin induced p53 targets, A0 up-regulated genes involved in the unfolded protein response (UPR) and response to heavy metals. Cisplatin 84-93 tumor protein p53 Homo sapiens 102-105 19578044-7 2009 Furthermore, p53 promotes cisplatin-induced apoptosis by directly binding and counteracting Bcl-x(L) antiapoptotic function. Cisplatin 26-35 tumor protein p53 Homo sapiens 13-16 19578044-8 2009 In conclusion, our findings suggest a novel mode of action for cisplatin to overcome Bcl-2-mediated protection against apoptosis, which requires preferential activation of Bak and p53-mediated upregulation of Noxa protein levels and lipid peroxidation. Cisplatin 63-72 tumor protein p53 Homo sapiens 180-183 19444912-3 2009 Mismatch-repair (MMR) and p53 have previously been shown to be important determinants of cisplatin resistance and can contribute to cisplatin resistance clinically. Cisplatin 89-98 tumor protein p53 Homo sapiens 26-29 19444912-3 2009 Mismatch-repair (MMR) and p53 have previously been shown to be important determinants of cisplatin resistance and can contribute to cisplatin resistance clinically. Cisplatin 132-141 tumor protein p53 Homo sapiens 26-29 19581934-2 2009 Drug-resistant KB cells selected with cisplatin or oxaliplatin were found to have increased p53 levels and in oxaliplatin-selected cells, a larger p53 predominantly in the cytoplasm. Cisplatin 38-47 tumor protein p53 Homo sapiens 92-95 19578756-0 2009 Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Cisplatin 35-44 tumor protein p53 Homo sapiens 87-90 19578756-0 2009 Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Cisplatin 35-44 tumor protein p53 Homo sapiens 105-108 19578756-4 2009 In the present study, using MTT-based assays, Western blotting and semi-quantitative RT-PCR, we examined the apoptosis-related cellular responses to cisplatin exposure in two human urinary bladder cancer cell lines characterized by different malignancy grade and p53 genetic status. Cisplatin 149-158 tumor protein p53 Homo sapiens 263-266 19578756-5 2009 Both RT4 (grade I; wild-type p53) and T24 (grade III; mutant p53) cell types proved to be vulnerable to cisplatin apoptotic activity, albeit in a grade-dependent and drug dose-specific manner, as demonstrated by the proteolytic processing profiles of Caspase-8, Caspase-9, Caspase-3, and the Caspase repertoire characteristic substrates PARP and Lamin A/C, as well. Cisplatin 104-113 tumor protein p53 Homo sapiens 61-64 19578756-6 2009 The differential resistance of RT4 and T24 cells to cisplatin-induced apoptosis was associated with an RT4-specific phosphorylation (Ser15; Ser392) pattern of p53, together with structural amputations of the Akt and XIAP anti-apoptotic regulators. Cisplatin 52-61 tumor protein p53 Homo sapiens 159-162 19347880-5 2009 Additionally, Rad51d (E233G) conferred increased cisplatin resistance of an MCF7 cell line in which p53 expression was stably knocked down by shRNAp53, indicating that the effect of this variant is dependent upon p53 status. Cisplatin 49-58 tumor protein p53 Homo sapiens 100-103 19470675-0 2009 siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. Cisplatin 46-55 tumor protein p53 Homo sapiens 18-21 19470675-10 2009 siRNA to p53 was also effective in a model of cisplatin-induced kidney injury. Cisplatin 46-55 tumor protein p53 Homo sapiens 9-12 19603033-2 2009 In addition, the mismatch repair protein, hMLH1, has been linked to DNA damage-induced apoptosis by cisplatin by both p53-dependent and -independent mechanisms. Cisplatin 100-109 tumor protein p53 Homo sapiens 118-121 19052714-0 2009 TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cisplatin 122-131 tumor protein p53 Homo sapiens 0-4 19052714-6 2009 CONCLUSION: The TP53 codon 72 SNP was found to be predictive of the response to chemotherapy and correlate with the time to progression in patients with advanced gastric cancer treated with paclitaxel and cisplatin chemotherapy. Cisplatin 205-214 tumor protein p53 Homo sapiens 16-20 19347880-0 2009 Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines. Cisplatin 0-9 tumor protein p53 Homo sapiens 87-90 19347880-3 2009 We describe in this report that the Rad51d (E233G) genetic variant confers increased cisplatin resistance and cell growth phenotypes in human breast carcinoma cell lines with a mutant p53 gene (BT20 and T47D) but not with a wild-type p53 gene (MCF-7). Cisplatin 85-94 tumor protein p53 Homo sapiens 184-187 19347880-3 2009 We describe in this report that the Rad51d (E233G) genetic variant confers increased cisplatin resistance and cell growth phenotypes in human breast carcinoma cell lines with a mutant p53 gene (BT20 and T47D) but not with a wild-type p53 gene (MCF-7). Cisplatin 85-94 tumor protein p53 Homo sapiens 234-237 19242657-0 2009 Tunicamycin suppresses cisplatin-induced HepG2 cell apoptosis via enhancing p53 protein nuclear export. Cisplatin 23-32 tumor protein p53 Homo sapiens 76-79 19242657-4 2009 In order to further explore the mechanism underlying tumor resistance to cisplatin, we observed that increased nuclear export of endogenous p53 protein by pharmacological inducers of ER stress, such as tunicamycin, was associated with the suppression of cisplatin-induced apoptosis. Cisplatin 73-82 tumor protein p53 Homo sapiens 140-143 19242657-4 2009 In order to further explore the mechanism underlying tumor resistance to cisplatin, we observed that increased nuclear export of endogenous p53 protein by pharmacological inducers of ER stress, such as tunicamycin, was associated with the suppression of cisplatin-induced apoptosis. Cisplatin 254-263 tumor protein p53 Homo sapiens 140-143 19242657-5 2009 These results suggested that tumor suppressor p53 protein may play a key role in cisplatin-induced HepG2 cells apoptosis. Cisplatin 81-90 tumor protein p53 Homo sapiens 46-49 19347880-5 2009 Additionally, Rad51d (E233G) conferred increased cisplatin resistance of an MCF7 cell line in which p53 expression was stably knocked down by shRNAp53, indicating that the effect of this variant is dependent upon p53 status. Cisplatin 49-58 tumor protein p53 Homo sapiens 147-150 19528459-4 2009 Moreover, activation of p53, p53-dependent expression of p21 and p21-dependent senescence were observed in sigma-KO, but not parental cells after a treatment with a low cisplatin dose. Cisplatin 169-178 tumor protein p53 Homo sapiens 24-27 19217709-0 2009 Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines. Cisplatin 52-61 tumor protein p53 Homo sapiens 8-11 19217709-6 2009 We report herein that lung cancer cell lines expressing wild-type p53, when exposed to cisplatin treatment, induced COX-2 (mRNA and protein), with concurrent synthesis of prostaglandins (PGE(2)). Cisplatin 87-96 tumor protein p53 Homo sapiens 66-69 19217709-8 2009 Further, after silencing of wild-type p53 expressed in A549 cells by RNA interference, cisplatin was no longer able to induce COX-2 expression. Cisplatin 87-96 tumor protein p53 Homo sapiens 38-41 19217709-9 2009 Therefore, we suggest that induction of COX-2 by cisplatin in NSCLC cell lines is dependent on p53. Cisplatin 49-58 tumor protein p53 Homo sapiens 95-98 19328230-0 2009 Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation. Cisplatin 0-9 tumor protein p53 Homo sapiens 35-38 19328230-5 2009 Cisplatin treatment in the presence of an iNOS inhibitor (1400W) allowed p53 mitochondrial translocation. Cisplatin 0-9 tumor protein p53 Homo sapiens 73-76 19528459-4 2009 Moreover, activation of p53, p53-dependent expression of p21 and p21-dependent senescence were observed in sigma-KO, but not parental cells after a treatment with a low cisplatin dose. Cisplatin 169-178 tumor protein p53 Homo sapiens 29-32 19528459-5 2009 CONCLUSION: A 14-3-3sigma-dependent mechanism inhibits p53 activation in parental cells treated with a low cisplatin dose, thereby blocking p21 expression that is essential for senescence and consequently conferring to the parental cells a significant degree of resistance to cisplatin. Cisplatin 107-116 tumor protein p53 Homo sapiens 55-58 19528459-5 2009 CONCLUSION: A 14-3-3sigma-dependent mechanism inhibits p53 activation in parental cells treated with a low cisplatin dose, thereby blocking p21 expression that is essential for senescence and consequently conferring to the parental cells a significant degree of resistance to cisplatin. Cisplatin 276-285 tumor protein p53 Homo sapiens 55-58 19471670-7 2009 In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated OVCAR-3 cells. Cisplatin 28-37 tumor protein p53 Homo sapiens 3-6 19199318-8 2009 ARO cells are highly resistant to apoptosis and express both p53 and Gal-3, which are increased upon cisplatin treatment. Cisplatin 101-110 tumor protein p53 Homo sapiens 61-64 19471670-7 2009 In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated OVCAR-3 cells. Cisplatin 28-37 tumor protein p53 Homo sapiens 57-60 19471670-7 2009 In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated OVCAR-3 cells. Cisplatin 28-37 tumor protein p53 Homo sapiens 57-60 19471670-7 2009 In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated OVCAR-3 cells. Cisplatin 28-37 tumor protein p53 Homo sapiens 57-60 19471670-9 2009 CONCLUSION: The synergistic growth inhibition by combination of Ad-p53 and cisplatin may depend on the p53 status and the temporal sequence of cisplatin treatment, suggesting judicious selective application of this strategy in clinical trials. Cisplatin 75-84 tumor protein p53 Homo sapiens 103-106 19471670-9 2009 CONCLUSION: The synergistic growth inhibition by combination of Ad-p53 and cisplatin may depend on the p53 status and the temporal sequence of cisplatin treatment, suggesting judicious selective application of this strategy in clinical trials. Cisplatin 143-152 tumor protein p53 Homo sapiens 67-70 18824293-5 2009 Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. Cisplatin 89-98 tumor protein p53 Homo sapiens 16-19 19240372-0 2009 The p53-induced Siva-1 plays a significant role in cisplatin-mediated apoptosis. Cisplatin 51-60 tumor protein p53 Homo sapiens 4-7 19240372-3 2009 METHODS: Cisplatin treated HCT116 colorectal carcinoma cells (p53+/+ and -/-) were used in the study. Cisplatin 9-18 tumor protein p53 Homo sapiens 62-65 19240372-6 2009 RESULTS: Treatment with cisplatin induced Siva-1 expression in a p53 dependent manner. Cisplatin 24-33 tumor protein p53 Homo sapiens 65-68 18716605-4 2008 Genistein also decreased cisplatin-induced apoptosis by regulating p53 induction in kidney. Cisplatin 25-34 tumor protein p53 Homo sapiens 67-70 18823952-5 2008 Cisplatin caused an increase in the translocation of p53 into the nucleus in the presence of lower effective concentrations of benomyl while a decrease in the nuclear accumulation of p53 was observed in the presence of high concentrations of benomyl suggesting that the stabilized microtubules assist in the nuclear transportation of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 53-56 18948736-3 2008 Indeed, we show that the disruption of the protein complex mutantp53/p73 and the consequent restoration of p73 transcriptional effects, through the activity of short interfering peptides, render mutant p53 cells more prone to the killing of adriamycin and cisplatin. Cisplatin 256-265 tumor protein p53 Homo sapiens 65-68 18487078-5 2008 Cell lines with p53 mutations were slightly more sensitive to cisplatin than those with wild-type p53. Cisplatin 62-71 tumor protein p53 Homo sapiens 16-19 18682572-0 2008 Regulation and pathological role of p53 in cisplatin nephrotoxicity. Cisplatin 43-52 tumor protein p53 Homo sapiens 36-39 18682572-3 2008 Recent studies, using both in vitro and in vivo experimental models, have suggested a critical role for p53 in cisplatin nephrotoxicity. Cisplatin 111-120 tumor protein p53 Homo sapiens 104-107 18682572-6 2008 Further research may integrate p53 signaling with other nephrotoxic signaling pathways, providing a comprehensive understanding of cisplatin nephrotoxicity and leading to the development of effective renoprotective strategies during cancer therapy. Cisplatin 131-140 tumor protein p53 Homo sapiens 31-34 18512237-2 2008 Here we show that p53 mutations in stromal fibroblasts, a genetic lesion that is detectable in primary breast, prostate and probably other cancers, while they accelerate tumorigenesis they also sensitize tumours against conventional chemotherapy by doxorubicin and cis-platinum. Cisplatin 265-277 tumor protein p53 Homo sapiens 18-21 18768816-4 2008 It is shown that postmeiotic segregation 2 (PMS2), an MMR protein, is required for cisplatin-induced activation of p73, a member of the p53 family of transcription factors with proapoptotic activity. Cisplatin 83-92 tumor protein p53 Homo sapiens 136-139 19024321-4 2008 All of the cells were collected after treated with 10 micromol/L cisplatin for 24 h. The expressions of p53 mRNA and protein were detected by real-time RT-PCR and Western blot analysis. Cisplatin 65-74 tumor protein p53 Homo sapiens 104-107 18391982-0 2008 Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Cisplatin 31-40 tumor protein p53 Homo sapiens 152-155 18391982-3 2008 Our results showed that a combined CDDP/triptolide therapy induced apoptosis in urothelial cancer cell lines with wild-type p53, but not in those with mutant-type p53 or normal human urothelium. Cisplatin 35-39 tumor protein p53 Homo sapiens 124-127 18391982-4 2008 As the mechanism, triptolide suppressed CDDP-induced p53 transcriptional activity, leading to p21 attenuation, which promoted apoptosis via the activation of c-Jun N-terminal kinase (JNK) and Bax. Cisplatin 40-44 tumor protein p53 Homo sapiens 53-56 18468580-3 2008 Cisplatin (cDDP) yields intra- and inter-strand DNA cross-links and several proteins that recognise cDDP-induced DNA damage, such as p53, are also targets of poly(ADP-ribosyl)ation. Cisplatin 0-9 tumor protein p53 Homo sapiens 133-136 18452174-7 2008 Both energy inhibitors strongly potentiated non-apoptotic concentrations of cisplatin in p53-wildtype as well as in p53-deficient, cisplatin-resistant HCT-116 colon carcinoma cells. Cisplatin 76-85 tumor protein p53 Homo sapiens 89-92 18452174-9 2008 We conclude that the long-term effects of cisplatin potentiation are important and either p53-independent or improved by a lack of p53. Cisplatin 42-51 tumor protein p53 Homo sapiens 90-93 18452174-9 2008 We conclude that the long-term effects of cisplatin potentiation are important and either p53-independent or improved by a lack of p53. Cisplatin 42-51 tumor protein p53 Homo sapiens 131-134 18421307-11 2008 In summary, HIF-1 targeted therapy to reverse hypoxia-related cisplatin resistance depends on normal p53 status. Cisplatin 62-71 tumor protein p53 Homo sapiens 101-104 18559494-0 2008 Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 18-21 18559494-2 2008 Although p53 and FLICE-like inhibitory protein (FLIP) are determinants of CDDP sensitivity in ovarian cancer, the interaction between p53 and FLIP remains poorly understood. Cisplatin 74-78 tumor protein p53 Homo sapiens 9-12 18559494-3 2008 Here, using two chemosensitive ovarian cancer cell lines and various molecular and cellular approaches, we show that CDDP induces p53-dependent FLIP ubiquitination and degradation, and apoptosis in vitro. Cisplatin 117-121 tumor protein p53 Homo sapiens 130-133 18559494-4 2008 Moreover, we showed that Itch (an E3 ligase) forms a complex with FLIP and p53 upon CDDP treatment. Cisplatin 84-88 tumor protein p53 Homo sapiens 75-78 18559494-5 2008 These results suggest that p53 facilitates FLIP down-regulation by CDDP-induced FLIP ubiquitination and proteasomal degradation. Cisplatin 67-71 tumor protein p53 Homo sapiens 27-30 18468580-3 2008 Cisplatin (cDDP) yields intra- and inter-strand DNA cross-links and several proteins that recognise cDDP-induced DNA damage, such as p53, are also targets of poly(ADP-ribosyl)ation. Cisplatin 11-15 tumor protein p53 Homo sapiens 133-136 18468580-3 2008 Cisplatin (cDDP) yields intra- and inter-strand DNA cross-links and several proteins that recognise cDDP-induced DNA damage, such as p53, are also targets of poly(ADP-ribosyl)ation. Cisplatin 100-104 tumor protein p53 Homo sapiens 133-136 18468580-4 2008 We compared the effects of treatments with cDDP and the PARPs inhibitor PJ34 in p53 mutated carcinoma cell lines (HeLa, KB, HT29) that exhibited differential sensitivities to the drugs, in terms of cell growth inhibition and onset of apoptosis. Cisplatin 43-47 tumor protein p53 Homo sapiens 80-83 18506185-0 2008 Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Cisplatin 0-9 tumor protein p53 Homo sapiens 92-95 18223681-3 2008 During cisplatin (CDDP)-mediated apoptosis in neuroblastoma SH-SY5Y cells, p53 was induced to accumulate in association with an increase in expression levels of NEDL1. Cisplatin 7-16 tumor protein p53 Homo sapiens 75-78 18223681-3 2008 During cisplatin (CDDP)-mediated apoptosis in neuroblastoma SH-SY5Y cells, p53 was induced to accumulate in association with an increase in expression levels of NEDL1. Cisplatin 18-22 tumor protein p53 Homo sapiens 75-78 18506185-5 2008 The NO donor S-nitroso-N-acetylpenicillamine (SNAP) increased p53 protein levels and induced apoptosis in both cell types, and enhanced cisplatin-induced apoptosis in C13(*) cells in a p53-dependent manner (i.e., enhancement blocked by p53 siRNA). Cisplatin 136-145 tumor protein p53 Homo sapiens 185-188 18506185-5 2008 The NO donor S-nitroso-N-acetylpenicillamine (SNAP) increased p53 protein levels and induced apoptosis in both cell types, and enhanced cisplatin-induced apoptosis in C13(*) cells in a p53-dependent manner (i.e., enhancement blocked by p53 siRNA). Cisplatin 136-145 tumor protein p53 Homo sapiens 185-188 20731894-12 2008 The IC50 of pEGFP-p53(AS)-801D cell line(0.26+/-0.09 mug/mL) to Cisplatin(DDP) decreased markedly compared with 801D(0.55+/-0.19 mug/mL,P<0.05)and pEGFP-801D(0.77+/-0.13mug/mL,P<0.05). Cisplatin 64-73 tumor protein p53 Homo sapiens 18-21 18566213-5 2008 Indeed, we found that CDDP treatment induced the up-regulation of p53 in both sensitive and resistant A2780 cell lines. Cisplatin 22-26 tumor protein p53 Homo sapiens 66-69 18376141-1 2008 We showed that tumor cells with wild-type p53 and high levels of Bcl-x(L) are cisplatin resistant but are induced to undergo apoptosis by (-)-gossypol, making this a promising agent for overcoming cisplatin resistance. Cisplatin 78-87 tumor protein p53 Homo sapiens 42-45 18376141-1 2008 We showed that tumor cells with wild-type p53 and high levels of Bcl-x(L) are cisplatin resistant but are induced to undergo apoptosis by (-)-gossypol, making this a promising agent for overcoming cisplatin resistance. Cisplatin 197-206 tumor protein p53 Homo sapiens 42-45 18376141-3 2008 Conversely, tumor cells with low Bcl-x(L) expression and either wild type or mutant p53 are relatively cisplatin sensitive and do not exhibit such high levels of apoptosis. Cisplatin 103-112 tumor protein p53 Homo sapiens 84-87 18504201-0 2008 [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis]. Cisplatin 48-57 tumor protein p53 Homo sapiens 1-4 18504201-1 2008 OBJECTIVE: To explore the relation between p53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer (NSCLC). Cisplatin 90-99 tumor protein p53 Homo sapiens 43-46 18261847-0 2008 Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells. Cisplatin 35-44 tumor protein p53 Homo sapiens 20-23 18261847-5 2008 Although p73 appears to be implicated mainly in response to high stress conditions, the available results support a cooperation between p53 and p73 in cisplatin-induced apoptosis in sensitive cells. Cisplatin 151-160 tumor protein p53 Homo sapiens 136-139 18455581-1 2008 OBJECTIVE: The objective of this study is to establish clinical evidence that the p53 genotype can serve as a predictive marker for response to cisplatin-based induction therapy. Cisplatin 144-153 tumor protein p53 Homo sapiens 82-85 18296503-3 2008 The binding of hnRNPC1/C2 is strongly enhanced in response to the DNA-damaging drug cisplatin [cis-diamminedichloroplatinum(II)] and the cytostatic transcriptional inhibitor actinomycin D (dactinomycin), both known inducers of apoptosis and p53. Cisplatin 84-93 tumor protein p53 Homo sapiens 241-244 18296503-3 2008 The binding of hnRNPC1/C2 is strongly enhanced in response to the DNA-damaging drug cisplatin [cis-diamminedichloroplatinum(II)] and the cytostatic transcriptional inhibitor actinomycin D (dactinomycin), both known inducers of apoptosis and p53. Cisplatin 95-123 tumor protein p53 Homo sapiens 241-244 18505928-9 2008 p53 expression knockdown by small interfering RNA increased cisplatin sensitivity. Cisplatin 60-69 tumor protein p53 Homo sapiens 0-3 20731894-17 2008 By the assay of flow cytometer, G2 phase arrest was observed when pEGFP-p53(AS)-801D was treated with DDP. Cisplatin 102-105 tumor protein p53 Homo sapiens 72-75 18480997-9 2008 Western blotting showed that cisplatin decreased protein expression of E6 and increased protein expression of p53, p21 and Bax. Cisplatin 29-38 tumor protein p53 Homo sapiens 110-113 18454047-7 2008 The distinct p53 activation profile of LA-12 compared with cisplatin and doxorubicin provides a molecular explanation for the ability of this drug to treat cisplatin-resistant cells and indicates its potential usefulness as an alternative antitumour agent in first-line therapy or as a second-line therapy in patients with acquired cisplatin resistance. Cisplatin 156-165 tumor protein p53 Homo sapiens 13-16 18454047-7 2008 The distinct p53 activation profile of LA-12 compared with cisplatin and doxorubicin provides a molecular explanation for the ability of this drug to treat cisplatin-resistant cells and indicates its potential usefulness as an alternative antitumour agent in first-line therapy or as a second-line therapy in patients with acquired cisplatin resistance. Cisplatin 156-165 tumor protein p53 Homo sapiens 13-16 18480997-11 2008 It is concluded that cisplatin can induce apoptosis in HeLa cells by suppressing HPV E6 and thereby restoring the function of p53. Cisplatin 21-30 tumor protein p53 Homo sapiens 126-129 18380010-6 2008 Cisplatin treatment decreased the amount of 39 kDa C-terminal ASK1 fragments in mutant p53 cell lines suggesting a decrease in cleavage associated with apoptosis. Cisplatin 0-9 tumor protein p53 Homo sapiens 87-90 18377724-6 2008 CAS overexpression enhanced p53 accumulation induced by doxorubicin, 5-fluorouracil, cisplatin, tamoxifen, and etoposide. Cisplatin 85-94 tumor protein p53 Homo sapiens 28-31 18174154-3 2008 During cisplatin-mediated apoptosis in COS7 cells in which the endogenous p53 is inactivated by SV40 large T antigen, p73 was induced to accumulate in association with a significant down-regulation of Plk1. Cisplatin 7-16 tumor protein p53 Homo sapiens 74-77 18310316-0 2008 Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Cisplatin 119-128 tumor protein p53 Homo sapiens 35-38 18310316-5 2008 We also characterized the relationship between the expression of p53, p53 isoforms, and p53 target genes following treatment with the DNA-damaging agent cisplatin. Cisplatin 153-162 tumor protein p53 Homo sapiens 65-68 18310316-5 2008 We also characterized the relationship between the expression of p53, p53 isoforms, and p53 target genes following treatment with the DNA-damaging agent cisplatin. Cisplatin 153-162 tumor protein p53 Homo sapiens 70-73 18310316-5 2008 We also characterized the relationship between the expression of p53, p53 isoforms, and p53 target genes following treatment with the DNA-damaging agent cisplatin. Cisplatin 153-162 tumor protein p53 Homo sapiens 70-73 18310316-9 2008 Treatment with cisplatin had differential effects on WTp53 and the small molecular weight form of p53 that were cell line dependent. Cisplatin 15-24 tumor protein p53 Homo sapiens 55-58 18064041-3 2008 Here, we have investigated the contribution of p53 and caspase-2 to apoptotic cell death and mitotic catastrophe in cisplatin-treated ovarian carcinoma cell lines. Cisplatin 116-125 tumor protein p53 Homo sapiens 47-50 18249159-4 2008 We show that the anti-cancer drug cisplatin or UV light activates both JNK and ERK in human glioblastoma cells lacking functional p53. Cisplatin 34-43 tumor protein p53 Homo sapiens 130-133 18191995-10 2008 While the level of p53 expression enhanced both the death-inducing and TRAIL-sensitizing effects of cisplatin, TRAIL-induced cell death was found to occur independent of p53. Cisplatin 100-109 tumor protein p53 Homo sapiens 19-22 18191995-12 2008 This result is due to both p53-dependent (cisplatin) and -independent (TRAIL) mechanisms. Cisplatin 42-51 tumor protein p53 Homo sapiens 27-30 18519232-4 2008 Cisplatin added to the culture medium leads to the significant increase of P53 expression and decrease of BCL-2 expression. Cisplatin 0-9 tumor protein p53 Homo sapiens 75-78 18267949-0 2008 p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells. Cisplatin 51-60 tumor protein p53 Homo sapiens 0-3 18267949-5 2008 We have investigated whether the p53 tumour suppressor status affects global NER of cisplatin-induced intrastrand cross links in human cells. Cisplatin 84-93 tumor protein p53 Homo sapiens 33-36 18267949-7 2008 We demonstrate that the absence of functional p53 leads to persistence of both cisplatin-induced intrastrand cross links in the genome, suggesting that p53 regulates NER of these DNA lesions. Cisplatin 79-88 tumor protein p53 Homo sapiens 46-49 18267949-7 2008 We demonstrate that the absence of functional p53 leads to persistence of both cisplatin-induced intrastrand cross links in the genome, suggesting that p53 regulates NER of these DNA lesions. Cisplatin 79-88 tumor protein p53 Homo sapiens 152-155 18267949-9 2008 Given the frequency of p53 mutations in human tumours, these results may have implications for the use of cisplatin in cancer chemotherapy. Cisplatin 106-115 tumor protein p53 Homo sapiens 23-26 18079115-0 2008 Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. Cisplatin 70-79 tumor protein p53 Homo sapiens 121-124 18079115-6 2008 The inhibition of AMPK in those cells and in xenografts of HCT116 resulted in a remarkable increase in cisplatin-induced apoptosis, which was associated with hyper-induction of the tumor suppressor p53. Cisplatin 103-112 tumor protein p53 Homo sapiens 198-201 18079115-7 2008 We further showed that ERK, but not ATM (ataxia telangiectasia mutated) and ATR (ATM- and Rad3-related) kinases, was involved in the hyper-induction of p53 by the inhibition of cisplatin-induced AMPK. Cisplatin 177-186 tumor protein p53 Homo sapiens 152-155 18206965-7 2008 Notably, FAK knockdown plus cisplatin triggered p53-dependent cell apoptosis, which was rescued by either full-length FAK or FAK FERM re-expression. Cisplatin 28-37 tumor protein p53 Homo sapiens 48-51 18095870-6 2008 Cells expressing the p53 mutants were either more sensitive to cisplatin and melphalan or more resistant than the untransfected cells, depending on the mutation. Cisplatin 63-72 tumor protein p53 Homo sapiens 21-24 17918180-0 2008 Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Cisplatin 13-22 tumor protein p53 Homo sapiens 86-89 17918180-5 2008 Cisplatin induced apoptosis in chemosensitive, but not chemoresistant cells, and this was inhibited by downregulation of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 121-124 17918180-6 2008 Cisplatin upregulated PUMA in a p53-dependent manner, and the presence of PUMA was necessary, but not sufficient for cisplatin-induced apoptosis. Cisplatin 0-9 tumor protein p53 Homo sapiens 32-35 17918180-7 2008 p53 was phosphorylated on numerous N-terminal residues, including Ser15, Ser20, in response to cisplatin in chemosensitive, but not chemoresistant cells. Cisplatin 95-104 tumor protein p53 Homo sapiens 0-3 17918180-8 2008 Furthermore, activation of Akt inhibited the cisplatin-induced upregulation of PUMA, and suppressed cisplatin-induced p53 phosphorylation, while inhibition of Akt increased total and phospho-p53 contents and sensitized p53 wild-type, chemoresistant cells to cisplatin-induced apoptosis. Cisplatin 45-54 tumor protein p53 Homo sapiens 191-194 17918180-8 2008 Furthermore, activation of Akt inhibited the cisplatin-induced upregulation of PUMA, and suppressed cisplatin-induced p53 phosphorylation, while inhibition of Akt increased total and phospho-p53 contents and sensitized p53 wild-type, chemoresistant cells to cisplatin-induced apoptosis. Cisplatin 45-54 tumor protein p53 Homo sapiens 191-194 17918180-8 2008 Furthermore, activation of Akt inhibited the cisplatin-induced upregulation of PUMA, and suppressed cisplatin-induced p53 phosphorylation, while inhibition of Akt increased total and phospho-p53 contents and sensitized p53 wild-type, chemoresistant cells to cisplatin-induced apoptosis. Cisplatin 100-109 tumor protein p53 Homo sapiens 118-121 17918180-8 2008 Furthermore, activation of Akt inhibited the cisplatin-induced upregulation of PUMA, and suppressed cisplatin-induced p53 phosphorylation, while inhibition of Akt increased total and phospho-p53 contents and sensitized p53 wild-type, chemoresistant cells to cisplatin-induced apoptosis. Cisplatin 100-109 tumor protein p53 Homo sapiens 118-121 17918180-9 2008 Finally, mutation of Ser15 and/or Ser20, but not of Ser37, to alanine significantly attenuated the ability of p53 to facilitate CDDP-induced apoptosis, and this was independent of PUMA expression. Cisplatin 128-132 tumor protein p53 Homo sapiens 110-113 17918180-10 2008 These results support the hypothesis that p53 is a determinant of CDDP sensitivity, and suggest that Akt contributes to chemoresistance, in part, by attenuating p53-mediated PUMA upregulation and phosphorylation of p53, which are essential, but independent determinants of sensitivity to CDDP-induced apoptosis. Cisplatin 66-70 tumor protein p53 Homo sapiens 42-45 17918180-10 2008 These results support the hypothesis that p53 is a determinant of CDDP sensitivity, and suggest that Akt contributes to chemoresistance, in part, by attenuating p53-mediated PUMA upregulation and phosphorylation of p53, which are essential, but independent determinants of sensitivity to CDDP-induced apoptosis. Cisplatin 66-70 tumor protein p53 Homo sapiens 161-164 17918180-10 2008 These results support the hypothesis that p53 is a determinant of CDDP sensitivity, and suggest that Akt contributes to chemoresistance, in part, by attenuating p53-mediated PUMA upregulation and phosphorylation of p53, which are essential, but independent determinants of sensitivity to CDDP-induced apoptosis. Cisplatin 66-70 tumor protein p53 Homo sapiens 161-164 17918180-10 2008 These results support the hypothesis that p53 is a determinant of CDDP sensitivity, and suggest that Akt contributes to chemoresistance, in part, by attenuating p53-mediated PUMA upregulation and phosphorylation of p53, which are essential, but independent determinants of sensitivity to CDDP-induced apoptosis. Cisplatin 288-292 tumor protein p53 Homo sapiens 161-164 17918180-10 2008 These results support the hypothesis that p53 is a determinant of CDDP sensitivity, and suggest that Akt contributes to chemoresistance, in part, by attenuating p53-mediated PUMA upregulation and phosphorylation of p53, which are essential, but independent determinants of sensitivity to CDDP-induced apoptosis. Cisplatin 288-292 tumor protein p53 Homo sapiens 161-164 17763999-0 2008 Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. Cisplatin 116-125 tumor protein p53 Homo sapiens 80-83 17763999-1 2008 Impaired tumor suppressor functions, such as deficient p53, are characteristic for glioblastoma multiforme (GBM) and can cause resistance to DNA-damaging agents like cisplatin. Cisplatin 166-175 tumor protein p53 Homo sapiens 55-58 17763999-4 2008 Using LN229 GBM cells, which express ING1 proteins and harbor mutant TP53, we are the first to show that DNA damage by cisplatin or ionizing radiation differentially induced the two major ING1 splicing isoforms. Cisplatin 119-128 tumor protein p53 Homo sapiens 69-73 17763999-9 2008 Also, ING1 down-regulation may sensitize GBM cells with deficient p53 to treatment with cisplatin. Cisplatin 88-97 tumor protein p53 Homo sapiens 66-69 17651689-8 2007 In summary, we concluded that the nuclear Trx-1 is required to resist apoptosis of MCF-7 cells induced by cisplatin, probably through up-regulating the anti-apoptotic gene, p53. Cisplatin 106-115 tumor protein p53 Homo sapiens 173-176 18003626-8 2008 p53-proficient cells were more sensitive than p53-deficient cells to cisplatin, (+/-)-anti-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide and UV-C; these differences in cellular sensitivity were more apparent in the 041 TR cells (up to 3.6-, 5.8- and 1.9-fold, respectively) than the WI38/VA13 cells (up to 2.3-, 1.4- and 1.4-fold, respectively). Cisplatin 69-78 tumor protein p53 Homo sapiens 0-3 18003626-8 2008 p53-proficient cells were more sensitive than p53-deficient cells to cisplatin, (+/-)-anti-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide and UV-C; these differences in cellular sensitivity were more apparent in the 041 TR cells (up to 3.6-, 5.8- and 1.9-fold, respectively) than the WI38/VA13 cells (up to 2.3-, 1.4- and 1.4-fold, respectively). Cisplatin 69-78 tumor protein p53 Homo sapiens 46-49 18006756-1 2007 PURPOSE: To determine the nature and potential pharmacologic reversibility of deficient TP53 expression and function in head and neck squamous cell carcinomas (HNSCC) with wild-type TP53, previously associated with decreased sensitivity to cisplatin therapy. Cisplatin 240-249 tumor protein p53 Homo sapiens 88-92 18006756-10 2007 CONCLUSIONS: Deficient TP53 mRNA and protein expression underlies decreased function in a subset of HNSCC with wild-type TP53 and can be restored together with cisplatin sensitization by quinacrine. Cisplatin 160-169 tumor protein p53 Homo sapiens 23-27 20020938-4 2008 Our studies showed that CAS over-expression increased p53 accumulation and apoptosis induced by 5-fluorouracil, doxorubicin, cisplatin, and tamoxifen in HT-29 cancer cells. Cisplatin 125-134 tumor protein p53 Homo sapiens 54-57 17505786-0 2007 Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Cisplatin 13-22 tumor protein p53 Homo sapiens 32-35 17505786-2 2007 The presence of wild type p53 has been suggested to be important for cisplatin cytotoxicity, hence we found that cisplatin induced apoptosis in cell lines with functional p53. Cisplatin 69-78 tumor protein p53 Homo sapiens 26-29 17505786-2 2007 The presence of wild type p53 has been suggested to be important for cisplatin cytotoxicity, hence we found that cisplatin induced apoptosis in cell lines with functional p53. Cisplatin 113-122 tumor protein p53 Homo sapiens 26-29 17505786-2 2007 The presence of wild type p53 has been suggested to be important for cisplatin cytotoxicity, hence we found that cisplatin induced apoptosis in cell lines with functional p53. Cisplatin 113-122 tumor protein p53 Homo sapiens 171-174 17698835-2 2007 Since the pro-apoptotic effect is associated with activation of p53, in this study we have investigated the efficacy of combination of ST1926 with cisplatin, a DNA-damaging agent that is known to induce p53-dependent apoptosis. Cisplatin 147-156 tumor protein p53 Homo sapiens 203-206 17505786-3 2007 Using the HCT116 colon carcinoma derived cell line we have established that the apoptotic activity of cisplatin requires the onset of a p53-mediated p38alpha MAPK pathway through generation of reactive oxygen species (ROS). Cisplatin 102-111 tumor protein p53 Homo sapiens 136-139 17505786-4 2007 HCT116 p53-deficient cells were much less sensitive to apoptosis by cisplatin than their p53wt counterparts, where apoptosis was strongly inhibited by antioxidants. Cisplatin 68-77 tumor protein p53 Homo sapiens 7-10 17505786-5 2007 Moreover, the presence of pifithrin-alpha, an inhibitor of p53 transcriptional activity, blocked cisplatin-induced apoptosis, reduced the generation of ROS produced upon cisplatin treatment. Cisplatin 97-106 tumor protein p53 Homo sapiens 59-62 17505786-5 2007 Moreover, the presence of pifithrin-alpha, an inhibitor of p53 transcriptional activity, blocked cisplatin-induced apoptosis, reduced the generation of ROS produced upon cisplatin treatment. Cisplatin 170-179 tumor protein p53 Homo sapiens 59-62 17505786-6 2007 In addition, we have identified p38alpha as the isoform necessary for cisplatin-induced apoptosis, upon activation by p53-mediated ROS production. Cisplatin 70-79 tumor protein p53 Homo sapiens 118-121 17505786-8 2007 We conclude that the p53/ROS/p38alpha MAPK cascade is essential for cisplatin-induced cell death in HCT116 cells and the subsequent p38alpha/p53 positive feedback loop strongly enhances the initial p53 activation. Cisplatin 68-77 tumor protein p53 Homo sapiens 21-24 17505786-8 2007 We conclude that the p53/ROS/p38alpha MAPK cascade is essential for cisplatin-induced cell death in HCT116 cells and the subsequent p38alpha/p53 positive feedback loop strongly enhances the initial p53 activation. Cisplatin 68-77 tumor protein p53 Homo sapiens 141-144 17505786-8 2007 We conclude that the p53/ROS/p38alpha MAPK cascade is essential for cisplatin-induced cell death in HCT116 cells and the subsequent p38alpha/p53 positive feedback loop strongly enhances the initial p53 activation. Cisplatin 68-77 tumor protein p53 Homo sapiens 141-144 17498666-7 2007 Cisplatin also inhibited the synthesis of HIF-1alpha protein for which p53 was dispensable. Cisplatin 0-9 tumor protein p53 Homo sapiens 71-74 17671694-9 2007 It is suggested that the cisplatin-resistance of CP70 cells is mediated by stabilizing p53. Cisplatin 25-34 tumor protein p53 Homo sapiens 87-90 17671694-11 2007 Therefore, pGSK-3beta-ser-9 may confer the cisplatin resistance of ovarian carcinomas through the stabilization of p53 expression. Cisplatin 43-52 tumor protein p53 Homo sapiens 115-118 17711579-9 2007 We identified 37 p53-responsive genes that were altered after cisplatin exposure. Cisplatin 62-71 tumor protein p53 Homo sapiens 17-20 17452332-8 2007 Thus, our results strongly suggest that the nuclear IKK-alpha-mediated accumulation of p73alpha is one of the novel molecular mechanisms to induce apoptotic cell death in response to CDDP, which may be particularly important in killing tumor cells with p53 mutation. Cisplatin 183-187 tumor protein p53 Homo sapiens 253-256 17555331-7 2007 When tumor cells treated with camptothecin or cisplatin were subsequently exposed to glutathione-enhancing agents, p53 underwent dethiolation accompanied by detectable increases in the level of p21waf1 expression, relative to the DNA-damaging drugs alone. Cisplatin 46-55 tumor protein p53 Homo sapiens 115-118 17611411-0 2007 P14ARF sensitizes human osteosarcoma cells to cisplatin-induced apoptosis in a p53-independent manner. Cisplatin 46-55 tumor protein p53 Homo sapiens 79-82 17611411-4 2007 This sensitization of cisplatin-induced apoptosis was associated with upregulation of p53, Bax and p21 in U2OS cells. Cisplatin 22-31 tumor protein p53 Homo sapiens 86-89 17611411-7 2007 Together, we show here p14ARF sensitizes human osteosarcoma cells to cisplatin-induced apoptosis in a p53-independent manner. Cisplatin 69-78 tumor protein p53 Homo sapiens 102-105 17195093-3 2007 Hypoxia-induced cell death was not associated with the activation of p53 while cisplatin-induced apoptosis is p53 dependent. Cisplatin 79-88 tumor protein p53 Homo sapiens 110-113 17113707-9 2007 Present findings indicate occurrence of sensitization to cisplatin by zoledronic acid in wild-type p53 osteosarcoma cells but not in p53-null cells nor in cells expressing a dominant-negative form of p53, supporting that wild-type p53 is required for synergistic interaction of cisplatin and zoledronic acid. Cisplatin 57-66 tumor protein p53 Homo sapiens 99-102 17146434-4 2007 Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Cisplatin 122-131 tumor protein p53 Homo sapiens 38-41 17146434-4 2007 Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Cisplatin 122-131 tumor protein p53 Homo sapiens 95-98 17510383-9 2007 Increased p53 and p73 responses following cisplatin treatment were also observed in HT1197 cells stably transfected with XPC cDNA. Cisplatin 42-51 tumor protein p53 Homo sapiens 10-13 17072341-5 2007 These experiments identify p53 as the main pathway producing a large-scale transcriptional response after cisplatin treatment in these cells containing wild-type p53. Cisplatin 106-115 tumor protein p53 Homo sapiens 27-30 17072341-5 2007 These experiments identify p53 as the main pathway producing a large-scale transcriptional response after cisplatin treatment in these cells containing wild-type p53. Cisplatin 106-115 tumor protein p53 Homo sapiens 162-165 17072341-6 2007 Consistent with a role for the p53 response in cisplatin sensitivity, knockdown of the p53 protein with small interfering RNA led to a twofold decrease in cell survival in the resistant cells. Cisplatin 47-56 tumor protein p53 Homo sapiens 31-34 17072341-6 2007 Consistent with a role for the p53 response in cisplatin sensitivity, knockdown of the p53 protein with small interfering RNA led to a twofold decrease in cell survival in the resistant cells. Cisplatin 47-56 tumor protein p53 Homo sapiens 87-90 17387280-3 2007 This mixed experimental-simulation approach enabled us to decode the dynamics of the cytostatic and cytotoxic responses to cisplatin and doxorubicin treatments in a p53--proficient colon carcinoma cell line (HCT-116) and in its p53-deficient counterpart. Cisplatin 123-132 tumor protein p53 Homo sapiens 165-168 17387280-3 2007 This mixed experimental-simulation approach enabled us to decode the dynamics of the cytostatic and cytotoxic responses to cisplatin and doxorubicin treatments in a p53--proficient colon carcinoma cell line (HCT-116) and in its p53-deficient counterpart. Cisplatin 123-132 tumor protein p53 Homo sapiens 228-231 17446929-2 2007 Here we demonstrated that the p53 family member p63 controls a pathway for p73-dependent cisplatin sensitivity specific to these "triple-negative" tumors. Cisplatin 89-98 tumor protein p53 Homo sapiens 30-33 17130844-5 2007 Consistently, such a protective effect can be at least partially due to the impairment of cisplatin-induced p53 activation, occurring early in committed, preapoptotic cells. Cisplatin 90-99 tumor protein p53 Homo sapiens 108-111 17283157-6 2007 Exposure to CDDP induced galectin-7 in cell lines with wild-type p53 but not in those with mutated p53. Cisplatin 12-16 tumor protein p53 Homo sapiens 65-68 17397945-6 2007 p53 siRNA prevented cisplatin-mediated up-regulation of FLJ11259 in NT2/D1 cells. Cisplatin 20-29 tumor protein p53 Homo sapiens 0-3 17397945-9 2007 In addition, chromatin immunoprecipitation assays indicate that p53 binds directly to this element in vivo and that binding is enhanced following cisplatin treatment. Cisplatin 146-155 tumor protein p53 Homo sapiens 64-67 17461764-9 2007 An extremely low concentration of cisplatin in addition to Ps-S-Oligos further up-regulated p53 activity, provoking massive apoptotic induction. Cisplatin 34-43 tumor protein p53 Homo sapiens 92-95 19690636-0 2007 BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells. Cisplatin 150-159 tumor protein p53 Homo sapiens 131-134 19690636-5 2007 Reduced expression of BRCA1 by transfection of BRCA1-siRNA resulted in a 5.3-fold increase in sensitivity to cisplatin in p53-wild A2780 cells, but not in p53-mutated A2780/CDDP and p53-deleted SKOV3 cells. Cisplatin 109-118 tumor protein p53 Homo sapiens 122-125 19690636-9 2007 However, cisplatin treatment under suppression of BRCA1 showed a significantly increased apoptosis along with up-regulation of p53 and p21 in A2780 cells. Cisplatin 9-18 tumor protein p53 Homo sapiens 127-130 17216584-6 2007 Conversely, Noxa transcription in response to the chemotherapeutic agents cisplatin or temozolomide was inhibited by p53 knockdown. Cisplatin 74-83 tumor protein p53 Homo sapiens 117-120 17216584-7 2007 Apoptosis in response to cisplatin or temozolomide was also inhibited by abrogation of p53 expression yet apoptosis in response to fenretinide or thapsigargin was unaffected. Cisplatin 25-34 tumor protein p53 Homo sapiens 87-90 17276397-4 2007 p53 accumulated in response to cisplatin (CDDP) and thereby promoting apoptosis in neuroblastoma SH-SY5Y cells bearing wild-type p53, whereas SK-N-AS cells did not undergo apoptosis. Cisplatin 31-40 tumor protein p53 Homo sapiens 0-3 17276397-4 2007 p53 accumulated in response to cisplatin (CDDP) and thereby promoting apoptosis in neuroblastoma SH-SY5Y cells bearing wild-type p53, whereas SK-N-AS cells did not undergo apoptosis. Cisplatin 42-46 tumor protein p53 Homo sapiens 0-3 17283157-7 2007 When the galectin-7 gene was transfected into cell lines with mutated p53, the sensitivity to CDDP increased compared with control transfectants. Cisplatin 94-98 tumor protein p53 Homo sapiens 70-73 17308072-0 2007 Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Cisplatin 112-121 tumor protein p53 Homo sapiens 17-20 17308072-7 2007 In the present study, we examined both intrinsic and death receptor-dependent apoptotic signaling in p53mu OVCAR3 EOC cell line, showing that these cells are less susceptible to cisplatin treatment as compared with p53 wild-type EOC cells and also resist CD95-mediated apoptosis due to inefficient formation of the death-inducing signaling complex and weak mitochondrial signal amplification. Cisplatin 178-187 tumor protein p53 Homo sapiens 101-104 17308072-9 2007 The synergy of cisplatin pretreatment and CD95 triggering in inducing cell death was also shown in p53mu tumor cells derived from ascitic fluid of advanced-stage EOC patients. Cisplatin 15-24 tumor protein p53 Homo sapiens 99-102 18161532-0 2007 Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells. Cisplatin 30-39 tumor protein p53 Homo sapiens 60-63 17211470-0 2007 Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Cisplatin 85-94 tumor protein p53 Homo sapiens 43-46 17211470-9 2007 These results suggest that immunostaining for TS and p53 protein is useful for pretreatment selection of gastric cancer patients unresponsive to S-1/cisplatin chemotherapy. Cisplatin 149-158 tumor protein p53 Homo sapiens 53-56 18161532-0 2007 Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells. Cisplatin 30-39 tumor protein p53 Homo sapiens 79-82 18161532-2 2007 The method was applied here to analyze the role of p53 in the effect of the anticancer drug cisplatin, distinguishing events occurring in the first generation of cells from those in the second and subsequent generations. Cisplatin 92-101 tumor protein p53 Homo sapiens 51-54 17848273-5 2007 RESULTS: HNSCC cell lines selected for cisplatin resistance had wild-type p53 and high levels of Bcl-xL. Cisplatin 39-48 tumor protein p53 Homo sapiens 74-77 17848273-6 2007 Expression of wild-type p53 in cell lines with low Bcl-xL enhanced cisplatin sensitivity. Cisplatin 67-76 tumor protein p53 Homo sapiens 24-27 17848273-7 2007 Expression of both Bcl-xL and wild-type p53 caused tumor cells to become cisplatin resistant. Cisplatin 73-82 tumor protein p53 Homo sapiens 40-43 17848273-9 2007 Novel agents that inhibit Bcl-xL or activate p53 function may target cisplatin-resistant HNSCC. Cisplatin 69-78 tumor protein p53 Homo sapiens 45-48 17848273-10 2007 CONCLUSION: Cisplatin resistance in HNSCC is mediated, at least in part, by high Bcl-xL and functional p53. Cisplatin 12-21 tumor protein p53 Homo sapiens 103-106 16849690-2 2006 Using cell culture models, recent work has suggested the involvement of p53 in renal cell apoptosis during cisplatin treatment. Cisplatin 107-116 tumor protein p53 Homo sapiens 72-75 17054906-4 2006 p53 was induced to be accumulated and associated with APP in response to cisplatin. Cisplatin 73-82 tumor protein p53 Homo sapiens 0-3 16849690-10 2006 During cisplatin incubation, VAD protected ATM and enhanced p53 phosphorylation. Cisplatin 7-16 tumor protein p53 Homo sapiens 60-63 16849690-11 2006 In vitro assay of protein kinase activity further showed that ATM immunoprecipitated from cisplatin-treated cells had significantly lower kinase activity toward p53 than that from control cells. Cisplatin 90-99 tumor protein p53 Homo sapiens 161-164 16931776-10 2006 In vitro exposure of hMSCs to cisplatin, vincristine, and etoposide resulted in an increased p53 expression, independent of apoptosis induction. Cisplatin 30-39 tumor protein p53 Homo sapiens 93-96 16981908-0 2006 DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner. Cisplatin 22-31 tumor protein p53 Homo sapiens 73-76 16894566-8 2006 Reintroduction of p53 decreases Akt1 and Akt2 activation and restores CDDP sensitivity in p53-null but not p53-null-Aurora-A cells. Cisplatin 70-74 tumor protein p53 Homo sapiens 18-21 16894566-8 2006 Reintroduction of p53 decreases Akt1 and Akt2 activation and restores CDDP sensitivity in p53-null but not p53-null-Aurora-A cells. Cisplatin 70-74 tumor protein p53 Homo sapiens 90-93 16894566-8 2006 Reintroduction of p53 decreases Akt1 and Akt2 activation and restores CDDP sensitivity in p53-null but not p53-null-Aurora-A cells. Cisplatin 70-74 tumor protein p53 Homo sapiens 90-93 17079468-5 2006 When U87MG (wild-type p53) and MCF-7 cells (wild-type p53) were exposed to adverse growth conditions of serum starvation or treated with the chemotherapeutic agent cisplatin, cells underwent apoptosis and cell cycle arrest accompanied by increase in p53 and HIC-1 transcript levels. Cisplatin 164-173 tumor protein p53 Homo sapiens 22-25 17079468-5 2006 When U87MG (wild-type p53) and MCF-7 cells (wild-type p53) were exposed to adverse growth conditions of serum starvation or treated with the chemotherapeutic agent cisplatin, cells underwent apoptosis and cell cycle arrest accompanied by increase in p53 and HIC-1 transcript levels. Cisplatin 164-173 tumor protein p53 Homo sapiens 54-57 17079468-5 2006 When U87MG (wild-type p53) and MCF-7 cells (wild-type p53) were exposed to adverse growth conditions of serum starvation or treated with the chemotherapeutic agent cisplatin, cells underwent apoptosis and cell cycle arrest accompanied by increase in p53 and HIC-1 transcript levels. Cisplatin 164-173 tumor protein p53 Homo sapiens 54-57 16690105-7 2006 In the gemcitabine plus cisplatin treatment arm compared to either alone, there was also downregulation of MSH2, p53, and ERCC1 expression. Cisplatin 24-33 tumor protein p53 Homo sapiens 113-116 16826413-9 2006 In addition, to study whether wild type p53 was expressed, induction of p53 by cis-platinum was assessed by Western blot. Cisplatin 79-91 tumor protein p53 Homo sapiens 72-75 16826413-16 2006 In POSE and NPOSE, p53 was induced by cis-platinum to a similar extent. Cisplatin 38-50 tumor protein p53 Homo sapiens 19-22 16981908-3 2006 It has been demonstrated previously that DNA modification with the antitumor drug cisplatin inhibits p53 binding to a synthetic p53 DNA-binding site. Cisplatin 82-91 tumor protein p53 Homo sapiens 101-104 16981908-3 2006 It has been demonstrated previously that DNA modification with the antitumor drug cisplatin inhibits p53 binding to a synthetic p53 DNA-binding site. Cisplatin 82-91 tumor protein p53 Homo sapiens 128-131 16981908-4 2006 Here we demonstrate that the effects of global DNA modification with cisplatin on binding of the p53 or p73 proteins to various p53 DNA-binding sites differed significantly, depending on the nucleotide sequence of the given target site. Cisplatin 69-78 tumor protein p53 Homo sapiens 97-100 16981908-4 2006 Here we demonstrate that the effects of global DNA modification with cisplatin on binding of the p53 or p73 proteins to various p53 DNA-binding sites differed significantly, depending on the nucleotide sequence of the given target site. Cisplatin 69-78 tumor protein p53 Homo sapiens 128-131 16981908-7 2006 Distinct effects of cisplatin DNA modification on the recognition of different response elements by the p53 family proteins may have impacts on regulation pathways in cisplatin-treated cells. Cisplatin 20-29 tumor protein p53 Homo sapiens 104-107 16981908-7 2006 Distinct effects of cisplatin DNA modification on the recognition of different response elements by the p53 family proteins may have impacts on regulation pathways in cisplatin-treated cells. Cisplatin 167-176 tumor protein p53 Homo sapiens 104-107 16545436-0 2006 Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Cisplatin 65-74 tumor protein p53 Homo sapiens 98-101 16797627-5 2006 In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. Cisplatin 33-42 tumor protein p53 Homo sapiens 162-165 16797627-5 2006 In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. Cisplatin 33-42 tumor protein p53 Homo sapiens 249-252 16797627-5 2006 In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. Cisplatin 33-42 tumor protein p53 Homo sapiens 249-252 16797627-5 2006 In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. Cisplatin 44-48 tumor protein p53 Homo sapiens 162-165 16797627-5 2006 In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. Cisplatin 44-48 tumor protein p53 Homo sapiens 249-252 16797627-5 2006 In this study, we show that AZT, cisplatin (CDDP) and docetaxel (DTX) all induce unique molecular responses in OVCAR-3 ovarian carcinoma cells carrying a mutated p53, while in A2780, ovarian carcinoma and MCF-7 breast carcinoma cells with wild type p53, all of these drugs cause similar p53 responses. Cisplatin 44-48 tumor protein p53 Homo sapiens 249-252 16815295-0 2006 p73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53. Cisplatin 62-71 tumor protein p53 Homo sapiens 84-87 16815295-4 2006 p73 and MDM2 were kept at low levels in the cisplatin-sensitive KB-3-1 cells, whereas p53 was induced to be phosphorylated at Ser-15 in response to cisplatin. Cisplatin 148-157 tumor protein p53 Homo sapiens 86-89 16815295-5 2006 In contrast, p73 and MDM2 were expressed at higher levels, and cisplatin-mediated p53 phosphorylation was undetectable in the cisplatin-resistant KCP-4 cells. Cisplatin 63-72 tumor protein p53 Homo sapiens 82-85 16815295-7 2006 Collectively, our results suggest that a loss of the cisplatin sensitivity is at least in part due to a lack of cisplatin-induced p53 phosphorylation, and p73 might cooperate with MDM2 to be involved in this process. Cisplatin 112-121 tumor protein p53 Homo sapiens 130-133 16545436-3 2006 Activation of p53 is a key determinant of sensitivity to cisplatin-induced apoptosis. Cisplatin 57-66 tumor protein p53 Homo sapiens 14-17 16773194-1 2006 The present study aims to investigate the role of p73 in response to cisplatin treatment in p53 wild-type neuroblastoma SH-SY5Y cells. Cisplatin 69-78 tumor protein p53 Homo sapiens 92-95 16773194-2 2006 Results showed that cisplatin induced a dose-dependent up-regulation of p53, p73, and a number of p53-responsive genes. Cisplatin 20-29 tumor protein p53 Homo sapiens 72-75 16773194-2 2006 Results showed that cisplatin induced a dose-dependent up-regulation of p53, p73, and a number of p53-responsive genes. Cisplatin 20-29 tumor protein p53 Homo sapiens 98-101 16773194-7 2006 Collectively, our results suggest that wt-p53 SH-SY5Y cells respond to cisplatin by inducing p73 isoform regulation and sustaining p53-dependent apoptosis that is independent of TAp73alpha. Cisplatin 71-80 tumor protein p53 Homo sapiens 42-45 16773194-7 2006 Collectively, our results suggest that wt-p53 SH-SY5Y cells respond to cisplatin by inducing p73 isoform regulation and sustaining p53-dependent apoptosis that is independent of TAp73alpha. Cisplatin 71-80 tumor protein p53 Homo sapiens 131-134 16544101-3 2006 Apoptosis induced in HeLa cells at 24 h of cisplatin treatment was confirmed by nuclear fragmentation, increase in subdiploid population and the enhanced activation of ERK and upregulation of p53. Cisplatin 43-52 tumor protein p53 Homo sapiens 192-195 15990222-0 2006 Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cisplatin 62-71 tumor protein p53 Homo sapiens 13-16 15990222-3 2006 Cells (UL-3A, UL-3B) that recovered from cisplatin (Cis) and paclitaxel (Tax) treatments showed higher levels of p53, mdr-1 and chemoresistance than untreated controls. Cisplatin 41-50 tumor protein p53 Homo sapiens 113-116 21144296-12 2006 Meanwhile the apoptotic rate of A549 cells was 28.99%+-1.07% in Ad-p53+DDP group, which was significantly higher than that in Ad-p53 group (15.35%+-1.31%, P < 0.001) and DDP group (1.74%+-0.77%, P < 0.001). Cisplatin 71-74 tumor protein p53 Homo sapiens 67-70 16731756-9 2006 We conclude that separate from effects on sensitivity to the acute cytotoxic effect of cisplatin, loss of MMR, especially when combined with loss of p53, results in rapid evolution of cisplatin resistance during sequential rounds of drug exposure that is likely mediated by enhanced mutagenic translesion synthesis. Cisplatin 184-193 tumor protein p53 Homo sapiens 149-152 16731756-10 2006 The DNA damage response activated by cisplatin is accompanied by a p53- and MMR-dependent increase in homologous recombination even between adduct-free sequences. Cisplatin 37-46 tumor protein p53 Homo sapiens 67-70 16596182-2 2006 While the role of p53 in CDDP-induced cell death has been stressed, evidence exists that CDDP can also kill p53-mutated cells. Cisplatin 89-93 tumor protein p53 Homo sapiens 108-111 16596182-8 2006 Therefore, the JNK pathway appears to be an ideal target for the modulation of the lethal action of CDDP in multiple types of p53-mutated cells. Cisplatin 100-104 tumor protein p53 Homo sapiens 126-129 16518417-0 2006 Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Cisplatin 23-32 tumor protein p53 Homo sapiens 90-93 16731756-0 2006 DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Cisplatin 90-99 tumor protein p53 Homo sapiens 24-27 16731756-4 2006 Loss of either MMR or p53 alone increased the rate of development of resistance to cisplatin by 1.8- and 2.4-fold, respectively; however, loss of both MMR and p53 increased the rate by 4.8-fold. Cisplatin 83-92 tumor protein p53 Homo sapiens 22-25 16731756-4 2006 Loss of either MMR or p53 alone increased the rate of development of resistance to cisplatin by 1.8- and 2.4-fold, respectively; however, loss of both MMR and p53 increased the rate by 4.8-fold. Cisplatin 83-92 tumor protein p53 Homo sapiens 159-162 16731756-8 2006 In the p53- and MMR-proficient cells, cisplatin induced a 17-fold increase in homologous recombination even when the recombining sequences that did not contain cisplatin adducts; the magnitude of induction was even greater in cells that had lost either one or both functions. Cisplatin 38-47 tumor protein p53 Homo sapiens 7-10 16518417-4 2006 On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53 (RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53. Cisplatin 73-77 tumor protein p53 Homo sapiens 116-119 16518417-4 2006 On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53 (RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53. Cisplatin 73-77 tumor protein p53 Homo sapiens 191-194 16518417-4 2006 On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53 (RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53. Cisplatin 73-77 tumor protein p53 Homo sapiens 191-194 16518417-5 2006 In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner. Cisplatin 20-24 tumor protein p53 Homo sapiens 33-36 16518417-7 2006 These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways. Cisplatin 70-74 tumor protein p53 Homo sapiens 117-120 16518417-7 2006 These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways. Cisplatin 70-74 tumor protein p53 Homo sapiens 133-136 21144296-13 2006 The apoptotic rate of GLC-82 cells was 62.98%+-2.43% in Ad-p53+DDP group, which was significantly higher than that in Ad-p53 group (20.88%+-0.71%, P < 0.001) and DDP group (6.91%+-1.52%, P < 0.001). Cisplatin 63-66 tumor protein p53 Homo sapiens 59-62 16644573-0 2006 p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Cisplatin 56-65 tumor protein p53 Homo sapiens 0-3 16211088-0 2006 Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cisplatin 82-91 tumor protein p53 Homo sapiens 20-23 16540663-9 2006 Inhibition of Akt facilitated Smac release and sensitized chemoresistant cells to CDDP in a p53-dependent manner. Cisplatin 82-86 tumor protein p53 Homo sapiens 92-95 16549753-0 2006 Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 110-113 16549753-8 2006 RESULTS: There was increased expression of p16, p21, p53, BCLxL, and BCLxS genes with cisplatin treatment in the CCL23 and CCL23AS cells. Cisplatin 86-95 tumor protein p53 Homo sapiens 53-56 16549753-15 2006 CONCLUSIONS: These results, in combination with increased expression of the p53 downstream effecter p21, indicate that the cisplatin-induced cell cycle arrest operates through the p16/p53-dependent pathway, and a caspase-independent pathway may be involved. Cisplatin 123-132 tumor protein p53 Homo sapiens 76-79 16549753-15 2006 CONCLUSIONS: These results, in combination with increased expression of the p53 downstream effecter p21, indicate that the cisplatin-induced cell cycle arrest operates through the p16/p53-dependent pathway, and a caspase-independent pathway may be involved. Cisplatin 123-132 tumor protein p53 Homo sapiens 184-187 16300733-0 2006 Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain. Cisplatin 15-24 tumor protein p53 Homo sapiens 40-43 16300733-0 2006 Recognition of cisplatin-damaged DNA by p53 protein: critical role of the p53 C-terminal domain. Cisplatin 15-24 tumor protein p53 Homo sapiens 74-77 16300733-1 2006 It was shown previously that the p53 protein can recognize DNA modified with antitumor agent cisplatin (cisPt-DNA). Cisplatin 93-102 tumor protein p53 Homo sapiens 33-36 16540663-0 2006 Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cisplatin 13-22 tumor protein p53 Homo sapiens 67-70 16540663-1 2006 Akt is a determinant of cisplatin [cis-diammine-dichloroplatinum (CDDP)] resistance in ovarian cancer cells, and this may be related to the regulation of p53. Cisplatin 24-33 tumor protein p53 Homo sapiens 154-157 16540663-1 2006 Akt is a determinant of cisplatin [cis-diammine-dichloroplatinum (CDDP)] resistance in ovarian cancer cells, and this may be related to the regulation of p53. Cisplatin 35-64 tumor protein p53 Homo sapiens 154-157 16540663-1 2006 Akt is a determinant of cisplatin [cis-diammine-dichloroplatinum (CDDP)] resistance in ovarian cancer cells, and this may be related to the regulation of p53. Cisplatin 66-70 tumor protein p53 Homo sapiens 154-157 16540663-5 2006 Here we show that CDDP induces mitochondrial p53 accumulation, the mitochondrial release of Smac, cytochrome c, and HTR/Omi, and apoptosis in chemosensitive but not in resistant ovarian cancer cells. Cisplatin 18-22 tumor protein p53 Homo sapiens 45-48 16364249-0 2006 TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Cisplatin 40-51 tumor protein p53 Homo sapiens 0-4 16644573-8 2006 Xenografts with p53 mutation showed significantly higher resistance to cisplatin (p < 0.001) and also tumours with cyclin D1 amplification showed significantly higher resistance (p < 0.001). Cisplatin 71-80 tumor protein p53 Homo sapiens 16-19 16951535-11 2006 These results indicated that some p53-null non-small cell lung cancers could be successfully treated when X-ray radiotherapy was administered with subsequent or concurrent cisplatin chemotherapy. Cisplatin 172-181 tumor protein p53 Homo sapiens 34-37 16228292-2 2005 We characterized the effects of bcl-2 antisense and cisplatin combination therapy in two human isogenic breast carcinoma cells p53(+)MCF-7 and p53(-)MCF-7/E6. Cisplatin 52-61 tumor protein p53 Homo sapiens 143-146 16533421-6 2006 Moreover, it appeared that wildtype p53 was required for sensitization to cisplatin because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Cisplatin 74-83 tumor protein p53 Homo sapiens 36-39 16533421-6 2006 Moreover, it appeared that wildtype p53 was required for sensitization to cisplatin because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Cisplatin 74-83 tumor protein p53 Homo sapiens 152-155 16533421-6 2006 Moreover, it appeared that wildtype p53 was required for sensitization to cisplatin because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Cisplatin 74-83 tumor protein p53 Homo sapiens 152-155 16533421-6 2006 Moreover, it appeared that wildtype p53 was required for sensitization to cisplatin because the effect was marginal in A549 and Calu-1 cells, where the p53 pathway is altered and simultaneous restoration of p53 and Fhit in Calu-1 cells increased cisplatin sensitivity. Cisplatin 246-255 tumor protein p53 Homo sapiens 36-39 16099193-7 2005 After cisplatin-induced DNA damage, the increasing levels of p53 lead to the trans-activation of a number of genes but not of p21(Waf1/Cip1), preferentially directing TGCT cells into apoptosis or programmed cell death, both via the mitochondrial and the death receptor apoptosis pathways. Cisplatin 6-15 tumor protein p53 Homo sapiens 61-64 16327987-0 2006 Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Cisplatin 125-134 tumor protein p53 Homo sapiens 13-16 16327987-0 2006 Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Cisplatin 125-134 tumor protein p53 Homo sapiens 77-80 16327987-1 2006 Cisplatin is a DNA-damaging chemotherapeutic drug that may have a role in the adjuvant chemotherapy of several solid tumors, such as malignant glioblastoma, and the status of p53 tumor suppressor protein is a critical determinant of cisplatin chemosensitivity. Cisplatin 0-9 tumor protein p53 Homo sapiens 175-178 16327987-1 2006 Cisplatin is a DNA-damaging chemotherapeutic drug that may have a role in the adjuvant chemotherapy of several solid tumors, such as malignant glioblastoma, and the status of p53 tumor suppressor protein is a critical determinant of cisplatin chemosensitivity. Cisplatin 233-242 tumor protein p53 Homo sapiens 175-178 16327987-2 2006 In the present study, we showed the relationship of p53 status and chemosensitivity of cisplatin between two human malignant glioblastoma cell lines, A172 and T98G, harboring wild-type and mutant-type p53, respectively. Cisplatin 87-96 tumor protein p53 Homo sapiens 52-55 16327987-2 2006 In the present study, we showed the relationship of p53 status and chemosensitivity of cisplatin between two human malignant glioblastoma cell lines, A172 and T98G, harboring wild-type and mutant-type p53, respectively. Cisplatin 87-96 tumor protein p53 Homo sapiens 201-204 16327987-5 2006 Cisplatin induced the accumulation of p53 and p21 proteins in A172 cells, but not in T98G cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 38-41 16327987-7 2006 These data strongly suggest that the expression of p53 is essential for the cytotoxic effect of cisplatin in human malignant glioblastoma cells, A172 and T98G, and the introduction of apoptotic signal molecules, such as p53, will be beneficial to achieve chemosensitivity in malignant glioma. Cisplatin 96-105 tumor protein p53 Homo sapiens 51-54 17135787-0 2006 Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells. Cisplatin 66-75 tumor protein p53 Homo sapiens 37-40 16169939-4 2005 We further analyzed the signaling pathways underlying these effects, and we showed that both RDCs and cisplatin induced p53 and p73 protein levels but with different intensities and kinetics. Cisplatin 102-111 tumor protein p53 Homo sapiens 120-123 16096850-7 2005 In OMS, apoptosis increased, cell proliferation decreased, and p53/p21 expression increased more pronounced following CDDP+RT. Cisplatin 118-122 tumor protein p53 Homo sapiens 63-66 16232203-7 2005 We found that p53 was produced in tumor cells and xenografts treated with a combination of AdEgr-p53 and cisplatin. Cisplatin 105-114 tumor protein p53 Homo sapiens 14-17 16120770-9 2005 We also observed a decrease in E7 expression with a concurrent increase in p53 protein levels upon cotreatment with shRNA and cisplatin over that seen with individual treatment alone. Cisplatin 126-135 tumor protein p53 Homo sapiens 75-78 16120770-10 2005 Our results provide strong evidence that loss of E6 and E7 results in increased sensitivity to cisplatin, probably because of increased p53 levels. Cisplatin 95-104 tumor protein p53 Homo sapiens 136-139 16232203-10 2005 Cisplatin-inducible p53 gene therapy may provide a means to control transgene expression while enhancing the effectiveness of commonly used chemotherapeutic agents. Cisplatin 0-9 tumor protein p53 Homo sapiens 20-23 16232203-0 2005 Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements. Cisplatin 0-9 tumor protein p53 Homo sapiens 21-24 16203773-0 2005 Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Cisplatin 8-17 tumor protein p53 Homo sapiens 167-170 16232203-5 2005 Wt-p53 production in cultured tumor cells and xenografts treated with the combination of AdEgr-p53 and cisplatin were detected by enzyme-linked immunosorbent assays. Cisplatin 103-112 tumor protein p53 Homo sapiens 3-6 16203773-11 2005 Cisplatin sensitivity was highly reduced in the group with loss of nuclear p53 signal compared with those with detectable nuclear signal. Cisplatin 0-9 tumor protein p53 Homo sapiens 75-78 16203773-13 2005 CONCLUSION: Taken together, these data suggest that "loss of nuclear p53 signal" correlates with cisplatin resistance in HNSCC. Cisplatin 97-106 tumor protein p53 Homo sapiens 69-72 15940259-0 2005 A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Cisplatin 43-52 tumor protein p53 Homo sapiens 2-5 15940259-8 2005 Interestingly, in p53 knockdown cells nearly the entire set of identified cisplatin targets fail to respond or have a diminished response to cisplatin, suggesting that many are new direct or indirect targets of p53 including GPR87, STK17A, INPP5D, FLJ11259, and EPS8L2. Cisplatin 74-83 tumor protein p53 Homo sapiens 18-21 15940259-7 2005 Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Cisplatin 31-40 tumor protein p53 Homo sapiens 18-21 15940259-8 2005 Interestingly, in p53 knockdown cells nearly the entire set of identified cisplatin targets fail to respond or have a diminished response to cisplatin, suggesting that many are new direct or indirect targets of p53 including GPR87, STK17A, INPP5D, FLJ11259, and EPS8L2. Cisplatin 74-83 tumor protein p53 Homo sapiens 211-214 15940259-8 2005 Interestingly, in p53 knockdown cells nearly the entire set of identified cisplatin targets fail to respond or have a diminished response to cisplatin, suggesting that many are new direct or indirect targets of p53 including GPR87, STK17A, INPP5D, FLJ11259, and EPS8L2. Cisplatin 141-150 tumor protein p53 Homo sapiens 18-21 15940259-7 2005 Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Cisplatin 31-40 tumor protein p53 Homo sapiens 64-67 15940259-7 2005 Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Cisplatin 31-40 tumor protein p53 Homo sapiens 64-67 15940259-7 2005 Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Cisplatin 152-161 tumor protein p53 Homo sapiens 18-21 16077963-9 2005 These results indicated that the type of p53 expression in cancer cells could be a promising factor in predicting response to FP therapy and the administration of CDDP prior to 5-FU may be more effective in inducing apoptosis of gastric cancer cells with wild-type p53 expression. Cisplatin 163-167 tumor protein p53 Homo sapiens 265-268 16077963-0 2005 The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Cisplatin 53-57 tumor protein p53 Homo sapiens 104-107 15983031-1 2005 We demonstrate the role of p53-mediated caspase-2 activation in the mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-treated renal tubular epithelial cells. Cisplatin 128-137 tumor protein p53 Homo sapiens 27-30 15983031-8 2005 Caspase-2 activation was a critical response from p53, which was markedly induced and phosphorylated in cisplatin-treated cells. Cisplatin 104-113 tumor protein p53 Homo sapiens 50-53 15983031-10 2005 The p53 inhibitor pifithrin-alpha or p53 siRNA prevented both cisplatin-induced caspase-2 activation and mitochondrial release of AIF. Cisplatin 62-71 tumor protein p53 Homo sapiens 4-7 15983031-10 2005 The p53 inhibitor pifithrin-alpha or p53 siRNA prevented both cisplatin-induced caspase-2 activation and mitochondrial release of AIF. Cisplatin 62-71 tumor protein p53 Homo sapiens 37-40 15983031-11 2005 Caspase-2 activation was dependent on the p53-responsive gene, PIDD, a death domain-containing protein that was induced by cisplatin in a p53-dependent manner. Cisplatin 123-132 tumor protein p53 Homo sapiens 42-45 15983031-11 2005 Caspase-2 activation was dependent on the p53-responsive gene, PIDD, a death domain-containing protein that was induced by cisplatin in a p53-dependent manner. Cisplatin 123-132 tumor protein p53 Homo sapiens 138-141 15983031-12 2005 These results suggest that caspase-2 activation mediated by p53 is an important pathway involved in the mitochondrial release of AIF in response to cisplatin injury. Cisplatin 148-157 tumor protein p53 Homo sapiens 60-63 16012788-0 2005 Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Cisplatin 68-78 tumor protein p53 Homo sapiens 9-12 16020667-2 2005 We observed that larynx preservation and response to chemotherapy is significantly associated with p53 overexpression, and that most HNSCC cell lines with mutant p53 are more sensitive to cisplatin than those with wild-type p53. Cisplatin 188-197 tumor protein p53 Homo sapiens 162-165 16020667-7 2005 Thus, cisplatin selected for wild-type p53 and high Bcl-x(L) expression in these cells. Cisplatin 6-15 tumor protein p53 Homo sapiens 39-42 16020667-10 2005 Thus, cisplatin-resistant cells seem to depend on wild-type p53 and Bcl-x(L) for survival and BH3 mimetic agents, such as (-)-gossypol, may be useful adjuncts to overcome cisplatin resistance in HNSCC. Cisplatin 6-15 tumor protein p53 Homo sapiens 60-63 16020667-2 2005 We observed that larynx preservation and response to chemotherapy is significantly associated with p53 overexpression, and that most HNSCC cell lines with mutant p53 are more sensitive to cisplatin than those with wild-type p53. Cisplatin 188-197 tumor protein p53 Homo sapiens 162-165 16277093-0 2005 Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Cisplatin 149-158 tumor protein p53 Homo sapiens 14-17 15870870-0 2005 Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. Cisplatin 37-46 tumor protein p53 Homo sapiens 82-85 15850808-0 2005 Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells. Cisplatin 44-53 tumor protein p53 Homo sapiens 37-40 15850808-4 2005 In addition, the cisplatin sensitivity of the PDT-resistant HT29 variants and several other clonal variants of HT29 cells correlated with increased BNip3 and decreased mutant p53 protein levels, but not Hsp27 protein levels. Cisplatin 17-26 tumor protein p53 Homo sapiens 175-178 15920103-8 2005 Transcriptional activation of p21(WAF1/CIP1) and Bax by p53 on exposure to cisplatin was completely blocked by introducing the p53 decoy oligonucleotide. Cisplatin 75-84 tumor protein p53 Homo sapiens 56-59 15956257-8 2005 Treatment of melanoma cells with cisplatin induces DNA damage and cytotoxicity, which is thought to be via p53-dependent and -independent mechanisms. Cisplatin 33-42 tumor protein p53 Homo sapiens 107-110 15870947-8 2005 Our findings also indicate that anti-apoptotic Bcl-xL and pro-apoptotic p53 are necessary but not sufficient for resistance to cisplatin-induced apoptosis in NSCLC cells. Cisplatin 127-136 tumor protein p53 Homo sapiens 72-75 15920103-8 2005 Transcriptional activation of p21(WAF1/CIP1) and Bax by p53 on exposure to cisplatin was completely blocked by introducing the p53 decoy oligonucleotide. Cisplatin 75-84 tumor protein p53 Homo sapiens 127-130 15886465-5 2005 The expression of p53 protein was increased after treatment with cisplatin and 5-FU, but not radiation. Cisplatin 65-74 tumor protein p53 Homo sapiens 18-21 15886465-10 2005 Cisplatin induced p53-dependent apoptosis and p21(WAF1/CIP1)-independent S-phase cell cycle arrest and 5-FU induced p53 and p21(WAF1/CIP1)-dependent G1-phase cell cycle arrest, not apoptosis. Cisplatin 0-9 tumor protein p53 Homo sapiens 18-21 15886465-11 2005 Cisplatin and 5-FU induced p53-dependent pathways, but radiation p53-independent pathway. Cisplatin 0-9 tumor protein p53 Homo sapiens 27-30 15886465-11 2005 Cisplatin and 5-FU induced p53-dependent pathways, but radiation p53-independent pathway. Cisplatin 0-9 tumor protein p53 Homo sapiens 65-68 15618970-0 2005 Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cisplatin 99-108 tumor protein p53 Homo sapiens 20-23 15578696-2 2005 Transfection of mutant p53 (R175H) to p53-null osteosarcoma Saos-2 cells suppressed apoptosis induced by doxorubicin (DOX), cisplatin and gamma radiation. Cisplatin 124-133 tumor protein p53 Homo sapiens 23-26 15578696-2 2005 Transfection of mutant p53 (R175H) to p53-null osteosarcoma Saos-2 cells suppressed apoptosis induced by doxorubicin (DOX), cisplatin and gamma radiation. Cisplatin 124-133 tumor protein p53 Homo sapiens 38-41 15810875-7 2005 Furthermore, we demonstrated that the removal of endogenous nitric oxide in melanoma cell lines led to increased sensitivity to cisplatin-induced apoptosis in a p53-dependent manner. Cisplatin 128-137 tumor protein p53 Homo sapiens 161-164 15797377-2 2005 Here we show that RAD001 (everolimus), a rapamycin derivative, dramatically enhances cisplatin-induced apoptosis in wild-type p53, but not mutant p53 tumor cells. Cisplatin 85-94 tumor protein p53 Homo sapiens 126-129 15797377-4 2005 We further show that RAD001 sensitizes cells to cisplatin by inhibiting p53-induced p21 expression. Cisplatin 48-57 tumor protein p53 Homo sapiens 72-75 15842252-7 2005 p53-independent apoptosis was seen with cisplatin treatment, a novel finding. Cisplatin 40-49 tumor protein p53 Homo sapiens 0-3 15842252-9 2005 Cisplatin may induce p53-independent apoptosis. Cisplatin 0-9 tumor protein p53 Homo sapiens 21-24 15652229-9 2005 Western blot analysis indicated a concentration-dependent p53 level increase in both lines (higher after cisplatin treatment). Cisplatin 105-114 tumor protein p53 Homo sapiens 58-61 16335246-3 2005 An increase in p53 protein expression was found in A549 and MCF7 (WT) cells treated with cisplatin, methotrexate, and doxorubicin, whereas the level of p53 was not statistically significantly changed in the MCF7 DOX/R cells. Cisplatin 89-98 tumor protein p53 Homo sapiens 15-18 15691646-1 2005 We measured the expression of the p53 nuclear protein and epidermal growth factor receptor (EGFR) in 46 biopsy samples from patients with advanced head and neck cancer treated with induction combination chemotherapy of 5-fluorouracil, cisplatin, and paclitaxel. Cisplatin 235-244 tumor protein p53 Homo sapiens 34-37 15496615-6 2005 Expression of tumor suppressor p53 and the cell cycle regulatory protein p21 was stimulated within 5 to 10 min by cisplatin in p53-positive LX-1 small cell lung carcinoma cells, and this effect was blocked by NAC. Cisplatin 114-123 tumor protein p53 Homo sapiens 31-34 15496615-6 2005 Expression of tumor suppressor p53 and the cell cycle regulatory protein p21 was stimulated within 5 to 10 min by cisplatin in p53-positive LX-1 small cell lung carcinoma cells, and this effect was blocked by NAC. Cisplatin 114-123 tumor protein p53 Homo sapiens 127-130 15496615-7 2005 In p53-negative SKOV3 cells, cisplatin toxicity and NAC chemoprotection remained effective, suggesting that chemoprotection may be mediated through both p53-dependent and -independent pathways. Cisplatin 29-38 tumor protein p53 Homo sapiens 3-6 15492778-8 2004 In addition, it is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, PKC, MAPK and PI3K/Akt. Cisplatin 59-68 tumor protein p53 Homo sapiens 297-300 15854392-0 2005 [Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation]. Cisplatin 111-120 tumor protein p53 Homo sapiens 135-138 15854392-8 2005 It was found that P53 protein translocated from nuclear to cytoplasm and could not phosphorate after the stimulation of cisplatin. Cisplatin 120-129 tumor protein p53 Homo sapiens 18-21 15854392-12 2005 CONCLUSIONS: p53 mutation induced by cisplatin/carboplatin might play an important role in the development of acquired multi-drug resistance of lung cancer chemotherapy. Cisplatin 37-46 tumor protein p53 Homo sapiens 13-16 15619007-2 2005 Isogenic and isophenotypic human thyroid papillary carcinoma cell line variants for p53 differently expressed cycle genes after cisplatin treatment. Cisplatin 128-137 tumor protein p53 Homo sapiens 84-87 15619007-4 2005 While cisplatin treatment increased their expression in p53 wild-type cells it decreased it in cells with inactivated p53 and had no or less effect on cells with mutated p53. Cisplatin 6-15 tumor protein p53 Homo sapiens 56-59 15720258-5 2005 It is known that the tumor-suppressor proteins p53 and p73, and the oncoprotein c-Myc, which function as transcription factors, influence cellular sensitivity to cisplatin. Cisplatin 162-171 tumor protein p53 Homo sapiens 47-50 16122187-1 2005 PURPOSE: In this study the relationship between therapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and of the expression of proliferation markers (ki67 and S-phase fraction) and tumour suppressor gene p53 was analyzed using a human ovarian cancer xenograft model. Cisplatin 73-82 tumor protein p53 Homo sapiens 224-227 15860933-8 2005 Moreover, overexpression of both wild-type p53 and exogenous PKCdelta in MKN28 increased cisplatin-induced cell death in MKN28. Cisplatin 89-98 tumor protein p53 Homo sapiens 43-46 15860933-9 2005 CONCLUSION: These results suggest that PKCdelta, in cooperation with p53, possibly regulates cisplatin-induced caspase-3-mediated cell death in gastric cancer. Cisplatin 93-102 tumor protein p53 Homo sapiens 69-72 15611505-0 2004 Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. Cisplatin 38-47 tumor protein p53 Homo sapiens 14-18 15258697-4 2004 At the lowest doses, the TGFbeta-RII-mutated and KRAS2-mutated cell line, TOV-21G, and the BRCA2-mutated cell line, TOV-81D, demonstrated a significantly higher sensitivity to cisplatin and gamma-irradiation than the TP53-mutated cell lines, TOV-112D and OV-90. Cisplatin 176-185 tumor protein p53 Homo sapiens 217-221 15258697-5 2004 At higher doses, differences between the TP53-mutated lines were observed with TOV-112D being less sensitive to cisplatin than OV-90 that also harbors a CDNK2A mutation. Cisplatin 112-121 tumor protein p53 Homo sapiens 41-45 15608418-0 2005 p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to cisplatin exposure. Cisplatin 99-108 tumor protein p53 Homo sapiens 0-3 15608418-3 2005 The objective of the present study was to analyse the expression profiles of p53 family members in squamous cell carcinomas of the head and neck (HNSCC) and their alterations caused by exposure to the clinically active drug cisplatin. Cisplatin 224-233 tumor protein p53 Homo sapiens 77-80 15619007-4 2005 While cisplatin treatment increased their expression in p53 wild-type cells it decreased it in cells with inactivated p53 and had no or less effect on cells with mutated p53. Cisplatin 6-15 tumor protein p53 Homo sapiens 118-121 15619007-4 2005 While cisplatin treatment increased their expression in p53 wild-type cells it decreased it in cells with inactivated p53 and had no or less effect on cells with mutated p53. Cisplatin 6-15 tumor protein p53 Homo sapiens 118-121 15619007-5 2005 These results show that in a well-defined system, different alterations of p53 can lead to a different regulation of genes and hence to either resistance or sensitivity to cisplatin. Cisplatin 172-181 tumor protein p53 Homo sapiens 75-78 15860933-0 2005 Overexpression of protein kinase Cdelta enhances cisplatin-induced cytotoxicity correlated with p53 in gastric cancer cell line. Cisplatin 49-58 tumor protein p53 Homo sapiens 96-99 15860933-2 2005 Cisplatin is one of the DNA-damaging agents and several factors including p53 are related to the sensitivity to cisplatin in cancer. Cisplatin 0-9 tumor protein p53 Homo sapiens 74-77 15860933-2 2005 Cisplatin is one of the DNA-damaging agents and several factors including p53 are related to the sensitivity to cisplatin in cancer. Cisplatin 112-121 tumor protein p53 Homo sapiens 74-77 15860933-4 2005 In our present study, we examined whether overexpression of PKCdelta and p53 increases the sensitivity of the human gastric cancer cell line, MKN28, which has a mutation of p53 gene, to cisplatin. Cisplatin 186-195 tumor protein p53 Homo sapiens 73-76 15665582-3 2004 UV-damage and the damage caused by certain chemotherapeutics including cisplatin and nitrogen mustards are known to be repaired by the nucleotide excision repair (NER) pathway which is reportedly regulated by p53 and its downstream genes. Cisplatin 71-80 tumor protein p53 Homo sapiens 209-212 15386387-0 2004 Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity. Cisplatin 58-67 tumor protein p53 Homo sapiens 9-12 15386387-3 2004 In our study, we examined the effect of expressing a human p53 cDNA, encoding a histidine to leucine amino acid substitution at codon 179 (H179L), on the ability of wild-type p53-containing NIH3T3 cells to respond to treatment with the chemotherapeutic cisplatin. Cisplatin 253-262 tumor protein p53 Homo sapiens 59-62 15386387-3 2004 In our study, we examined the effect of expressing a human p53 cDNA, encoding a histidine to leucine amino acid substitution at codon 179 (H179L), on the ability of wild-type p53-containing NIH3T3 cells to respond to treatment with the chemotherapeutic cisplatin. Cisplatin 253-262 tumor protein p53 Homo sapiens 175-178 15386387-6 2004 In contrast, cells stably expressing H179L-p53 arrested in S-phase following cisplatin treatment, which correlated with a marked decrease in the expression of cdc2, cyclin B1 and cyclin A, and a decrease in CDK2 and cyclin A-associated kinase activity. Cisplatin 77-86 tumor protein p53 Homo sapiens 43-46 15386387-7 2004 Interestingly, H179L p53 expressing cells underwent apoptosis earlier than control cells, indicating that this aberrant p53 may enhance cisplatin chemosensitivity. Cisplatin 136-145 tumor protein p53 Homo sapiens 21-24 15386387-7 2004 Interestingly, H179L p53 expressing cells underwent apoptosis earlier than control cells, indicating that this aberrant p53 may enhance cisplatin chemosensitivity. Cisplatin 136-145 tumor protein p53 Homo sapiens 120-123 15386387-8 2004 These data suggest that dominant-negative p53 can influence the expression and activity of CDK complexes, thereby modifying cell behavior following cisplatin-induced genotoxicity. Cisplatin 148-157 tumor protein p53 Homo sapiens 42-45 15382061-11 2004 In contrast to the antitumor action of cisplatin, which is known to be hampered by p53 dysfunction, we show that RuCl2(KTZ)2 is active irrespective of p53 functional status against several adherent tumor cells and synergizes with anti-EGF receptor C225 MAb to kill tumor spheroids resistant to either agent. Cisplatin 39-48 tumor protein p53 Homo sapiens 83-86 15492778-8 2004 In addition, it is generally accepted that cytotoxicity of cisplatin is mediated through induction of apoptosis and arrest of cell cycle resulting from its interaction with DNA, such as the formation of cisplatin-DNA adducts, which activates multiple signaling pathways, including those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, PKC, MAPK and PI3K/Akt. Cisplatin 203-212 tumor protein p53 Homo sapiens 297-300 15452549-8 2004 Microarray analysis revealed the induction of p53-regulated genes and regulators of checkpoint control and apoptosis in pxn100 tumours following cisplatin-treatment. Cisplatin 145-154 tumor protein p53 Homo sapiens 46-49 15452549-11 2004 Our observations show that a marked in vivo response to cisplatin can occur via p53-dependent apoptosis or independently of p53 status in human ovarian xenografts. Cisplatin 56-65 tumor protein p53 Homo sapiens 80-83 15452549-11 2004 Our observations show that a marked in vivo response to cisplatin can occur via p53-dependent apoptosis or independently of p53 status in human ovarian xenografts. Cisplatin 56-65 tumor protein p53 Homo sapiens 124-127 15548364-2 2004 Besides, p73 was shown to be activated by only a subset of signals that activate p53, such as gamma-irradiation and cisplatin, but not by other common genotoxic stress-inducing agents such as ultraviolet (UV) irradiation, although many of these signals are also capable of inducing p53-independent cell death. Cisplatin 116-125 tumor protein p53 Homo sapiens 81-84 15486204-0 2004 Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Cisplatin 137-146 tumor protein p53 Homo sapiens 57-60 15486204-3 2004 In contrast, on average, cells with mutant p53 are more resistant to the effect of cisplatin. Cisplatin 83-92 tumor protein p53 Homo sapiens 43-46 15486204-4 2004 It has been hypothesized that the sensitivity or resistance of tumor cells to cisplatin might be also associated with cell cycle control and repair processes that involve p53. Cisplatin 78-87 tumor protein p53 Homo sapiens 171-174 15486204-6 2004 This study, using gel-mobility-shift assays, was undertaken to examine the interactions of active and latent p53 protein with DNA fragments and oligodeoxyribonucleotide duplexes modified by BBR3464 in a cell free medium and to compare these results with those describing the interactions of these proteins with DNA modified by cisplatin. Cisplatin 327-336 tumor protein p53 Homo sapiens 109-112 15486204-7 2004 The results indicate that structurally different DNA adducts of BBR3464 and cisplatin exhibit a different efficiency to affect the binding affinity of the modified DNA to p53 protein. Cisplatin 76-85 tumor protein p53 Homo sapiens 171-174 15486204-8 2004 It has been suggested that different structural perturbations induced in DNA by the adducts of BBR3464 and cisplatin produce a differential response to p53 protein activation and recognition and that a "molecular approach" to control of downstream effects such as protein recognition and pathways of apoptosis induction may consist in design of structurally unique DNA adducts as cell signals. Cisplatin 107-116 tumor protein p53 Homo sapiens 152-155 15390206-0 2004 Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Cisplatin 122-131 tumor protein p53 Homo sapiens 12-15 15390206-11 2004 Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Bcl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). Cisplatin 127-136 tumor protein p53 Homo sapiens 78-81 15364135-2 2004 p53 Overexpression has been associated with resistance to cisplatin-based chemotherapy in patients (pts) with NSCLC. Cisplatin 58-67 tumor protein p53 Homo sapiens 0-3 15289875-4 2004 CDDP treatment caused steady induction of p53 protein in both cancer cell types, although it was more dramatic in CDDP-resistant HEp-2 cells, which was correlated well with p53 Ser15 phosphorylation, but not with the expression level of HPV type 18 E6 oncoprotein in these cells. Cisplatin 0-4 tumor protein p53 Homo sapiens 42-45 15289875-4 2004 CDDP treatment caused steady induction of p53 protein in both cancer cell types, although it was more dramatic in CDDP-resistant HEp-2 cells, which was correlated well with p53 Ser15 phosphorylation, but not with the expression level of HPV type 18 E6 oncoprotein in these cells. Cisplatin 0-4 tumor protein p53 Homo sapiens 173-176 15289875-4 2004 CDDP treatment caused steady induction of p53 protein in both cancer cell types, although it was more dramatic in CDDP-resistant HEp-2 cells, which was correlated well with p53 Ser15 phosphorylation, but not with the expression level of HPV type 18 E6 oncoprotein in these cells. Cisplatin 114-118 tumor protein p53 Homo sapiens 173-176 15266324-4 2004 In vitro experiments on neoplastic germ cell lines showed that their exquisite sensitivity to CDDP could be attributed to p53-dependent and -independent pathways. Cisplatin 94-98 tumor protein p53 Homo sapiens 122-125 15603542-6 2004 Functional assays confirming cell dysfunction and increased apoptosis revealed the rat kidney to be more sensitive to the effects of cisplatin than human kidney as demonstrated by significant decreases in slice ATP and GSH levels, significant increases in caspase 9 and 3 activity, p53 protein levels, and increased DNA laddering. Cisplatin 133-142 tumor protein p53 Homo sapiens 282-285 21241554-1 2004 BACKGROUND: To assess the effects of exogenous p73 gene on chemosensitivity of wild-type p53 human lung adenocarcinoma cell A549 to cisplatin (DDP) and adriamycin (ADM). Cisplatin 132-141 tumor protein p53 Homo sapiens 89-92 15266324-5 2004 Applying cDNA macroarray, semiquantitative RT-PCR and Western blot analyses, blocking experiments, caspase activity assays, and morphological methods, we sought here to define the p53-independent pathway(s) involved in the CDDP-induced apoptosis. Cisplatin 223-227 tumor protein p53 Homo sapiens 180-183 15266324-6 2004 For this purpose, we used the human TGCT cell line NCCIT, the mutated p53 of which is known to remain inactive during the course of CDDP-induced apoptosis. Cisplatin 132-136 tumor protein p53 Homo sapiens 70-73 15266324-10 2004 Thus, our data suggest that CDDP mediates its p53-independent apoptosis-inducing effect on the malignant human testicular germ cells--at least partially--through activation of the MEK-ERK signalling pathway. Cisplatin 28-32 tumor protein p53 Homo sapiens 46-49 15167899-0 2004 Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cisplatin 28-37 tumor protein p53 Homo sapiens 56-59 15167899-2 2004 However, as there is also some evidence to the contrary, we studied the relationship of the p53 status to the cellular response of glioma cells that were exposed to cisplatin. Cisplatin 165-174 tumor protein p53 Homo sapiens 92-95 15167899-5 2004 In U87MG cells, blocking the p53 response by antisense oligonucleotides also sensitized the cells to 2.5 microg/ml cisplatin, and shifted the cellular response from arrest to caspase 3-mediated apoptosis. Cisplatin 115-124 tumor protein p53 Homo sapiens 29-32 15197326-2 2004 The p53-family members, p63 and p73, are highly similar to p53, yet are differentially activated by IR, UV and cis-platinum via ATM and c-abl/ATR signaling pathways. Cisplatin 111-123 tumor protein p53 Homo sapiens 4-7 15197326-2 2004 The p53-family members, p63 and p73, are highly similar to p53, yet are differentially activated by IR, UV and cis-platinum via ATM and c-abl/ATR signaling pathways. Cisplatin 111-123 tumor protein p53 Homo sapiens 59-62 15353127-12 2004 The XPC defect reduces the cisplatin treatment-mediated p53 response. Cisplatin 27-36 tumor protein p53 Homo sapiens 56-59 15024021-4 2004 During the cisplatin-induced apoptosis in human neuroblastoma SH-SY5Y cells, the expression level of Plk1 was significantly decreased both at mRNA and protein levels, whereas cisplatin treatment caused a remarkable stabilization of p53. Cisplatin 11-20 tumor protein p53 Homo sapiens 232-235 15248926-2 2004 The purpose of this study was to evaluate the relationship of the cisplatin sensitivity/prognosis with the expression of excision repair cross complement-1 (ERCC-1), metallothionein (MT), and p53 in the paraffin-embedded tissue of advanced non-small cell lung cancer (NSCLC). Cisplatin 66-75 tumor protein p53 Homo sapiens 192-195 15096505-3 2004 We have demonstrated that DNA damage by doxorubicin and cisplatin caused a steady elevation of the R2 protein in p53(-/-) HCT-116 human colon carcinoma cells but induced degradation of the protein in p53(+/+) cells. Cisplatin 56-65 tumor protein p53 Homo sapiens 113-116 15096505-3 2004 We have demonstrated that DNA damage by doxorubicin and cisplatin caused a steady elevation of the R2 protein in p53(-/-) HCT-116 human colon carcinoma cells but induced degradation of the protein in p53(+/+) cells. Cisplatin 56-65 tumor protein p53 Homo sapiens 200-203 15150572-6 2004 In particular, we found that CA-Akt-expressing cells displayed increased expression of the antiapoptotic Bcl-2 family member protein Bcl-x(l), and a delayed onset of the p53 pathway after treatment with cisplatin or Mitoxantrone. Cisplatin 203-212 tumor protein p53 Homo sapiens 170-173 15024021-4 2004 During the cisplatin-induced apoptosis in human neuroblastoma SH-SY5Y cells, the expression level of Plk1 was significantly decreased both at mRNA and protein levels, whereas cisplatin treatment caused a remarkable stabilization of p53. Cisplatin 175-184 tumor protein p53 Homo sapiens 232-235 15102660-10 2004 A multivariate analysis, including tumor stage, gender, TP53 mutations, and MMP3 polymorphism, showed that the 6A/6A genotype was an independent factor of response to 5-fluorouracil-cisplatin chemotherapy in head and neck cancer patients with an odds ratio of 6.7 as compared with the 5A/5A genotype. Cisplatin 182-191 tumor protein p53 Homo sapiens 56-60 15107491-6 2004 Western blot hybridization results revealed that the XPC defect reduced the p53 responses to the cisplatin treatment. Cisplatin 97-106 tumor protein p53 Homo sapiens 76-79 15107491-8 2004 These results suggest that the XPC protein plays a critical role in initiating the cisplatin DNA damaging treatment-mediated signal transduction process, resulting in activation of the p53 pathway and cell cycle arrest that allow DNA repair and apoptosis to take place. Cisplatin 83-92 tumor protein p53 Homo sapiens 185-188 15135086-12 2004 Our results suggest also that aside from the BCR/ABL other factors such as p53 level, signal transduction pathways and DNA repair processes can be responsible for the increased sensitivity of K562 cells to cisplatin compared with normal lymphocytes. Cisplatin 206-215 tumor protein p53 Homo sapiens 75-78 15026814-10 2004 Gene transfer of p53 14/19 in combination with the administration of doxorubicin or cisplatin is a potential therapeutic approach for cancers expressing high levels of Mdm2. Cisplatin 84-93 tumor protein p53 Homo sapiens 17-20 14527925-1 2004 Functional regulation of p53 protein, a critical regulator of cell cycle and apoptosis, was investigated in fiberoptic bronchoscopy biopsy samples taken from 23 patients suffering from recurrent squamous cell lung cancer by analyzing the expression and phosphorylation status of the p53 at Ser15 and Ser20 before and after treatment with radiotherapy/cisplatin/vinorelbine. Cisplatin 351-360 tumor protein p53 Homo sapiens 25-28 14981545-7 2004 However, treatment with ADR or cisplatin is accompanied by a significant increase and redistribution of RAD6 to DNA, and RAD6, RAD18, PCNA, phosphohistone H3, as well as p53 proteins are all found in the DNA fractions. Cisplatin 31-40 tumor protein p53 Homo sapiens 170-173 15010816-0 2004 Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Cisplatin 79-88 tumor protein p53 Homo sapiens 14-17 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 188-197 tumor protein p53 Homo sapiens 164-167 14729469-0 2004 Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Cisplatin 98-107 tumor protein p53 Homo sapiens 54-57 14729469-5 2004 HIPK2 gene silencing efficiently reduces the p53-mediated transcriptional activation of apoptotic gene promoters as well as apoptotic cell death after treatment with cisplatin. Cisplatin 166-175 tumor protein p53 Homo sapiens 45-48 14729469-6 2004 These findings, along with the involvement of p53 phosphorylation at serine 46 (Ser46) in the transcriptional activation of apoptotic gene promoters, suggest a critical role for HIPK2 in triggering p53-dependent apoptosis in response to the antineoplastic drug cisplatin. Cisplatin 261-270 tumor protein p53 Homo sapiens 198-201 14991767-0 2004 Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 19-22 14991767-2 2004 Treatment with 0-20 microM cisplatin for 24 h in HPV16 E6 containing SiHa cells suppressed E6 mRNA, reduced E6 protein, and restored p53 expression in dose-dependent manners. Cisplatin 27-36 tumor protein p53 Homo sapiens 133-136 14991767-4 2004 After 0-10 microM cisplatin treatment, slightly more apoptotic cells appeared from SiHa cells than those from dominant negative p53-transfected SiHa cells. Cisplatin 18-27 tumor protein p53 Homo sapiens 128-131 14991767-7 2004 These accompanied with prolonged p53 restoration in irradiated-SiHa cells after 24 h cisplatin treatment and thereafter. Cisplatin 85-94 tumor protein p53 Homo sapiens 33-36 14991767-10 2004 Therefore, cisplatin restored p53 expression and prolonged IR-induced p53 restoration would be possible candidates to response more sub-G(1) apoptosis in irradiated SiHa cells. Cisplatin 11-20 tumor protein p53 Homo sapiens 30-33 14576150-0 2004 Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. Cisplatin 46-55 tumor protein p53 Homo sapiens 79-82 14576150-7 2004 Strikingly, we observed that the depletion of nitric oxide inhibits cisplatin-induced wild type p53 accumulation and p21(Waf1/Cip1/Sdi1) expression in melanoma cells. Cisplatin 68-77 tumor protein p53 Homo sapiens 96-99 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 5-14 tumor protein p53 Homo sapiens 23-26 14576150-8 2004 When cisplatin-induced p53 binding to the p21(Waf1/Cip1/Sdi1) promoter was examined, it was found that nitric oxide depletion significantly reduced the presence of p53-DNA complexes after cisplatin treatment. Cisplatin 5-14 tumor protein p53 Homo sapiens 164-167 14576150-9 2004 Furthermore, dominant negative inhibition of p53 activity enhanced cisplatin-induced apoptosis. Cisplatin 67-76 tumor protein p53 Homo sapiens 45-48 14576150-10 2004 Together, these data strongly suggest that endogenously produced nitric oxide is required for cisplatin-induced p53 activation and p21(Waf1/Cip1/Sdi1) expression, which can regulate melanoma sensitivity to cisplatin. Cisplatin 94-103 tumor protein p53 Homo sapiens 112-115 14712316-7 2003 Adding cisplatin to rAAV-p53-infected cells led to a significant growth inhibition between 81 and 91% indicating a synergistic effect between cisplatin and rAAV-p53. Cisplatin 7-16 tumor protein p53 Homo sapiens 25-28 21310133-4 2003 Cisplatin could obviously down-regulate telomerase activity, decrease S phase cells, increase G0/G1 phase cells, decline the expressions of bcl-2 and PCNA proteins and induce the expression of p53 protein of SLC-89 cells in a concentration-dependent fashion. Cisplatin 0-9 tumor protein p53 Homo sapiens 193-196 21310133-5 2003 CONCLUSIONS: Cisplatin can obviously inhibit the proliferation of SLC-89, change the distribution of cell cycle, decline telomerase activity and expressions of bcl-2 and PCNA proteins, and induce expression of p53 protein, which may be the important mechanisms of cisplatin"s anticancer action. Cisplatin 13-22 tumor protein p53 Homo sapiens 210-213 15033732-9 2003 We observed an increase of cellular p53 after cisplatin (CP) treatment. Cisplatin 46-55 tumor protein p53 Homo sapiens 36-39 14662026-0 2003 Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cisplatin 22-26 tumor protein p53 Homo sapiens 67-70 14662026-2 2003 Because the oncoprotein E6, derived from HPV, inhibits the function of p53 protein, the inhibition of apoptosis via the p53 pathway by HPV may be related to cisplatin (CDDP)-sensitivity in cervical cancer. Cisplatin 157-166 tumor protein p53 Homo sapiens 71-74 14662026-2 2003 Because the oncoprotein E6, derived from HPV, inhibits the function of p53 protein, the inhibition of apoptosis via the p53 pathway by HPV may be related to cisplatin (CDDP)-sensitivity in cervical cancer. Cisplatin 157-166 tumor protein p53 Homo sapiens 120-123 14662026-2 2003 Because the oncoprotein E6, derived from HPV, inhibits the function of p53 protein, the inhibition of apoptosis via the p53 pathway by HPV may be related to cisplatin (CDDP)-sensitivity in cervical cancer. Cisplatin 168-172 tumor protein p53 Homo sapiens 71-74 14662026-2 2003 Because the oncoprotein E6, derived from HPV, inhibits the function of p53 protein, the inhibition of apoptosis via the p53 pathway by HPV may be related to cisplatin (CDDP)-sensitivity in cervical cancer. Cisplatin 168-172 tumor protein p53 Homo sapiens 120-123 14662026-7 2003 After exposure to LMB or CDDP alone, we observed weak p53 staining in HeLa, SiHa and Yumoto cells. Cisplatin 25-29 tumor protein p53 Homo sapiens 54-57 14662026-8 2003 Nuclear p53 staining was significantly increased by combined treatment with CDDP and LMB in HeLa and SiHa cells, but not in Yumoto cells. Cisplatin 76-80 tumor protein p53 Homo sapiens 8-11 14662026-9 2003 The expression of p53 and Bax protein increased with exposure to CDDP and was enhanced by LMB in HeLa and SiHa cells. Cisplatin 65-69 tumor protein p53 Homo sapiens 18-21 14662026-10 2003 The present study demonstrated that LMB enhanced CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cisplatin 49-53 tumor protein p53 Homo sapiens 94-97 14712316-7 2003 Adding cisplatin to rAAV-p53-infected cells led to a significant growth inhibition between 81 and 91% indicating a synergistic effect between cisplatin and rAAV-p53. Cisplatin 7-16 tumor protein p53 Homo sapiens 161-164 14712316-7 2003 Adding cisplatin to rAAV-p53-infected cells led to a significant growth inhibition between 81 and 91% indicating a synergistic effect between cisplatin and rAAV-p53. Cisplatin 142-151 tumor protein p53 Homo sapiens 25-28 14513366-10 2003 CONCLUSION: These studies demonstrate that cisplatin and DACH-Ac-Pt differentially phosphorylate p53 through independent DNA damage-induced pathways, and that the kinase-mediated phosphorylation of p53 at Ser-15 or Ser-392 is unaltered in resistance. Cisplatin 43-52 tumor protein p53 Homo sapiens 97-100 14513366-1 2003 PURPOSE: Resistance to chemotherapeutic drugs is a hallmark of many human cancers, which can occur independent of p53 gene status; however, the presence of wild-type p53 in chemorefractory tumors confers greater resistance to cisplatin, but such tumors do not display complete cross-resistance to the platinum analog (1R,2R-diaminocyclohexane)(trans-diacetato)(dichloro)platinumIV (DACH-Ac-Pt). Cisplatin 226-235 tumor protein p53 Homo sapiens 166-169 14513366-10 2003 CONCLUSION: These studies demonstrate that cisplatin and DACH-Ac-Pt differentially phosphorylate p53 through independent DNA damage-induced pathways, and that the kinase-mediated phosphorylation of p53 at Ser-15 or Ser-392 is unaltered in resistance. Cisplatin 43-52 tumor protein p53 Homo sapiens 198-201 14513366-2 2003 In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53. Cisplatin 124-133 tumor protein p53 Homo sapiens 65-68 14513366-2 2003 In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53. Cisplatin 124-133 tumor protein p53 Homo sapiens 84-87 14513366-2 2003 In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53. Cisplatin 124-133 tumor protein p53 Homo sapiens 84-87 14693272-7 2003 To determine whether cisplatin increases sensitivity of J82 cells to Ad5CMV-p53, we performed median effect analysis for cisplatin combined with Ad5CMV-p53 or DL312. Cisplatin 21-30 tumor protein p53 Homo sapiens 76-79 14513366-2 2003 In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53. Cisplatin 148-157 tumor protein p53 Homo sapiens 65-68 14513366-2 2003 In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53. Cisplatin 148-157 tumor protein p53 Homo sapiens 84-87 14513366-2 2003 In this article we examine DNA damage-induced phosphorylation of p53 and downstream p53-dependent transactivation events in cisplatin-sensitive and cisplatin-resistant human cancer cell lines possessing wild-type p53. Cisplatin 148-157 tumor protein p53 Homo sapiens 84-87 14513366-3 2003 METHODS: Western-blot analysis was utilized to study the effect of cisplatin and the analog on p53 phosphorylation and p53-dependent target genes. Cisplatin 67-76 tumor protein p53 Homo sapiens 95-98 14513366-3 2003 METHODS: Western-blot analysis was utilized to study the effect of cisplatin and the analog on p53 phosphorylation and p53-dependent target genes. Cisplatin 67-76 tumor protein p53 Homo sapiens 119-122 14612499-1 2003 We established previously that X-linked inhibitor of apoptosis protein (Xiap) is a determinant of cisplatin (CDDP) resistance in human ovarian cancer cells and that down-regulation of Xiap sensitizes cells to CDDP in the presence of wild-type p53. Cisplatin 98-107 tumor protein p53 Homo sapiens 243-246 14612499-1 2003 We established previously that X-linked inhibitor of apoptosis protein (Xiap) is a determinant of cisplatin (CDDP) resistance in human ovarian cancer cells and that down-regulation of Xiap sensitizes cells to CDDP in the presence of wild-type p53. Cisplatin 109-113 tumor protein p53 Homo sapiens 243-246 14612499-1 2003 We established previously that X-linked inhibitor of apoptosis protein (Xiap) is a determinant of cisplatin (CDDP) resistance in human ovarian cancer cells and that down-regulation of Xiap sensitizes cells to CDDP in the presence of wild-type p53. Cisplatin 209-213 tumor protein p53 Homo sapiens 243-246 14612499-5 2003 Furthermore, dominant-negative Akt sensitizes ovarian cancer cells to CDDP (10 micro M), an effect that is absent in cells expressing mutant p53 or treated with the p53 inhibitor pifithrin-alpha-hydrobromide (30 micro M) but restored by exogenous wild-type p53. Cisplatin 70-74 tumor protein p53 Homo sapiens 165-168 14612499-5 2003 Furthermore, dominant-negative Akt sensitizes ovarian cancer cells to CDDP (10 micro M), an effect that is absent in cells expressing mutant p53 or treated with the p53 inhibitor pifithrin-alpha-hydrobromide (30 micro M) but restored by exogenous wild-type p53. Cisplatin 70-74 tumor protein p53 Homo sapiens 165-168 14612499-6 2003 CDDP increased p53, decreased Xiap content, and induced apoptosis in OV2008 cells but not in the resistant counterpart (C13*). Cisplatin 0-4 tumor protein p53 Homo sapiens 15-18 14612499-10 2003 These results suggest that whereas Xiap, Akt2, and p53 are important mediators of chemoresistance in ovarian cancer cells, Akt2 may be an important regulator of both Xiap and p53 contents after CDDP challenge. Cisplatin 194-198 tumor protein p53 Homo sapiens 175-178 14534679-8 2003 Mechanisms explaining cisplatin resistance include the reduction in cisplatin accumulation inside cancer cells because of barriers across the cell membrane, the faster repair of cisplatin adducts, the modulation of apoptotic pathways in various cells, the upregulation in transcription factors, the loss of p53 and other protein functions and a higher concentration of glutathione and metallothioneins in some type of tumors. Cisplatin 22-31 tumor protein p53 Homo sapiens 307-310 14534679-9 2003 A number of experimental strategies to overcome cisplatin resistance are at the preclinical or clinical level such as introduction of the bax gene, inhibition of the JNK pathway, introduction of a functional p53 gene, treatment of tumors with aldose reductase inhibitors and others. Cisplatin 48-57 tumor protein p53 Homo sapiens 208-211 14693272-0 2003 Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Cisplatin 95-104 tumor protein p53 Homo sapiens 11-14 14619538-2 2003 HCT116 had wild-type p53 expression and 5-fluorouracil (5-FU) in combination with cisplatinum (CDDP) increased both Sub G1 DNA content and the proportion of apoptotic cells. Cisplatin 95-99 tumor protein p53 Homo sapiens 21-24 14562046-4 2003 In cells responding to cisplatin, although p53 is stabilized and activated, EBV latent gene expression appears to inhibit the accumulation of newly synthesized p21(WAF1/CIP1) and the downregulation of cyclin D2 that occur in the normal cells. Cisplatin 23-32 tumor protein p53 Homo sapiens 43-46 14619538-5 2003 These results indicate that the type of p53 expression might play an important role in the determination of response to low-dose CDDP + 5-FU therapy in colon cancer patients. Cisplatin 129-133 tumor protein p53 Homo sapiens 40-43 12893182-6 2003 Repair of cisplatin-induced DNA damage was reduced in A2780 cells overexpressing MDM2, compared to A2780 cells in which wild-type p53 function was intact. Cisplatin 10-19 tumor protein p53 Homo sapiens 130-133 12871714-1 2003 We examined ultraviolet (UV) irradiation and cisplatin treatment damage formation and repair efficiency in the p53 tumor suppressor gene of various cultured cell lines and lymphocytes using a nonradioactive multiplex long quantitative polymerase chain reaction (QPCR) assay, which amplified a 7-kb fragment of the target gene and a 500-bp fragment of the template control to successfully increase the sensitivity and reliability of the assay. Cisplatin 45-54 tumor protein p53 Homo sapiens 111-114 12871714-5 2003 The data indicated that the lesion frequency in the p53 gene was 1.27-1.75 times higher in the H23 cisplatin-sensitive cell than in the H1435 cisplatin-resistant cell at the IC(70) dose. Cisplatin 99-108 tumor protein p53 Homo sapiens 52-55 12871714-5 2003 The data indicated that the lesion frequency in the p53 gene was 1.27-1.75 times higher in the H23 cisplatin-sensitive cell than in the H1435 cisplatin-resistant cell at the IC(70) dose. Cisplatin 142-151 tumor protein p53 Homo sapiens 52-55 12884349-0 2003 P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Cisplatin 29-38 tumor protein p53 Homo sapiens 0-3 12884349-3 2003 METHODS: To determine the relationship of p53 mutations to sensitivity to cisplatin in vitro, 23 head and neck squamous cell carcinoma (HNSCC) cell lines were analyzed for cisplatin sensitivity, p53 expression, and p53 mutation status. Cisplatin 74-83 tumor protein p53 Homo sapiens 42-45 12884349-7 2003 CONCLUSIONS: These in vitro data support a role for mutation of the p53 tumor suppressor gene as a marker for response to cisplatin in HNSCC. Cisplatin 122-131 tumor protein p53 Homo sapiens 68-71 12690107-6 2003 When Ad-Bid and cisplatin were used together, chemosensitivity was restored in p53-null H358 cells, increasing death from 35% following treatment with cisplatin and Ad-LacZ to >90% death with Ad-Bid and cisplatin (Ad-Bid alone induced 50% cell death under these conditions). Cisplatin 16-25 tumor protein p53 Homo sapiens 79-82 12690107-6 2003 When Ad-Bid and cisplatin were used together, chemosensitivity was restored in p53-null H358 cells, increasing death from 35% following treatment with cisplatin and Ad-LacZ to >90% death with Ad-Bid and cisplatin (Ad-Bid alone induced 50% cell death under these conditions). Cisplatin 151-160 tumor protein p53 Homo sapiens 79-82 12690107-6 2003 When Ad-Bid and cisplatin were used together, chemosensitivity was restored in p53-null H358 cells, increasing death from 35% following treatment with cisplatin and Ad-LacZ to >90% death with Ad-Bid and cisplatin (Ad-Bid alone induced 50% cell death under these conditions). Cisplatin 151-160 tumor protein p53 Homo sapiens 79-82 12810654-11 2003 The ansamycins inhibited DDP-induced activation of caspases 8 and 3 in HT29 and HCTp5.2 but not in HCT116 cells, which we postulate to be the basis for higher survival of p53-deficient cells when treated with combinations of the two drugs. Cisplatin 25-28 tumor protein p53 Homo sapiens 171-174 12839966-7 2003 Binding of mtTFA to cisplatin-modified DNA was significantly enhanced by p53, whereas binding to oxidized DNA was inhibited. Cisplatin 20-29 tumor protein p53 Homo sapiens 73-76 21266112-0 2003 [Effect of exogenous wild type p53 expression on sensitization of lung cancer cell line to cisplatin and cloning of the corresponding genes]. Cisplatin 91-100 tumor protein p53 Homo sapiens 31-34 21266112-1 2003 BACKGROUND: To isolate and clone the cisplatin genes in 801-D cell line, a kind of lung cancer cell line, with the emphasis of the objective genes regulated by wild type p53 (wtp53). Cisplatin 37-46 tumor protein p53 Homo sapiens 170-173 21266112-10 2003 It is possible for p53 to regulate the sensitization of lung cancer cells to cisplatin through its downstream target genes. Cisplatin 77-86 tumor protein p53 Homo sapiens 19-22 12601175-0 2003 Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Cisplatin 114-123 tumor protein p53 Homo sapiens 52-55 12926120-4 2003 The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Cisplatin 31-40 tumor protein p53 Homo sapiens 108-111 12926120-4 2003 The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Cisplatin 31-40 tumor protein p53 Homo sapiens 151-154 12926120-4 2003 The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Cisplatin 42-46 tumor protein p53 Homo sapiens 108-111 12926120-4 2003 The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Cisplatin 42-46 tumor protein p53 Homo sapiens 151-154 12534345-9 2003 These results provide novel information on the functional interplay between CTF2 and p53/p73 as important determinants of their function in cell proliferation, apoptosis, DNA repair and cisplatin resistance. Cisplatin 186-195 tumor protein p53 Homo sapiens 85-88 12694871-0 2003 Recognition of DNA modified by antitumor cisplatin by "latent" and "active" protein p53. Cisplatin 41-50 tumor protein p53 Homo sapiens 84-87 12694871-4 2003 Binding of active, latent, and in vitro-activated p53 protein to DNA fragments modified by antitumor cisplatin was studied using electrophoretic mobility shift assay in agarose gels and immunoblotting analysis. Cisplatin 101-110 tumor protein p53 Homo sapiens 50-53 12694871-5 2003 We found that both latent and active p53 forms bound to random sequences of DNA globally modified by cisplatin with a higher affinity than to unmodified DNA. Cisplatin 101-110 tumor protein p53 Homo sapiens 37-40 12694871-8 2003 Competition experiments involving a 20-bp consensus sequence of p53 suggested that the p53 core domain was a primary binding site of the active p53 when it bound to DNA fragments lacking consensus sequence, but modified by cisplatin. Cisplatin 223-232 tumor protein p53 Homo sapiens 64-67 12694871-8 2003 Competition experiments involving a 20-bp consensus sequence of p53 suggested that the p53 core domain was a primary binding site of the active p53 when it bound to DNA fragments lacking consensus sequence, but modified by cisplatin. Cisplatin 223-232 tumor protein p53 Homo sapiens 87-90 12694871-8 2003 Competition experiments involving a 20-bp consensus sequence of p53 suggested that the p53 core domain was a primary binding site of the active p53 when it bound to DNA fragments lacking consensus sequence, but modified by cisplatin. Cisplatin 223-232 tumor protein p53 Homo sapiens 87-90 12796400-0 2003 Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Cisplatin 92-101 tumor protein p53 Homo sapiens 36-39 12894503-3 2003 Caffeine, a nonspecific inhibitor of ATR, enhanced the cytotoxic effect of cisplatin, modestly decreased the p53 and p21WAF-1 response to cisplatin, and affected the cdc2-p34/cyclin B1 complex by decreasing both cyclin B1 protein accumulation and cdc2-p34 tyrosine 15 phosphorylation. Cisplatin 138-147 tumor protein p53 Homo sapiens 109-112 12668287-0 2003 Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cisplatin 88-97 tumor protein p53 Homo sapiens 38-41 12668287-3 2003 The aim of this study was to investigate the independent prognostic significance of p53 overexpression in patients with ovarian carcinoma who are treated with cisplatin. Cisplatin 159-168 tumor protein p53 Homo sapiens 84-87 12668287-12 2003 These findings suggest that overexpression of p53 in ovarian carcinoma is associated with unfavorable clinical outcome in patients treated with cisplatin-based chemotherapy. Cisplatin 144-153 tumor protein p53 Homo sapiens 46-49 12668287-13 2003 Therefore, detection of p53 overexpression using the DO7 antibody may be considered as a predictive marker of chemoresistance for cisplatin in patients with ovarian carcinoma. Cisplatin 130-139 tumor protein p53 Homo sapiens 24-27 12570658-5 2003 Among the main pathways affecting cell sensitivity of these drugs a role for p53 has been proposed at least for cisplatin and BBR 3464. Cisplatin 112-121 tumor protein p53 Homo sapiens 77-80 12824923-0 2003 Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression. Cisplatin 24-52 tumor protein p53 Homo sapiens 101-104 15314976-0 2003 Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin. Cisplatin 124-133 tumor protein p53 Homo sapiens 14-17 12499281-9 2002 In contrast, dominant negative p53 or ectopic HPV 16 E6 sensitized the cells to cisplatin. Cisplatin 80-89 tumor protein p53 Homo sapiens 31-34 12499093-0 2003 Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Cisplatin 59-68 tumor protein p53 Homo sapiens 13-16 12499093-1 2003 PURPOSE: Tumors with p53 overexpression have been associated with enhanced resistance to cisplatin-based chemotherapy in a few and small studies involving non-small cell lung cancer. Cisplatin 89-98 tumor protein p53 Homo sapiens 21-24 12499093-8 2003 In multivariate analyses p53 positive immunostaining was identified as an independent predictive factor for resistance to cisplatin-based chemotherapy (P=0.006). Cisplatin 122-131 tumor protein p53 Homo sapiens 25-28 12499093-9 2003 CONCLUSIONS: Our study confirmed an association of p53 immunostaining and response rate of patients treated with cisplatin-based chemotherapy. Cisplatin 113-122 tumor protein p53 Homo sapiens 51-54 14512646-14 2003 Although some basic studies provide some important supports, studies including larger patient cohorts would still be required to prove the hypothesis that p53 and HER-2/neu-coexpressing tumors have a worse prognosis and are more resistant to a cisplatin-based multidrug regimen. Cisplatin 244-253 tumor protein p53 Homo sapiens 155-158 12497212-0 2003 Sensitivity to cisplatin treatment of human K1 thyroid carcinoma cell lines with altered p53 function. Cisplatin 15-24 tumor protein p53 Homo sapiens 89-92 12439598-3 2002 Activation of ERK is required for accumulation and phosphorylation of p53 following cisplatin treatment. Cisplatin 84-93 tumor protein p53 Homo sapiens 70-73 12478472-6 2002 The regulation of p21(WAF1) after cisplatin or BBR 3464 exposure required a p53 signal, as documented using stable transfectants expressing a dominant-negative form of p53 (175(his)). Cisplatin 34-43 tumor protein p53 Homo sapiens 76-79 12478472-6 2002 The regulation of p21(WAF1) after cisplatin or BBR 3464 exposure required a p53 signal, as documented using stable transfectants expressing a dominant-negative form of p53 (175(his)). Cisplatin 34-43 tumor protein p53 Homo sapiens 168-171 12439598-8 2002 Treatment of cells with PD98059 or UO126 after cisplatin incubation or inhibition of signaling through ERK by tetracycline-regulated expression of dominant-inhibitory ERK enhanced resistance to cisplatin in p53-negative osteosarcoma cells and reduced cisplatin-induced apoptosis. Cisplatin 194-203 tumor protein p53 Homo sapiens 207-210 12439598-8 2002 Treatment of cells with PD98059 or UO126 after cisplatin incubation or inhibition of signaling through ERK by tetracycline-regulated expression of dominant-inhibitory ERK enhanced resistance to cisplatin in p53-negative osteosarcoma cells and reduced cisplatin-induced apoptosis. Cisplatin 194-203 tumor protein p53 Homo sapiens 207-210 12439598-9 2002 P53 was stabilized and phosphorylated in a MEK1-dependent manner after cisplatin incubation in Kelly neuroblastoma cells. Cisplatin 71-80 tumor protein p53 Homo sapiens 0-3 12481430-1 2002 DNA damaging agents such as cisplatin arrest cell cycle progression at either G1, S, or G2 phase, although the G1 arrest is only seen in cells expressing the wild-type p53 tumor suppressor protein. Cisplatin 28-37 tumor protein p53 Homo sapiens 168-171 12376463-7 2002 Cisplatin induced p53 independent apoptosis in both head and neck cancer cell lines. Cisplatin 0-9 tumor protein p53 Homo sapiens 18-21 12481430-8 2002 This analogue abrogated S and G2 phase arrest and enhanced cytotoxicity induced by cisplatin only in p53 defective cells. Cisplatin 83-92 tumor protein p53 Homo sapiens 101-104 12481427-8 2002 Moreover, 11R-p53 enhanced the cisplatin-dependent induction of apoptosis of the cells. Cisplatin 31-40 tumor protein p53 Homo sapiens 14-17 12492119-0 2002 Regulation of p53 stabilization by DNA damage and protein kinase C. We have demonstrated previously that the protein kinase C (PKC) signal transduction pathway acts upstream of caspases to regulate caspase activation and apoptosis induced by the DNA-damaging agent cisplatin (CP). Cisplatin 265-274 tumor protein p53 Homo sapiens 14-17 12209989-0 2002 Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Cisplatin 71-80 tumor protein p53 Homo sapiens 10-13 12065694-2 2002 The goal of these studies was to examine the role of p53, caspase 3, 8, and 9, and mitochondria in the signaling of cisplatin-induced apoptosis. Cisplatin 116-125 tumor protein p53 Homo sapiens 53-56 12065694-9 2002 Furthermore, 50% of cisplatin-induced RPTC apoptosis is independent of p53 and caspases 3, 8, and 9. Cisplatin 20-29 tumor protein p53 Homo sapiens 71-74 12065694-6 2002 Cisplatin increased nuclear p53 expression 4 h after treatment, preceding both caspase 3 activation and chromatin condensation. Cisplatin 0-9 tumor protein p53 Homo sapiens 28-31 12065694-7 2002 Treatment with the p53 inhibitor alpha-2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone (PFT) before cisplatin exposure inhibited p53 nuclear expression at 4, 8, and 12 h and inhibited phosphatidylserine externalization and caspase 3 activation at 12 h. Neither DEVD-fmk nor ZVAD-fmk inhibited cisplatin-induced p53 nuclear expression. Cisplatin 118-127 tumor protein p53 Homo sapiens 19-22 12065694-7 2002 Treatment with the p53 inhibitor alpha-2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone (PFT) before cisplatin exposure inhibited p53 nuclear expression at 4, 8, and 12 h and inhibited phosphatidylserine externalization and caspase 3 activation at 12 h. Neither DEVD-fmk nor ZVAD-fmk inhibited cisplatin-induced p53 nuclear expression. Cisplatin 311-320 tumor protein p53 Homo sapiens 19-22 12065694-8 2002 Both DEVD-fmk and ZVAD-fmk completely inhibited caspase 3 activity but, like PFT, partially inhibited cisplatin-induced chromatin condensation, annexin V labeling, and DNA hypoploidy after 24 h. These data demonstrate that at least 50% of cisplatin-induced apoptosis in RPTC is mediated by p53 and that p53 activates caspase 3 independently of either caspase 9 or 8 or mitochondrial dysfunction. Cisplatin 102-111 tumor protein p53 Homo sapiens 290-293 12065694-8 2002 Both DEVD-fmk and ZVAD-fmk completely inhibited caspase 3 activity but, like PFT, partially inhibited cisplatin-induced chromatin condensation, annexin V labeling, and DNA hypoploidy after 24 h. These data demonstrate that at least 50% of cisplatin-induced apoptosis in RPTC is mediated by p53 and that p53 activates caspase 3 independently of either caspase 9 or 8 or mitochondrial dysfunction. Cisplatin 102-111 tumor protein p53 Homo sapiens 303-306 12048682-0 2002 [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin]. Cisplatin 97-106 tumor protein p53 Homo sapiens 22-25 12093475-0 2002 JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Cisplatin 20-29 tumor protein p53 Homo sapiens 120-123 12082025-2 2002 Here we show that the treatment of cells with low doses of gamma-irradiation or cisplatin resulted in an immediate enhancement of p53-dependent DNA repair, measured by base excision repair (BER) activity. Cisplatin 80-89 tumor protein p53 Homo sapiens 130-133 12048682-1 2002 OBJECTIVE: To assess the effect of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin. Cisplatin 120-129 tumor protein p53 Homo sapiens 45-48 12048682-9 2002 CONCLUSION: The exogenous introduction of wild-type p53 cDNA into ovarian cancer SKOV-3 cells increased the chemotherapy sensitivity to cisplatin. Cisplatin 136-145 tumor protein p53 Homo sapiens 52-55 12007018-10 2002 Cisplatin-induced p21 transactivation assays and G(1) cell cycle arrest analyses showed that p21 transactivation and G(1) arrest occurred in both CCSK and CMN cultures, demonstrating integrity of the p53 signal transduction pathway. Cisplatin 0-9 tumor protein p53 Homo sapiens 200-203 12058967-5 2002 Ultraviolet light, cisplatin, and nitrogen mustards produce damage that is repaired by a p53-regulated pathway. Cisplatin 19-28 tumor protein p53 Homo sapiens 89-92 12170778-2 2002 We find that the Xeroderma Pigmentosum Complementation group E (XPE) mutated Damaged-DNA binding protein p48 (DDB2) is upregulated by BRCA1 in a p53-dependent manner following UVC, Adriamycin, or Cisplatin exposure. Cisplatin 196-205 tumor protein p53 Homo sapiens 145-148 11991255-3 2002 In Hep3B cells, apoptosis induced by cisplatin was p53-independent, and was associated with up-regulation of cell cycle regulators, pro-apoptotic genes, growth receptors, and genes involved in signal transduction. Cisplatin 37-46 tumor protein p53 Homo sapiens 51-54 11861384-11 2002 The induction of apoptosis and the expression of phospho-Ser15 and phospho-Ser20 in these cells were also enhanced by the combination of Ad-p53 and other DNA-damaging agents such as cisplatin and bichloroethyl nitrosourea. Cisplatin 182-191 tumor protein p53 Homo sapiens 140-143 21315017-0 2002 [Effects of p53 antisense RNA on malignant phenotype and sensitivity to cisplatin of human lung cancer cell line]. Cisplatin 72-81 tumor protein p53 Homo sapiens 12-15 21315017-1 2002 BACKGROUND: To study the effects of extraneous p53 antisense RNA on malignant growth and sensitivity to cisplatin of human lung cancer cell line. Cisplatin 104-113 tumor protein p53 Homo sapiens 47-50 21315017-13 2002 The sensitivity of PEGFP-p53(AS)-801D cells to cisplatin was increased. Cisplatin 47-56 tumor protein p53 Homo sapiens 25-28 21315017-15 2002 CONCLUSIONS: p53 mutation at 248 code plays an important role on malignant growth and resistance to cisplatin of human lung cancer cell line 801D. Cisplatin 100-109 tumor protein p53 Homo sapiens 13-16 21315017-16 2002 Malignant growth of cells with p53 deletion and mutation at 248 codon can be inhibited by extraneous p53 antisense RNA, and simultaneously the sensitivity to cisplatin is also increased. Cisplatin 158-167 tumor protein p53 Homo sapiens 31-34 12599424-0 2002 [Effects of wild-type p53 gene transfection on the growth and cisplatin sensitivity of cervical cancer cell line HeLa]. Cisplatin 62-71 tumor protein p53 Homo sapiens 22-25 11812076-10 2002 The present in vitro study showed that wild-type p53 gene transduction significantly enhanced sensitivity to CDDP and the apoptotic index in HRA cells. Cisplatin 109-113 tumor protein p53 Homo sapiens 49-52 11734333-5 2002 Low-dose cisplatin induced a transient G(1) arrest, S phase block and upregulation of p53 and p21(WAF1/CIP1) expression in HepG2, but not in Hep3B cells. Cisplatin 9-18 tumor protein p53 Homo sapiens 86-89 11734333-7 2002 In HepG2, upregulation of p53 and p21(WAF1/CIP1) was observed before apoptosis occurred, suggesting that cisplatin-induced apoptosis in HepG2 might be p53-dependent. Cisplatin 105-114 tumor protein p53 Homo sapiens 26-29 11734333-7 2002 In HepG2, upregulation of p53 and p21(WAF1/CIP1) was observed before apoptosis occurred, suggesting that cisplatin-induced apoptosis in HepG2 might be p53-dependent. Cisplatin 105-114 tumor protein p53 Homo sapiens 151-154 11734333-10 2002 In conclusion, cisplatin induced apoptosis in hepatoma cells via both p53-dependent and -independent pathways. Cisplatin 15-24 tumor protein p53 Homo sapiens 70-73 12197224-4 2002 We hypothesized that tumors staining for p53 would be resistant to cisplatin. Cisplatin 67-76 tumor protein p53 Homo sapiens 41-44 12599424-7 2002 Wild-type p53-positive HeLa was more sensitive to cisplatin, compared with the control cell lines. Cisplatin 50-59 tumor protein p53 Homo sapiens 10-13 11761456-0 2001 Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cisplatin 44-53 tumor protein p53 Homo sapiens 14-17 12658781-6 2002 When combined treatment of wild-type p53 gene transfection and cisplatin was used, that was significantly increased [IR (91.64 +/- 1.00)%, (94.98 +/- 1.67)%, (95.32 +/- 2.01)%, (95.65 +/- 1.00)%]. Cisplatin 63-72 tumor protein p53 Homo sapiens 37-40 11761456-7 2001 These results provide evidence that ERK activity during the cisplatin DNA damage response, regulates in part, these cell cycle control (p21WAF1, Gadd45), DNA repair (Gadd45) and p53-regulatory (Mdm2) proteins. Cisplatin 60-69 tumor protein p53 Homo sapiens 178-181 11761456-3 2001 Furthermore, we have demonstrated that cisplatin-induced ERK activation is required for optimal p53 protein accumulation following cisplatin-induced DNA damage. Cisplatin 39-48 tumor protein p53 Homo sapiens 96-99 11761456-3 2001 Furthermore, we have demonstrated that cisplatin-induced ERK activation is required for optimal p53 protein accumulation following cisplatin-induced DNA damage. Cisplatin 131-140 tumor protein p53 Homo sapiens 96-99 11761456-4 2001 In the present study, we expanded our investigations to examine the effect of cisplatin-induced ERK activation on the expression of p53-targeted genes that have been shown to be important in the cellular response to DNA damage including Bax, Bcl-2, Bcl-x1, Cyclin G, Gadd45, p21WAF1, and Mdm2. Cisplatin 78-87 tumor protein p53 Homo sapiens 132-135 11489880-3 2001 Restoration of p53 triggered a G(2)/M cell cycle arrest and enhanced BAX protein expression, without inducing apoptosis or potentiating the cytotoxic effect of etoposide, vincristine, and cis-platinum. Cisplatin 188-200 tumor protein p53 Homo sapiens 15-18 11595686-8 2001 Resistance to adjuvant cisplatin or carboplatin chemotherapy was significantly more frequent in patients with p53 overexpression (P = 0.001) or p53 missense mutations (P = 0.008) than patients with normal p53. Cisplatin 23-32 tumor protein p53 Homo sapiens 110-113 11709715-5 2001 We found that TCR-deficient (XP-A, XP-B and CS-B) fibroblasts were more sensitive than TCR-proficient cells (XP-C and normal) to both UV light and cisplatin treatment and this increase in sensitivity was not p53 dependent. Cisplatin 147-156 tumor protein p53 Homo sapiens 208-211 11709715-8 2001 Therefore, we propose that p53 protects against UV- and cisplatin-induced apoptosis in a TCR-dependent manner and that p53 does not contribute strongly to the induction of apoptosis in TCR-deficient fibroblasts. Cisplatin 56-65 tumor protein p53 Homo sapiens 27-30 11709715-0 2001 P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Cisplatin 44-53 tumor protein p53 Homo sapiens 0-3 11576999-13 2001 Since over 50% of human tumors contain a functionally defective p53 that reduces sensitivity to commonly used chemotherapeutic agents, such as etoposide and cisplatin, the ability of tachpyridine to induce apoptosis independently of p53 may offer an advantage in anti-tumor therapy. Cisplatin 157-166 tumor protein p53 Homo sapiens 64-67 11595686-8 2001 Resistance to adjuvant cisplatin or carboplatin chemotherapy was significantly more frequent in patients with p53 overexpression (P = 0.001) or p53 missense mutations (P = 0.008) than patients with normal p53. Cisplatin 23-32 tumor protein p53 Homo sapiens 144-147 11595686-8 2001 Resistance to adjuvant cisplatin or carboplatin chemotherapy was significantly more frequent in patients with p53 overexpression (P = 0.001) or p53 missense mutations (P = 0.008) than patients with normal p53. Cisplatin 23-32 tumor protein p53 Homo sapiens 144-147 11471984-1 2001 The objective was to test the hypothesis that wild-type p53-function is required for the enhancement of the cytotoxicity of cis-diammine-dichloroplatinum(II) (cDDP) cytotoxicity by hyperthermia (HT). Cisplatin 124-157 tumor protein p53 Homo sapiens 56-59 11774736-6 2001 p53 gene transduction markedly enhanced the sensitivity to cisplatin (CDDP) and CDDP-induced apoptosis, but did not affect the sensitivity to paclitaxel (PTX) nor PTX-induced apoptosis in ovarian cancer cells without p53 gene. Cisplatin 59-68 tumor protein p53 Homo sapiens 0-3 11774736-6 2001 p53 gene transduction markedly enhanced the sensitivity to cisplatin (CDDP) and CDDP-induced apoptosis, but did not affect the sensitivity to paclitaxel (PTX) nor PTX-induced apoptosis in ovarian cancer cells without p53 gene. Cisplatin 70-74 tumor protein p53 Homo sapiens 0-3 11774736-6 2001 p53 gene transduction markedly enhanced the sensitivity to cisplatin (CDDP) and CDDP-induced apoptosis, but did not affect the sensitivity to paclitaxel (PTX) nor PTX-induced apoptosis in ovarian cancer cells without p53 gene. Cisplatin 80-84 tumor protein p53 Homo sapiens 0-3 11774736-7 2001 The combination treatment with a recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) and CDDP significantly suppressed tumor growth of ovarian cancer cells with and without p53 gene, compared with a single treatment of either AxCAp53 or CDDP in ovarian cancer xenograft. Cisplatin 248-252 tumor protein p53 Homo sapiens 77-80 11774736-7 2001 The combination treatment with a recombinant adenovirus carrying a wild-type p53 gene (AxCAp53) and CDDP significantly suppressed tumor growth of ovarian cancer cells with and without p53 gene, compared with a single treatment of either AxCAp53 or CDDP in ovarian cancer xenograft. Cisplatin 248-252 tumor protein p53 Homo sapiens 91-94 11774736-10 2001 In conclusion, p53 gene status contributes the sensitivity to CDDP in ovarian cancer. Cisplatin 62-66 tumor protein p53 Homo sapiens 15-18 11774736-11 2001 Additionally, combination treatment of p53 gene transduction and CDDP may be an effective therapeutic modality for ovarian cancer without wild-type p53 gene. Cisplatin 65-69 tumor protein p53 Homo sapiens 148-151 11551417-6 2001 Cisplatin treatment dramatically increased p53 expression in parental cells but not in H460/CIS cells which expressed basal levels of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 43-46 11551417-6 2001 Cisplatin treatment dramatically increased p53 expression in parental cells but not in H460/CIS cells which expressed basal levels of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 134-137 11471984-1 2001 The objective was to test the hypothesis that wild-type p53-function is required for the enhancement of the cytotoxicity of cis-diammine-dichloroplatinum(II) (cDDP) cytotoxicity by hyperthermia (HT). Cisplatin 159-163 tumor protein p53 Homo sapiens 56-59 11435891-0 2001 Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. Cisplatin 50-59 tumor protein p53 Homo sapiens 24-27 11435891-7 2001 RESULTS: The expression of all forms of mutant p53 protein except p53His273 enhanced sensitivity to cisplatin and doxorubicin. Cisplatin 100-109 tumor protein p53 Homo sapiens 47-50 11435891-7 2001 RESULTS: The expression of all forms of mutant p53 protein except p53His273 enhanced sensitivity to cisplatin and doxorubicin. Cisplatin 100-109 tumor protein p53 Homo sapiens 66-69 11482451-8 2001 In the TP53 mutant cell lines, DU145 and BM1604, dose enhancement factors (EFs) were found to be in the region of 4.20 for cisplatin, 3.70 for vinblastine, and 3.20 for etoposide. Cisplatin 123-132 tumor protein p53 Homo sapiens 7-11 11384107-4 2001 IC(50)to cisplatin (CDDP) was 12.9 microM for SK-OV-3 cells and 9.2 microM for p53 gene-transducted SK-OV-3 cells. Cisplatin 9-18 tumor protein p53 Homo sapiens 79-82 11384107-4 2001 IC(50)to cisplatin (CDDP) was 12.9 microM for SK-OV-3 cells and 9.2 microM for p53 gene-transducted SK-OV-3 cells. Cisplatin 20-24 tumor protein p53 Homo sapiens 79-82 11384107-6 2001 Additionally, p53 gene transduction significantly enhanced CDDP-induced apoptosis. Cisplatin 59-63 tumor protein p53 Homo sapiens 14-17 11384107-8 2001 In SK-OV-3 cells with transduction of the p53 gene, the expression of p53 and Bax proteins increased after exposure to CDDP. Cisplatin 119-123 tumor protein p53 Homo sapiens 42-45 11384107-8 2001 In SK-OV-3 cells with transduction of the p53 gene, the expression of p53 and Bax proteins increased after exposure to CDDP. Cisplatin 119-123 tumor protein p53 Homo sapiens 70-73 11340581-2 2001 We recently reported that the acquisition of cisplatin resistance in an ovarian carcinoma cell line (IGROV-1) was associated with mutation of p53 and collateral sensitivity to paclitaxel. Cisplatin 45-54 tumor protein p53 Homo sapiens 142-145 11482451-9 2001 In the TP53 wild-type cell line, LNCaP, the enhancement factors were low and in the region of 1.20 for cisplatin, vinblastine and etoposide. Cisplatin 103-112 tumor protein p53 Homo sapiens 7-11 11350044-3 2001 In this study we compared the cisplatin-induced response of p53 protein and its downstream targets p21WAF-1 and Mdm2 in the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. Cisplatin 30-39 tumor protein p53 Homo sapiens 60-63 11350044-3 2001 In this study we compared the cisplatin-induced response of p53 protein and its downstream targets p21WAF-1 and Mdm2 in the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. Cisplatin 124-133 tumor protein p53 Homo sapiens 60-63 11350044-3 2001 In this study we compared the cisplatin-induced response of p53 protein and its downstream targets p21WAF-1 and Mdm2 in the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70. Cisplatin 124-133 tumor protein p53 Homo sapiens 60-63 11350044-4 2001 A higher dose of cisplatin and a longer exposure time was required to achieve the same level of p53, p21WAF-1, and Mdm2 protein accumulation in the cisplatin-resistant CP70 cells versus cisplatin-sensitive A2780 cells. Cisplatin 17-26 tumor protein p53 Homo sapiens 96-99 11350044-5 2001 A significant difference between the two cell lines was observed in cisplatin-induced stabilization of p53 protein. Cisplatin 68-77 tumor protein p53 Homo sapiens 103-106 11350044-8 2001 These results demonstrate that in A2780 and CP70 cells resistance to cisplatin correlates with prolonged p53 protein stabilization and accumulation. Cisplatin 69-78 tumor protein p53 Homo sapiens 105-108 11477455-6 2001 The combination of Ad5CMV-p53 and cisplatin resulted in approximately 25% greater cytotoxicity compared to that observed with cisplatin alone in either cell line. Cisplatin 126-135 tumor protein p53 Homo sapiens 26-29 11279186-7 2001 In addition, only major 1,2-GG intrastrand cross-links of cisplatin are responsible for this enhanced binding affinity of p53. Cisplatin 58-67 tumor protein p53 Homo sapiens 122-125 11279186-8 2001 The data base on structures of various DNA adducts of cisplatin and transplatin reveals distinctive structural features of 1,2-intrastrand cross-links of cisplatin, suggesting a unique role for this adduct in the binding of p53 to DNA lacking the consensus sequence. Cisplatin 54-63 tumor protein p53 Homo sapiens 224-227 11279186-8 2001 The data base on structures of various DNA adducts of cisplatin and transplatin reveals distinctive structural features of 1,2-intrastrand cross-links of cisplatin, suggesting a unique role for this adduct in the binding of p53 to DNA lacking the consensus sequence. Cisplatin 154-163 tumor protein p53 Homo sapiens 224-227 11279186-9 2001 The results support the hypothesis that the mechanism of antitumor activity of cisplatin may also be associated with its efficiency to affect the binding affinity of platinated DNA to active p53 protein. Cisplatin 79-88 tumor protein p53 Homo sapiens 191-194 11497278-2 2001 We studied the mechanism of the growth-inhibitory effect of cisplatin (CDDP) on human pancreatic cancer cells in connection with the status of the p53 gene and expression of the bcl-2 family. Cisplatin 60-69 tumor protein p53 Homo sapiens 147-150 11497278-2 2001 We studied the mechanism of the growth-inhibitory effect of cisplatin (CDDP) on human pancreatic cancer cells in connection with the status of the p53 gene and expression of the bcl-2 family. Cisplatin 71-75 tumor protein p53 Homo sapiens 147-150 11497278-7 2001 Increased expression of bax and reduced expression of bcl-2 are involved in the growth-inhibitory effect of CDDP on pancreatic cancer cells with wild-type p53 gene. Cisplatin 108-112 tumor protein p53 Homo sapiens 155-158 11279186-0 2001 Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. Cisplatin 51-60 tumor protein p53 Homo sapiens 133-136 11279186-3 2001 DNA interactions of active wild-type human p53 protein with DNA fragments and oligodeoxyribonucleotide duplexes modified by antitumor cisplatin and its clinically ineffective trans isomer (transplatin) were investigated by using a gel mobility shift assay. Cisplatin 134-143 tumor protein p53 Homo sapiens 43-46 11279186-4 2001 It was found that DNA adducts of cisplatin reduced binding affinity of the consensus DNA sequence to p53, whereas transplatin adducts did not. Cisplatin 33-42 tumor protein p53 Homo sapiens 101-104 11279186-5 2001 This result was interpreted to mean that the precise steric fit required for the formation and stability of the tetrameric complex of p53 with the consensus sequence cannot be attained, as a consequence of severe conformational perturbations induced in DNA by cisplatin adducts. Cisplatin 260-269 tumor protein p53 Homo sapiens 134-137 11279186-6 2001 The results also demonstrate an increase of the binding affinity of p53 to DNA lacking the consensus sequence and modified by cisplatin but not by transplatin. Cisplatin 126-135 tumor protein p53 Homo sapiens 68-71 11125280-2 2001 The aim of the study was to evaluate the relationship between p53 protein accumulation, p53 gene mutation and response to cisplatin-based chemotherapy in patients with ovarian carcinoma considering conventional clinicopathological parameters. Cisplatin 122-131 tumor protein p53 Homo sapiens 62-65 11313183-7 2001 In astrocytoma cells, cisplatin treatment resulted in the upregulation of p53, p21 and bax, while only p21 induction was observed after BBR3464 treatment. Cisplatin 22-31 tumor protein p53 Homo sapiens 74-77 11313183-8 2001 In cisplatin-resistant cells, the reduced sensitivity to cisplatin paralleled a resistance to the induction of p53/p21 pathway by cisplatin, while the same doses of BBR3464 induced p21 to a similar extent in the resistant cells as in the parental cells. Cisplatin 3-12 tumor protein p53 Homo sapiens 111-114 11313183-8 2001 In cisplatin-resistant cells, the reduced sensitivity to cisplatin paralleled a resistance to the induction of p53/p21 pathway by cisplatin, while the same doses of BBR3464 induced p21 to a similar extent in the resistant cells as in the parental cells. Cisplatin 57-66 tumor protein p53 Homo sapiens 111-114 11313183-8 2001 In cisplatin-resistant cells, the reduced sensitivity to cisplatin paralleled a resistance to the induction of p53/p21 pathway by cisplatin, while the same doses of BBR3464 induced p21 to a similar extent in the resistant cells as in the parental cells. Cisplatin 57-66 tumor protein p53 Homo sapiens 111-114 11106654-0 2001 Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. Cisplatin 41-50 tumor protein p53 Homo sapiens 17-20 11106654-6 2001 Cisplatin-modified DNA binding by HMG1 was significantly enhanced by p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 69-72 11125280-0 2001 Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Cisplatin 103-112 tumor protein p53 Homo sapiens 27-30 11125280-1 2001 p53 alterations are considered as one of the most important factors responsible for drug resistance in ovarian carcinomas, although the relationship between p53 gene status and response to cisplatin-based chemotherapy in ovarian cancer patients remains unclear. Cisplatin 189-198 tumor protein p53 Homo sapiens 157-160 11295094-6 2001 Pre-treatment with cis-diamminedichloroplatinum (II) (CDDP) at 0.1 microg/ml significantly suppressed tumor cell viability in NY and HuO-3N1 (mutated), but not in the other three lines including HT-1080 carrying the wild-type p53 gene, implying the existence of different mechanisms for the tumor suppressive effect of p53 gene transfection and CDDP. Cisplatin 19-52 tumor protein p53 Homo sapiens 226-229 11295094-6 2001 Pre-treatment with cis-diamminedichloroplatinum (II) (CDDP) at 0.1 microg/ml significantly suppressed tumor cell viability in NY and HuO-3N1 (mutated), but not in the other three lines including HT-1080 carrying the wild-type p53 gene, implying the existence of different mechanisms for the tumor suppressive effect of p53 gene transfection and CDDP. Cisplatin 19-52 tumor protein p53 Homo sapiens 319-322 11295094-6 2001 Pre-treatment with cis-diamminedichloroplatinum (II) (CDDP) at 0.1 microg/ml significantly suppressed tumor cell viability in NY and HuO-3N1 (mutated), but not in the other three lines including HT-1080 carrying the wild-type p53 gene, implying the existence of different mechanisms for the tumor suppressive effect of p53 gene transfection and CDDP. Cisplatin 54-58 tumor protein p53 Homo sapiens 226-229 11295094-6 2001 Pre-treatment with cis-diamminedichloroplatinum (II) (CDDP) at 0.1 microg/ml significantly suppressed tumor cell viability in NY and HuO-3N1 (mutated), but not in the other three lines including HT-1080 carrying the wild-type p53 gene, implying the existence of different mechanisms for the tumor suppressive effect of p53 gene transfection and CDDP. Cisplatin 54-58 tumor protein p53 Homo sapiens 319-322 11295094-7 2001 These results indicate that wild-type p53 gene transfection with CDDP is a promising therapy for some, but not all, non-resectable bone-and soft tissue sarcomas, regardless of intrinsic p53 gene status. Cisplatin 65-69 tumor protein p53 Homo sapiens 38-41 11295099-0 2001 Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines. Cisplatin 56-65 tumor protein p53 Homo sapiens 125-128 11401473-6 2001 Accumulation of P53 and its target gene bax then sensitized HeLa cells to cell-cycle arrest, cell death/apoptosis induced by cisplatin, and etoposide. Cisplatin 125-134 tumor protein p53 Homo sapiens 16-19 11267864-5 2001 Cisplatin-resistant A2780/cDDP had a p53 mutation and exhibited attenuated Bax induction after cisplatin treatment, which may explain why supplementation of Bax was effective in this chemoresistant ovarian cancer. Cisplatin 0-9 tumor protein p53 Homo sapiens 37-40 11125280-2 2001 The aim of the study was to evaluate the relationship between p53 protein accumulation, p53 gene mutation and response to cisplatin-based chemotherapy in patients with ovarian carcinoma considering conventional clinicopathological parameters. Cisplatin 122-131 tumor protein p53 Homo sapiens 88-91 11125280-7 2001 A significant correlation between p53 accumulation and p53 gene alteration and poor response to cisplatin-based chemotherapy was shown. Cisplatin 96-105 tumor protein p53 Homo sapiens 34-37 11125280-7 2001 A significant correlation between p53 accumulation and p53 gene alteration and poor response to cisplatin-based chemotherapy was shown. Cisplatin 96-105 tumor protein p53 Homo sapiens 55-58 11125280-9 2001 A strong p53 expression especially accompanied by p53 changes detectable by PCR-SSCP analysis appears to be a good indicator of the resistance to cisplatin-based chemotherapy. Cisplatin 146-155 tumor protein p53 Homo sapiens 9-12 11125280-9 2001 A strong p53 expression especially accompanied by p53 changes detectable by PCR-SSCP analysis appears to be a good indicator of the resistance to cisplatin-based chemotherapy. Cisplatin 146-155 tumor protein p53 Homo sapiens 50-53 11342217-0 2001 p53 binds to cisplatin-damaged DNA. Cisplatin 13-22 tumor protein p53 Homo sapiens 0-3 11342217-1 2001 We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Cisplatin 93-124 tumor protein p53 Homo sapiens 52-55 11342217-1 2001 We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Cisplatin 93-124 tumor protein p53 Homo sapiens 67-70 11342217-1 2001 We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Cisplatin 93-124 tumor protein p53 Homo sapiens 67-70 11342217-1 2001 We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Cisplatin 126-135 tumor protein p53 Homo sapiens 52-55 11342217-1 2001 We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Cisplatin 126-135 tumor protein p53 Homo sapiens 67-70 11342217-1 2001 We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Cisplatin 126-135 tumor protein p53 Homo sapiens 67-70 11342217-7 2001 Taken together, these results suggest that in addition to binding to p53 DNA binding sites, p53 also interacts with cisplatin-damaged DNA molecules. Cisplatin 116-125 tumor protein p53 Homo sapiens 69-72 11342217-7 2001 Taken together, these results suggest that in addition to binding to p53 DNA binding sites, p53 also interacts with cisplatin-damaged DNA molecules. Cisplatin 116-125 tumor protein p53 Homo sapiens 92-95 11326311-0 2001 Cisplatinum and taxol induce different patterns of p53 phosphorylation. Cisplatin 0-11 tumor protein p53 Homo sapiens 51-54 11245458-0 2001 P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cisplatin 145-154 tumor protein p53 Homo sapiens 0-3 11405176-0 2001 Mitomycin C and cisplatin enhanced the antitumor activity of p53-expressing adenovirus in cervical cancer cells. Cisplatin 16-25 tumor protein p53 Homo sapiens 61-64 11245458-1 2001 This study examined how the DNA mismatch repair (MMR) system and p53 interact to maintain genomic integrity in the presence of the mutagenic stress induced by cisplatin (DDP). Cisplatin 159-168 tumor protein p53 Homo sapiens 65-68 11162602-6 2001 However, cisplatin neither reduced cyclin B1 expression nor induced G2 phase arrest, while it induced a comparable amount of p53 protein. Cisplatin 9-18 tumor protein p53 Homo sapiens 125-128 11462854-0 2001 Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods. Cisplatin 72-81 tumor protein p53 Homo sapiens 110-113 11326311-1 2001 Posttranslational modifications of p53 induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines. Cisplatin 85-96 tumor protein p53 Homo sapiens 35-38 11326311-1 2001 Posttranslational modifications of p53 induced by two widely used anticancer agents, cisplatinum (DDP) and taxol were investigated in two human cancer cell lines. Cisplatin 98-101 tumor protein p53 Homo sapiens 35-38 11099651-10 2000 Many of the "fingerprint genes" identified in these studies were consistent with previous observations reported in the literature (e. g., the well-characterized induction by cisplatin of p53-regulated transcripts such as p21(waf1/cip1) and PCNA [proliferating cell nuclear antigen]). Cisplatin 174-183 tumor protein p53 Homo sapiens 187-190 11495153-11 2001 The presence of serum p53-Abs was associated with decreased in vitro chemosensitivity to CDDP and 5-FU. Cisplatin 89-93 tumor protein p53 Homo sapiens 22-25 11175336-4 2000 We found the formation of previously unreported nuclear complexes between the tumor suppressor protein p53 and the pro-apoptotic protein Bax, in human melanoma cell lines induced into apoptosis following cisplatin exposure. Cisplatin 204-213 tumor protein p53 Homo sapiens 103-106 11175336-6 2000 Three channel fluorescence laser scanning confocal image microscopy revealed that the nuclear Bax/p53 complexes remained in the nucleus and localized proximal to DNA fragmentation sites as assayed by TUNEL after cisplatin exposure. Cisplatin 212-221 tumor protein p53 Homo sapiens 98-101 11175336-7 2000 Two human melanoma cell lines, expressing wt p53, were induced into apoptosis after cisplatin exposure, however they differed in the timing of this induction. Cisplatin 84-93 tumor protein p53 Homo sapiens 45-48 11175336-9 2000 The degree of apoptosis induced by different concentrations of cisplatin correlated with the amount of nuclear Bax/p53 complexes. Cisplatin 63-72 tumor protein p53 Homo sapiens 115-118 11156235-8 2000 These data suggest that LOH at chromosome 17p13 is associated with a good clinical response to cisplatin-based chemotherapy, suggesting that altered p53 function might render cells more sensitive to therapy. Cisplatin 95-104 tumor protein p53 Homo sapiens 149-152 11096420-0 2000 Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. Cisplatin 90-99 tumor protein p53 Homo sapiens 103-107 11096420-3 2000 In the TP53-mutated cell lines MeWo and 4451, the survival ratio at 7 Gy measured by colony formation was 2.3-2.8, 8.6-85 and 52-74 for daunorubicin, melphalan and cisplatin, respectively. Cisplatin 164-173 tumor protein p53 Homo sapiens 7-11 11079169-17 2000 The concomitant use of cisplatin, an inducer of apoptosis that is dependent on the normal function of p53, makes the interpretation of these results difficult. Cisplatin 23-32 tumor protein p53 Homo sapiens 102-105 11008128-8 2000 Additionally, the combination of ALLnL and cisplatin potently increased p53 levels in cell lysates and stimulated the binding of p53 to chromatin. Cisplatin 43-52 tumor protein p53 Homo sapiens 72-75 11008128-8 2000 Additionally, the combination of ALLnL and cisplatin potently increased p53 levels in cell lysates and stimulated the binding of p53 to chromatin. Cisplatin 43-52 tumor protein p53 Homo sapiens 129-132 11205289-0 2000 Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism. Cisplatin 88-97 tumor protein p53 Homo sapiens 25-28 11205289-9 2000 In conclusion our results suggested that DOTAP is an efficient vector for mediating gene transfer in pleural metastatic cells offering advantages compared to viral vectors, while tumor suppressor genes such as p53 may be good candidates in combination with conventional therapy with CDDP that could be further developed for their use in local cancer gene therapy. Cisplatin 283-287 tumor protein p53 Homo sapiens 210-213 11032919-0 2000 Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer. Cisplatin 67-76 tumor protein p53 Homo sapiens 31-34 11032919-8 2000 It is suggested that high p53 expression levels in tumors correlate with both good response to cisplatin-based chemotherapy and good survival of patients with advanced NSCLC. Cisplatin 95-104 tumor protein p53 Homo sapiens 26-29 11034077-2 2000 A2780 human ovarian carcinoma cells, which are sensitive to cisplatin and paclitaxel, express wild-type p53 and exhibit a p53-mediated increase in p21 in response to the chemotherapeutic agents. Cisplatin 60-69 tumor protein p53 Homo sapiens 122-125 11034077-6 2000 Experiments with additional ovarian carcinoma cell lines revealed that PI3K is involved in the expression of p21 induced by cisplatin or paclitaxel in OVCAR-10 cells, which have wild-type p53, but not in OVCAR-5 cells, which lack functional p53. Cisplatin 124-133 tumor protein p53 Homo sapiens 188-191 11034077-6 2000 Experiments with additional ovarian carcinoma cell lines revealed that PI3K is involved in the expression of p21 induced by cisplatin or paclitaxel in OVCAR-10 cells, which have wild-type p53, but not in OVCAR-5 cells, which lack functional p53. Cisplatin 124-133 tumor protein p53 Homo sapiens 241-244 11798837-2 2000 METHODS: Human lung adenocarcinoma cell line GLC-82 was transfected with adenovirus-mediated p53 gene (Ad-p53) combining with administration of either kind of chemotherapeutic agents-cisplatin (CDDP) and arsenic trioxide (As(2)O(3)). Cisplatin 183-192 tumor protein p53 Homo sapiens 93-96 10974634-6 2000 (c) Treatment of tumour cells by either gamma radiation or by cisplatin resulted in the induction of p53 independent of the origin of the tumour. Cisplatin 62-71 tumor protein p53 Homo sapiens 101-104 10974634-7 2000 (d) Susceptibility of two cell lines, one with and one without constitutive expression of p53 showed that the expressing cells were more sensitive to gamma radiation (the percentage inhibition at 250 cGy was 57% versus -15%, P<0.01), and also cisplatin (the percentage inhibition at 1 microgram/ml was 71.0+/-6.0 versus 2.6+/-7.0, P<0.001). Cisplatin 246-255 tumor protein p53 Homo sapiens 90-93 10974634-13 2000 Alternatively, if TP53 is wild-type, then the increased levels of p53 expression would enable the cells to become more susceptible to DNA damaging treatments such as cisplatin or gamma radiation. Cisplatin 166-175 tumor protein p53 Homo sapiens 18-22 10974634-13 2000 Alternatively, if TP53 is wild-type, then the increased levels of p53 expression would enable the cells to become more susceptible to DNA damaging treatments such as cisplatin or gamma radiation. Cisplatin 166-175 tumor protein p53 Homo sapiens 66-69 10974635-3 2000 In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX. Cisplatin 146-155 tumor protein p53 Homo sapiens 65-69 10974635-3 2000 In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX. Cisplatin 146-155 tumor protein p53 Homo sapiens 86-90 10974635-3 2000 In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX. Cisplatin 157-161 tumor protein p53 Homo sapiens 65-69 10974635-3 2000 In SK-OV-3 and KP cells, which have a homozygous deletion of the TP53 gene, wild-type TP53 gene-transduction markedly enhanced the sensitivity to cisplatin (CDDP), but did not enhance the sensitivity to PTX. Cisplatin 157-161 tumor protein p53 Homo sapiens 86-90 10974635-5 2000 After exposure to CDDP, p53 and Bax protein expression increased and Bcl-xL expression decreased in the KF cells and TP53 gene-transducted SK-OV-3 cells. Cisplatin 18-22 tumor protein p53 Homo sapiens 24-27 10974635-5 2000 After exposure to CDDP, p53 and Bax protein expression increased and Bcl-xL expression decreased in the KF cells and TP53 gene-transducted SK-OV-3 cells. Cisplatin 18-22 tumor protein p53 Homo sapiens 117-121 10974635-7 2000 Therefore, the role of p53 in CDDP-induced apoptosis depends upon the cell type. Cisplatin 30-34 tumor protein p53 Homo sapiens 23-26 10974636-1 2000 To clarify the effect of a combination treatment consisting of a recombinant adenovirus carrying a wild-type TP53 gene (AxCATP53) and cisplatin (CDDP), we examined p53-dependent apoptosis in ovarian cancer xenografts with and without the wild-type TP53 gene. Cisplatin 145-149 tumor protein p53 Homo sapiens 164-167 11798837-2 2000 METHODS: Human lung adenocarcinoma cell line GLC-82 was transfected with adenovirus-mediated p53 gene (Ad-p53) combining with administration of either kind of chemotherapeutic agents-cisplatin (CDDP) and arsenic trioxide (As(2)O(3)). Cisplatin 183-192 tumor protein p53 Homo sapiens 106-109 11798837-2 2000 METHODS: Human lung adenocarcinoma cell line GLC-82 was transfected with adenovirus-mediated p53 gene (Ad-p53) combining with administration of either kind of chemotherapeutic agents-cisplatin (CDDP) and arsenic trioxide (As(2)O(3)). Cisplatin 194-198 tumor protein p53 Homo sapiens 93-96 11798837-9 2000 CONCLUSION: After introduced into GLC-82 cells, Ad-p53 shows enhanced therapeutic efficiency for GLC-82 cells when combined with CDDP or As(2)O(3). Cisplatin 129-133 tumor protein p53 Homo sapiens 51-54 10925118-4 2000 RESULTS: Ad5CMV-p53 substantially enhanced cisplatin chemosensitivity in a dose-dependent manner, reducing the median IC(50) by more than 50%. Cisplatin 43-52 tumor protein p53 Homo sapiens 16-19 10891529-0 2000 Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Cisplatin 17-26 tumor protein p53 Homo sapiens 138-141 10891529-0 2000 Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. Cisplatin 17-26 tumor protein p53 Homo sapiens 143-146 10842327-7 2000 P53 induction occurred in HPV-16 E6 and HPV-16 E6/E7 expressing cells after exposure to cisplatin or MMC, though never to levels found in normal untreated HKCs. Cisplatin 88-97 tumor protein p53 Homo sapiens 0-3 10941537-0 2000 Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer. Cisplatin 10-19 tumor protein p53 Homo sapiens 155-158 10941537-8 2000 Pre-exposure to cisPt based chemotherapy appears to result in the emergence of cisPt resistance, elevated intracellular GSH levels as well as p53 positivity. Cisplatin 16-21 tumor protein p53 Homo sapiens 142-145 10885602-0 2000 Histological response of cisplatin predicts patients" survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Cisplatin 156-165 tumor protein p53 Homo sapiens 89-92 10885602-4 2000 Furthermore, to evaluate the relationship between the effect of preoperative cisplatin treatment and p53 and cyclin D1 expression, we investigated p53 and cyclin D1 expression in pretreatment biopsy samples using an immunohistochemical analysis and compared the results with the histological effect to cisplatin in the resected oesophagus. Cisplatin 77-86 tumor protein p53 Homo sapiens 101-104 10885602-5 2000 The cases that showed immunohistochemical p53 staining in the pretreatment biopsy samples were resistant to cisplatin (P = 0.032). Cisplatin 108-117 tumor protein p53 Homo sapiens 42-45 10918568-0 2000 Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Cisplatin 93-102 tumor protein p53 Homo sapiens 64-67 10918568-1 2000 The contributions of defective mismatch repair and mutated p53 to cisplatin resistance of human tumor cells were analysed. Cisplatin 66-75 tumor protein p53 Homo sapiens 59-62 10918568-7 2000 Firstly, separate introduction of a p53 defect into A2780 cells significantly increased their cisplatin resistance; defective hMLH1 provided less extensive protection. Cisplatin 94-103 tumor protein p53 Homo sapiens 36-39 10918568-9 2000 Both approaches indicate that defective p53 status is a major determinant of cisplatin resistance and defective mismatch repair is a minor, and independent, contributor. Cisplatin 77-86 tumor protein p53 Homo sapiens 40-43 10898536-8 2000 Furthermore, considerable evidence indicates that mutated p53 plays a significant role in the development of cisplatin resistance since several genes implicated in drug resistance and apoptosis (e.g. mismatch repair, bcl-2, high mobility group proteins, DNA polymerases alpha and beta, PCNA, and insulin-like growth factor) are known to be regulated by the p53 oncoprotein. Cisplatin 109-118 tumor protein p53 Homo sapiens 58-61 10898536-8 2000 Furthermore, considerable evidence indicates that mutated p53 plays a significant role in the development of cisplatin resistance since several genes implicated in drug resistance and apoptosis (e.g. mismatch repair, bcl-2, high mobility group proteins, DNA polymerases alpha and beta, PCNA, and insulin-like growth factor) are known to be regulated by the p53 oncoprotein. Cisplatin 109-118 tumor protein p53 Homo sapiens 357-360 10762058-1 2000 Cytotoxic effect of either cisplatin or p53 gene transfection of lung cancer cells may be different depending on the p53 status of cells. Cisplatin 27-36 tumor protein p53 Homo sapiens 117-120 10811471-1 2000 The infection of recombinant adenovirus expressing wild-type p53 (Ad-p53) to lung cancer cells that harbor mutant p53 genes improves their response to cis-diamminedichloroplatinum(II). Cisplatin 151-179 tumor protein p53 Homo sapiens 61-64 10811471-1 2000 The infection of recombinant adenovirus expressing wild-type p53 (Ad-p53) to lung cancer cells that harbor mutant p53 genes improves their response to cis-diamminedichloroplatinum(II). Cisplatin 151-179 tumor protein p53 Homo sapiens 69-72 10811471-1 2000 The infection of recombinant adenovirus expressing wild-type p53 (Ad-p53) to lung cancer cells that harbor mutant p53 genes improves their response to cis-diamminedichloroplatinum(II). Cisplatin 151-179 tumor protein p53 Homo sapiens 69-72 10811471-4 2000 Ad-p53 and DNA-damaging agents (cis-diamminedichloroplatinum(II), etoposide, and 7-ethyl-10-hydrocycamptothecin) showed synergistic effects in six of seven cell lines but additive effects against a p53-mutated cell line. Cisplatin 32-60 tumor protein p53 Homo sapiens 3-6 10811471-4 2000 Ad-p53 and DNA-damaging agents (cis-diamminedichloroplatinum(II), etoposide, and 7-ethyl-10-hydrocycamptothecin) showed synergistic effects in six of seven cell lines but additive effects against a p53-mutated cell line. Cisplatin 32-60 tumor protein p53 Homo sapiens 198-201 10762058-7 2000 These results suggest that cisplatin induced p53 protein phosphorylation and may activate the downstream of p53 gene expression such as p21 and Bax. Cisplatin 27-36 tumor protein p53 Homo sapiens 45-48 10762058-7 2000 These results suggest that cisplatin induced p53 protein phosphorylation and may activate the downstream of p53 gene expression such as p21 and Bax. Cisplatin 27-36 tumor protein p53 Homo sapiens 108-111 10692490-1 2000 Wild-type p53 is frequently mutated in late-stage ovarian cancer and has been proposed as a determinant of cisplatin chemosensitivity. Cisplatin 107-116 tumor protein p53 Homo sapiens 10-13 10717525-9 2000 Clinically a good response to CDDP-based chemo(thermo)therapy for NSCLC patients with tumour residue or recurrence, was observed only in those with p53-negative accumulation and GML gene expression, in agreement with in vitro results. Cisplatin 30-34 tumor protein p53 Homo sapiens 148-151 11240661-0 2000 Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Cisplatin 13-22 tumor protein p53 Homo sapiens 89-92 11240661-0 2000 Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Cisplatin 13-22 tumor protein p53 Homo sapiens 167-170 11240661-8 2000 Together, the results suggest that alterations in tumor growth and gene mutations characterize cDDP-resistance in OVCAR-3 cells, and viral replacement of one of these defective genes (p53) may provide an effective treatment for elimination of drug-resistant cells. Cisplatin 95-99 tumor protein p53 Homo sapiens 184-187 10741907-10 2000 Meanwhile, Ad-p53 gene transfer combined with taxol, cisplatin, doxorubicin or mitomycin C was shown to be even more effective in suppressing growth in the two cell lines. Cisplatin 53-62 tumor protein p53 Homo sapiens 14-17 10692490-10 2000 Our results suggest that the loss of functional p53 can increase cisplatin cytotoxicity in A2780, with loss of G(1)/S checkpoint control and decreased cisplatin-DNA adduct repair, but these effects can be circumvented by the use of JM335, which forms different DNA-platinum adducts. Cisplatin 65-74 tumor protein p53 Homo sapiens 48-51 10692490-10 2000 Our results suggest that the loss of functional p53 can increase cisplatin cytotoxicity in A2780, with loss of G(1)/S checkpoint control and decreased cisplatin-DNA adduct repair, but these effects can be circumvented by the use of JM335, which forms different DNA-platinum adducts. Cisplatin 151-160 tumor protein p53 Homo sapiens 48-51 10653876-0 2000 Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. Cisplatin 55-64 tumor protein p53 Homo sapiens 20-23 10706117-10 2000 In addition, standard chemotherapeutic agents (paclitaxol and cisplatin) showed a synergistic effect when combined with ONYX-015, and this effect was p53 mutant dependent. Cisplatin 62-71 tumor protein p53 Homo sapiens 150-153 10706125-12 2000 Functional analysis of two immortalized lymphoblastoid cell lines derived from patients with the p53 13964GC mutation demonstrated prolonged in vitro survival in response to cisplatinum treatment and showed decreased chemotherapy-induced apoptosis. Cisplatin 174-185 tumor protein p53 Homo sapiens 97-100 10653876-1 2000 PURPOSE: To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non-small-cell lung cancer (NSCLC). Cisplatin 116-125 tumor protein p53 Homo sapiens 73-76 10974929-1 2000 The purpose of the study was to assess the expression of p53 in non-small cell lung cancer (NSCLC) before and after treatment with cisplatin and vepeside (PE) and to define a relationship between p53 expression and responsiveness to chemotherapy prior to surgery. Cisplatin 131-140 tumor protein p53 Homo sapiens 57-60 10769661-0 2000 Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Cisplatin 43-52 tumor protein p53 Homo sapiens 107-110 10769661-1 2000 The present study was performed to investigate whether the introduction of a wild-type p53 gene into human osteosarcoma cells could alter the growth rate and enhance the cytocidal effect of cisplatin (CDDP) and the synergistic antitumor effect of caffeine. Cisplatin 190-199 tumor protein p53 Homo sapiens 87-90 10769661-1 2000 The present study was performed to investigate whether the introduction of a wild-type p53 gene into human osteosarcoma cells could alter the growth rate and enhance the cytocidal effect of cisplatin (CDDP) and the synergistic antitumor effect of caffeine. Cisplatin 201-205 tumor protein p53 Homo sapiens 87-90 10769661-4 2000 The colorimetric WST-1 assay demonstrated that Saos2/p53 cells were twice as sensitive to CDDP alone at a 50% inhibition concentration than the parental Saos2 cells. Cisplatin 90-94 tumor protein p53 Homo sapiens 53-56 10769661-5 2000 Caffeine significantly potentiated the cytocidal effect of CDDP in the Saos2/p53 cells. Cisplatin 59-63 tumor protein p53 Homo sapiens 77-80 10769661-6 2000 Furthermore, the TUNEL assay revealed that following treatment both with CDDP alone and with CDDP combined with caffeine, a higher percentage of the Saos2/p53 cells underwent apoptosis than did the parental Saos2 cells. Cisplatin 73-77 tumor protein p53 Homo sapiens 155-158 10769661-6 2000 Furthermore, the TUNEL assay revealed that following treatment both with CDDP alone and with CDDP combined with caffeine, a higher percentage of the Saos2/p53 cells underwent apoptosis than did the parental Saos2 cells. Cisplatin 93-97 tumor protein p53 Homo sapiens 155-158 10769661-7 2000 Therefore the cytocidal effect of CDDP and the synergistic antitumor effect of caffeine are enhanced by the introduction of a wild-type p53 gene into a human osteosarcoma cell line null for p53. Cisplatin 34-38 tumor protein p53 Homo sapiens 136-139 10769676-0 2000 Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. Cisplatin 34-43 tumor protein p53 Homo sapiens 17-20 10769676-2 2000 In this study, the requirement for p53 in the cisplatin-induced apoptosis of human bladder cancer cells TSGH-8301 was investigated. Cisplatin 46-55 tumor protein p53 Homo sapiens 35-38 10769676-6 2000 RESULTS: Cells containing an exogenous mutant p53 sequence had increased sensitivity to cisplatin by undergoing apoptosis compared with parental TSGH8301 cells. Cisplatin 88-97 tumor protein p53 Homo sapiens 46-49 10769676-9 2000 CONCLUSION: The transfectants had lost the expression of mutant p53 during selection; however, they could still enhance the expression of wild-type p53, which conferred sensitivity to cisplatin. Cisplatin 184-193 tumor protein p53 Homo sapiens 148-151 10644891-7 2000 The representative cell line NCI-H1437 cells transfected with wild-type p53 gene (H1437/wtp53) showed a dramatic increase in susceptibility to three anticancer agents (7-fold to cisplatin, 21-fold to etoposide, and 20-fold to camptothecin) compared to untransfected or neotransfected H1437 cells. Cisplatin 178-187 tumor protein p53 Homo sapiens 72-75 10626356-0 1999 Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. Cisplatin 93-102 tumor protein p53 Homo sapiens 8-11 10571245-1 1999 DNA-damaging agents such as cisplatin arrest cell cycle progression at either the G1, S, or G2 phase, although the G1 arrest is seen only in cells expressing the wild-type p53 tumor suppressor protein. Cisplatin 28-37 tumor protein p53 Homo sapiens 172-175 10571245-4 1999 We show here that UCN-01 at non-cytotoxic concentrations abrogated S and G2 arrest induced by cisplatin in two p53-defective human breast cancer cell lines. Cisplatin 94-103 tumor protein p53 Homo sapiens 111-114 10632346-0 1999 Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Cisplatin 96-105 tumor protein p53 Homo sapiens 20-23 10568814-0 1999 Cisplatin-induced p53-independent growth arrest and cell death in cancer cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 18-21 10568814-5 1999 These findings provide further evidence that cells carrying mutations resulting in loss of function in the p53 gene can be killed by cisplatin via a p53-independent route with some similarities to replicative senescence, but not apoptosis. Cisplatin 133-142 tumor protein p53 Homo sapiens 107-110 10568814-5 1999 These findings provide further evidence that cells carrying mutations resulting in loss of function in the p53 gene can be killed by cisplatin via a p53-independent route with some similarities to replicative senescence, but not apoptosis. Cisplatin 133-142 tumor protein p53 Homo sapiens 149-152 10569615-0 1999 Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. Cisplatin 41-50 tumor protein p53 Homo sapiens 114-117 10569615-1 1999 PURPOSE: The objective of this study was to characterize the effect of mutant-type p53 and Bcl-2 expression on the sensitivity to cisplatin in a human bladder cancer cell line both in vitro and in vivo. Cisplatin 130-139 tumor protein p53 Homo sapiens 83-86 10569615-3 1999 The effects of the overexpression of mutant-type p53, Bcl-2, or both on the sensitivity to cisplatin and the apoptotic features in vitro were evaluated by the MTT assay, staining with Hoechst 33258 and a DNA fragmentation assay. Cisplatin 91-100 tumor protein p53 Homo sapiens 49-52 10569615-5 1999 RESULTS: The introduction of mutant-type p53 or Bcl-2 conferred resistance to cisplatin on KoTCC-1 cells through the inhibition of apoptosis. Cisplatin 78-87 tumor protein p53 Homo sapiens 41-44 10569615-7 1999 Furthermore, the KoTCC-1 cells transfected with both mutant-type p53 and Bcl-2 exhibited significantly higher resistance to cisplatin treatment than cells transfected with mutant-type p53 or Bcl-2 alone in experimental models in vivo. Cisplatin 124-133 tumor protein p53 Homo sapiens 65-68 10569615-7 1999 Furthermore, the KoTCC-1 cells transfected with both mutant-type p53 and Bcl-2 exhibited significantly higher resistance to cisplatin treatment than cells transfected with mutant-type p53 or Bcl-2 alone in experimental models in vivo. Cisplatin 124-133 tumor protein p53 Homo sapiens 184-187 10569615-8 1999 CONCLUSIONS: These findings suggest that the overexpression of both mutant-type p53 and Bcl-2 in bladder cancer cells synergistically interferes with the therapeutic effect of cisplatin through the inhibition of the apoptotic pathway. Cisplatin 176-185 tumor protein p53 Homo sapiens 80-83 10589764-0 1999 TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Cisplatin 79-88 tumor protein p53 Homo sapiens 0-4 10531402-0 1999 Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Cisplatin 14-25 tumor protein p53 Homo sapiens 42-45 10531402-0 1999 Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Cisplatin 14-25 tumor protein p53 Homo sapiens 57-60 10585464-9 1999 cis-Diamminedichloroplatinum (II) (CDDP) induced p53 activation and p21 transactivation. Cisplatin 0-33 tumor protein p53 Homo sapiens 49-52 10585464-9 1999 cis-Diamminedichloroplatinum (II) (CDDP) induced p53 activation and p21 transactivation. Cisplatin 35-39 tumor protein p53 Homo sapiens 49-52 10585464-10 1999 The p53-dependent p21 transactivation induced by CDDP was inhibited by mTRX overexpression, suggesting that TRX-dependent redox regulation is physiologically involved in p53 regulation. Cisplatin 49-53 tumor protein p53 Homo sapiens 4-7 10585464-10 1999 The p53-dependent p21 transactivation induced by CDDP was inhibited by mTRX overexpression, suggesting that TRX-dependent redox regulation is physiologically involved in p53 regulation. Cisplatin 49-53 tumor protein p53 Homo sapiens 170-173 10665656-0 1999 Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Cisplatin 0-9 tumor protein p53 Homo sapiens 62-65 10665656-7 1999 Transfection of wild-type p53 gene enhanced the cytotoxicity of cisplatin and cisplatin-induced apoptosis in HeLa cells but not in HeLa/CDDP cells, although it caused p53 overexpression in both cell lines. Cisplatin 64-73 tumor protein p53 Homo sapiens 26-29 10665656-7 1999 Transfection of wild-type p53 gene enhanced the cytotoxicity of cisplatin and cisplatin-induced apoptosis in HeLa cells but not in HeLa/CDDP cells, although it caused p53 overexpression in both cell lines. Cisplatin 78-87 tumor protein p53 Homo sapiens 26-29 10697522-0 1999 De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Cisplatin 72-81 tumor protein p53 Homo sapiens 21-24 10697522-0 1999 De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line. Cisplatin 72-81 tumor protein p53 Homo sapiens 44-47 10697522-2 1999 We investigated the relationship between p53 status and the development of resistance to cisplatin in osteosarcoma cell lines. Cisplatin 89-98 tumor protein p53 Homo sapiens 41-44 10697522-9 1999 Furthermore, p53 induction was lost in OST/R cells after cisplatin exposure. Cisplatin 57-66 tumor protein p53 Homo sapiens 13-16 10697522-10 1999 CONCLUSIONS: De novo deletions of the p53 gene and wild-type p53 were associated with the acquisition of cisplatin-resistance in osteosarcoma. Cisplatin 105-114 tumor protein p53 Homo sapiens 38-41 10697522-10 1999 CONCLUSIONS: De novo deletions of the p53 gene and wild-type p53 were associated with the acquisition of cisplatin-resistance in osteosarcoma. Cisplatin 105-114 tumor protein p53 Homo sapiens 61-64 10674873-3 1999 Repair of cisplatin-induced DNA damage was reduced in MCF7 cells overexpressing Mdm2, compared to MCF7 cells in which wild-type p53 function was intact. Cisplatin 10-19 tumor protein p53 Homo sapiens 128-131 10674873-6 1999 MCF7 cells with intact wild-type p53, on the other hand, arrested primarily in G2/M phase after cisplatin treatment. Cisplatin 96-105 tumor protein p53 Homo sapiens 33-36 10674873-7 1999 These findings indicate that Mdm2 overexpression can recapitulate the effect of p53 mutations on DNA repair of cisplatin lesions. Cisplatin 111-120 tumor protein p53 Homo sapiens 80-83 10626356-8 1999 The data indicate that cisplatin resistance due to an increase in DNA damage tolerance can arise through a loss of p53 function, and that functional activation of latent wild-type p53 by the analog facilitates cell death and circumvents this resistance mechanism. Cisplatin 23-32 tumor protein p53 Homo sapiens 115-118 10471039-0 1999 A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Cisplatin 62-71 tumor protein p53 Homo sapiens 111-114 10550840-6 1999 High levels of p53 expression and DNA-damaging agents like cisplatin (Platinol) and ionizing radiation work synergistically to induce apoptosis in cancer cells. Cisplatin 59-68 tumor protein p53 Homo sapiens 15-18 10550840-6 1999 High levels of p53 expression and DNA-damaging agents like cisplatin (Platinol) and ionizing radiation work synergistically to induce apoptosis in cancer cells. Cisplatin 70-78 tumor protein p53 Homo sapiens 15-18 10471039-8 1999 The results showed that the transfer of functional p53 resulted in a marked (tenfold) reduction of cellular chemosensitivity to the multinuclear platinum complex but in a moderate sensitization to cisplatin. Cisplatin 197-206 tumor protein p53 Homo sapiens 51-54 10500967-6 1999 Urothelial cancers harboring p53 aberration may be resistant to cisplatin-based chemotherapy because of impairment of apoptosis induction. Cisplatin 64-73 tumor protein p53 Homo sapiens 29-32 10615232-1 1999 This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy. Cisplatin 191-200 tumor protein p53 Homo sapiens 119-122 10383145-7 1999 Mitogen activation further suppressed cisplatin-induced p53 expression, and the inhibition was mainly dependent on the Ca2+ pathway. Cisplatin 38-47 tumor protein p53 Homo sapiens 56-59 10437915-0 1999 Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Cisplatin 24-33 tumor protein p53 Homo sapiens 13-16 10437915-1 1999 We have previously shown that p53 mutations are associated with cisplatin resistance in ovarian carcinoma IGROV-1/Pt 1 cells. Cisplatin 64-73 tumor protein p53 Homo sapiens 30-33 10437915-10 1999 This is the first observation that indicates that a subpopulation of p53 mutant cells can occasionally be selected by cisplatin treatment. Cisplatin 118-127 tumor protein p53 Homo sapiens 69-72 10220573-9 1999 When grown in CultiSphers, cells with abrogated p53 function (A549/16E6 and NCI-H1299) were less sensitive to cisplatin than the corresponding monolayer cells, indicating that the decrease in sensitivity is p53 independent. Cisplatin 110-119 tumor protein p53 Homo sapiens 48-51 10225454-3 1999 Mutant (mt) p53-expressing NCCIT and S2 (no p53 protein) were both readily triggered into apoptosis by cisplatin and doxorubicin, while wild-type(wt)-p53-transactivation-competent 2102 EP cells failed to undergo drug-induced apoptosis. Cisplatin 103-112 tumor protein p53 Homo sapiens 12-15 10223459-11 1999 CONCLUSIONS: The present study indicates that clotrimazole inhibits cell proliferation accompanied by morphological changes toward differentiation of glioblastoma cells and that this drug synergistically enhances the antitumor effect of cisplatin by inducing wild-type p53-mediated apoptosis. Cisplatin 237-246 tumor protein p53 Homo sapiens 269-272 10339661-4 1999 However, the sensitivity to radiation was significantly improved by the transduction and T.Tn/p53 cells became markedly susceptible to cisplatin and etoposide compared with parental cells. Cisplatin 135-144 tumor protein p53 Homo sapiens 94-97 10389868-7 1999 Furthermore, significant statistical differences in chemosensitivity to 5-fluorouracil and CDDP were revealed depending on the presence of serum p53 antibodies. Cisplatin 91-95 tumor protein p53 Homo sapiens 145-148 9931282-5 1999 Cisplatin caused an 11-fold increase of recombination frequency in yeast and induced transcriptional activation of the DNA damage-associated promoters such as the minimum promoter containing p53 response elements and the GADD45 promoter in addition to activating the promoters for c-fos, heat shock protein 70, metallothionine IIa, and the minimum promoter containing nuclear factor kappa(kappa)B response elements. Cisplatin 0-9 tumor protein p53 Homo sapiens 191-194 10100719-13 1999 In particular, the greater activity of DACH-acetato-Pt in cisplatin-resistant wild-type p53 ovarian tumor models can be ascribed to its ability to more efficiently induce p53 protein and activate p53 functions. Cisplatin 58-67 tumor protein p53 Homo sapiens 88-91 10100719-13 1999 In particular, the greater activity of DACH-acetato-Pt in cisplatin-resistant wild-type p53 ovarian tumor models can be ascribed to its ability to more efficiently induce p53 protein and activate p53 functions. Cisplatin 58-67 tumor protein p53 Homo sapiens 171-174 10100719-13 1999 In particular, the greater activity of DACH-acetato-Pt in cisplatin-resistant wild-type p53 ovarian tumor models can be ascribed to its ability to more efficiently induce p53 protein and activate p53 functions. Cisplatin 58-67 tumor protein p53 Homo sapiens 171-174 10096970-0 1999 The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. Cisplatin 82-91 tumor protein p53 Homo sapiens 4-8 10096970-1 1999 BACKGROUND: The cytotoxic effects of cisplatin and anthracyclins have been attributed to apoptosis induction, which has been recognized as a major function of the TP53 gene. Cisplatin 37-46 tumor protein p53 Homo sapiens 163-167 10096970-10 1999 CONCLUSIONS: In a small cohort of patients with advanced non-small cell lung cancer we found a direct link between normal TP53 genotype and response to cisplatin-based induction treatment and also between mutant genotype and resistance to treatment, whereas p53 immunohistochemical result was predictive of neither. Cisplatin 152-161 tumor protein p53 Homo sapiens 122-126 10096970-10 1999 CONCLUSIONS: In a small cohort of patients with advanced non-small cell lung cancer we found a direct link between normal TP53 genotype and response to cisplatin-based induction treatment and also between mutant genotype and resistance to treatment, whereas p53 immunohistochemical result was predictive of neither. Cisplatin 152-161 tumor protein p53 Homo sapiens 258-261 10100719-0 1999 Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Cisplatin 21-30 tumor protein p53 Homo sapiens 14-17 10100719-3 1999 Cisplatin was relatively more effective against mutant or null p53 cell lines (continuous drug exposure IC50, 1.2-3.3 microM) than it was against those harboring wild-type p53 (IC50, 2.8-9.9 microM). Cisplatin 0-9 tumor protein p53 Homo sapiens 63-66 10100719-3 1999 Cisplatin was relatively more effective against mutant or null p53 cell lines (continuous drug exposure IC50, 1.2-3.3 microM) than it was against those harboring wild-type p53 (IC50, 2.8-9.9 microM). Cisplatin 0-9 tumor protein p53 Homo sapiens 172-175 10100719-6 1999 Differences between the two platinum agents were also evident in cell cycle studies: cisplatin arrested both wild-type and mutant p53 cells in G2-M, whereas DACH-acetato-Pt arrested wild-type p53 cells in G1 and mutant p53 cells in G2-M. Cisplatin 85-94 tumor protein p53 Homo sapiens 130-133 9989808-3 1999 Here we report on the correlation between inhibition of mRNA synthesis and the induction of p53, p21WAF1 and apoptosis in diploid human fibroblasts treated with either UV light, cisplatin or the RNA synthesis inhibitors actinomycin D, DRB, H7 and alpha-amanitin. Cisplatin 178-187 tumor protein p53 Homo sapiens 92-95 9989808-6 1999 Furthermore, cisplatin-induced accumulation of active p53 in repair-deficient XP-A cells occurred despite the lack of DNA strand break induction. Cisplatin 13-22 tumor protein p53 Homo sapiens 54-57 9927204-7 1999 In contrast, p53His175 and p53His273 exerted very similar effects on the cellular response to cisplatin; both conferred increased resistance to low concentrations of the drug (2.5 microg/ml), but did not protect at all against high concentrations (10 microg/ml). Cisplatin 94-103 tumor protein p53 Homo sapiens 13-16 10527075-0 1999 In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Cisplatin 60-72 tumor protein p53 Homo sapiens 39-42 10063313-0 1999 The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Cisplatin 25-34 tumor protein p53 Homo sapiens 57-60 10063313-8 1999 Cancer cells with the natural expression of bcl-2 and p53 mutation may be more resistant to cisplatin and less susceptible to apoptosis. Cisplatin 92-101 tumor protein p53 Homo sapiens 54-57 10527075-1 1999 We have recently reported that mutations of the tumor suppressor p53 gene are associated with the development of resistance to cis-platinum in human ovarian cancer cells, and that adenovirus-mediated reintroduction of the wild-type p53 (wtp53) gene in ovarian tumor cells resulted in the sensitization of tumor cells to cis-diamminedichloroplatinum (II) (CDDP). Cisplatin 127-139 tumor protein p53 Homo sapiens 65-68 10527075-1 1999 We have recently reported that mutations of the tumor suppressor p53 gene are associated with the development of resistance to cis-platinum in human ovarian cancer cells, and that adenovirus-mediated reintroduction of the wild-type p53 (wtp53) gene in ovarian tumor cells resulted in the sensitization of tumor cells to cis-diamminedichloroplatinum (II) (CDDP). Cisplatin 320-353 tumor protein p53 Homo sapiens 65-68 10527075-1 1999 We have recently reported that mutations of the tumor suppressor p53 gene are associated with the development of resistance to cis-platinum in human ovarian cancer cells, and that adenovirus-mediated reintroduction of the wild-type p53 (wtp53) gene in ovarian tumor cells resulted in the sensitization of tumor cells to cis-diamminedichloroplatinum (II) (CDDP). Cisplatin 320-353 tumor protein p53 Homo sapiens 232-235 10527075-1 1999 We have recently reported that mutations of the tumor suppressor p53 gene are associated with the development of resistance to cis-platinum in human ovarian cancer cells, and that adenovirus-mediated reintroduction of the wild-type p53 (wtp53) gene in ovarian tumor cells resulted in the sensitization of tumor cells to cis-diamminedichloroplatinum (II) (CDDP). Cisplatin 355-359 tumor protein p53 Homo sapiens 65-68 10527075-1 1999 We have recently reported that mutations of the tumor suppressor p53 gene are associated with the development of resistance to cis-platinum in human ovarian cancer cells, and that adenovirus-mediated reintroduction of the wild-type p53 (wtp53) gene in ovarian tumor cells resulted in the sensitization of tumor cells to cis-diamminedichloroplatinum (II) (CDDP). Cisplatin 355-359 tumor protein p53 Homo sapiens 232-235 10527075-3 1999 treatment of CDDP-resistant tumor cells expressing mutant p53 (mutp53) with a recombinant adenovirus expressing wtp53 (Adwtp53) would result in the sensitization of resistant cells to CDDP. Cisplatin 13-17 tumor protein p53 Homo sapiens 58-61 10527075-3 1999 treatment of CDDP-resistant tumor cells expressing mutant p53 (mutp53) with a recombinant adenovirus expressing wtp53 (Adwtp53) would result in the sensitization of resistant cells to CDDP. Cisplatin 184-188 tumor protein p53 Homo sapiens 58-61 9788435-4 1998 Whereas p21waf1 overexpression conferred increased resistance to killing by either drug, p53 overexpression enhanced the cytotoxic effect of cisplatin but protected against etoposide cytotoxicity. Cisplatin 141-150 tumor protein p53 Homo sapiens 89-92 9951689-4 1998 Chemosensitivity data, according to a short-term assay (FMCA), indicated that tumours with p53 mutation were more resistant to cisplatin and cyclophosphamide. Cisplatin 127-136 tumor protein p53 Homo sapiens 91-94 9837785-3 1998 Cell cycle arrest and apoptosis were evaluated in LCL expressing varying p53 levels achieved by treating the cells with increasing concentrations of cisplatin, and we supplemented this approach with experiments in EBV-infected Burkitt"s lymphoma (BL) cells transfected with a temperature-sensitive (ts) mutant human p53 and studies in LCL infected with recombinant adenoviruses expressing wt and ts mutant p53. Cisplatin 149-158 tumor protein p53 Homo sapiens 73-76 9811465-0 1998 Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Cisplatin 87-96 tumor protein p53 Homo sapiens 50-53 9811465-3 1998 We found that compared to the parental cell line, cells overexpressing mutant p53 (either 246val or 135ser) exhibited decreased apoptosis in response to gamma-radiation or cisplatin as measured by: propidium iodide (PI) staining of the cellular DNA (cell cycle analysis) and decrease in PARP (poly ADP-ribose polymerase) cleavage as detected by Western blotting. Cisplatin 172-181 tumor protein p53 Homo sapiens 78-81 9811465-4 1998 Interestingly the cells expressing mutant p53(135ser) protein were less resistant to cisplatin-induced apoptosis than the p53(246val)-bearing cell line. Cisplatin 85-94 tumor protein p53 Homo sapiens 42-45 9811465-5 1998 A significant decrease in the G1/S arrest assayed by bromodeoxyuridine and PI staining (cell cycle/proliferation assay) was also observed in response to irradiation and cisplatin in cell lines expressing either of the mutant p53 constructs. Cisplatin 169-178 tumor protein p53 Homo sapiens 225-228 9811465-6 1998 A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and gamma-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. Cisplatin 120-129 tumor protein p53 Homo sapiens 174-177 9811465-8 1998 Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. Cisplatin 24-33 tumor protein p53 Homo sapiens 92-95 9811465-8 1998 Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. Cisplatin 24-33 tumor protein p53 Homo sapiens 155-158 9811465-9 1998 These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Cisplatin 42-51 tumor protein p53 Homo sapiens 95-98 9811465-9 1998 These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Cisplatin 42-51 tumor protein p53 Homo sapiens 146-149 9811465-10 1998 Finally these results indicate that both irradiation and cisplatin should be used with caution in the treatment of lymphoid tumors bearing mutations of p53. Cisplatin 57-66 tumor protein p53 Homo sapiens 152-155 10081494-0 1998 EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway. Cisplatin 91-120 tumor protein p53 Homo sapiens 132-135 10081494-8 1998 Since CDDP and carboplatin damage DNA and then activate c-abl and the JNK/SAPK pathway, EAT/mcl-1 may inhibit p53-independent apoptosis through a c-abl/JNK (SAPK)-dependent mechanism. Cisplatin 6-10 tumor protein p53 Homo sapiens 110-113 9772293-7 1998 The accumulated p53 was biochemically active, as measured in a transient transfection assay upon treatment with gemcitabine, cisplatin, etoposide, and Taxol. Cisplatin 125-134 tumor protein p53 Homo sapiens 16-19 9893672-0 1998 A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Cisplatin 96-124 tumor protein p53 Homo sapiens 62-65 9893672-0 1998 A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Cisplatin 96-124 tumor protein p53 Homo sapiens 133-136 9893672-3 1998 It was found that the sensitivity of the cells to CDDP correlated with the amount of infectious units of virus per cell of AxCAp53 which correlated with p53 protein expression. Cisplatin 50-54 tumor protein p53 Homo sapiens 127-130 9731490-7 1998 Given the role of p53 in the response of cells to irradiation, we evaluated whether p53 function affects the observed radiation-induced resistance to cisplatin. Cisplatin 150-159 tumor protein p53 Homo sapiens 84-87 9731490-8 1998 By examining isogenic cell lines differing only in p53 function, we demonstrated that radiation conferred resistance to cisplatin independently of p53. Cisplatin 120-129 tumor protein p53 Homo sapiens 51-54 9713990-6 1998 Under conditions of cellular stress (ultraviolet irradiation or exposure to bleomycin or cisplatin), expression of TP53TG1 was induced in a wild-type TP53-dependent manner, indicating that this gene is likely to play an important role in the signaling pathway of TP53 and may function in response to cellular damage. Cisplatin 89-98 tumor protein p53 Homo sapiens 115-119 9713990-6 1998 Under conditions of cellular stress (ultraviolet irradiation or exposure to bleomycin or cisplatin), expression of TP53TG1 was induced in a wild-type TP53-dependent manner, indicating that this gene is likely to play an important role in the signaling pathway of TP53 and may function in response to cellular damage. Cisplatin 89-98 tumor protein p53 Homo sapiens 150-154 9664115-3 1998 Treatment with cisplatin and carboplatin also provoked an increase in the level of p53 and p21, and a lowering in Bcl-2. Cisplatin 15-24 tumor protein p53 Homo sapiens 83-86 9703286-3 1998 The TP53 status has been analysed at the DNA level in tumours from 45 ovarian cancer patients randomized to treatment with paclitaxel and cisplatin or cyclophosphamide and cisplatin. Cisplatin 138-147 tumor protein p53 Homo sapiens 4-8 9703286-3 1998 The TP53 status has been analysed at the DNA level in tumours from 45 ovarian cancer patients randomized to treatment with paclitaxel and cisplatin or cyclophosphamide and cisplatin. Cisplatin 172-181 tumor protein p53 Homo sapiens 4-8 9713515-5 1998 RESULTS: The introduction of wild-type p53 gene into HT1376 markedly enhanced the sensitivity to cisplatin in vitro. Cisplatin 97-106 tumor protein p53 Homo sapiens 39-42 9698467-0 1998 Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). Cisplatin 92-120 tumor protein p53 Homo sapiens 23-26 9698467-5 1998 Restoration of wild-type p53 phenotype by transfection of SKOV3 cells with a p53 cDNA expression vector showed reversal of sensitization by Lisofylline to CDDP cytotoxicity. Cisplatin 155-159 tumor protein p53 Homo sapiens 25-28 9698467-5 1998 Restoration of wild-type p53 phenotype by transfection of SKOV3 cells with a p53 cDNA expression vector showed reversal of sensitization by Lisofylline to CDDP cytotoxicity. Cisplatin 155-159 tumor protein p53 Homo sapiens 77-80 9698467-8 1998 Our results show that the combination of CDDP and Lisofylline preferentially sensitizes p53-defective cancer cells to the cytotoxic effect of CDDP by a yet undetermined mechanism. Cisplatin 41-45 tumor protein p53 Homo sapiens 88-91 9698467-8 1998 Our results show that the combination of CDDP and Lisofylline preferentially sensitizes p53-defective cancer cells to the cytotoxic effect of CDDP by a yet undetermined mechanism. Cisplatin 142-146 tumor protein p53 Homo sapiens 88-91 9458352-0 1998 Role of p53 and apoptosis in sensitization of cis-diamminedichloroplatinum antitumor activity by interleukin-1 in ovarian carcinoma cells. Cisplatin 46-74 tumor protein p53 Homo sapiens 8-11 9681825-5 1998 Apoptosis caused by DNA damage induced with gamma-irradiation, doxorubicin or cisplatin, was enhanced in cells expressing wild type p53 as compared to that seen in parental p53 non-producer cells; mutant p53 expressing clones were found to be more resistant to apoptosis induced by these factors. Cisplatin 78-87 tumor protein p53 Homo sapiens 132-135 9620551-0 1998 Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Cisplatin 41-50 tumor protein p53 Homo sapiens 64-68 9620551-8 1998 The simplest explanation for the resistance of this subset of GCTs that are resistant to cisplatin-based chemotherapy, is the inability of the cells to mount an apoptotic response following exposure due to a functionally inactivating mutation in the TP53 gene. Cisplatin 89-98 tumor protein p53 Homo sapiens 250-254 9652752-5 1998 In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21waf1 protein expression. Cisplatin 45-49 tumor protein p53 Homo sapiens 80-83 9607592-3 1998 The sensitization ratio due to the transfected wt p53 varied from about 2-fold for cisplatin to over 50-fold for thymidine. Cisplatin 83-92 tumor protein p53 Homo sapiens 50-53 9584207-0 1998 Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 155-158 9584207-1 1998 We investigated the roles of p53 and Bcl-2 homologues in the induction of apoptosis by cisplatin and paclitaxel in wild-type p53-expressing human ovarian carcinoma cells and cisplatin-resistant derivatives that have lost p53 function. Cisplatin 87-96 tumor protein p53 Homo sapiens 29-32 9485023-0 1998 Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cisplatin 41-50 tumor protein p53 Homo sapiens 24-27 9485023-0 1998 Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cisplatin 67-76 tumor protein p53 Homo sapiens 24-27 9485023-2 1998 Our studies were initiated by asking whether the translational product of the p53 gene is associated with cisplatin resistance in the 2780CP human ovarian tumor model. Cisplatin 106-115 tumor protein p53 Homo sapiens 78-81 9485023-3 1998 We have demonstrated by single-strand conformation polymorphism analysis and sequencing that p53 in parental cisplatin-sensitive A2780 cells was wild type. Cisplatin 109-118 tumor protein p53 Homo sapiens 93-96 9485023-9 1998 In parallel investigations using the Western technique, exposure of A2780 cells to clinically relevant concentrations of cisplatin (1-20 microM) resulted in time- and dose-dependent increases in p53, together with coordinate increases in p21Waf1/Cip1. Cisplatin 121-130 tumor protein p53 Homo sapiens 195-198 9485023-11 1998 The results indicate that a defect exists in the signal transduction pathway for p53 induction following cisplatin-induced DNA damage in 2780CP cells, and this may represent a significant mechanism of cisplatin resistance. Cisplatin 105-114 tumor protein p53 Homo sapiens 81-84 9485023-11 1998 The results indicate that a defect exists in the signal transduction pathway for p53 induction following cisplatin-induced DNA damage in 2780CP cells, and this may represent a significant mechanism of cisplatin resistance. Cisplatin 201-210 tumor protein p53 Homo sapiens 81-84 9635829-0 1998 Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Cisplatin 36-45 tumor protein p53 Homo sapiens 14-17 9635829-5 1998 We next analysed the relationship between p53 status and cisplatin-induced up-regulation of p53, and the susceptibility to cisplatin-induced apoptosis. Cisplatin 57-66 tumor protein p53 Homo sapiens 42-45 9635829-5 1998 We next analysed the relationship between p53 status and cisplatin-induced up-regulation of p53, and the susceptibility to cisplatin-induced apoptosis. Cisplatin 57-66 tumor protein p53 Homo sapiens 92-95 9635829-11 1998 The present study suggests that, at least in our panel of TGCT cell lines, hypersensitivity for cisplatin-induced apoptosis might not be necessarily correlated with the presence of wild-type p53 and is probably not associated with Bcl-2 and Bax expression. Cisplatin 96-105 tumor protein p53 Homo sapiens 191-194 9584207-8 1998 These data suggest that apoptosis in A2780 and A2780/cp70 is associated with an increased level of Bak and 21 kDa Bax after drug-induced damage and that functional p53 may be required for this effect after cisplatin but not after paclitaxel. Cisplatin 206-215 tumor protein p53 Homo sapiens 164-167 9619834-8 1998 The p53 gene was found to be wild-type in all cases where mdm2-P2 levels were induced by cisplatin. Cisplatin 89-98 tumor protein p53 Homo sapiens 4-7 9636834-1 1998 BACKGROUND: Alteration in apoptosis pathways (in particular mutations of p53 gene) may result in resistance of ovarian carcinoma to cisplatin. Cisplatin 132-141 tumor protein p53 Homo sapiens 73-76 9506540-3 1998 When p53 was expressed at sublethal levels, it sensitized cells to the DNA-damaging drugs Adriamycin, mitomycin C, actinomycin D, etoposide (VP16), cisplatin and CPT11. Cisplatin 148-157 tumor protein p53 Homo sapiens 5-8 9458352-4 1998 IL-1 and CDDP treatment induced p53 protein in NIH:OVCAR-3 tumor cells. Cisplatin 9-13 tumor protein p53 Homo sapiens 32-35 9458352-7 1998 The synergistic interactions of IL-1 with CDDP may involve the enhancement of p53-dependent apoptosis. Cisplatin 42-46 tumor protein p53 Homo sapiens 78-81 9548450-1 1998 It has been controversial whether cancer cells harboring loss or inactivation of the tumor suppressor p53 are resistant or sensitive to DNA-damaging agents including cisplatin and doxorubicin. Cisplatin 166-175 tumor protein p53 Homo sapiens 102-105 9508372-3 1998 Cisplatin, at 10 microM, virtually killed all the cells in the wild-type p53 cell lines, while 57-95% of the cells in the mutant p53 cell lines survived (P = 0.005). Cisplatin 0-9 tumor protein p53 Homo sapiens 73-76 9508372-8 1998 Cisplatin, camptothecin and vincristine all induced apoptosis in wild-type p53 melanoma cells, but not in mutant p53 cells. Cisplatin 0-9 tumor protein p53 Homo sapiens 75-78 9455805-3 1998 Here, using normal human fibroblasts (NHFs), we show that cisplatin and UV radiation induce G2/M arrest which is temporally linked to p53-protein induction. Cisplatin 58-67 tumor protein p53 Homo sapiens 134-137 9389577-6 1997 We further demonstrated that the p53-independent differential cisplatin sensitivity among the testicular germ cell tumour (TGCT) cell lines was not due to differences in cellular cisplatin accumulation or DNA platination. Cisplatin 62-71 tumor protein p53 Homo sapiens 33-36 9498829-7 1998 Interestingly, apoptosis occurred in mt-p53 tumors although only at high doses of cisplatin and not at the magnitude detected in wt-p53 tumors. Cisplatin 82-91 tumor protein p53 Homo sapiens 40-43 9474928-5 1998 Restoration of wild-type p53 function markedly enhanced the antitumor effect of a common chemotherapeutic agent, cisplatin, in human non-small cell lung cancer cells as well as human colon cancer cells. Cisplatin 113-122 tumor protein p53 Homo sapiens 25-28 9700726-0 1998 DNA binding activities of p53 protein following cisplatin damage of ovarian cells. Cisplatin 48-57 tumor protein p53 Homo sapiens 26-29 9700726-1 1998 In this study the transactivation potential and DNA binding activities of p53 protein were examined following exposure of A2780 cells, a human ovarian carcinoma cell line, to the DNA damaging agent, cis-diamminedichloroplatinum II (cisplatin). Cisplatin 199-230 tumor protein p53 Homo sapiens 74-77 9700726-1 1998 In this study the transactivation potential and DNA binding activities of p53 protein were examined following exposure of A2780 cells, a human ovarian carcinoma cell line, to the DNA damaging agent, cis-diamminedichloroplatinum II (cisplatin). Cisplatin 232-241 tumor protein p53 Homo sapiens 74-77 9700726-7 1998 At low doses of cisplatin, these latent pools of p53 increased in parallel with mdm-2 gene activation and were detectable as early as 4 h following cisplatin treatment. Cisplatin 16-25 tumor protein p53 Homo sapiens 49-52 9700726-7 1998 At low doses of cisplatin, these latent pools of p53 increased in parallel with mdm-2 gene activation and were detectable as early as 4 h following cisplatin treatment. Cisplatin 148-157 tumor protein p53 Homo sapiens 49-52 9700726-9 1998 Even though cisplatin-induced p53 lacked sequence-specific DNA binding activity, it does possess an increased affinity for cisplatin-damaged duplex DNA molecules. Cisplatin 12-21 tumor protein p53 Homo sapiens 30-33 9700726-9 1998 Even though cisplatin-induced p53 lacked sequence-specific DNA binding activity, it does possess an increased affinity for cisplatin-damaged duplex DNA molecules. Cisplatin 123-132 tumor protein p53 Homo sapiens 30-33 9700726-10 1998 This represents the first identification where cisplatin treatment induces a p53 protein, lacking sequence-specific DNA binding but with an increased affinity for platinated DNA molecules. Cisplatin 47-56 tumor protein p53 Homo sapiens 77-80 9403032-7 1997 Since HeLa cells lost most of their p53 protein due to a specific E6-dependent degradation, cisplatin could be inhibiting this degradation, since the p53 total levels were not increased during the exposure to the drug. Cisplatin 92-101 tumor protein p53 Homo sapiens 150-153 9389577-9 1997 We conclude that the cisplatin-induced apoptotic pathway in TGCT cell lines might be p53-independent and is probably not associated with differences in the Bcl-2/Bax rheostat. Cisplatin 21-30 tumor protein p53 Homo sapiens 85-88 9359484-4 1997 Treatment with the chemotherapeutic drug cisplatin following infection with a replication-deficient, recombinant adenoviral vector expressing wt-p53 (termed AdCMVp53) significantly suppressed the growth of WiDr cells compared to single treatments alone. Cisplatin 41-50 tumor protein p53 Homo sapiens 145-148 9815601-10 1997 The degree of sensitization to CDDP conferred by UCN-01, however, was found to correlate with p53 gene status. Cisplatin 31-35 tumor protein p53 Homo sapiens 94-97 9536982-3 1997 In this study, we have analysed the relationships between p53 protein induction, cell cycle arrest and cell survival following exposure of normal human fibroblasts (NHFs) to various genotoxic agents such as cisplatin, UV radiation and gamma radiation. Cisplatin 207-216 tumor protein p53 Homo sapiens 58-61 9815601-11 1997 p53 wild-type cells seem to be more sensitive to the cytotoxic effects of the combination of UCN-01 + CDDP than the p53 mutant cells. Cisplatin 102-106 tumor protein p53 Homo sapiens 0-3 9413185-6 1997 The results suggested that in Panc-1 cells cisplatin and VP-16 induced apoptotic cell death which was mediated through the interaction of Bax expression in the presence of mutated p53. Cisplatin 43-52 tumor protein p53 Homo sapiens 180-183 9815601-12 1997 This was confirmed in cells in which p53 wild-type function was restored by transfection of p53 cDNA, but these cells are also significantly more sensitive to CDDP alone. Cisplatin 159-163 tumor protein p53 Homo sapiens 37-40 9312058-7 1997 In vivo generation of a C-terminal cleavage product of endogenous p53 similar in size to p50(DeltaC) correlated with up-regulation of p21 expression in ML-1 cells exposed to either adriamycin or cisplatin. Cisplatin 195-204 tumor protein p53 Homo sapiens 66-69 21590120-2 1997 Pentoxifylline has recently been shown to sensitize breast cancer cells in which the wild-type p53 function was abrogated to cisplatin-induced apoptosis. Cisplatin 125-134 tumor protein p53 Homo sapiens 95-98 9291435-6 1997 Our results suggest that mdm-2, which is known to disrupt p53 function, sensitizes ovarian-cancer cells to cisplatin/cyclophosphamide, possibly by inhibition of p53-mediated G1 cell-cycle arrest and p53-stimulated nucleotide-excision repair. Cisplatin 107-116 tumor protein p53 Homo sapiens 58-61 9291435-6 1997 Our results suggest that mdm-2, which is known to disrupt p53 function, sensitizes ovarian-cancer cells to cisplatin/cyclophosphamide, possibly by inhibition of p53-mediated G1 cell-cycle arrest and p53-stimulated nucleotide-excision repair. Cisplatin 107-116 tumor protein p53 Homo sapiens 161-164 9291435-6 1997 Our results suggest that mdm-2, which is known to disrupt p53 function, sensitizes ovarian-cancer cells to cisplatin/cyclophosphamide, possibly by inhibition of p53-mediated G1 cell-cycle arrest and p53-stimulated nucleotide-excision repair. Cisplatin 107-116 tumor protein p53 Homo sapiens 161-164 9212237-7 1997 At the same time, we found strong induction of p53, waf-1 and bax protein levels after CDDP treatment in the A2780, but not in the A2780-DX3, cell line. Cisplatin 87-91 tumor protein p53 Homo sapiens 47-50 9212237-10 1997 A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. Cisplatin 97-101 tumor protein p53 Homo sapiens 133-136 9212237-10 1997 A significant proportion of p53 in A2780-DX3 cells was found in the cytoplasmic compartment, and CDDP treatment induced a functional p53 protein in the nucleus of A2780 much more strongly than in A2780-DX3, which coincides with an increase of transcriptional activity of p53 in treated A2780 cells. Cisplatin 97-101 tumor protein p53 Homo sapiens 133-136 9212237-11 1997 We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP-dependent p53-accumulation pathway. Cisplatin 40-44 tumor protein p53 Homo sapiens 119-122 9212237-11 1997 We propose that the cross-resistance to CDDP in the A2780-DX3 cell line may be due to inactivation of a CDDP-dependent p53-accumulation pathway. Cisplatin 104-108 tumor protein p53 Homo sapiens 119-122 8945622-4 1996 When exposed to DNA-damaging agents, cisplatin or mitomycin C, apoptosis was induced in RT4 with the wild-type (wt) p53/wt p21, whereas T24 with the p53 non-sense mutation/wt p21 was resistant. Cisplatin 37-46 tumor protein p53 Homo sapiens 116-119 9186003-3 1997 Cisplatin-treated cells arrest in the G1 phase of the cell cycle, most likely due to a signal generated by the stabilization of p53 and the subsequent induction of p21WAF-1/Cip1. Cisplatin 0-9 tumor protein p53 Homo sapiens 128-131 9374378-4 1997 Drug resistance was associated with considerably enhanced expression of the p53 suppressor protein in HeLa-C3 cells after cisplatin exposure but seemed not to be regulated by the bcl-2-dependent pathway. Cisplatin 122-131 tumor protein p53 Homo sapiens 76-79 9323493-0 1997 Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis. Cisplatin 108-117 tumor protein p53 Homo sapiens 35-38 9323493-2 1997 After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. Cisplatin 22-31 tumor protein p53 Homo sapiens 135-138 9323493-2 1997 After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. Cisplatin 22-31 tumor protein p53 Homo sapiens 282-285 9323493-3 1997 The levels of p53 protein increased after treatment with cisplatin in MKN-74 cells. Cisplatin 57-66 tumor protein p53 Homo sapiens 14-17 8968086-2 1996 Recently published data have suggested a possible role of p53 in nucleotide excision repair: an association of p53 and xeroderma pigmentosum group B protein and a greater sensitivity to cisplatin of RKO cells transfected with the E6 protein of human papilloma virus (inactivating p53). Cisplatin 186-195 tumor protein p53 Homo sapiens 58-61 8967975-1 1996 With the use of clonogenic survival assays, we show that wild-type p53-expressing A2780 human ovarian cell lines transfected with a dominant negative mutant p53 gene (codon 143, valine to alanine) acquired cross-resistance to ionizing radiation, cisplatin, doxorubicin, and 1-beta-D-arabinofuranosylcytosine. Cisplatin 246-255 tumor protein p53 Homo sapiens 67-70 8967975-1 1996 With the use of clonogenic survival assays, we show that wild-type p53-expressing A2780 human ovarian cell lines transfected with a dominant negative mutant p53 gene (codon 143, valine to alanine) acquired cross-resistance to ionizing radiation, cisplatin, doxorubicin, and 1-beta-D-arabinofuranosylcytosine. Cisplatin 246-255 tumor protein p53 Homo sapiens 157-160 9815771-4 1997 In IGROV-1/Pt1 cells, cisplatin resistance has been ascribed to a reduced susceptibility to apoptosis as a consequence of p53 mutation and inactivation of its function. Cisplatin 22-31 tumor protein p53 Homo sapiens 122-125 9815771-5 1997 In the A2780 cisplatin-resistant subline, which retained the wild-type p53 gene status, the development of resistance has been possibly related to increased cell ability to repair drug-induced DNA damage. Cisplatin 13-22 tumor protein p53 Homo sapiens 71-74 9174048-1 1997 We have previously shown that p53 disruption sensitizes certain cancer cell types to cisplatin (CDDP) (Fan et al., 1995). Cisplatin 85-94 tumor protein p53 Homo sapiens 30-33 9174048-1 1997 We have previously shown that p53 disruption sensitizes certain cancer cell types to cisplatin (CDDP) (Fan et al., 1995). Cisplatin 96-100 tumor protein p53 Homo sapiens 30-33 9174048-9 1997 Investigations into a possible cause of this enhanced sensitivity revealed that HCT-116 cells lacking p53 or p21 function exhibited a reduced ability to repair cisplatin-damaged CAT-reporter plasmids transfected into the cells. Cisplatin 160-169 tumor protein p53 Homo sapiens 102-105 9010220-0 1997 Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Cisplatin 77-86 tumor protein p53 Homo sapiens 18-21 9010220-1 1997 Loss of p53 function is associated with the acquisition of cisplatin resistance in the human ovarian adenocarcinoma A2780 cell line. Cisplatin 59-68 tumor protein p53 Homo sapiens 8-11 9010220-7 1997 A synthetic peptide, representing the predicted amino acid sequence of this GSE, conferred resistance to cisplatin when introduced into A2780 cells and inhibited the sequence specific DNA binding activity of p53 protein in vitro. Cisplatin 105-114 tumor protein p53 Homo sapiens 208-211 9010220-8 1997 Overall, these results directly indicate that inactivation of p53 function confers cisplatin resistance in these human ovarian tumour cells. Cisplatin 83-92 tumor protein p53 Homo sapiens 62-65 9013707-0 1997 The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Cisplatin 126-135 tumor protein p53 Homo sapiens 4-7 9013707-0 1997 The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Cisplatin 126-135 tumor protein p53 Homo sapiens 54-57 9013707-8 1997 Overexpression of another p53-regulated gene, GADD45, by contrast, protected cells from cisplatin killing. Cisplatin 88-97 tumor protein p53 Homo sapiens 26-29 9013707-9 1997 These findings suggest that different downstream effectors of the p53 pathway may exert different effects on cellular survival after treatment with cancer chemotherapy drugs such as cisplatin. Cisplatin 182-191 tumor protein p53 Homo sapiens 66-69 9563008-0 1997 Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Cisplatin 17-29 tumor protein p53 Homo sapiens 86-89 9563008-2 1997 We have examined the role of wild-type p53 in resistance to cis-diamminedichloroplatinum (II) (CDDP) in human ovarian cancer cells using a recombinant adenovirus containing human wild-type p53 cDNA (Adwtp53). Cisplatin 60-93 tumor protein p53 Homo sapiens 39-42 9563008-3 1997 In this study we used the human ovarian A2780 tumor cells (wtp53), which are sensitive to CDDP and A2780/CP tumor cells (nonfunctional/mutant p53) and are resistant to CDDP. Cisplatin 90-94 tumor protein p53 Homo sapiens 61-64 8945622-4 1996 When exposed to DNA-damaging agents, cisplatin or mitomycin C, apoptosis was induced in RT4 with the wild-type (wt) p53/wt p21, whereas T24 with the p53 non-sense mutation/wt p21 was resistant. Cisplatin 37-46 tumor protein p53 Homo sapiens 149-152 8911337-1 1996 A more effective gene therapy strategy for lung cancer using sequential cisplatin administration and adenovirus-mediated p53 gene transfer was developed on the basis of our previous observation of enhanced expression of a reporter gene in malignant cells exposed to cisplatin before gene transfer. Cisplatin 266-275 tumor protein p53 Homo sapiens 121-124 9042268-3 1996 The cytotoxic effects of DNA-crosslinking chemotherapeutica such as cisplatin could be enhanced by mutated p53 which is no longer able to repair drug-induced DNA damage. Cisplatin 68-77 tumor protein p53 Homo sapiens 107-110 8903408-5 1996 Introduction of WT-p53 into AFP-positive HCC cells by retroviral infection markedly inhibited their clonal growth in monolayer and soft agar cultures, and increased the sensitivity of these cells to the chemotherapeutic drug, cisplatin. Cisplatin 226-235 tumor protein p53 Homo sapiens 19-22 8950204-4 1996 Northern blot analyses showed that p53 and p21Waf1/Cip1 mRNA were detectable in all untreated cells, and increasing amounts of these transcripts were identified in all cell lines treated with cisplatin. Cisplatin 192-201 tumor protein p53 Homo sapiens 35-38 8950204-7 1996 Our results show that there were differences in sensitivity to cisplatin among four types of high risk HPV-positive cells, possibly due to different levels of p21Waf1/Cip1 up-regulation by functional p53. Cisplatin 63-72 tumor protein p53 Homo sapiens 200-203 8911337-2 1996 Transfer of the normal (wildtype) p53 gene into cisplatin-treated H1299 cells, in which p53 is homozygously deleted, resulted in up to a 60% further inhibition of cell proliferation in vitro than p53 transfer into untreated H1299 cells. Cisplatin 48-57 tumor protein p53 Homo sapiens 34-37 8911337-2 1996 Transfer of the normal (wildtype) p53 gene into cisplatin-treated H1299 cells, in which p53 is homozygously deleted, resulted in up to a 60% further inhibition of cell proliferation in vitro than p53 transfer into untreated H1299 cells. Cisplatin 48-57 tumor protein p53 Homo sapiens 88-91 8911337-2 1996 Transfer of the normal (wildtype) p53 gene into cisplatin-treated H1299 cells, in which p53 is homozygously deleted, resulted in up to a 60% further inhibition of cell proliferation in vitro than p53 transfer into untreated H1299 cells. Cisplatin 48-57 tumor protein p53 Homo sapiens 88-91 8911337-3 1996 The cisplatin plus p53 gene transfer strategy yielded significantly greater apoptosis and tumor growth suppression in an animal model of subcutaneous H1299 tumor nodules than wildtype p53 gene transfer alone. Cisplatin 4-13 tumor protein p53 Homo sapiens 184-187 8911337-4 1996 The timing of cisplatin administration and p53 gene transfer was shown to be critical: cisplatin administration simultaneous with or subsequent to p53 gene transfer was less effective than cisplatin-first sequential treatment. Cisplatin 14-23 tumor protein p53 Homo sapiens 147-150 8911337-4 1996 The timing of cisplatin administration and p53 gene transfer was shown to be critical: cisplatin administration simultaneous with or subsequent to p53 gene transfer was less effective than cisplatin-first sequential treatment. Cisplatin 87-96 tumor protein p53 Homo sapiens 43-46 8911337-4 1996 The timing of cisplatin administration and p53 gene transfer was shown to be critical: cisplatin administration simultaneous with or subsequent to p53 gene transfer was less effective than cisplatin-first sequential treatment. Cisplatin 87-96 tumor protein p53 Homo sapiens 43-46 8808702-0 1996 WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Cisplatin 87-96 tumor protein p53 Homo sapiens 42-45 8895543-0 1996 Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Cisplatin 53-62 tumor protein p53 Homo sapiens 32-35 8895543-16 1996 Therefore, the presence of non-functional p53 in resistant cells might be involved in the relative failure of cisplatin-induced apoptosis in these cells. Cisplatin 110-119 tumor protein p53 Homo sapiens 42-45 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 103-131 tumor protein p53 Homo sapiens 53-56 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 133-142 tumor protein p53 Homo sapiens 53-56 8808702-6 1996 In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. Cisplatin 219-228 tumor protein p53 Homo sapiens 53-56 8808702-7 1996 In contrast, the p53-independent apoptosis of GB-1 glioma cells by cisplatin did not express WAF1/CIP1. Cisplatin 67-76 tumor protein p53 Homo sapiens 17-20 8760308-4 1996 We show here that A-T cells are more sensitive than normal lymphoblastoid cells to cisplatin treatment but the rate of induction of p53 by cisplatin is similar in both cell types. Cisplatin 139-148 tumor protein p53 Homo sapiens 132-135 8920796-0 1996 Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Cisplatin 92-101 tumor protein p53 Homo sapiens 14-17 8920796-10 1996 Our study seems to define the relationship between p53 expression and sensitivity to cisplatin based chemotherapy in locally advanced cervical carcinoma, supporting the notion that the cytotoxic action of cisplatin can activate p53 mediated apoptosis. Cisplatin 85-94 tumor protein p53 Homo sapiens 51-54 8920796-10 1996 Our study seems to define the relationship between p53 expression and sensitivity to cisplatin based chemotherapy in locally advanced cervical carcinoma, supporting the notion that the cytotoxic action of cisplatin can activate p53 mediated apoptosis. Cisplatin 85-94 tumor protein p53 Homo sapiens 228-231 8920796-10 1996 Our study seems to define the relationship between p53 expression and sensitivity to cisplatin based chemotherapy in locally advanced cervical carcinoma, supporting the notion that the cytotoxic action of cisplatin can activate p53 mediated apoptosis. Cisplatin 205-214 tumor protein p53 Homo sapiens 51-54 8920796-10 1996 Our study seems to define the relationship between p53 expression and sensitivity to cisplatin based chemotherapy in locally advanced cervical carcinoma, supporting the notion that the cytotoxic action of cisplatin can activate p53 mediated apoptosis. Cisplatin 205-214 tumor protein p53 Homo sapiens 228-231 8760308-6 1996 The use of a reporter assay to determine the functional status of p53 confirmed the results obtained in the induction experiments with cisplatin. Cisplatin 135-144 tumor protein p53 Homo sapiens 66-69 8616869-2 1996 We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are differently expressed in the ovarian cell line A2780 and its cisplatin-resistant variant 2780CP, with the resistant line overexpressing both proteins. Cisplatin 152-161 tumor protein p53 Homo sapiens 29-32 8687228-0 1996 [Therapeutic effect of adenovirus-mediated transfer of the wild-type p53 gene with cisplatin]. Cisplatin 83-92 tumor protein p53 Homo sapiens 69-72 8653690-0 1996 Modulation of p53 expression by human recombinant interferon-alpha2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cisplatin 99-108 tumor protein p53 Homo sapiens 14-17 8653690-1 1996 G3361/CP cells, a cisplatin (CDDP)-resistant subclone of the human melanoma cell line G3361, overexpress wild-type p53 protein and demonstrate an increase in the percentage of cells in G0--G1 arrest compared to parental cells. Cisplatin 29-33 tumor protein p53 Homo sapiens 115-118 8653690-3 1996 These findings suggest that recombinant IFN-alpha2a disrupts p53-mediated cell cycle regulation to restore CDDP sensitivity in G3361/CP cells. Cisplatin 107-111 tumor protein p53 Homo sapiens 61-64 8667426-15 1996 UCN-01 markedly enhanced the cell-killing activity of cisplatin in MCF-7 cells defective for p53 function. Cisplatin 54-63 tumor protein p53 Homo sapiens 93-96 8616869-3 1996 Transfection of the A2780 cells with a Bcl-2- or p53-expressing plasmid increases resistance to various drugs, including cisplatin, suggesting that Bcl-2 and p53 expression may influence the sensitivity of ovarian cancer cell lines to chemotherapy. Cisplatin 121-130 tumor protein p53 Homo sapiens 49-52 8616869-3 1996 Transfection of the A2780 cells with a Bcl-2- or p53-expressing plasmid increases resistance to various drugs, including cisplatin, suggesting that Bcl-2 and p53 expression may influence the sensitivity of ovarian cancer cell lines to chemotherapy. Cisplatin 121-130 tumor protein p53 Homo sapiens 158-161 8631030-8 1996 The delay in S phase progression was coincident with the induction of p53 protein levels in LXSN-containing HFFs, suggesting a role for p53 in DNA repair of cisplatin-induced damage. Cisplatin 157-166 tumor protein p53 Homo sapiens 70-73 8630996-2 1996 Since the p53 gene becomes inactivated in over one-half of advanced ovarian carcinoma, in this study we have examined the relationships between p53 gene alterations, p53 immunoreactivity, and response to cisplatin-based chemotherapy in ovarian cancer patients. Cisplatin 204-213 tumor protein p53 Homo sapiens 144-147 8630996-2 1996 Since the p53 gene becomes inactivated in over one-half of advanced ovarian carcinoma, in this study we have examined the relationships between p53 gene alterations, p53 immunoreactivity, and response to cisplatin-based chemotherapy in ovarian cancer patients. Cisplatin 204-213 tumor protein p53 Homo sapiens 10-13 8630996-2 1996 Since the p53 gene becomes inactivated in over one-half of advanced ovarian carcinoma, in this study we have examined the relationships between p53 gene alterations, p53 immunoreactivity, and response to cisplatin-based chemotherapy in ovarian cancer patients. Cisplatin 204-213 tumor protein p53 Homo sapiens 144-147 8630996-11 1996 A significant correlation has been found between p53 accumulation, type of mutation (i.e., missense mutations), and pathological response to cisplatin-based therapy. Cisplatin 141-150 tumor protein p53 Homo sapiens 49-52 8631030-8 1996 The delay in S phase progression was coincident with the induction of p53 protein levels in LXSN-containing HFFs, suggesting a role for p53 in DNA repair of cisplatin-induced damage. Cisplatin 157-166 tumor protein p53 Homo sapiens 136-139 8521409-4 1995 We show here that cis-diamminedichloroplatinum (cisplatin) induces the expression of interleukin-1 beta-converting enzyme (ICE), a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, in murine and human malignant glioma cells during apoptosis regardless of their p53 status. Cisplatin 18-46 tumor protein p53 Homo sapiens 284-287 9081399-20 1996 Several genes are involved in control of this process; these include the p53 gene, mutations of which have been linked to cisplatin resistance in our laboratory studies, as well as in clinical trials with carboplatin. Cisplatin 122-131 tumor protein p53 Homo sapiens 73-76 8564971-0 1996 Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cisplatin 20-29 tumor protein p53 Homo sapiens 57-60 8564971-8 1996 Following exposure to ionizing radiation or cisplatin, accumulation of the p53 protein was markedly enhanced only in the sensitive cells. Cisplatin 44-53 tumor protein p53 Homo sapiens 75-78 8564971-13 1996 Taken together, these observations support a role for mutations of the p53 gene in the development of cisplatin resistance in ovarian cancer as a consequence of loss of the ability of p53 to transactivate bax, an apoptosis-inducing gene. Cisplatin 102-111 tumor protein p53 Homo sapiens 71-74 8564971-13 1996 Taken together, these observations support a role for mutations of the p53 gene in the development of cisplatin resistance in ovarian cancer as a consequence of loss of the ability of p53 to transactivate bax, an apoptosis-inducing gene. Cisplatin 102-111 tumor protein p53 Homo sapiens 184-187 8521409-4 1995 We show here that cis-diamminedichloroplatinum (cisplatin) induces the expression of interleukin-1 beta-converting enzyme (ICE), a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, in murine and human malignant glioma cells during apoptosis regardless of their p53 status. Cisplatin 48-57 tumor protein p53 Homo sapiens 284-287 8519417-5 1995 Transient wild-type p53 expression after high-efficiency gene transfer by a p53 adenovirus also sensitized the cells to cisplatin and correlated with the induction of apoptosis. Cisplatin 120-129 tumor protein p53 Homo sapiens 20-23 8519417-5 1995 Transient wild-type p53 expression after high-efficiency gene transfer by a p53 adenovirus also sensitized the cells to cisplatin and correlated with the induction of apoptosis. Cisplatin 120-129 tumor protein p53 Homo sapiens 76-79 8519417-4 1995 Stable transfectants that co-expressed mutant and wild-type p53 had enhanced sensitivity to cisplatin and gamma radiation, compared with parental cells, control vector-transduced cells, and transduced cells that had lost expression of wild-type p53. Cisplatin 92-101 tumor protein p53 Homo sapiens 60-63 7585548-0 1995 Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cisplatin 56-65 tumor protein p53 Homo sapiens 9-12 7585548-2 1995 In vitro studies indicate that p53 can modulate cisplatin-induced cytotoxicity, but the molecular genetic features determining response or resistance to cisplatin in vivo must be defined. Cisplatin 48-57 tumor protein p53 Homo sapiens 31-34 7585548-8 1995 Only 7 of 52 cases examined before and after chemotherapy treatment exhibited a change in the level of p53 expression after cisplatin-based chemotherapy. Cisplatin 124-133 tumor protein p53 Homo sapiens 103-106 7585548-9 1995 These results indicate that cisplatin alters p53 expression infrequently and suggest a direct link between aberrant p53 expression and resistance to cisplatin-based chemotherapy in NSCLC. Cisplatin 28-37 tumor protein p53 Homo sapiens 45-48 7585548-9 1995 These results indicate that cisplatin alters p53 expression infrequently and suggest a direct link between aberrant p53 expression and resistance to cisplatin-based chemotherapy in NSCLC. Cisplatin 149-158 tumor protein p53 Homo sapiens 116-119 7478541-4 1995 Examination of Bcl-2 and p53 protein levels in pairs of cis-platin sensitive and resistant ovarian cell lines demonstrated that the resistant variants over-express Bcl-2 and/or p53, apparently due to progressive expansion of Bcl-2 and/or p53 positive subpopulations during the in vitro development of resistance. Cisplatin 56-66 tumor protein p53 Homo sapiens 25-28 7588628-1 1995 Cisplatin treatment of Epstein-Barr virus-immortalized human B lymphoblastoid cell lines (LCLs) results in p53-mediated apoptosis which occurs largely in a population of cells at the G1/S boundary of the cell cycle. Cisplatin 0-9 tumor protein p53 Homo sapiens 107-110 7761100-4 1995 In this study, we show that the expression of both wild-type p53 and MDM2 (murine double minute 2) proteins was induced when cis-diamminedichloroplatinum (cisplatin) caused apoptosis in human glioblastoma U87-MG cells, which expressed neither wild-type p53 nor MDM2 protein prior to treatment. Cisplatin 125-153 tumor protein p53 Homo sapiens 253-256 7761100-4 1995 In this study, we show that the expression of both wild-type p53 and MDM2 (murine double minute 2) proteins was induced when cis-diamminedichloroplatinum (cisplatin) caused apoptosis in human glioblastoma U87-MG cells, which expressed neither wild-type p53 nor MDM2 protein prior to treatment. Cisplatin 155-164 tumor protein p53 Homo sapiens 253-256 7712469-0 1995 Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cisplatin 67-76 tumor protein p53 Homo sapiens 14-17 7712469-5 1995 Survival assays showed that p53 disruption sensitized MCF-7 cells to cisplatin (CDDP) but not to several other DNA-damaging agents. Cisplatin 69-78 tumor protein p53 Homo sapiens 28-31 7712469-5 1995 Survival assays showed that p53 disruption sensitized MCF-7 cells to cisplatin (CDDP) but not to several other DNA-damaging agents. Cisplatin 80-84 tumor protein p53 Homo sapiens 28-31 7712469-6 1995 CDDP sensitization was not limited to MCF-7 cells since p53 disruption in human colon carcinoma RKO cells also enhanced sensitivity to CDDP. Cisplatin 0-4 tumor protein p53 Homo sapiens 56-59 7712469-6 1995 CDDP sensitization was not limited to MCF-7 cells since p53 disruption in human colon carcinoma RKO cells also enhanced sensitivity to CDDP. Cisplatin 135-139 tumor protein p53 Homo sapiens 56-59 7712469-7 1995 Contrary to the other DNA-damaging agents tested, CDDP-induced DNA lesions are repaired extensively by nucleotide excision, and in agreement with a defect in this process, MCF-7/E6 and MCF-7/mu-p53 cells exhibited a reduced ability to repair a CDDP-damaged chloramphenicol acetyltransferase-reporter plasmid transfected into the cells. Cisplatin 50-54 tumor protein p53 Homo sapiens 194-197 7712469-8 1995 Therefore, we attributed the increased CDDP sensitivity of MCF-7 cells with disrupted p53 to defects in G1 checkpoint control, nucleotide excision repair, or both. Cisplatin 39-43 tumor protein p53 Homo sapiens 86-89 7712469-12 1995 Our results show that a combination of CDDP and pentoxifylline is capable of synergistic and preferential killing of p53-defective tumor cells that do not readily undergo apoptosis. Cisplatin 39-43 tumor protein p53 Homo sapiens 117-120 7729416-8 1995 When the physiologically activated primary B cells were exposed to cisplatin, although p53 accumulated as in LCLs, the outcome was growth-arrest rather than gross cell death. Cisplatin 67-76 tumor protein p53 Homo sapiens 87-90 7954409-1 1994 The present study assessed the role of the p53 tumor suppressor gene in cell cycle arrest and apoptosis following treatment of Burkitt"s lymphoma and lymphoblastoid cell lines with gamma-rays, etoposide, nitrogen mustard, and cisplatin. Cisplatin 226-235 tumor protein p53 Homo sapiens 43-46 7954409-8 1994 We also observed an inverse sensitivity relationship between nitrogen mustard/cisplatin and etoposide in the mutant p53 lines and this was found to correlate with topoisomerase II mRNA levels in the cells. Cisplatin 78-87 tumor protein p53 Homo sapiens 116-119 8406999-0 1993 Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Cisplatin 41-50 tumor protein p53 Homo sapiens 26-29 8406999-1 1993 We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug cis-diamminedichloroplatinum (II), cisplatin. Cisplatin 103-131 tumor protein p53 Homo sapiens 17-20 8406999-1 1993 We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug cis-diamminedichloroplatinum (II), cisplatin. Cisplatin 138-147 tumor protein p53 Homo sapiens 17-20 8406999-2 1993 The majority of the independent cisplatin-resistant clones isolated by a single selection with cisplatin from the ovarian tumour cell line A2780 showed increased levels of p53 protein compared to the parental cell line. Cisplatin 32-41 tumor protein p53 Homo sapiens 172-175 8406999-2 1993 The majority of the independent cisplatin-resistant clones isolated by a single selection with cisplatin from the ovarian tumour cell line A2780 showed increased levels of p53 protein compared to the parental cell line. Cisplatin 95-104 tumor protein p53 Homo sapiens 172-175 8406999-3 1993 Elevated p53 protein levels were also observed in cisplatin-resistant ovarian human tumour lines isolated after multiple exposures to cisplatin (A2780/cp70 and OVIP/DDP). Cisplatin 50-59 tumor protein p53 Homo sapiens 9-12 8406999-3 1993 Elevated p53 protein levels were also observed in cisplatin-resistant ovarian human tumour lines isolated after multiple exposures to cisplatin (A2780/cp70 and OVIP/DDP). Cisplatin 134-143 tumor protein p53 Homo sapiens 9-12 8406999-8 1993 Transfection of a mutant p53 gene construct (containing a mutation at codon 143, val to ala) into the A2780/cp70 resistant cells conferred a significantly increased sensitivity to cisplatin, suggesting that p53 is a direct determinant of cisplatin resistance in these cells. Cisplatin 180-189 tumor protein p53 Homo sapiens 25-28 8406999-8 1993 Transfection of a mutant p53 gene construct (containing a mutation at codon 143, val to ala) into the A2780/cp70 resistant cells conferred a significantly increased sensitivity to cisplatin, suggesting that p53 is a direct determinant of cisplatin resistance in these cells. Cisplatin 180-189 tumor protein p53 Homo sapiens 207-210 8406999-8 1993 Transfection of a mutant p53 gene construct (containing a mutation at codon 143, val to ala) into the A2780/cp70 resistant cells conferred a significantly increased sensitivity to cisplatin, suggesting that p53 is a direct determinant of cisplatin resistance in these cells. Cisplatin 238-247 tumor protein p53 Homo sapiens 25-28 8406999-8 1993 Transfection of a mutant p53 gene construct (containing a mutation at codon 143, val to ala) into the A2780/cp70 resistant cells conferred a significantly increased sensitivity to cisplatin, suggesting that p53 is a direct determinant of cisplatin resistance in these cells. Cisplatin 238-247 tumor protein p53 Homo sapiens 207-210 33773191-11 2021 DS-1 treatment in combination with cisplatin could enhance activated p-p53 (Ser15) and p53 downstream signaling (Bax, Bcl-2, and Akt), leading to a higher level of apoptosis. Cisplatin 35-44 tumor protein p53 Homo sapiens 71-74 21573382-5 1993 Three patients responded to cisplatinum chemotherapy treatment, two of whom had p53 positive staining. Cisplatin 28-39 tumor protein p53 Homo sapiens 80-83 8485705-2 1993 Activation of p53-DNA binding was seen for treatment with radiation, hydrogen peroxide, actinomycin D, Adriamycin, etoposide, camptothecin, 5-fluorouracil, mitomycin C, and cisplatin. Cisplatin 173-182 tumor protein p53 Homo sapiens 14-17 33773191-11 2021 DS-1 treatment in combination with cisplatin could enhance activated p-p53 (Ser15) and p53 downstream signaling (Bax, Bcl-2, and Akt), leading to a higher level of apoptosis. Cisplatin 35-44 tumor protein p53 Homo sapiens 87-90 34876239-5 2021 However, the expression levels of other tumor-related factors, including Ki67, p27, p53, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), caspase-3 (Cas-3), matrix metallopeptidase 2 (MMP2) and vascular endothelial growth factor (VEGF) proteins, were constantly maintained in the tumors of all three substrains after cisplatin treatment. Cisplatin 329-338 tumor protein p53 Homo sapiens 84-87 34597653-0 2022 Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. Cisplatin 45-54 tumor protein p53 Homo sapiens 95-98 33034274-7 2020 P53-upregulated modulator of apoptosis, which is essential in the modulation of cisplatin sensitivity in a variety of cancers, acts as a downstream effector of Nipped-B-like protein. Cisplatin 80-89 tumor protein p53 Homo sapiens 0-3 33034274-9 2020 Conversely, the silencing of P53-upregulated modulator of apoptosis in Nipped-B-like protein-depleted esophageal squamous cell carcinoma rendered cells resistant to cisplatin. Cisplatin 165-174 tumor protein p53 Homo sapiens 29-32 33034274-11 2020 In summary, our study addresses the involvement of Nipped-B-like protein in the development of esophageal squamous cell carcinoma, and the modulation of cisplatin sensitivity via regulation of P53-upregulated modulator of apoptosis. Cisplatin 153-162 tumor protein p53 Homo sapiens 193-196 34731023-4 2021 Recent Advances: Cisplatin ototoxicity results from several mechanisms, including: redox imbalance caused by reactive oxygen species (ROS) production and lipid peroxidation, activation of inflammation, p53 and its downstream pathways that culminate in apoptosis. Cisplatin 17-26 tumor protein p53 Homo sapiens 202-205 34822033-0 2021 USP39 attenuates the antitumor activity of cisplatin on colon cancer cells dependent on p53. Cisplatin 43-52 tumor protein p53 Homo sapiens 88-91 34822033-9 2021 Further studies show that USP39 regulates cisplatin-induced apoptosis dependent on p53. Cisplatin 42-51 tumor protein p53 Homo sapiens 83-86 34822033-11 2021 Collectively, our findings reveal that USP39 might be a negative factor of the p53 mediated cisplatin sensitivity of colon cancer, and suggest USP39 as a potential molecular target for cisplatin chemotherapy of colon cancer. Cisplatin 92-101 tumor protein p53 Homo sapiens 79-82 34822033-11 2021 Collectively, our findings reveal that USP39 might be a negative factor of the p53 mediated cisplatin sensitivity of colon cancer, and suggest USP39 as a potential molecular target for cisplatin chemotherapy of colon cancer. Cisplatin 185-194 tumor protein p53 Homo sapiens 79-82 34212455-6 2021 Knocking down TP53 in TP53-wild-type cells induced synergism of MK-1775 and CDDP. Cisplatin 76-80 tumor protein p53 Homo sapiens 22-26 34832966-10 2021 Treatment with cisplatin, melphalan, or 9-cis RA decreased p53 expression levels in SK-N-FI cells but not in SK-N-Be (2). Cisplatin 15-24 tumor protein p53 Homo sapiens 59-62 34769213-0 2021 The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors. Cisplatin 20-29 tumor protein p53 Homo sapiens 12-16 34769213-6 2021 The full knock-out of TP53 in 2102Ep and resistant NCCIT resulted in an increase in cisplatin resistance, suggesting a contributing role for P53, even in NCCIT, in which P53 had been reported to be non-functional. Cisplatin 84-93 tumor protein p53 Homo sapiens 22-26 34769213-6 2021 The full knock-out of TP53 in 2102Ep and resistant NCCIT resulted in an increase in cisplatin resistance, suggesting a contributing role for P53, even in NCCIT, in which P53 had been reported to be non-functional. Cisplatin 84-93 tumor protein p53 Homo sapiens 141-144 34769213-6 2021 The full knock-out of TP53 in 2102Ep and resistant NCCIT resulted in an increase in cisplatin resistance, suggesting a contributing role for P53, even in NCCIT, in which P53 had been reported to be non-functional. Cisplatin 84-93 tumor protein p53 Homo sapiens 170-173 34769213-7 2021 In conclusion, these results suggest that TP53 mutations contribute to the cisplatin-resistant phenotype of mediastinal GCTs and, therefore, are a potential candidate for targeted treatment. Cisplatin 75-84 tumor protein p53 Homo sapiens 42-46 34528900-7 2021 Metformin sensitized A549 and HCC 827 cells (but not H1299 and H358 cells) to cisplatin in a P53-dependent manner, changing its subcellular localization to the mitochondria. Cisplatin 78-87 tumor protein p53 Homo sapiens 93-96 34528900-8 2021 Treatment with a sub-lethal dose of cisplatin increased Jarid1b expression, yet downregulated P53 levels, protecting A549Res cells from metformin-induced chemosensitization to cisplatin and favored a glycolytic phenotype. Cisplatin 36-45 tumor protein p53 Homo sapiens 94-97 34528900-8 2021 Treatment with a sub-lethal dose of cisplatin increased Jarid1b expression, yet downregulated P53 levels, protecting A549Res cells from metformin-induced chemosensitization to cisplatin and favored a glycolytic phenotype. Cisplatin 176-185 tumor protein p53 Homo sapiens 94-97 34528900-0 2021 Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells. Cisplatin 40-49 tumor protein p53 Homo sapiens 61-64 34528900-3 2021 Here we test if the presence of P53 could predict the activity of metformin as an adjuvant for cisplatin-based therapy in non-small cell lung cancer (NSCLC). Cisplatin 95-104 tumor protein p53 Homo sapiens 32-35 34212455-5 2021 MK-1775 synergized with CDDP to block proliferation, inducing apoptosis and mitotic catastrophe in TP53-mutant UC cells but not in TP53-wild-type cells. Cisplatin 24-28 tumor protein p53 Homo sapiens 99-103 34212455-6 2021 Knocking down TP53 in TP53-wild-type cells induced synergism of MK-1775 and CDDP. Cisplatin 76-80 tumor protein p53 Homo sapiens 14-18 34212455-7 2021 In UMUC3 cell xenografts and two patient-derived xenograft lines with MDM2 overexpression, in which the p53/cell cycle pathway was inactivated, AZD-1775 combined with CDDP suppressed tumor growth inducing both M-phase entry and apoptosis, whereas AZD-1775 alone was as effective as the combination in RT4 cell xenografts. Cisplatin 167-171 tumor protein p53 Homo sapiens 104-107 34212455-11 2021 Differential anti-tumor efficacy of WEE1 blockade alone or combined with CDDP may exist according to p53/cell cycle pathway activity, which may be predictable using an ex vivo 3D primary culture system. Cisplatin 73-77 tumor protein p53 Homo sapiens 101-104 34445588-5 2021 It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Cisplatin 182-191 tumor protein p53 Homo sapiens 86-90 34445588-5 2021 It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Cisplatin 234-243 tumor protein p53 Homo sapiens 86-90 34261004-5 2021 From a list of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis factor (FAS), and sestrin-1 (SESN1) genes responsible for modifying signaling pathways, including the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. Cisplatin 45-54 tumor protein p53 Homo sapiens 236-239 34281219-2 2021 The exquisite cisplatin sensitivity has been mainly explained by the over-expression in GCTs of wild-type TP53 protein and the lack of TP53 somatic mutations; however, several other mechanisms seem to be involved, many of which remain still elusive. Cisplatin 14-23 tumor protein p53 Homo sapiens 106-110 34165168-0 2021 MicroRNA-10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells. Cisplatin 23-32 tumor protein p53 Homo sapiens 56-59 34165168-6 2021 In functional assays, upregulation of the p53 signaling pathway following cisplatin treatment was associated with decreased levels of miR-10b and upregulation of the luciferase activity of wild-type, but not 1,584, 2,032-dual-mutant, p53 3"-UTR. Cisplatin 74-83 tumor protein p53 Homo sapiens 42-45 34165168-7 2021 The ectopic expression of miR-10b-agomir attenuated the stability of p53 3"-UTR and the expression of p53 and its downstream effectors induced by cisplatin. Cisplatin 146-155 tumor protein p53 Homo sapiens 69-72 34165168-7 2021 The ectopic expression of miR-10b-agomir attenuated the stability of p53 3"-UTR and the expression of p53 and its downstream effectors induced by cisplatin. Cisplatin 146-155 tumor protein p53 Homo sapiens 102-105 34165168-8 2021 By contrast, the knockdown of miR-10b induced the stability of p53 3"-UTR and increased levels of p53 and the sensitivity of A549 cells to cisplatin treatment. Cisplatin 139-148 tumor protein p53 Homo sapiens 63-66 34165168-8 2021 By contrast, the knockdown of miR-10b induced the stability of p53 3"-UTR and increased levels of p53 and the sensitivity of A549 cells to cisplatin treatment. Cisplatin 139-148 tumor protein p53 Homo sapiens 98-101 34165168-12 2021 These findings indicate a novel pathway in which cisplatin induces the levels of p53 by increasing mRNA stability via miR-10b, indicating a novel oncogenic role of miR-10b in promoting the malignant characteristics of non-small cell lung carcinoma. Cisplatin 49-58 tumor protein p53 Homo sapiens 81-84 34281219-2 2021 The exquisite cisplatin sensitivity has been mainly explained by the over-expression in GCTs of wild-type TP53 protein and the lack of TP53 somatic mutations; however, several other mechanisms seem to be involved, many of which remain still elusive. Cisplatin 14-23 tumor protein p53 Homo sapiens 135-139 34281219-4 2021 In the following report we explore the complex role of TP53 in GCTs cisplatin-sensitivity and resistance mechanisms, passing through several recent genomic studies, as well as its role in GCT patients with SCs, going through our experience of Center of reference for both GCTs and cancer predisposing syndromes. Cisplatin 68-77 tumor protein p53 Homo sapiens 55-59 34204834-5 2021 While CisPt + RSV treatment induced apoptosis in PE/CA-PJ49 cells by inhibition of BCL-2 associated with high levels of MDM-2 and subsequently led to inhibition of TP53 gene expression. Cisplatin 6-11 tumor protein p53 Homo sapiens 164-168 34204834-4 2021 In FaDu cells, combined CisPt + RSV treatment induced an increase in apoptosis, which was associated with an increase in c-MYC and TP53 and a decrease in BCL-2 expression. Cisplatin 24-29 tumor protein p53 Homo sapiens 131-135 34063628-5 2021 Interestingly, pretreatment with jorunnamycin A at 0.5 muM for 24 h considerably sensitized lung CSCs to cisplatin-induced apoptosis, as evidenced by upregulated p53 and decreased Bcl-2 in jorunnamycin A-pretreated CSC-enriched spheroids. Cisplatin 105-114 tumor protein p53 Homo sapiens 162-165 35487028-9 2022 We observed that both p53 (p = 0.0006) and Delta40p53 (p = 0.0014) induced apoptosis in cisplatin-treated SiHa cells; however in cisplatin-treated HeLa cells, only p53 induced apoptosis (p = 0.0029). Cisplatin 88-97 tumor protein p53 Homo sapiens 22-25 34183962-10 2021 Piperine (20 muM) and cisplatin (5 muM) for 24 h induce apoptosis strongly through reduction of Bcl-2 and increase of caspase 3, p53, caspase 9, and Bax. Cisplatin 22-31 tumor protein p53 Homo sapiens 129-132 34183962-11 2021 Conclusion: Piperine in combination with cisplatin could trigger p53-mediated apoptosis more effective than cisplatin alone in MCF-7 breast cancer cells, reducing the toxic dose of cisplatin used in cancer chemotherapy. Cisplatin 41-50 tumor protein p53 Homo sapiens 65-68 34183962-11 2021 Conclusion: Piperine in combination with cisplatin could trigger p53-mediated apoptosis more effective than cisplatin alone in MCF-7 breast cancer cells, reducing the toxic dose of cisplatin used in cancer chemotherapy. Cisplatin 181-190 tumor protein p53 Homo sapiens 65-68 34915755-7 2021 Moreover, Cisplatin-induced activation of mammalian target of rapamycin mTOR and inactivation of AMPK/PI3K/Akt signal pathway, and was coupled with induction of p53 activity and the executioner caspase3 to induce apoptotic renal cell death. Cisplatin 10-19 tumor protein p53 Homo sapiens 161-164 35346500-14 2022 The potential pathways relative to cisplatin resistance were obtained, such as p53 signaling pathway and Oxidative phosphorylation. Cisplatin 35-44 tumor protein p53 Homo sapiens 79-82 35487028-9 2022 We observed that both p53 (p = 0.0006) and Delta40p53 (p = 0.0014) induced apoptosis in cisplatin-treated SiHa cells; however in cisplatin-treated HeLa cells, only p53 induced apoptosis (p = 0.0029). Cisplatin 88-97 tumor protein p53 Homo sapiens 164-167 35487028-11 2022 Our findings suggest a possible therapeutic application for the combining of p53 or Delta40p53 with cisplatin to induce an increased apoptosis of cancer cells expressing E6 isoforms from HPV-16. Cisplatin 100-109 tumor protein p53 Homo sapiens 77-80 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Cisplatin 164-173 tumor protein p53 Homo sapiens 72-75 35636434-5 2022 In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Cisplatin 164-173 tumor protein p53 Homo sapiens 215-218 35608342-5 2022 In addition, p53 levels increase in HPV16+ head and neck cancer cell lines following treatment with cisplatin. Cisplatin 100-109 tumor protein p53 Homo sapiens 13-16 35522909-0 2022 Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53. Cisplatin 39-48 tumor protein p53 Homo sapiens 161-164 35522909-11 2022 CONCLUSIONS: These findings indicate that exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53. Cisplatin 81-90 tumor protein p53 Homo sapiens 203-206 35167826-1 2022 Cisplatin is a member of a widely utilized class of chemotherapeutic agent that initiates DNA damage response, cell cycle arrest, and p53-dependent apoptotic cell death in concert with DNA-platinum adduct formation. Cisplatin 0-9 tumor protein p53 Homo sapiens 134-137 35073843-6 2022 Using this approach, we predicted that: (1) cisplatin promotes the anti-tumor activity of TP53 family members but suppresses the cancer-inducing function of MYCs; (2) inhibition of RELA and E2F1 is pivotal for leflunomide to exhibit antiproliferative activity; and (3) CHD8 mediates valproic acid-induced autism. Cisplatin 44-53 tumor protein p53 Homo sapiens 90-94 35456022-0 2022 Apoptotic and DNA Damage Effect of 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose in Cisplatin-Resistant Non-Small Lung Cancer Cells via Phosphorylation of H2AX, CHK2 and p53. Cisplatin 79-88 tumor protein p53 Homo sapiens 165-168 35328718-0 2022 p62 Promotes the Mitochondrial Localization of p53 through Its UBA Domain and Participates in Regulating the Sensitivity of Ovarian Cancer Cells to Cisplatin. Cisplatin 148-157 tumor protein p53 Homo sapiens 47-50 35328718-5 2022 We found that the combined use of the proteasome inhibitor epoxomicin and cisplatin led to the accumulation of p53 and sequestosome1(p62) in the mitochondria, downregulated mitochondrial DNA (mtDNA) transcription, inhibited mitochondrial functions, and ultimately promoted apoptosis by enhancing cisplatin sensitivity in ovarian cancer cells. Cisplatin 74-83 tumor protein p53 Homo sapiens 111-114 35328718-5 2022 We found that the combined use of the proteasome inhibitor epoxomicin and cisplatin led to the accumulation of p53 and sequestosome1(p62) in the mitochondria, downregulated mitochondrial DNA (mtDNA) transcription, inhibited mitochondrial functions, and ultimately promoted apoptosis by enhancing cisplatin sensitivity in ovarian cancer cells. Cisplatin 296-305 tumor protein p53 Homo sapiens 111-114 34995485-5 2022 When CAPE was combined with cisplatin in nine cell lines representative of various histotypes a synergistic effect was observed in TOV112D cells and in the cisplatin-resistant IGROV-1/Pt1 variant, both of endometrioid type and carrying mutant TP53. Cisplatin 28-37 tumor protein p53 Homo sapiens 243-247 35205642-7 2022 Cisplatin-induced and EP300-dependent transcriptional activation of ABCC10 was only possible in the presence of p53. Cisplatin 0-9 tumor protein p53 Homo sapiens 112-115 35468881-0 2022 JMJD2C mediates the MDM2/p53/IL5RA axis to promote CDDP resistance in uveal melanoma. Cisplatin 51-55 tumor protein p53 Homo sapiens 25-28 35070983-13 2021 The KEGG pathway analysis revealed that quercetin and cisplatin may affect cervical cancer through platinum drug resistance and the p53 and HIF-1 pathways. Cisplatin 54-63 tumor protein p53 Homo sapiens 132-135 34994335-10 2022 These compounds combined with cisplatin caused upregulation in the pro-apoptotic Bax, Bid, caspase-3, caspase-8, caspase-9, Fas, and p53 gene expressions while downregulating anti-apoptotic DFFA, NFkB1, and Bcl2 gene expressions. Cisplatin 30-39 tumor protein p53 Homo sapiens 133-136